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Abstract
Gene expression profiling and expanded 
immunohistochemistry tests to guide the use of adjuvant 
chemotherapy in breast cancer management: a systematic 
review and cost-effectiveness analysis
S Ward,1* A Scope,1 R Rafia,1 A Pandor,1 S Harnan,1 P Evans1 and L Wyld2
1School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2Royal Hallamshire Hospital, Sheffield, UK
*Corresponding author
Background: Gene expression profiling (GEP) and expanded immunohistochemistry (IHC) 
tests aim to improve decision-making relating to adjuvant chemotherapy for women with 
early breast cancer.
Objective: The aim of this report is to assess the clinical effectiveness and cost-
effectiveness of nine GEP and expanded IHC tests compared with current prognostic tools 
in guiding the use of adjuvant chemotherapy in patients with early breast cancer in England 
and Wales. The nine tests are BluePrint, Breast Cancer Index (BCI), IHC4, MammaPrint, 
Mammostrat, NPI plus (NPI+), OncotypeDX, PAM50 and Randox Breast Cancer Array.
Data sources: Databases searched included MEDLINE, MEDLINE In-Process & Other 
Non-Indexed Citations, EMBASE and The Cochrane Library. Databases were searched 
from January 2009 to May 2011 for the OncotypeDX and MammaPrint tests and from 
January 2002 to May 2011 for the other tests.
Review methods: A systematic review of the evidence on clinical effectiveness (analytical 
validity, clinical validity and clinical utility) and cost-effectiveness was conducted. An 
economic model was developed to evaluate the cost-effectiveness of adjuvant 
chemotherapy treatment guided by four of the nine test (OncotypeDX, IHC4, MammaPrint 
and Mammostrat) compared with current clinical practice in England and Wales, using 
clinicopathological parameters, in women with oestrogen receptor-positive (ER+), lymph 
node-negative (LN–), human epidermal growth factor receptor type 2-negative (HER2–) 
early breast cancer.
Results: The literature searches for clinical effectiveness identified 5993 citations, of which 
32 full-text papers or abstracts (30 studies) satisfied the criteria for the effectiveness 
review. A narrative synthesis was performed. Evidence for OncotypeDX supported the 
prognostic capability of the test. There was some evidence on the impact of the test on 
decision-making and to support the case that OncotypeDX predicts chemotherapy benefit; 
however, few studies were UK based and limitations in relation to study design were 
identified. Evidence for MammaPrint demonstrated that the test score was a strong 
independent prognostic factor, but the evidence is non-UK based and is based on small 
sample sizes. Evidence on the Mammostrat test showed that the test was an independent 
prognostic tool for women with ER+, tamoxifen-treated breast cancer. The three studies 
appeared to be of reasonable quality and provided data from a UK setting (one study). One 
large study reported on clinical validity of the IHC4 test, with IHC4 score a highly significant 
predictor of distant recurrence. This study included data from a UK setting and appeared to 
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be of reasonable quality. Evidence for the remaining five tests (PAM50, NPI+, BCI, BluePrint 
and Randox) was limited. The economic analysis suggests that treatment guided using 
IHC4 has the greatest potential to be cost-effective at a £20,000 threshold, given the low 
cost of the test; however, further research is needed on the analytical validity and clinical 
utility of IHC4, and the exact cost of the test needs to be confirmed. Current limitations in 
the evidence base produce significant uncertainty in the results. OncotypeDX has a more 
robust evidence base, but further evidence on its impact on decision-making in the UK and 
the predictive ability of the test in an ER+, LN–, HER– population receiving current drug 
regimens is needed. For MammaPrint and Mammostrat there were significant gaps in the 
available evidence and the estimates of cost-effectiveness produced were not considered 
to be robust by the External Assessment Group.
Limitations: Methodological weaknesses in the clinical evidence base relate to 
heterogeneity of patient cohorts and issues arising from the retrospective nature of the 
evidence. Further evidence is required on the clinical utility of all of the tests and on UK-
based populations. A key area of uncertainty relates to whether the tests provide 
prognostic or predictive ability.
Conclusions: The clinical evidence base for OncotypeDX is considered to be the most 
robust. The economic analysis suggested that treatment guided using IHC4 has the most 
potential to be cost-effective at a threshold of £20,000; however, the evidence base to 
support IHC4 needs significant further research.
Study registration: PROSPERO 2011:CRD42011001361, available from 
www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42011001361.
Funding: The National Institute for Health Research Health Technology 
Assessment programme.
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Glossary
Technical terms and abbreviations are used throughout this report. The meaning is usually clear from the context, but a glossary is provided for the non-specialist reader.
Adjuvant! Online A computer program designed to provide estimates of the benefits of adjuvant 
endocrine therapy and chemotherapy.
Adjuvant therapy Adjuvant therapy is treatment that is given in addition to the primary (initial) 
treatment. It is designed to help reach the primary treatment goal (e.g. disease eradication). 
Adjuvant therapy for cancer usually refers to chemotherapy, hormonal therapy or radiotherapy 
when administered after primary surgery to help decrease the risk of the cancer recurring 
(coming back). 
Amplification In genetics, an increase in the frequency of replication of a deoxyribonucleic 
acid segment.
Analytical validity The ability of the test to accurately and reliably measure the expression of 
messenger ribonucleic acid or proteins by breast cancer tumour cells.
Axillary lymph nodes Located in the armpit area, they receive lymph fluid from the arm, breast 
and ipsilateral (same side) upper torso.
Chemotherapy The use of medication(s) (drugs) that are toxic to cancer cells, given with the 
aim of killing the cells or preventing or slowing their growth.
Clinical utility The utility of the test in relation to harm, impact on clinical decision-making, 
evidence of improvement in outcomes and health-care costs. 
Clinical validity The degree to which the test could accurately predict the risk of an outcome 
and discriminate patients with different outcomes.
Cohort study A study that follows groups of people with and without the condition of interest 
over time to study outcomes.
Endocrine therapy Treatment of cancer by removing and/or blocking the effects of hormones 
that stimulate the growth of cancer cells.
External Assessment Group An independent group of researchers commissioned by the 
National Institute for Health and Care Excellence to review the evidence on a group of 
technologies. The External Assessment Group includes researchers who assess the quality of 
studies on the treatments, and health economists who look at whether or not the treatments 
are good value for money. The Diagnostics Assessment Committee bases its discussions on the 
diagnostics assessment report produced by the External Assessment Group.
Gene expression Gene expression refers to the translation of the information encoded in 
a gene into an ribonucleic acid (RNA) transcript. Expressed transcripts include messenger 
RNAs, which are translated into proteins, as well as other types of RNA, such as transfer RNA, 
ribosomal RNA, micro RNA and non-coding RNA, that are not translated into protein. Gene 
expression is a highly specific process by which cells switch genes on and off in a timely manner, 
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xii Glossary
according to their state. The study of mRNA expression in a cell is an indirect way to study the 
protein counterpart.
Gene expression profiling This term refers to any genomic techniques that measure the 
fraction of the genes that are expressed in a specific sample. It refers to techniques that allow the 
assessment of the expression of more than one gene at a time, such as microarray analysis after 
the use of real-time reverse transcription-polymerase chain reaction to amplify levels of genetic 
material to measureable levels. 
Grading Assessing the degree of aggressiveness of a malignant tumour based usually on the 
appearance of its cells under the microscope. 
Histology An examination of the cellular characteristics of a tissue using a microscope. 
Hazard ratio The hazard ratio (HR) is an estimate of the ratio of the hazard rate in two groups. 
It is broadly equivalent to relative risk and is useful when the risk is not constant over a given 
period as it uses information collected at different times. The term is typically used in the context 
of survival over time. If the HR = 0.5 then the relative risk of dying (or some other health event) 
in one group is half the risk of dying in the other group. 
Hormone receptor Protein molecules with a specific conformation that bind to hormones in the 
cell’s environment and trigger hormone-dependent changes in the cell’s behaviour.
Human epidermal growth factor receptor A molecule on the surface of a cell that interacts 
with a specific growth factor and helps to control how rapidly the cells grow. 
IHC4 The IHC4 test uses immunohistochemistry technology to assess the levels of four key 
proteins in a breast cancer sample – oestrogen receptor (ER), progesterone receptor (PR), 
human epidermal growth factor receptor type 2 (HER2) and Ki-67. The final algorithm for IHC4 
calculates a risk score for distant recurrence based on these four proteins in addition to classical 
clinical and pathological variables (composite risk score IHC4 + clinical score termed IHC4 in 
our report).
Immunohistochemistry A technique that uses antibodies to identify specific molecules in 
tissues, which are examined and scored by a pathologist using a microscope.
Ki-67 Antigen KI-67 is a molecule that can be easily detected in growing cells in order to gain an 
understanding of the rate at which the cells within a tumour are growing.
Lymph nodes Small bean-shaped glands that are part of the lymphatic system. White blood cells 
in the lymph nodes attack bacteria and viruses as they pass through the node.
Malignant Cancerous cells that can invade into nearby tissue and spread to other parts of 
the body. 
Mammography The process of taking a mammogram – a soft-tissue radiograph of the breast – 
which may be used to evaluate a lump or which may be used as a screening test in women with 
no signs or symptoms of breast cancer. 
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Mastectomy Surgical removal of the breast. 
Metastases Deposits of cancer in the body at a site distant from the primary site. 
Nottingham Prognostic Index The Nottingham Prognostic Index (NPI) is a composite 
prognostic parameter involving both time-dependent factors and aspects of biological 
aggressiveness. The NPI score is based on a mix of grade, lymph node involvement and tumour 
size. To calculate the score, add numerical grade (1, 2 or 3), lymph node score (negative = 1, 
one to three nodes = 2, more than three nodes = 3) and 0.2 × tumour size in cm. Patients can 
be divided into three prognostic groups on the basis of the NPI score: a good prognostic 
group (NPI < 3.4), a moderate prognostic group (3.4 < NPI < 5.4) and a poor prognostic group 
(NPI > 5.4).
Polymerase chain reaction The polymerase chain reaction (PCR) is a molecular biology 
technique for isolating and exponentially amplifying a deoxyribonucleic acid sequence of interest 
in vitro by enzymatic replication. This technique has been extensively modified to perform a 
wide array of tasks. It is a common tool in medical and biological research. PCR is now used to 
obtain the sequence of genes, diagnose hereditary diseases, identify genetic fingerprints (forensic 
medicine), detect infectious diseases and create transgenic organisms. Coupled to reverse 
transcription it is used to amplify ribonucleic acid molecules. 
Predictive molecular markers A molecule that is assessed to predict the likely response 
to a specific treatment, for example oestrogen receptor to predict the likely response to 
endocrine therapy. 
Prognosis A prediction of the likely outcome or course of a disease; the chance of recovery, 
recurrence or death. 
Prognostic factors Disease characteristics that are correlated with the course of the disease and 
which are used to predict the likely outcomes. 
Reverse transcription-polymerase chain reaction The reverse transcription-polymerase 
chain reaction (RT-PCR) is a variant of PCR, a laboratory technique commonly used in 
molecular biology to generate many copies of a deoxyribonucleic acid (DNA) sequence using a 
process termed ‘amplification’. In RT-PCR the ribonucleic acid strand of interest is first reverse 
transcribed into its DNA complement (complementary DNA, or cDNA) using the enzyme 
reverse transcriptase, and the resulting cDNA is amplified using traditional or real-time PCR. 
Staging Clinical description of the size and spread of a patient’s tumour, allocated by 
internationally agreed categories. 
Systemic therapy/treatment Medicine, usually given by mouth or injection, to treat the whole 
body rather than targeting one specific area. 
Transcription In genetics, the process by which genetic information on a strand of 
deoxyribonucleic acid is used to synthesise a strand of complementary ribonucleic acid. 
Translation In genetics, the process by which a messenger ribonucleic acid molecule specifies 
the linear sequence of amino acids on a ribosome for protein synthesis.
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List of abbreviations
AC doxorubicin and cyclophosphamide 
AIC academic-in-confidence
AML acute myeloid leukaemia
AST adjuvant systemic treatment
ATAC Arimidex, Tamoxifen, Alone or in Combination trial
BCA Breast Cancer Array
BCI Breast Cancer Index
BCSD breast cancer-specific death
BCSS breast cancer-specific survival
BNF British National Formulary
BSA body surface area
CAF cyclophosphamide, doxorubicin and fluorouracil
CBO Dutch Institute for Healthcare Improvement
cDNA complementary deoxyribonucleic acid
CEAC cost-effectiveness acceptability curve
CHF congestive heart failure
CG Clinical Guideline
CI  confidence interval 
CIC commercial-in-confidence
CISH chromogenic in situ hybridisation
CMF cyclophosphamide, methotrexate and 5-fluorouracil
DARE Database of Abstracts of Reviews of Effects
DCIS  ductal carcinoma in situ 
DCS Decisional Conflict Scale
DDFS distant disease-free survival
DFS  disease-free survival 
DMFS distant metastasis-free survival
DNA deoxyribonucleic acid
DRFI distant recurrence-free interval
DRFS distant recurrence-free survival
EAG External Assessment Group
EBCTCG Early Breast Cancer Trialists’ Collaborative Group
ECRIC Eastern Cancer Registration and Information Centre
EGFR epidermal growth factor receptor
EORTC European Organisation for Research and Treatment in Cancer
EQ-5D European Quality of Life-5 Dimensions
ER oestrogen receptor (ER+ is ER positive and ER– is ER negative)
FEC 5-fluorouracil, epirubicin and cyclophosphamide
FEC-D 5-flurouracil, epirubicin and cyclophosphamide-docetaxel
FEC-P 5-fluorouracil, epirubicin, cyclophosphamide and paclitaxel
FFPE formalin-fixed paraffin-embedded 
G-CSF granulocyte colony-stimulating factor
GEP  gene expression profiling 
HER2 human epidermal growth factor receptor type 2 
HR hazard ratio 
HTA Health Technology Assessment
ICER incremental cost-effectiveness ratio
IHC immunohistochemistry 
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LCIS lobular carcinoma in situ
LN lymph node
LR-X2 likelihood ratio chi-square
MF methotrexate and 5-fluorouracil
MGI Molecular Grade Index
MINDACT  Microarray In Node-negative Disease may Avoid ChemoTherapy 
mRNA messenger ribonucleic acid
NCCN National Comprehensive Cancer Network
NICE National Institute for Health and Care Excellence
NIH National Institutes of Health
NPI  Nottingham Prognostic Index 
NPI+ Nottingham Prognostic Index Plus
NPV negative predictive value
NSABP National Surgical Adjuvant Breast and Bowel Project
OHTA Ontario Health Technology Assessment
OPTIMA Optimal Personalised Treatment of breast cancer using Multi-parameter Analysis
OS overall survival
PR progesterone receptor
PPV positive predictive value
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analysis
PSA probabilistic sensitivity analysis
PSSRU Personal Social Services Research Unit
QALY quality-adjusted life-year
RCT randomised controlled trial
RFI recurrence-free interval
RFS recurrence-free survival
RNA ribonucleic acid
RS recurrence score 
RSPC integration of RS and clinicopathological factors
RT-PCR reverse transcription-polymerase chain reaction 
SE standard error 
SEER Surveillance, Epidemiology and End Results 
STAI State-Trait Anxiety Inventory
TAILORx Trial Assigning Individualized Options for Treatment
TC docetaxel and cyclophosphamide
TNM tumour, nodes, metastases classification system for cancer stage of the UICC
TTDR time to distant recurrence
WMCIU West Midland Cancer Intelligence Unit 
Note
This monograph is based on the Diagnostic Assessment Report produced for NICE. The full 
report contained a considerable number of data that were deemed commercial-in-confidence 
and/or academic-in-confidence. The full report was used by the Appraisal Committee at NICE 
in their deliberations. The full report with each piece of commercial-in-confidence and/or 
academic-in-confidence data removed and replaced by the statement ‘commercial-in-confidence 
and/or academic-in-confidence information (or data) removed’ is available on the NICE website: 
www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining 
readability, but some sections, sentences, tables and figures have been removed. Readers should 
bear in mind that the discussion, conclusions and implications for practice and research are 
based on all the data considered in the original full NICE report.
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Background
Prognostic tools such as the Nottingham Prognostic Index (NPI) and Adjuvant! Online are 
currently used in the UK to assist decision-making relating to adjuvant chemotherapy for women 
with early breast cancer at intermediate or high risk of recurrence following primary surgery. 
These tools use pathological parameters, for example tumour size, grade and lymph node status 
in the case of NPI, with the addition of oestrogen receptor (ER) status, age and comorbidity 
for Adjuvant! Online. Such tools are imperfect and some women with early breast cancer may 
be over- or undertreated, resulting in unnecessary use of chemotherapy for some women or 
avoidable deaths in women for whom chemotherapy was withheld.
Gene expression profiling (GEP) and expanded immunohistochemistry (IHC) (or protein 
expression) tests aim to improve the targeting of chemotherapy by more accurately identifying 
patients who will gain most benefit from it. These tests either aim to more accurately measure 
the risk of cancer recurrence by incorporating a wider range of biomarkers than standard 
clinicopathological algorithms or seek to identify breast cancer subtypes, which provide 
information on recurrence risk.
Nine tests were included in this assessment, as per the National Institute for Health and Care 
Excellence (NICE) scope. Six use GEP technology: the Randox Breast Cancer Array (Randox 
Laboratories, Crumlin, UK), MammaPrint® (Agendia, Amsterdam, the Netherlands), BluePrint™ 
(Agendia, Amsterdam, the Netherlands), the PAM50 gene expression assay (ARUP Laboratories, 
Salt Lake City, UT, USA), OncotypeDX™ (Genomic Health Inc., Redwood City, CA, USA) and 
the Breast Cancer Index℠ (bioTheranostics Inc., San Diego, CA, USA); and three use IHC 
technology: IHC4 [The National Institute for Health Research (NIHR) Specialist Biomedical 
Research Centre (BRC) for Cancer is a partnership between The Royal Marsden NHS Foundation 
Trust and The Institute of Cancer Research (ICR); see http://www.cancerbrc.org/Highlights/
Breast_Cancer_highlights/index.shtml], Mammostrat® (Clarient Inc., Aliso Viejo, CA) and NPI 
plus (NPI+) (University of Nottingham, Nottingham, UK).
Objective
The objective of this study was to evaluate the clinical effectiveness and cost-effectiveness of GEP 
and expanded IHC tests compared with existing prognostic tools in guiding the use of adjuvant 
chemotherapy in women with early breast cancer in England and Wales.
Methods
A systematic review of the evidence on the clinical effectiveness of nine GEP and expanded IHC 
tests to guide the use of chemotherapy in breast cancer management was conducted. For two of 
the tests (OncotypeDX and MammaPrint) the review updated two existing systematic reviews. 
Several electronic databases (including MEDLINE, MEDLINE In-Process & Other Non-Indexed 
Citations, EMBASE and The Cochrane Library) were searched from January 2002 to May 2011 
(for the OncotypeDX and MammaPrint tests searches were conducted from January 2009). 
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Outcome measures included analytical validity, clinical validity and clinical utility. The study 
by Altman (2001) was used to assess the methodological quality of included studies (Altman D. 
Systematic reviews in health care: systematic reviews of evaluations of prognostic variables. BMJ 
2001;323:224–8).
A systematic review of economic evaluations was also undertaken. In addition, two economic 
evaluations were submitted by Genomic Health and Clarient for the use of OncotypeDX and 
Mammostrat in the UK respectively.
A probabilistic model was developed by the External Assessment Group (EAG) using a lifetime 
horizon. Following a review of the evidence available, only four of the nine tests were included 
in the economic evaluation. Analysis was undertaken for women with ER-positive (ER+), lymph 
node-negative (LN–) and human epidermal growth factor receptor type 2-negative (HER2–) 
early breast cancer from a NHS perspective. These tests were assessed as an addition to existing 
prognostic tools. A subgroup analysis was conducted in women with a NPI score ≤ 3.4 and 
women with a NPI score > 3.4. The model used UK-specific data where possible.
In the comparator arm of the economic model, the proportion of patients receiving 
chemotherapy under current practice was informed by cancer registry data, reflecting the use of 
current prognostic tools such as NPI and Adjuvant! Online to guide the use of chemotherapy. 
In the intervention arm the targeting of patients to receive chemotherapy was dependent on 
the classification of risk by the new test. The natural history of breast cancer was then simulated 
using a cohort state transition model, taking into account the reduction in the risk of recurrence 
associated with chemotherapy. Evidence for the benefit of chemotherapy (reduction in the risk of 
recurrence) by risk group for the new tests was taken directly from the studies identified through 
the systematic review of the literature, despite the identified limitations of the studies. Patients 
were able to move between five possible health states – recurrence free, distant recurrence, local 
recurrence, long-term adverse events and death (from breast cancer, adverse events or other 
causes). Results were reported in terms of cost per quality-adjusted life-year (QALY).
Results
Nature, description and quality of the available evidence
The literature searches identified 5993 citations, of which 32 full-text papers or abstracts 
(representing 30 studies) were included in the review. Supplementary information submitted by 
the manufacturers was also presented. This evidence was summarised but was not subjected to 
the systematic review process. Additional studies that did not meet the inclusion criteria for the 
systematic review were used to populate the economic model.
The study populations were generally heterogeneous in the nature of their inclusion criteria 
although the majority of evidence examined ER+, LN– populations. Most studies included a 
small number of participants, although a few studies included over 1000 patients. Follow-up 
was short or not reported for a large number of studies. Only six studies were specific to a UK 
population (three for OncotypeDX, one for NPI+, one for IHC4 and one for Mammostrat).
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Summary of the benefits and risks of gene expression profiling and 
expanded immunohistochemistry tests
OncotypeDX
Clinical
Previous systematic reviews OncotypeDX was reported to be furthest along the validation 
pathway. In terms of clinical validity these reviews reported evidence that the OncotypeDX 
recurrence score was significantly correlated with disease-free-survival and overall survival. 
One study was reported that reported a significant benefit from the use of chemotherapy in the 
OncotypeDX high-risk group, although it was highlighted within the review that the study may 
have been subject to bias.
Current review The current review identified 12 additional studies on the OncotypeDX test. 
Further larger studies have now reported, which support the prognostic capability of the 
OncotypeDX test. In particular, one large-scale UK-based study, in postmenopausal women with 
ER+, LN– early breast cancer, reported that an increase in risk score was significantly associated 
with an increased risk of distant recurrence. Furthermore, the evidence base has been extended 
to include the LN+ population, and there are the beginnings of an evidence base for the validity 
of OncotypeDX in different populations such as Japanese patients. Four studies presented 
evidence on the impact of OncotypeDX on clinical decision-making, indicating that the use 
of OncotypeDX leads to changes in decision-making for between 31.5% and 38% of patients. 
However, only one of these studies was UK based and limitations in relation to study design 
were identified.
Economic
Two economic studies were identified. Both studies compared the use of OncotypeDX with 
Adjuvant! Online. These studies were non-UK studies and were not considered generalisable 
to the UK setting. The economic evaluation submitted by Genomic Health estimated the 
incremental cost for treatment guided using OncotypeDX to be £6232 per QALY gained 
compared with current clinical practice in the UK, although a number of limitations with regard 
to the analysis were highlighted.
A de novo economic model was built by the EAG and estimated the cost per QALY gained to be 
£29,502 compared with current clinical practice, assuming that the test was offered to all woman 
with ER+, LN–, HER2– early breast cancer, under our base-case assumptions. This analysis 
assumed OncotypeDX to be predictive of the benefit of chemotherapy, based on evidence from 
the Paik et al. study, although weaknesses relating to this study are highlighted. (Paik S, Tang G, 
Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women 
with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–34.) 
A subgroup analysis was performed and showed that the incremental cost-effectiveness ratio 
(ICER) for OncotypeDX compared with current clinical practice was reduced to £9774 per 
QALY gained if OncotypeDX was to be offered to women with a (NPI > 3.4) only. Compared 
with current clinical practice, OncotypeDX had a 12.4% (all women) and 91.6% (NPI > 3.4) 
probability of being considered cost-effective when using a threshold of £20,000 per QALY 
gained respectively, although the quality of the data in the model was considered relatively weak. 
Key areas of uncertainly relate to assumptions about the benefits of chemotherapy in terms 
of relative risk reduction by risk group, the risk of recurrence over time and the impact of the 
new test on decision-making. The ICER increased substantially and was greater than £20,000 
per QALY gained for both analyses when assuming the same relative reduction in the risk of 
recurrence from chemotherapy for all patients irrespective of the OncotypeDX recurrence score 
classification, that is, assuming that the test is prognostic only.
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MammaPrint
Clinical
Previous systematic reviews There is a range of studies evaluating the prognostic ability of 
MammaPrint in heterogeneous populations; however, the previous reviews indicated that 
evidence relating to the clinical validity of MammaPrint was not always conclusive or supportive 
of the prognostic value of the test. In terms of clinical utility, the previous reviews identified one 
non-UK study which suggested that MammaPrint had an impact on clinical decision-making.
Current review Our review identified seven additional studies on the MammaPrint test. Four 
studies reported that the MammaPrint score is a strong independent prognostic factor and may 
provide additional value to standard clinicopathological measures, although the populations 
in all of these studies were relatively small. Six non-UK studies evaluated the clinical utility 
of MammaPrint. Five of the studies reported on test reclassification against currently used 
guidelines and one reported that treatment advice for 40% of patients would change, assuming 
that all patients classified as high risk and no patients classified as low risk would receive 
chemotherapy. However, none of the studies provided evidence of actual changes in treatment 
decisions following introduction of the test. A study on the benefit of chemotherapy by 
MammaPrint risk group was identified but omitted from the systematic review because it was 
based on a pooled analysis of six primary studies.
Economic
An analysis was carried out by the EAG to evaluate the use of MammaPrint in England and 
Wales but because of the limitations in the evidence available this was considered exploratory 
only and no base-case ICER was presented.
PAM50
Clinical
The evidence base for PAM50 is still relatively immature. The current review identified two 
analytical validity studies (reported in abstract form only) comparing the PAM50 test with 
standard IHC measurements. Four studies evaluated the clinical validity of PAM50; two of these 
are as yet unpublished. No evidence on clinical utility was identified.
Economic
The EAG did not model treatment guided using PAM50 because of gaps in the evidence base.
Mammostrat
Clinical
The current review identified three studies that provided data to support the use of the 
Mammostrat test as an independent prognostic tool for women with ER+, tamoxifen-treated 
breast cancer. Although the evidence base for the Mammostrat test is relatively immature, these 
studies included a large sample size, appeared to be of reasonable quality and provided data 
from a UK setting (one study). One study was identified for clinical utility but limitations were 
identified relating to this study.
Economic
The EAG conducted an exploratory analysis using the same model structure as for the 
OncotypeDX evaluation and unpublished data from a small sample from a non-UK population; 
however, because of the limitations in the evidence base, any conclusions drawn from this 
analysis are subject to significant uncertainty.
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IHC4
Clinical
No studies on analytical validity of the test were identified. The current review identified one 
study on the clinical validity of IHC4, which reports that the IHC4 score is a highly significant 
predictor of distant recurrence. This study was based on a large sample size and detailed the 
development of the test in one cohort and the external validation of the test in an independent 
cohort. The study also reported evidence comparing IHC4 with OncotypeDX. The review did not 
identify any published evidence on the clinical utility of IHC4 in terms of its impact on treatment 
decisions or its ability to predict chemotherapy benefit by risk group.
Economic
The EAG evaluated the cost-effectiveness of IHC4 in parallel with that of OncotypeDX as 
there was direct evidence between the two tests in a UK population from the same data source 
used to evaluate the cost-effectiveness of OncotypeDX. The IHC4 test was predicted to be 
dominant compared with current clinical practice in patients with ER+, LN–, HER2– early 
breast cancer, providing more QALYs at a lower cost. An incremental analysis was conducted 
comparing OncotypeDX, IHC4 and current clinical practice. When the treatment decision 
using OncotypeDX was compared with that using IHC4, the ICER for OncotypeDX increased to 
£64,111 per QALY gained if the tests were to be offered to all women and £31,125 if the tests were 
to be offered to women with a NPI > 3.4 only. IHC4 was predicted to remain dominant assuming 
the test to be prognostic only, that is, all women receiving chemotherapy derive the same relative 
benefit in terms of reduction in distant recurrences. However, because the evidence base for 
IHC4 is less developed than that for OncotypeDX, additional assumptions were required and the 
results are subject to greater uncertainty.
Nottingham Prognostic Index plus, Breast Cancer Index, BluePrint 
and Randox Breast Cancer Array
Clinical
Based on the limited available data identified for these tests, no firm conclusions can be drawn 
about their analytical validity, clinical validity (prognostic ability) and clinical utility. Further 
evidence on the prognostic and predictive ability of all of these tests is required.
Economic
No studies were identified in the systematic review of the economic literature. The EAG did not 
model treatment guided using these tests because of significant gaps in the evidence base.
Discussion
Strengths and limitations of the analyses and uncertainties
Clinical
Two of the tests (OncotypeDX and MammaPrint) have a reasonably large evidence base, 
although there are some methodological weaknesses relating to this evidence in terms of 
heterogeneity of patient cohorts and issues arising from the retrospective nature of the evidence, 
such as the relevance of the evidence to current methods of diagnosis, treatment and standards of 
care. The evidence base for OncotypeDX is considered to be the most robust. The MammaPrint 
evidence is typically based on observational data (small cohort studies) rather than randomised 
data, increasing the risk of selection bias. Both IHC4 and Mammostrat present early evidence of 
the prognostic ability of the tests based on large UK-based validation cohorts. Further evidence 
is required on the clinical utility of all of these tests, and on UK-based populations where this is 
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not currently available. The evidence base for the remaining five tests has significant gaps and is 
considered less robust.
Economic
Four of the nine tests were included in the economic evaluation by the EAG. The model used 
UK-specific evidence where possible, including the baseline use of chemotherapy, the risk of 
distant recurrence/recurrence and reclassification with the new test, so that its conclusions would 
be relevant to the UK setting. Our analysis focused on patients with ER+, LN–, HER2– early 
breast cancer as use of the tests in this population is supported by the most robust clinical 
evidence. Women with a NPI ≤ 3.4 and women with a NPI > 3.4 were modelled separately to 
account for the prognostic value of the current treatment decision based on clinicopathological 
parameters and to allow a scenario assuming that the test was offered to a subgroup of the 
population at intermediate risk to be conducted.
However, there are significant limitations with regard to the economic analyses. Results of all 
of the analyses have to be interpreted with caution and the results cannot be compared directly 
between tests. Given that no studies following patients from initial diagnosis through to final 
health outcomes were identified for any of the tests, the economic model needed to combine 
clinical data from several different sources in order to model how the results from the new tests 
translate into final outcomes in the form of QALYs. This resulted in significant uncertainties 
that were not adequately captured with the probabilistic sensitivity analysis – data used in the 
model were not always based on UK populations and were not always specifically based on the 
ER+, LN–, HER2– population of interest. Differences in the age of the study populations and the 
endocrine and chemotherapy regimens used in the studies compared with those in the model 
introduced further uncertainty. One key area of uncertainty is whether the tests are prognostic or 
predictive of the benefit of chemotherapy (i.e. do they allow identification of high-risk patients 
who would derive a greater relative benefit from chemotherapy). The ICER was very sensitive 
to this assumption. There were particular concerns relating to the studies used to estimate the 
benefit associated with chemotherapy for patients categorised by risk group by the new tests, in 
relation to both the study design and the populations included in these studies. The evidence 
base on the impact of the new tests on the selection of patients to receive chemotherapy was also 
lacking or not considered generalisable to the UK population. Univariate sensitivity analyses 
indicated that the ICER was sensitive to these assumptions.
A greater number of assumptions were required to model IHC4 compared with OncotypeDX 
because of data limitations for IHC4. There were more significant gaps in the evidence for 
MammaPrint and Mammostrat, and any conclusions that can be drawn from these exploratory 
analyses are subject to considerable uncertainty.
Conclusions
The OncotypeDX and MammaPrint tests have a reasonably large evidence base, although there 
are some methodological weaknesses relating to this evidence in terms of heterogeneity of patient 
cohorts and the use of retrospective data. The evidence base for OncotypeDX is considered to be 
the most robust. Two of the tests (IHC4 and Mammostrat) have presented early evidence of the 
prognostic ability of the tests, based on large UK-based validation cohorts, but further research 
is required. The clinical utility evidence for GEP and expanded IHC tests is limited by the lack of 
large prospective studies in UK populations. PAM50, BluePrint, Breast Cancer Index, NPI+ and 
Randox Breast Cancer Array have only limited clinical evidence to date.
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Ward et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced 
for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated 
with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha 
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
xxiii Health Technology Assessment 2013; Vol. 17: No. 44DOI: 10.3310/hta17440
The economic analysis suggests that the use of the new tests may result in small increases in 
QALYs compared with currently used prognostic tools, but current limitations in the evidence 
base introduce significant uncertainty in the results. A key area of uncertainty is whether 
tests are prognostic only or identify high-risk patients who will benefit more relatively from 
chemotherapy (from reductions in the risk of recurrence) than low-risk patients. The economic 
analyses suggested that, of the four tests considered, treatment guided using IHC4 has the 
greatest potential to be cost-effective at a £20,000 threshold, given the low cost of the test; 
however, further evidence on IHC4 is needed and the exact cost of using the test in the NHS 
needs to be investigated further. Although the OncotypeDX test has been shown to have the 
potential to be cost-effective at the £20,000 threshold for patients with a NPI > 3.4, further 
evidence is needed on the impact on decision-making in the UK and to clarify the predictive 
ability of the test specifically in an ER+, LN–, HER– population receiving current endocrine and 
chemotherapy regimens.
Implications for service provision
The impact of sending large numbers of samples to central testing facilities for pathology services, 
in terms of tissue tracking, pathologist and technical staff time, data input on receipt, etc., would 
need to be explored. Tests requiring the use of fresh tissue require a major change in practice with 
regard to the handling of tissue, with significant implications for service configuration and costs. 
The addition of expanded IHC-based tests is likely to fit more easily with current practice in the 
NHS. Quality assurance issues would need to be addressed, for example for the Ki-67 component 
of the IHC4 test, before these tests could be considered for use in clinical practice in the NHS.
The main research priorities relate to the reliability and reproducibility of the IHC4 test, along 
with further evidence of the prognostic ability of IHC4 compared with NPI and Adjuvant! 
Online. Further evidence on the predictive ability of all of the tests is also required. In addition, 
evidence to improve the understanding of the impact of these tests (for tests that provide a risk 
score/category and tests that provide subtype information only) on the management of patients 
in a UK population is urgently needed.
Study registration
This study is registered as PROSPERO 2011:CRD42011001361, available from www.crd.york.
ac.uk/PROSPERO/display_record.asp?ID=CRD42011001361.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the 
National Institute for Health Research.
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Chapter 1 
Background and definition of the 
decision problem
Condition and aetiology
Breast cancer is the most commonly diagnosed cancer in women in England and Wales. In 
2009 there were 42,305 new cases diagnosed. Treatment usually involves surgery to remove 
the primary tumour and any involved lymph nodes; this may be followed by radiation therapy, 
endocrine therapy and/or chemotherapy with or without trastuzumab depending on tumour and 
patient variables.
Aetiology, pathology and prognosis
Aetiology
The causes of breast cancer are not completely understood. A range of risk factors have been 
identified including genetic, hormonal and lifestyle factors.1
It has been estimated that 12% of women with breast cancer have one affected family member 
and 1% have two or more affected family members.2 Genetic predisposition is mediated by 
high-penetrance genes such as breast cancer 1 gene (BRCA1) and breast cancer 2 gene (BRCA2), 
responsible for around 80–90% of hereditary cancers, and low-penetrance genes, which confer 
increased and decreased risk.1
Environmental and lifestyle factors as well as genetic factors influence breast cancer risk. Asian 
migrants to the West have increased levels of risk compared with the indigenous population, 
whereas Asian Americans born in the West have incidence rates approximating the US average.3
Lifestyle and environmental factors thought to increase risk include hormonal factors such as 
taking the oral contraceptive pill or hormone replacement therapy, higher age of menopause, 
early age of menarche, late age of first birth and not giving birth. Factors that decrease risk 
include higher folate intake, higher number of pregnancies, breastfeeding and younger age at 
first birth.1
Obesity increases the risk of breast cancer in postmenopausal women.4 The picture is less clear 
for premenopausal women, in whom risk may be lower but prognosis poorer. Physical activity 
in adolescence and young adulthood confers a decreased risk of breast cancer,5 which may be 
mediated hormonally.
Pathology
Breast cancer starts with genetic changes in a single cell or a small group of cells in the 
epithelia of the ducts or the lobules of the breast. The genetic change allows cells to reproduce 
uncontrollably, creating a tumour. Tumours that have not yet spread to surrounding tissue 
are known as carcinoma in situ and may be ductal (DCIS) or lobular (LCIS). Once spread to 
surrounding tissue begins, a tumour is known as invasive. More rapid growth and spread occurs 
once a blood supply is secured. Cancer spreads via the lymphatic system or the bloodstream. 
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Lymphatic spread is usually first to the axillary lymph nodes. Spread via the bloodstream can lead 
to distant metastases in the bone or viscera that are incurable.
The presence or absence of axillary metastases is a key indicator of stage of disease and prognosis, 
and adjuvant therapy is planned, in part, based on their presence and extent.6 They are caused 
when a single or small number of cells detach from the main tumour, travel via the lymphatic 
system and establish themselves in the tissue of the lymph nodes. Axillary metastases occur 
in approximately 41% of cases7 and prognosis is better when there is no axillary spread. When 
metastases are present, axillary clearance is indicated to prevent further spread and ensure local 
disease control.
Prognosis
Overall, 5-year, age-standardised breast cancer survival rates are around 80%.8 Survival varies 
with age (Table 1) and stage of disease (Table 2).9
Other factors can affect prognosis. Clinicians may use tools such as the Nottingham Prognostic 
Index (NPI),10 which takes into account grade as well as size and spread, or Adjuvant! 
Online,11 which uses patient data such as age, tumour size, nodal involvement, hormonal 
receptor status and histological grade to predict disease course and treatment options. Good 
prognosis is associated with small tumour size, lymph node-negative (LN–) status, younger 
age, oestrogen receptor-positive (ER+) status and progesterone receptor-positive (PR+) status. 
Human epidermal growth factor receptor type 2 (HER2) overexpression is associated with 
poor prognosis.
Epidemiology and incidence
Incidence varies most with gender. Women are far more likely to get breast cancer than men. For 
both genders, incidence varies with age (Table 3). Just over 80% of cases occur in women aged 
≥ 50 years. In England and Wales, 2006 data demonstrate highest rates for women in the 60- to 
70-year age range.12
Incidence also varies with ethnicity. Asian, Chinese and black ethnic groups and those with 
mixed heritage have a lower incidence than the white ethnic group in England. Compared with 
the white group the rate ratios are 0.65, 0.75, 0.49 and 0.58 respectively.13
In both England14 and Wales15 those who are classed as most deprived have a lower incidence 
of breast cancer. However, there is some evidence to suggest that the trend for mortality is 
reversed, with better survival for those from more affluent areas. It is unclear why this is but 
TABLE 1 Five-year survival rates for women in England diagnosed during 2001–6
Age (years)
15–39 40–49 50–59 60–69 70–79 80–99
5-year survival rate (%) 81 86 89 87 78 64
TABLE 2 Five-year survival rates for women diagnosed in the West Midlands from 1985 to 1989 followed up to the end 
of 1999, as at January 2002
Stage of disease
I II III IV
5-year survival rate (%) 88 69 43 12
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it may be due to lower levels of screening compliance, worse overall general health status and 
lower levels of treatment because of limited access to health care16 and poorer compliance with 
treatment regimens.
Significance in terms of ill-health (burden of disease)
Breast cancer is the second largest cause of cancer death in women after lung cancer, with an 
age-standardised mortality rate of 26 per 100,000 women. In 2008 this constituted 10,716 deaths 
for women in England and Wales.17
Measurement of disease
Breast cancer has few obvious symptoms and can easily go undetected for a few years. Among the 
more noticeable symptoms are a palpable lump in the breast, a change in breast shape and skin 
appearance or changes to the nipple such as inversion, a rash or discharge.
A suspicious breast mass may be identified through screening or through presentation to a GP. 
Women between the ages of 50 and 70 years are routinely invited to attend regular screening 
(age range in the UK is changing to 47–73 years between 2010 and 2013). Screening is thought 
to have reduced breast cancer deaths in the 50–69 years age category by an estimated 6.4% in 
addition to the effects of tamoxifen, chemotherapy and earlier presentation outside of screening.18 
Screening increases the proportion of tumours detected in the early, more curable stages.
The breast mass and axillary areas are investigated clinically by palpation and mammography or 
ultrasound for younger women, and the status of the tumour confirmed by histology of biopsied 
tissue. Staging of the disease depends on tumour size, the number of involved lymph nodes 
and the presence or absence of distant metastases. Tumour size and axillary metastases can 
be estimated by clinical examination and imaging techniques, but definitive status is achieved 
through surgery. Those with small tumours and no axillary metastases have the best prognosis, 
whereas those with distant metastases are considered incurable.
Current methods for staging of breast cancer
Three main factors are used to stage breast cancer – tumour size, metastases to the regional 
lymph nodes and distant metastases. The tumour/node/metastases (TNM) staging system was 
developed and is maintained by the Union Internationale Contre le Cancer (UICC)19 and the 
American Joint Committee on Cancer (AJCC).20 T stage is classified according to the size of the 
tumour and degree of local infiltration; N stage is classified according to the number and location 
of metastases to the lymph nodes in the axilla, between the ribs (internal mammary nodes) 
and above or below the collarbone (supraclavicular and infraclavicular nodes); and M stage is 
classified by the presence of metastases beyond the breast and regional lymph nodes (Table 4).
TABLE 3 Incidence per 100,000 for England and Wales by age group and gender, 2006 
Age (years)
0–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
Women
Wales 0 2 21 64 123 186 256 286 324 328 254 201 199 213
England 0 8 20 53 141 185 270 274 321 327 252 190 183 202
Men
Wales 0 0 0 0 0 1 1 1 1 2 0 2 1 0
England 0 0 0 0 0 1 2 2 2 0 5 1 3 2
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The overall TNM stage of the cancer is defined as in Table 5. Early breast cancer is generally 
defined as cancer that has not spread beyond the breast or the ipsilateral axillary lymph nodes 
and which is confined to stages I, II or IIIA.21–23
TABLE 4 Descriptions of T, N and M stages
Description
T: tumour stage
Tx Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour ≤ 2 cm across
T2 Tumour 2–5 cm across
T3 Tumour > 5 cm across
T4 Tumour of any size with direct extension to skin or chest wall, or inflammatory breast cancer
N: lymph node stage
Nx Nodal stage cannot be assessed
N0 No metastases to any ipsilateral lymph nodes
N1 Metastases to one to three axillary nodes or axillary nodes that are mobile
N2 Metastases to four to nine axillary nodes, or axillary nodes that are fixed to one another or other structures, or clinically apparent metastases 
to internal mammary nodes
N3 Metastasis to nodes above or below the collarbone (supraclavicular/infraclavicular), or to both axillary and internal mammary nodes, or to 10+ 
axillary nodes
M: metastasis stage
Mx Presence of metastases cannot be assessed
M0 No distant metastases
M1 Distant metastases
Sources: Cancer Research UK21 and American Cancer Society.24
TABLE 5 Summary of TNM stages
Stage T N M
0 (DCIS/LCIS) Tis N0 M0
I T1 N0 M0
IIA T0–1 N1 M0
T2 N0 M0
IIB T2 N1 M0
T3 N0 M0
IIIA T0–2 N2 M0
T3 N1–2 M0
IIIB T4 N0–2 M0
IIIC T(any) N3 M0
IV T(any) N (any) M1
Sources: Cancer Research UK21 and American Cancer Society.24
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Current service provision
Management of early breast cancer
Patients diagnosed with early breast cancer currently follow the diagnosis/treatment pathway 
described in Figure 1.
Breast needle-core
biopsy diagnosis of
cancer
IHC for ER and
HER2
HER2 result
equivocal?
Assess ER and HER2
status, age,
suitability for
surgery
Neoadjuvant
chemotherapy,
e.g. poor prognosis
large tumour
Secondary surgical
resection
Assess with
post-operative
results from
resection specimen
Adjuvant
chemotherapy
Endocrine therapy
only
Adjuvant
chemotherapy and
endocrine therapy
Yes
No
FISH for HER2
Primary endocrine
therapy,
e.g. ER+ unfit for
surgery
Failure of
endocrine therapy
Primary surgical
resection
FIGURE 1 Diagnosis and management pathway in breast cancer. FISH, fluorescence in situ hybridisation; IHC, 
immunohistochemistry.
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Current guidelines
Current National Institute for Health and Care Excellence (NICE) clinical guidelines (CG80)7 
indicate that adjuvant therapy should be considered for all patients with early invasive breast 
cancer after surgery, based on assessment of the prognostic and predictive factors and the 
potential benefits and side effects of the treatment. These guidelines do not make specific 
reference to the use of gene expression profiling (GEP) or expanded immunohistochemistry 
(IHC) tests to aid decision-making. The guidelines do indicate that decisions should be made 
following discussion of these factors with the patient and recommend consideration of the use 
of Adjuvant! Online to support estimations of individual prognosis and the absolute benefit of 
adjuvant treatment for patients with early invasive breast cancer.7 The NPI is also commonly used 
as the basis for many local guidelines on the management of chemotherapy for patients with early 
breast cancer.
Adjuvant! Online
The Adjuvant! Online computer program is designed to provide estimates of the benefits of 
adjuvant endocrine therapy and chemotherapy. The current version of Adjuvant! Online does not 
include HER2 status and the potential benefit of trastuzumab. Patient and tumour characteristics 
are entered into the programme and provide an estimate of the baseline risk of mortality or 
relapse for patients without adjuvant therapy. Information about the efficacy of different therapy 
options is derived from Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-
analyses in order to provide estimates of the reduction in risk at 10 years of breast cancer-related 
death or relapse for selected treatments. These estimates are then provided on printed sheets in 
simple graphical and text formats to be used in consultations.
Nottingham Prognostic Index
The NPI is a composite prognostic parameter involving both time-dependent factors and aspects 
of biological aggressiveness. The NPI score is based on a mix of grade, lymph node involvement 
and tumour size. The score is calculated as follows: add numerical grade (1, 2 or 3), lymph 
node score (negative = 1, one to three nodes = 2, more than three nodes = 3) and 0.2 × tumour 
size in cm. Patients can be divided into three prognostic groups on the basis of the NPI score: 
a good prognostic group (NPI < 3.4), a moderate prognostic group (3.4 < NPI < 5.4) and a poor 
prognostic group (NPI > 5.4).
Clinical opinion suggests that there is wide variation in clinical practice between trusts in the UK, 
with some centres using Adjuvant! Online and/or NPI, in addition to other clinical parameters.
Description of technologies under assessment
Gene expression profiling and expanded IHC tests aim to improve the use of chemotherapy in 
breast cancer by improving the stratification of patients and identification of those patients who 
will gain most benefit from chemotherapy. These tests typically report two types of information 
– breast cancer subtype and/or risk of recurrence. Tests developed to provide information on 
subtypes can be used either before surgery for informing decisions on neoadjuvant therapy or 
after primary surgery for informing decisions on adjuvant chemotherapy. Tests predicting the 
risk of recurrence in a specific population are likely to be used after surgery, in conjunction 
with other information available about tumour size, grade, etc., to guide the use of adjuvant 
chemotherapy. These tests are typically indicated for women with ER+ and LN– tumours (and 
sometime LN+ tumours if number of nodes is small).
In conjunction with other information available about tumour size, grade, etc., test results 
are likely to be used to guide the decision on which patients should be offered adjuvant 
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chemotherapy. Tests that require samples to be sent away for central review following surgery 
may introduce a short delay (of up to 2–3 weeks) before the decision can be taken on whether or 
not to offer chemotherapy.
Nine tests were identified in the NICE scope25 and are included in this assessment: six are based 
on GEP and three on IHC (protein expression profiling) technology.
Gene expression profiling
Gene expression profiling tests assess the identity and number of messenger ribonucleic acid 
(mRNA) transcripts in a specific tissue sample. As only a fraction of the genes encoded in the 
genome of a cell are expressed by being transcribed into mRNA, gene expression profiling 
provides information about the activity of genes that give rise to these mRNA transcripts. Given 
that mRNA molecules are translated into proteins, changes in mRNA levels are ultimately related 
to changes in the protein composition of the cells, and consequently to changes in the properties 
and functions of tissues and cells (both normal and malignant) in the body.
Various assays are used in the management of breast cancer. These assays investigate the 
expression of specific panels of genes (also known as a gene profile or gene signature). 
They work by making use of different techniques to measure mRNA levels in breast cancer 
specimens, including real-time reverse transcription-polymerase chain reaction (RT-PCR) and 
deoxyribonucleic acid (DNA) microarrays. Many of these assays have been designed to measure 
the risk of cancer recurrence. Other uses of the assays include breast cancer subtyping (using 
molecular classification systems), predicting the likely benefit from certain types of therapy (e.g. 
chemotherapy) and diagnosing breast cancer.
There are various ways of preparing the RNA and different protocols are used to prepare the 
specimens [e.g. formalin-fixed paraffin-embedded (FFPE), snap-frozen and fresh samples]. Most 
UK hospitals currently base their pathology services around FFPE tissue and therefore the use of 
tests requiring fresh samples would raise major service configuration issues. Furthermore, there 
are varying algorithms that can be used to combine the raw data to obtain a summary measure. 
All of these factors can affect the reproducibility and reliability of GEP tests.
These tests provide an estimate of the risk of recurrence and/or information about the intrinsic 
molecular subtype of cancer. The definition of risk group varies between tests, that is, patients 
classified as high risk by the OncotypeDX test will be at a different level of risk from patients 
classified as high risk by the Mammostrat test. The definition of subtype is typically based on the 
classification system first described by Perou et al.26 in 2000 and refined to include five groups 
– luminal A, luminal B, HER2 amplified, basal-like and unclassified. Subtype information can 
potentially be used to provide an indication of risk. For instance, cancers identified as luminal 
A typically have better prognosis than those identified as luminal B and this information may 
therefore aid in the risk stratification of ER+ tumours.
The six gene expression profiling tests that are included are as follows:
1. The Randox Breast Cancer Array (BCA) (Randox Laboratories, Crumlin, UK) is a 
complementary DNA (cDNA)-based expression biochip assay that aims to accurately 
define the clinical subtypes of breast cancer tumours before initiating treatment. The target 
population is all individuals with diagnosed breast cancer.
2. MammaPrint® (Agendia, Amsterdam, the Netherlands) is based on microarray technology 
and uses a 70-gene expression profile. MammaPrint is intended as a prognostic test for 
women of all ages, LN– and LN+ (up to three nodes positive), with a tumour size of ≤ 5.0 cm. 
MammaPrint is used to determine the risk of distant recurrence of early breast cancer. 
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Patients are stratified into two distinct groups – low risk (good prognosis) or high risk (poor 
prognosis) of distant recurrence. It is cleared by the Food and Drug Administration as an in 
vitro diagnostic multivariate index assay.
3. BluePrint™ (Agendia, Amsterdam, the Netherlands) is used in addition to the MammaPrint 
test for molecular subtyping. It is an 80-gene microarray with a target population of patients 
with early-stage (stage I or II), LN– or LN+ (up to three nodes positive), ER+ or ER– breast 
cancer. BluePrint provides information on breast cancer subtype using three categories: 
basal-type, luminal-type and ERBB2-type cancers.
4. The PAM50 gene expression assay (ARUP Laboratories, Salt Lake City, UT, USA) identifies 
the major intrinsic biological subtypes of breast cancer. The current version of the test 
provides classification of breast cancer subtype and quantitative values for (gene/protein) 
ESR1/ER, PGR/PR, ERBB2/HER2, proliferation score and luminal score (ER pathway). The 
PAM50 Breast Cancer Intrinsic Classifier test is recommended for all patients diagnosed with 
invasive breast cancer, regardless of stage or ER status.
5. OncotypeDX™ (Genomic Health Inc., Redwood City, CA, USA) quantifies gene expression 
for 21 genes in breast cancer tissue using RT-PCR. It predicts the likelihood of recurrence in 
women of all ages with newly diagnosed stage I or II, ER+, LN– or LN+ (up to three nodes) 
breast cancer treated with tamoxifen. The test assigns the breast cancer a recurrence score 
(RS) and a risk category: low (RS < 18), intermediate (18 ≤ RS ≤ 30) or high (RS ≥ 31). The test 
also reports ER, PR and HER2 status.
6. The Breast Cancer Index (BCI)℠ (bioTheranostics Inc., San Diego, CA, USA) is a RT-PCR 
assessment of the ratio of expression of two genes, HOXB13 and IL17BR, combined with the 
five gene Molecular Grade Index (MGI) and gives an indication of recurrence risk. The target 
population is those with ER+ and LN– early breast cancer. The BCI RS ranges from 0 to 10 
and divides patients into three risk groups: low risk is defined as a score < 5, intermediate risk 
is a score of 5–6.3 and high risk is a score ≥ 6.4.
Key details of the individual GEP tests are provided in Table 6.
Expanded immunohistochemistry (protein expression profiling) tests
Immunohistochemistry markers are being developed to provide similar information to that given 
by the GEP tests. Some of these tests offer the advantage of using existing IHC technology (such 
as ER and HER2 markers), which is routinely available in all UK pathology departments.
The three included expanded IHC tests for protein expression are:
1. The IHC4 test (academic sponsor: Royal Marsden Hospital and Queen Mary, University of 
London) assesses the levels of four key proteins in a breast cancer sample: ER, PR, HER2 
and Ki-67. The IHC4 score is calculated based on the percentage of cells positive for Ki67 
and PR (0–100%); the Histoscore (a measure of the percentage of cells positive multiplied 
by the intensity, range 0–300) for ER status; and the tumour HER2 status, expressed 
as a binary measure (positive/negative). The final algorithm for IHC4 calculates a risk 
score for distant recurrence based on ER, PR, HER2 and Ki-67 in addition to classical 
clinical and pathological variables (composite risk score IHC4 + clinical score referred 
to as IHC4 in our report). Of note, an online calculator is expected to be available at the 
beginning of 2012 (Professor Mitch Dowsett, Royal Marsden Hospital, London, July 2011, 
personal communication).
2. The Mammostrat test uses five immunohistochemical markers [solute carrier family 7 
(amino acid transporter light chain, L system), member 5 (SLC7A5), HpaII tiny fragments 
locus 9c protein (HTF9C), protein 53 (p53), N-myc downstream regulated 1 (NDRG1) 
and carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)] to stratify 
patients into risk groups to inform treatment decisions. These markers are independent of 
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one another and do not directly measure either proliferation or hormone receptor status. The 
test calculates a relative risk of recurrence through the use of a weighted algorithm, which 
is interpreted in the context of published clinical studies of appropriate patient populations. 
Patients are classified into three risk categories: prognostic index ≤ 0, defined as the low-risk 
group; prognostic index > 0 and ≤ 0.7, defined as the moderate-risk group; and prognostic 
index > 0.7, defined as the high-risk group.
3. NPI plus (NPI+) (University of Nottingham) is a biomarker-based prognostic assay that 
integrates 10 predictive biomarkers [ER, PR, HER2, cytokeratin s/b (CK5/6), CK7/8, 
epidermal growth factor receptor (EGFR), HER3, HER4, p53, mucin 1 (MUC1; cell surface 
associated)] of long-term survival and therapeutic response with existing clinical and 
molecular pathology knowledge to support individualised clinical decision-making. This test 
is under development and outputs/presentation are not yet finalised.
Key details of the individual IHC tests are provided in Table 7.
TABLE 6 Gene expression profiling tests
OncotypeDX MammaPrint PAM50 BCI BluePrint Randox BCA
Function Risk of 
recurrence 
Risk of 
recurrence
Subtyping Risk of recurrence Subtyping – to 
be used after 
MammaPrint
Subtyping
Technology RT-PCR 
(21 genes)
Microarray  
(70 genes) 
Microarray  
(55 genes)
RT-PCR, 
HOXB13 : IL17BR ratio 
and Molecular Grade 
Index (seven genes)
Microarray  
(80 genes) 
Low-density 
biochip array 
Location of 
testing
Central testing 
– USA 
Central testing – 
Amsterdam and 
Irvine, USA
Central Central Central testing 
– USA 
Local – purchase 
of array 
processing unit 
Type of sample FFPE Fresh (use of 
FFPE to be 
introduced in 
2012) 
FFPE FFPE Fresh Fresh
Staining material Resection/core 
biopsy
Resection Resection/core 
biopsy
Resection Resection/core 
biopsy
Resection/core 
biopsy
Population ER+, LN–; also 
LN+ (one to 
three nodes)
ER+ (or ER–), 
LN– and LN+ 
(one to three 
nodes)
All women ER +, LN– All – previously 
split into risk 
group by 
MammaPrint
All women
Key output of test RS score – 
point estimate 
of the 10-year 
risk of 
recurrence
Risk of 
recurrence 
score – high/
low (based 
on distant 
recurrence at 
5 years) 
Five subtypes: 
luminal A, luminal 
B, HER2, basal-
like and normal-
like 
BCI RS Three subtypes: 
basal-type, 
luminal-type 
and ERBB2-type 
cancers
Five subtypes: 
luminal A, luminal 
B, HER2, basal-
like and normal-
like
Presentation of 
results
RS and 
risk group 
(low < 18, 
intermediate 
18–30, high 
≥ 31)
Two categories: 
low and high risk 
Subtype and 
quantitative 
values for 
proliferation, 
luminal gene 
expression, ESR1, 
PGR and ERBB2
Risk score: 0–10. 
Three risk groups: 
(low ≤ 5, intermediate 
5 –6.3, high ≥ 6.4) 
and 10-year risk of 
distant recurrence
Subtype Unknown
Commercially 
available in the 
UK
Yes Yes Yes Yes Yes No
Cost £2580 £2675 US$3200 US$3200 (assuming 
20% discount)
No additional cost 
(over and above 
MammaPrint)
Unknown
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Current usage of gene expression profiling and expanded 
immunohistochemistry tests in the NHS
Use of these tests has been limited within the NHS to date. The OncotypeDX test has been 
available in the UK since 2007.27 There are two ongoing clinical trials for OncotypeDX with some 
UK recruitment. Outside of this the use of OncotypeDX in the NHS appears to be relatively 
limited, with a small amount of self-funding by NHS patients, occasional primary care trust 
funding and charitable funding. Private health insurers offer reimbursement on a case-by-case 
basis. Use of the other GEP and expanded IHC tests appears to be negligible.
Cost of the tests
The cost of each test is included in Tables 6 and 7.
Fresh tissue collection is not routine in the NHS and so there will be additional costs associated 
with tests requiring fresh tissue samples. These costs could be considerable at hospitals where the 
dissection facilities are already filled to capacity (which is likely to be a significant proportion of 
hospitals) and where explicit staffing for collection of fresh tissue is not already in place. This is 
discussed further in Chapter 3, Model inputs: general.
Description of the decision problem
Background
Since 2002 NICE has recommended that women at intermediate or high risk of recurrence who 
have not had neoadjuvant chemotherapy should normally be offered a multiagent chemotherapy 
that includes anthracyclines.28 Chemotherapy is defined as the use of cytotoxic medications 
with the intention of preventing cancer recurrence in patients. It should be noted that, for the 
purposes of this assessment, chemotherapy does not include other forms of systemic therapy 
such as endocrine treatments or targeted biological therapy (trastuzumab).
Meta-analyses of randomised controlled trials (RCTs) by the EBCTCG have indicated that the 
use of adjuvant chemotherapy (chemotherapy following surgery) is associated with a reduction in 
TABLE 7 Expanded IHC tests
IHC4 NPI+ Mammostrat
Function Risk of recurrence Subtyping and risk of recurrence Subtyping and risk of recurrence
Technology Combines four IHC tests and clinical 
parameters to derive prognostic score
Uses 10 biomarkers to derive 
prognostic score (plus others – to be 
defined) 
Uses five biomarkers to derive risk 
score
Location of testing Local? (but quality assurance issues 
need to be addressed)
Not known Central 
Type of sample FFPE FFPE FFPE
Staining material Resection/core biopsy Resection/core biopsy Resection/core biopsy
Population Postmenopausal, ER+, LN– All women, age 18–79 years ER+, LN–, tamoxifen treated
Key output of test Continuous IHC4 score Not yet finalised. To include biological 
class and projected survival 
Risk index and risk group 
Presentation of results IHC4 risk score Not yet finalised. Likely to be similar 
to Adjuvant! Online
Risk groups: high, moderate and 
low
Commercially available 
in the UK
Algorithm available. Quality assurance 
issues to be addressed
No No
Cost Approx. £100–200 Approx. £500 Approx. £1120–1620
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the risk of relapse and death in women with early-stage breast cancer.29 Although chemotherapy 
can reduce the likelihood of cancer recurrence and death for women with breast cancer, it has 
considerable adverse effects. Short-term and long-term adverse events will affect a proportion of 
patients receiving chemotherapy, imposing costs and reducing quality of life. Short-term adverse 
events that occur during chemotherapy are usually temporary and reversible. The most common 
side effects include nausea, vomiting, mouth soreness, diarrhoea, tiredness, hair loss and 
temporary lowering of the blood counts. Long-term side effects such as damage to the heart and 
a small increase in the risk of leukaemia are not reversible. Although chemotherapy may prevent 
relapse in some, not all women with early-stage breast cancer will benefit and many women 
remain recurrence free at 10 years without chemotherapy. However, a subset of patients with a 
‘good’ prognosis may still develop recurrence after curative surgery and adjuvant therapy. This 
presents a great challenge to clinicians in estimating prognosis and making the most appropriate 
therapeutic decisions relating to whether or not to use adjuvant chemotherapy in women with 
early-stage breast cancer.
Recommendations about which patients should receive chemotherapy are typically based on 
estimations of recurrence risk and expected benefit of therapy. Historically, clinicopathological 
factors, such as patient age, tumour size, nodal involvement, histological grade, ER expression, 
HER2 overexpression and comorbidities, have been assessed and considered alongside patient 
preference. In the UK, guidelines based on NPI and Adjuvant! Online have been developed to 
assist decision-making relating to adjuvant chemotherapy. These guidelines assist clinicians 
in deciding the benefits of prescribing chemotherapy for a particular patient. NPI provides 
information about prognosis that is largely based on pathological parameters (e.g. tumour size, 
grade and lymph node status), with the addition of ER receptor status, age and comorbidity for 
Adjuvant! Online. However, these clinicopathological tools are imperfect; different guidelines 
can give different results and it has been suggested that a proportion of women with early-stage 
breast cancer are over- or undertreated. This may result in unnecessary use of toxic and expensive 
chemotherapy for women who derive little or no benefit, or avoidable deaths in women for whom 
chemotherapy was withheld.
Role of new tests
Gene expression profiling and expanded IHC tests aim to improve the targeting of chemotherapy 
in breast cancer by improving the stratification and identification of patients who will gain most 
benefit from chemotherapy. The new tests will provide an indication of the risk of recurrence 
of patients (based on the results of an algorithm to estimate risk of recurrence or indirectly by 
identifying the cancer subtype). This is based on the knowledge that certain biological features 
of cancers may indicate an increased likelihood of rapid growth and metastatic potential. The 
management of these patients, that is, the decision whether or not to prescribe chemotherapy, 
will be influenced by the test results, and this may result in a change of management of patients 
compared with current practice (a decision made based on NPI and/or Adjuvant Online). By 
more accurately guiding the selection of patients to receive adjuvant chemotherapy in early 
breast cancer management, the use of GEP or expanded IHC tests in patients with early-stage 
breast cancer may improve health outcomes and quality of life compared with currently used 
decision-making protocols.
Comparators
The comparator is standard UK practice. This varies between trusts and encompasses the use of 
Adjuvant! Online and/or guidelines based on NPI to guide decisions on which patients with early 
breast cancer should be offered adjuvant chemotherapy.
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Identification of important subgroups
The NICE scope25 identifies the population under assessment as people diagnosed with early 
breast cancer. However, many of the GEP and expanded IHC tests have been developed for 
use in a specific subpopulation or currently have evidence of efficacy only within a specific 
subpopulation. For tests providing a risk of recurrence output, the majority of evidence relates 
to populations with ER+, LN– early breast cancer. Some of these tests also have more limited 
evidence in LN+ populations (for patients with one to three nodes involved) and in patients with 
ER– disease.
These tests will have an impact on the health of patients only if they lead to changes in patient 
management. This is most likely to happen in populations in which the decision on whether or 
not to offer chemotherapy is currently uncertain. One such group is patients with ER–, LN–, 
HER2– early breast cancer for whom prognostic factors suggest that they are at intermediate risk. 
The definition of this ‘intermediate group’ is not clear-cut. Clinical advice suggests that patients 
with a NPI score of ≤ 3.4 are typically considered at low risk either using current prognostic tools 
(except for a few very young women with aggressive early breast cancer) or based on the new 
tests and are unlikely to receive chemotherapy; therefore, their management is unlikely to change. 
Few patients with ER–, LN–, HER2– early breast cancer will have a NPI score > 5.4 and therefore 
those with a NPI score > 3.4 can be considered as being at intermediate risk.
Current treatment protocols indicate that women with HER2+, ER– early breast cancer or with 
several positive nodes are likely to receive chemotherapy in most centres in England and Wales. 
Although the use of GEP or expanded IHC tests might be able to spare chemotherapy in a 
proportion of these patients, the evidence base for the use of these tests in this population is more 
limited and clinical opinion therefore considered the assessment of these tests in this population 
to be a lower priority.
Patients with ER+ LN–, HER2– early breast cancer are therefore considered to be an important 
population in which to assess these tests, given the current evidence base. Within this population 
those at intermediate risk for whom the decision about whether or not to offer chemotherapy is 
not clear cut are considered to be an important subgroup.
Outcomes
The clinical effectiveness review will consider the clinical effectiveness of the tests in relation to:
 ■ Analytical validity (i.e. the ability of the test to accurately and reliably measure the expression 
of mRNA or proteins by breast cancer tumour cells).
 ■ Clinical validity (i.e. the degree to which the test could accurately predict the risk of an 
outcome such as disease recurrence and discriminate patients with different outcomes). This 
relates to the prognostic ability of the test.
 ■ Clinical utility (i.e. the ability of the test to discriminate between those who will have more 
or less benefit from a therapeutic intervention). This includes evidence relating to how the 
tests will influence decision-making in terms of which patients will be offered chemotherapy 
and evidence relating to the predictive ability of the test, that is, the extent to which the test 
identifies those patients who will benefit most in terms of the relative reduction in the risk of 
recurrence from treatment.
The outcomes of interest for the economic evaluation are the morbidity and mortality associated 
with invasive breast cancer and its treatment. Outcomes from the model are expressed in terms of 
cost per quality-adjusted life-year (QALY).
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Aim and objectives of the assessment
The overall aim of the assessment is to assess the clinical effectiveness, effect on patient outcomes 
and cost-effectiveness of the new GEP and expanded IHC tests.
The objectives of the assessment are:
 ■ To conduct a systematic review of the published evidence on the clinical effectiveness 
and cost-effectiveness of the nine GEP and expanded IHC tests. In relation to clinical 
effectiveness, evidence relating to the following outcomes will be sought:
 – analytical validity – the ability of the test to accurately and reliably measure the 
expression of mRNA or proteins by breast cancer tumour cells
 – clinical validity – the degree to which the test can accurately predict the risk of an 
outcome (typically distant recurrence) and discriminate patients with different 
outcomes; this relates to the prognostic ability of the test
 – clinical utility – the ability of the test to discriminate between those who will have more 
or less benefit from a therapeutic intervention.
 ■ To develop a decision model to investigate the benefits, harms and cost-effectiveness of the 
GEP and expanded IHC tests compared with current prognostic tools to guide the use of 
adjuvant chemotherapy in early breast cancer. Outcomes from the model are expressed in 
terms of cost per QALY.
Note
This report contains reference to confidential information provided as part of the NICE appraisal 
process. This information has been removed from the report and the results, discussions and 
conclusions of the report do not include the confidential information. These sections are clearly 
marked in the report.
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Chapter 2 
Assessment of clinical effectiveness
A systematic review of the evidence on the clinical effectiveness of nine GEP and expanded IHC tests to guide the use of adjuvant chemotherapy in breast cancer management was 
undertaken according to the general principles recommended in the Centre for Reviews and 
Dissemination (CRD) guidance for undertaking systematic reviews,30 the Preferred Reporting 
Items for Systematic Reviews and Meta-analysis (PRISMA) statement31 and the NICE 
Diagnostic Assessment Programme Interim Methods Statement.32 The review protocol can 
be accessed at www.nice.org.uk/nicemedia/live/13283/54425/54425.pdf and is registered as 
PROSPERO 2011:CRD4201100136, available from www.crd.york.ac.uk/PROSPERO/full_doc.
asp?ID=CRD42011001361.
In addition to the systematic review evidence, a separate section summarising supplementary 
evidence provided by the manufacturers of the tests will be presented within the section relating 
to each test. This evidence will simply be summarised and will not be subject to the stages of the 
systematic review as it is not evidence derived as part of the systematic review process.
Methods for reviewing effectiveness
Background context
The present review evaluates nine prognostic tests for guiding chemotherapy treatment decisions 
in early-stage breast cancer.
For two of the nine tests (OncotypeDX and MammaPrint) the current review updates an existing 
systematic review of GEP tests for breast cancer. Two previous systematic reviews33,34 reviewed 
the literature relating to both OncotypeDX and MammaPrint (one34 is an update of the other33). 
In the Marchionni et al.33 review the authors conducted an exhaustive literature review of 
various electronic databases (covering biomedical literature) between 1990 and 2006. Additional 
sources included the grey literature (conference proceedings), hand searching the reference 
lists of included studies and pertinent reviews, contacting the manufacturers of the two tests 
and regulatory authorities and querying experts in the field. In the Smartt review,34 the authors 
updated the Marchionni et al.33 review by updating the search strategy to include all relevant 
available literature between January 2007 and December 2009. Further details are provided in 
Overview of existing systematic reviews of the OncotypeDX and MammaPrint tests.
In the present review, new search strategies were developed for all of the nine tests based 
on scoping searches (and strategies reported in the two existing systematic reviews for the 
OncotypeDX and MammaPrint tests).
Identification of studies
Electronic databases
Studies were identified by searching the following electronic databases:
 ■ MEDLINE (via Ovid SP) 1950–May 2011
 ■ MEDLINE In-Process & Other Non-Indexed Citations (via Ovid SP) 1950–May 2011
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 ■ EMBASE (via Ovid SP) 1980–May 2011
 ■ Cochrane Central Register of Controlled Trials (CENTRAL) (via Cochrane Library Issue 3, 
2011)
 ■ Cochrane Database of Systematic Reviews (CDSR) (via Cochrane Library Issue 8, 2011)
 ■ NHS Database of Abstracts of Reviews of Effects (DARE) (via Cochrane Library Issue 3, 
2011)
 ■ Health Technology Assessment (HTA) database (via Cochrane Library Issue 3, 2011)
 ■ BIOSIS previews (via Ovid SP) 1926–May 2011
 ■ Web of Science (includes Science Citation Index and Conference Proceedings Citation 
Index) (via WOK) 1899–May 2011.
Extensive searches were undertaken to identify all literature relating to the clinical effectiveness 
of GEP and expanded IHC tests to guide the use of chemotherapy in breast cancer management. 
Sensitive keyword strategies using free text and, where available, thesaurus terms using Boolean 
operators and database-specific syntax were developed to search the electronic databases. 
Synonyms related to the condition (i.e. breast cancer) were combined with synonyms related to 
the test (i.e. MammaPrint, OncotypeDX, Randox BCA, BluePrint, PAM50, BCI, IHC4, NPI+).
Searches were not restricted by publication type or language; however, all searches were limited 
by date. For the OncotypeDX and MammaPrint tests, the searches were restricted to January 
2009–May 2011 as the search strategies from the existing systematic reviews appear to be of 
good quality and are clearly reported and, as a result, all studies up to 2009 would have been 
identified. For the remaining seven tests, the searches were restricted to January 2002–May 2011. 
The first evidence for the GEP and expanded IHC tests was reported in 2002 for OncotypeDX 
and MammaPrint. As these are the most established tests and the furthest along the validation 
pathway, evidence for subsequent tests will not predate this. An example of the MEDLINE search 
strategy is provided in Appendix 1.
Other resources
To identify additional published, unpublished and ongoing studies, the reference lists of all 
relevant studies (including existing systematic reviews) and information received by the 
manufacturers were hand searched and key experts in the field were contacted.
All identified citations from the electronic searches and other resources were imported into 
and managed using the Reference Manager bibliographic software version 12.0 (Thomson 
ResearchSoft, San Francisco, CA, USA).
Inclusion and exclusion criteria
The inclusion of potentially relevant articles was undertaken using a two-stage process. First, 
one experienced systematic reviewer screened all titles and abstracts and excluded any citations 
that clearly did not meet the inclusion criteria. Second, the full manuscripts of all potentially 
eligible articles were assessed for inclusion by the same reviewer. At each step, articles that did 
not satisfy the inclusion criteria were excluded. Any uncertainties in the selection process were 
resolved through discussion with a second reviewer. The relevance of each article for the clinical 
effectiveness review was assessed according to the following criteria.
Population
All people diagnosed with early invasive breast cancer being treated in the adjuvant setting were 
included. People diagnosed with early invasive breast cancer being treated in the neoadjuvant 
setting were excluded.
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Index test
The following GEP tests or expanded IHC tests (that guide treatment decisions in early breast 
cancer management) were included:
 ■ OncotypeDX
 ■ MammaPrint
 ■ BluePrint
 ■ PAM50
 ■ BCI
 ■ Randox BCA
 ■ Mammostrat
 ■ IHC4
 ■ NPI+.
Reference standard
There was no existing reference standard for the index tests.
Comparator
For studies of clinical validity and clinical utility, relevant comparators were those used in current 
UK clinical practice. Specifically, studies with Adjuvant! Online and/or NPI as comparators 
to predict risk of recurrence and survival for patients with early breast cancer were sought, 
although studies including other comparators and those without a comparator were eligible for 
inclusion. Further details of the comparators are included in Description of technologies under 
assessment (it should be noted that, by definition, no comparator was necessary for studies of 
analytical validity).
Outcomes
The following outcome measures (where reported) were included:
 ■ Analytical validity – the ability of the test to accurately and reliably measure the expression of 
mRNA or proteins by breast cancer tumour cells, that is, repeatability and reproducibility.
 ■ Clinical validity – the degree to which the test can accurately predict the risk of an outcome 
(typically distant recurrence) and discriminate patients with different outcomes. This relates 
to the prognostic ability of the test – does the test have evidence on clinical validity and has 
this been externally validated (in an independent data set).
 ■ Clinical utility – the ability of the test to discriminate between those who will have more or 
less benefit from a therapeutic intervention.
Clinical utility relates to improvements in clinical outcomes such as overall survival (OS), 
disease-free survival (DFS), chemotherapy toxicity or quality of life. Based on the conclusion of 
previous reviews it is not anticipated that prospective studies reporting on long-term outcomes 
such as OS will be available. In the absence of such studies the following outcomes were to 
be included:
 ■ Reclassification of risk compared with existing prognostic variables (correlations between 
test score and score on existing measures such as NPI, Adjuvant! Online), that is, how does 
the test change the classification of risk for patients.
 ■ Impact of the test results on clinical decision-making – how do the tests results translate into 
changes in decision-making, for example changes in the proportion of patients receiving 
adjuvant chemotherapy.
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 ■ Predictive ability of the test – does the test accurately predict patients who will benefit most 
from chemotherapy, that is, do patients classified as high risk benefit more in relative terms 
than patients classified as low risk.
 ■ Quality of life – directly as a result of knowledge of the test score (e.g. reduction in anxiety) 
or indirectly through changes in the use of chemotherapy (and consequent changes in quality 
of life).
Study design
All study designs were included. For the outcome of analytical validity, studies incorporating any 
pathology method were included. For the outcomes of clinical validity and clinical utility, priority 
was given to prospective RCT data if available. In the absence of these data prospective and 
retrospective cohort studies and case–control studies with and without a comparator were eligible 
for inclusion.
Reviews of primary studies were not included in the review of clinical effectiveness but were 
retained for discussion and identification of additional studies. The following publication types 
were excluded from the review: animal models, preclinical and biological studies, editorials, 
opinions, studies applied only to breast cancer biology, studies published only in languages other 
than English (unless no other comparable data exist) and non-peer-reviewed reports in which 
insufficient methodological details are reported to allow critical appraisal of the study quality.
Data abstraction strategy
Data abstraction was performed by one reviewer into a standardised data extraction form 
and independently checked for accuracy by another reviewer. Discrepancies were resolved by 
discussion and if agreement could not be reached a third reviewer was consulted. When multiple 
publications of the same study were identified, data were extracted and reported as a single study. 
Where appropriate, the authors of the studies (or the manufacturer/sponsor of the test) were 
contacted to provide further details in cases in which information was missing from the articles.
The following information was extracted for all studies when reported: study details [author, year 
of publication, country, study design, number of eligible patients, number of included patients, 
follow-up time, evidence type (analytical validity, clinical validity, clinical utility), funding], 
patient characteristics (age, lymph node status, ER status, tumour size, grade, HER2 status, mean 
NPI score, and treatment) and results [outcomes/end points, results (in the format presented 
in the study), authors’ conclusions]. Numerical data extracted from the studies were varied and 
included the following: numbers and percentages of patients having a change in management as a 
result of the test, association between test score and risk of outcomes [distant recurrence, time to 
distant recurrence (TTDR)] [p-values and associated hazard ratios and 95% confidence intervals 
(CIs)], correlation between test score and comparator score, differences (p-values) between cases 
and control subjects on test score.
Critical appraisal strategy
There are no validated (or widely agreed) tools for the assessment of prognostic (predictive 
factor) studies and there is little empirical evidence to support the importance of particular study 
features affecting the reliability of findings, including the avoidance of bias. Although there are 
several published quality assessment checklists for assessing prognostic studies in cancer,35,36 
they vary considerably, both in their content and complexity. For this review a generic list of 
important methodological features recommended by Altman37 was deemed to be the most 
appropriate (useful) to assess the internal validity of the included studies. Further details on the 
methodological assessment tool are provided in Appendix 2.
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The methodological quality of each included study was assessed by one reviewer and checked by 
another reviewer using the criteria recommended by Altman.36 Any discrepancies were resolved 
by discussion, with involvement of a third reviewer when necessary. Blinding of the quality 
assessor to author, institution or journal was not considered necessary. The quality assessment 
items recommended by Altman employed six dimensions relating to the risks of bias of 
prognostic studies and included the following: sample of participants, follow-up of participants, 
outcome, prognostic variable, analysis and treatment subsequent to inclusion in cohort. Study 
quality was assessed with each item scored as ‘yes’, ‘no’ or ‘unclear’. When a study was reported 
in more than one publication, its quality was assessed on the basis of the combined data from all 
relevant publications. Studies were rated as high quality if they received a positive assessment of 
at least 17 out of 21 methodological quality items.
As the current review updates two existing systematic reviews of GEP tests for breast cancer 
(OncotypeDX and MammaPrint tests), the methodological quality of these two systematic 
reviews was assessed using the criteria recommended by Shea et al.38 (assessment of multiple 
systematic reviews – AMSTAR). The quality assessment checklist for assessing systematic reviews 
included items on a priori design, data extraction, literature searching, quality assessment, 
data synthesis, publication bias and conflicts of interest. Further details on the methodological 
assessment tool together with the details of the assessment of each review are provided in 
Appendix 3.
Methods of data synthesis
Studies that met the entry criteria were eligible for inclusion in meta-analyses if this was 
appropriate in terms of comparability of the study populations, outcomes and diagnostic 
thresholds, and if the studies were unlikely to be biased. However, because of the degree of 
heterogeneity, meta-analysis was not considered appropriate. The presentation of results is 
therefore limited to a narrative review. The results were grouped in separate sections by test. For 
each test a summary of the evidence in terms of evidence type, overall quality and key findings 
was presented in table form at the beginning of the results section. More detailed summaries of 
the evidence were presented in narrative form in the subsequent sections, arranged by evidence 
type. Studies relating to analytical validity were detailed first, followed by those relating to clinical 
validity and then those relating to clinical utility. The studies relating to clinical utility were 
further divided when possible by those relating to the predictive ability of the test (benefit of 
chemotherapy), reclassification of risk against existing prognostic variables, changes in treatment 
recommendations, quality of life and patient anxiety. A summary of the evidence was then 
presented, again by evidence type.
Results
This section will first provide an overview of the evidence from the two existing systematic 
reviews of GEP tests (OncotypeDX and MammaPrint) for breast cancer. Second, this section will 
present the results of the current systematic review of each of the nine tests. Where applicable, 
supplementary evidence (from the manufacturers and other sources) will also be provided.
Overview of existing systematic reviews of the OncotypeDX and 
MammaPrint tests
In January 2008, Marchionni et al.33 published a systematic review of the impact of GEP tests 
on breast cancer outcomes. The objective of the review was to examine the available evidence 
relating to the analytical and clinical validity of breast cancer GEP in predicting disease 
recurrence and the clinical utility of these tests in improving chemotherapy choices and patient 
outcomes. Three gene signatures and their commercially available tests were reviewed: the 
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OncotypeDX test, the MammaPrint test and the two-gene ratio test (HOXB13 : IL17BR) (not the 
subject of this review). In 2010, Smartt34 updated this systematic review and included all relevant 
evidence from January 2007 to December 2009.
Although a number of other systematic reviews examining GEP tests have been reported, it was 
felt that the Marchionni et al.33 and Smartt34 reviews were the most appropriate reviews to update. 
Other reviews predated those of the Marchionni et al.33 and Smartt34 reviews were considered to 
be of lower quality as they did not describe the search strategy and processes of the systematic 
review in as much detail or did not report the findings in as much detail.
The methodological quality of both systematic reviews was reasonably high (as assessed using the 
criteria recommended by Shea et al.;38 for further details see Appendix 3). Both reviews provided 
an a priori design, details of a comprehensive literature search and details of conflicts of interest 
both for the review and for the included studies and combined the findings of the studies in an 
appropriate way. Marchionni et al.33 provided details of duplicate study selection and detailed 
that data extraction had been performed by one reviewer and checked by a second, whereas this 
information was not provided for the Smartt review.34 Marchionni et al.33 stated that they had 
searched for and included grey literature as appropriate; however, although Smartt33 stated that 
the same procedure had been followed as for Marchionni et al.,33 no specific reference was made 
to searching or including grey literature. A list of included studies was provided by both reviews; 
however, a list of excluded studies was provided only for the Marchionni et al. review.33 In both 
reviews, characteristics tables for included studies were not clearly presented and appeared only 
in the appendices in the case of the Smartt review.34 Both reviews presented the methods used 
for quality assessment, although how this was actually carried out was presented in more detail 
in Smartt,33 and both reviews used study quality when formulating conclusions. Neither review 
assessed publication bias.
In total, 21 studies on the OncotypeDX test and 13 on the MammaPrint test were identified and 
included by Marchionni et al.33 and Smartt.34 A summary of the evidence type and overall quality 
of each study is provided for OncotypeDX and MammaPrint in Tables 8 and 9 respectively.
Summary of evidence: Marchionni et al.33
OncotypeDX
Marchionni et al.33 reported that OncotypeDX was furthest along the validation pathway, with 
strong retrospective evidence that it predicts distant metastasis and chemotherapy benefit to a 
clinically relevant extent over standard predictors in a well-defined clinical subgroup with clear 
treatment implications. A more detailed summary of the main results is provided in Appendix 4.
Analytical validity Marchionni et al.33 reported a number of studies on analytical validity and 
overall success rate of OncotypeDX. They concluded that evidence existed for some of the 
operational characteristics of this test but that there was limited evidence for the reproducibility 
of the test in terms of reproducibility across different samples of the same block and across 
samples from different blocks. No direct evidence was available about the effect of sample 
preparation. There was indirect evidence that the overall success rate of extracting analysable 
mRNA was fairly high. Centralisation was considered to be a current strength of OncotypeDX 
with regard to reproducibility.
Clinical validity Marchionni et al.33 reported fairly strong support for the clinical validity of 
OncotypeDX over and above that of standard clinical predictors in ER+, LN– and tamoxifen-
treated patients, with a clear treatment indication for adjuvant chemotherapy. Paik et al.47 showed 
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Ward et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced 
for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated 
with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha 
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
21 Health Technology Assessment 2013; Vol. 17: No. 44DOI: 10.3310/hta17440
TABLE 8 Existing data from Marchionni et al.32 and Smartt33 on OncotypeDX
Author (year) Evidence type Overall qualitya
bCronin et al. (2004)39 Analytical validity Not reported
bCronin et al. (2007)40 Analytical validity Not reported
bHabel et al. (2006)41 Analytical validity/clinical validity (prognosis) Not reported
bPaik et al. (2004)42 Analytical validity/clinical validity (prognosis) Not reported
bCobleigh et al. (2005)43 Analytical validity/clinical validity (prognosis) Not reported
bEsteva et al. (2005)44 Analytical validity/clinical validity (prognosis) Not reported
Bryant (2005)45 (poster)b Clinical validity (prognosis) Not reported
Hornberger et al. (2005)46 (poster)b Clinical validity (prognosis) Not reported
Paik et al. (2004)42 (poster)b Clinical validity (prognosis) Not reported
bOratz et al. (2007)48 Analytical validity/clinical utility (indirect evidence only) Not reported
bPaik et al. (2006)49 Analytical validity/clinical utility (indirect evidence only) Not reported
cGoldstein et al. (2008)50 Clinical validity Reasonably sound evidence
cWolf et al. (2008)51 Clinical validity Low-quality evidence
cAsad et al. (2008)52 Clinical utility (indirect evidence only) Low-quality evidence
cHenry et al. (2009)53 Clinical utility (indirect evidence only) Low-quality evidence
cLi et al. (2009)54 Clinical utility (indirect evidence only) Low-quality evidence
cRayhanabad et al. (2008)55 Clinical utility (indirect evidence only) Low-quality evidence
Erb et al. (2007)56 (abstract)c Clinical utility (indirect evidence only) Not reported
Gold et al. (2009)57 (abstract)c Clinical utility (indirect evidence only) Not reported
Lo et al. (2007)58 (abstract)c Clinical utility (indirect evidence only) Not reported
Shak et al. (2009)59 (abstract)c Clinical validity Not reported
a The quality of the included evidence was documented in narrative form but not categorised in the Marchionni et al. review; hence, 
overall quality was not reported for the studies included in that review. Furthermore, quality assessment for abstracts was not reported in 
either review.
b Data from Marchionni et al.33
c Data from Smartt.34
TABLE 9 Existing data from Marchionni et al.32 and Smartt33 on MammaPrint 
Author (year) Evidence type Overall qualitya
bAch et al. (2007)60 Analytical validity Not reported
bBuyse et al, (2006)61 Analytical validity/clinical validity Not reported
bGlas et al. (2006)62 Analytical validity/clinical validity Not reported
bVan’t Veer et al. (2002)63 Clinical validity Not reported
bvan de Vijver et al. (2002)64 Clinical validity Not reported
cMook et al. (2009)65 Clinical validity Reasonably sound evidence
cWittner et al. (2008)66 Clinical validity Low-quality evidence
cBueno-de-Mesquita et al. (2007)67 Clinical utility Reasonably sound evidence
Bender et al. (2009)68 (abstract)c Clinical utility Not reported
de Snoo et al. (2009)69 (abstract)c Clinical validity Not reported
Glas et al. (2008)70 (abstract)c Clinical validity Not reported
Knauer et al. (2009)71 (abstract)c Clinical validity Not reported
Saghatchian et al. (2009)72 (abstract)c Clinical validity Not reported
a The quality of the included evidence was documented in narrative form but not categorised in the Marchionni et al. review; hence, 
overall quality was not reported for the studies included in that review. Furthermore, quality assessment for abstracts was not reported in 
either review.
b Data from Marchionni et al.33
c Data from Smartt.34
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that RS was significantly correlated with DFS (p = < 0.001) and OS (p = < 0.001). RS alone was a 
better predictor of distant recurrence at 10 years than traditional clinicopathological predictors.
Clinical utility Marchionni et al.33 concluded that the Paik et al.49 study represented the strongest 
evidence for the clinical utility of the OncotypeDX test. Using data from ER+, LN– patients 
in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B20 trial, Paik et al.49 
compared a group of patients treated with tamoxifen and chemotherapy with a group treated 
with tamoxifen only. RS was found to be correlated with chemotherapy benefit, defined in terms 
of 10-year distant recurrence-free survival (DRFS), with a significant benefit from the use of 
chemotherapy in the high RS group (p = 0.001). However, in a multivariate analysis the benefit 
from chemotherapy was unclear because of large CIs in the low- and intermediate-risk groups. 
Marchionni et al.33 noted that, although prospective confirmation of these findings was required, 
this evidence provided reasonable justification in the interim for the use of the test by ER+, 
LN– women.
MammaPrint
The evidence reported by Marchionni et al.33 for MammaPrint was more limited. A more detailed 
summary of the main results is provided in Appendix 5.
Analytical validity Two technical studies60,62 provided evidence relating to the analytical validity of 
MammaPrint. Repeated gene expression measurements over time, within and across individual 
microarrays and across different laboratories, protocols, instruments and operators provided 
data on the variability and reproducibility of the test. Buyse et al.61 reported an overall success 
rate of the assay of 80.9%. Marchionni et al.33 concluded that, although these studies suggested 
that MammaPrint could be used in a clinical setting, they could not be considered to be direct 
validations of the assay. The review also noted that evidence underpinning the analytical 
validity of the test was obtained from a limited number of patients and a moderate number of 
replications. The only validation study using the MammaPrint assay (rather than the underlying 
70-gene signature) showed that only about 80% of fresh-frozen specimens were analysable.
Clinical validity Marchionni et al.33 concluded that, overall, the available published evidence 
supported MammaPrint as a better predictor of the 5-year risk of distant recurrence than 
traditional clinical predictors.61 Buyse et al.61 compared MammaPrint with Adjuvant! Online for 
prediction of distant metastases within 5 years and for death within 10 years. Similar sensitivities 
were found for both methods but a higher specificity was demonstrated for MammaPrint. 
However, the cohorts used were clinically heterogeneous, meaning that generalisations of the 
findings to a particular patient group are more difficult.
Clinical utility No evidence on the clinical utility of the test was reported.
Summary of evidence: Smartt34
The updated systematic review by Smartt34 found that the additional studies (published between 
January 2007 and December 2009) on OncotypeDX and MammaPrint addressed some but not 
all of the outstanding issues relating to the clinical validity and clinical utility of these tests. A 
summary of the main results is provided in Appendices 4 and 5.
OncotypeDX
Analytical validity No further evidence was reported.
Clinical validity Smartt34 identified two further studies50,51 on the clinical validity of OncotypeDX. 
Goldstein et al.50 reported that OncotypeDX was a more accurate predictor of relapse than 
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standard clinical features for hormone receptor-positive, chemotherapy/hormonal therapy-
treated patients and provides complementary information to standard clinicopathological 
measures. Wolf et al.51 assessed the correlation between standard clinical and pathological breast 
cancer characteristics and the RS in a cohort of Israeli breast cancer patients and compared 
the stratification of patients using the RS with that using commonly used clinical guidelines. 
Neither standard clinicopathological features nor the chosen clinical guidelines/assessment tools 
could reliably predict the RS among referred breast cancer patients. The clinical utility of these 
comparisons was not made clear.
Clinical utility Smartt34 identified four studies52,55,73,74 on the clinical utility of OncotypeDX. 
Smartt reported that the studies examined the ability of the test to predict response to treatment 
or its impact on clinical decision-making. The studies all reported a positive impact of the 
test on clinical decision-making and generally claimed that there was a reduction in the 
number of patients who were or would have been considered for chemotherapy. However, 
the studies generally had methodological weaknesses and were likely to have overestimated 
the effect/influence of the test and they were not designed to assess the effect of the test on 
clinical outcomes.
MammaPrint
Analytical validity No further evidence was reported.
Clinical validity Smartt34 identified two studies66,75 on the clinical validity of MammaPrint. Mook 
et al.75 reported that MammaPrint predicted disease outcome better than traditional clinical 
prognostic factors in patients with one to three positive nodes and was able to accurately identify 
node-positive patients with an excellent prognosis. The potential clinical utility of MammaPrint 
was demonstrated in 72 (34%) clinically high-risk patients with a good prognosis signature 
who had a 10-year breast cancer disease-specific survival of 94% and therefore might be spared 
chemotherapy. Wittner et al.66 reported a study on LN– patients. MammaPrint had a high 
negative predictive value (NPV) and provided some information that was additional to that 
provided by Adjuvant! Online. However, with an extremely low positive predictive value (PPV) 
and non-significant differences in OS between MammaPrint high- and low-risk patients, the 
prognostic utility of MammaPrint in this population remained unproven. Moreover, although 
MammaPrint classified a significant proportion of study patients as high risk, few of these 
developed metastatic disease.
Clinical utility Smartt34 identified one study on the clinical utility of MammaPrint. Bueno-de-
Mesquita et al.67 reported a prospective study of 427 patients with a MammaPrint profile. The 
study demonstrated a lack of congruence with well-known clinical guidelines for risk assessment 
in breast cancer; in approximately one-third of patients there was discordance. The addition of 
MammaPrint to the standard Dutch clinical assessment of risk (modified by patient preference) 
increased by 20 the number of patients receiving adjuvant systemic therapy. Follow-up was not 
long enough to provide evidence of its effect on clinical end points such as distant metastasis-free 
survival (DMFS) or its utility in predicting treatment benefit.
Key evidence gaps identified by these reviews
OncotypeDX
 ■ Analytical validity – there is limited evidence for the reproducibility of the tests in terms of 
reproducibility across different samples of the same block and across samples from different 
blocks. Centralisation was considered to be a current strength of OncotypeDX with regard 
to reproducibility.
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 ■ Clinical validity (prognostic ability of the tests) – there is fairly strong support for 
OncotypeDX over and above standard clinical predictors, but only in a well-defined 
population (ER+, LN–). Evidence is required to assess the stability of risk categories in 
other populations.
 ■ Clinical utility – very few of the studies, particularly in isolation, provided compelling 
evidence of the test’s clinical utility.
MammaPrint
 ■ Analytical validity – there were limited data on variability and reproducibility, with a limited 
number of patients and a moderate number of replications.
 ■ Clinical validity (prognostic ability of the tests) – evidence was based on retrospective data 
using clinically heterogeneous cohorts; evidence from RCTs is needed.
 ■ Clinical utility – very limited evidence was available on clinical utility; robust evidence on 
the prediction of chemotherapy benefit is required.
Marchionni et al.32 concluded (at the time of publication) that for both tests the relationship of 
predicted to observed risk in different populations needed further study, as did their incremental 
contribution, optimal implementation and relevance to patients on current therapies. Smartt34 
concluded that the largest volume of evidence related to the OncotypeDX test.
Studies included in the current systematic review
The literature searches identified 5993 potentially relevant citations. Of the titles and abstracts 
screened, 218 relevant full papers or abstracts were retrieved and assessed for inclusion. A flow 
chart describing the process of identifying relevant literature is shown in Figure 2. A total of 
32 citations evaluating the effectiveness of nine prognostic tests (for guiding chemotherapy 
treatment decisions in early-stage breast cancer) met the inclusion criteria. Figure 2 also shows 
the numbers of studies included for each prognostic test. Studies excluded from the review are 
listed in Appendix 6 (only those citations that were excluded after a full-text reading for reasons 
not immediately apparent from the full text).
OncotypeDX
OncotypeDX quantifies gene expression for 21 genes in breast cancer tissue using RT-PCR. It 
is intended to predict the likelihood of recurrence in women of all ages with newly diagnosed 
stage I or II, ER+, LN– or LN+ (up to three nodes) breast cancer treated with tamoxifen. The 
test assigns the breast cancer a RS and a risk category: low (RS ≤ 18), intermediate (18 ≤ RS ≤ 30) 
or high (RS ≥ 31). The test also reports ER, PR and HER2 status and can provide an indication 
of how responsive the cancer is likely to be to hormonal therapy. Further details are provided in 
Table 6.
Description of included studies
The present review identified an additional 12 studies (13 citations) for the OncotypeDX test. 
This included 11 fully published peer-reviewed papers and two meeting abstracts. Of these 
citations five were related to clinical validity and the remaining eight to clinical utility.
The design and patient characteristics of the 12 included studies are provided in Tables 10 and 
11 respectively. Most of the studies used a retrospective analysis of archived tumour samples 
together with a database of patient characteristics and prognostic information. Only three 
studies stated that the design was prospective.76–78 The majority of participants analysed in the 
studies were ER+, LN–, and the mean age was around 50–60 years. Most studies included a small 
number of participants (range 25–367), although three analysed relatively large cohorts [Dowsett 
et al.79 (n = 1231), Mamounas et al.80 and Tang et al.81 (both n = 1674 – analyses of the B14 and 
B20 trials)]. Follow-up was short or not reported for a number of studies; again, the exceptions 
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were the studies by Dowsett et al.79 (9 years) and Mamounas et al.80 and Tang et al.81 (minimum of 
10 years).
Quality of included studies: OncotypeDX
The methodological quality of the 12 included studies76–88 is summarised in Figure 3 (further 
details are provided in Appendix 7). Generally, only three studies (four citations) performed well, 
receiving a positive assessment for at least 17 out of 21 methodological quality items.80–82,84
Full-text articles and abstracts
from previous reviewsb
(n = 34) 
S
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lig
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ty
Id
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fic
at
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n
Records screened by title and abstract
(n = 5993)
Full-text articles assessed for
eligibility
(n = 218)
Excluded by title and abstract
(n = 5775)
Full-text articles and abstracts
(references) included
(n = 32; representing 30 studies)
In
cl
ud
ed
Full-text articles and abstracts excluded
(n = 186)
Reasons for exclusion
Review paper, n = 58
Abstracts which did not add to
the full published evidence base,
n = 59
Pooled analysis, n = 4
Not a relevant test/research
version of test, n = 23
Reported in previous review, n = 8
Not relevant to the question, e.g.
case study, n = 29
Not available within timescale, n = 2
•
•
•
•
•
•
•
Studies included in narrative synthesis  
OncotypeDXa•
•
•
•
•
•
•
•
•
o Existing data (n = 21)b
o New data (n = 12 studies; 13 citations)
MammaPrint
o Existing data (n = 13)b
o New data (n = 7) 
MammaPrint and Blueprint (n = 1)
PAM50 (n = 6 studies; 7 citations)
Breast Cancer Index (n = 1)
Randox (n = 0; information from manufacturer,
n = 1)
Mammostrat (n = 3 )
IHC4 (n = 1)a
NPI+ (n = 0; information from manufacturer, n = 3)
Records identified through
database searching
(n = 5990)   
Additional records identified
through other sources
(n = 3)   
FIGURE 2 Prognosis review: PRISMA (adapted) flow chart. a, one paper is included for both OncotypeDX and IHC4 as 
it contains data relating to both tests; b, from the systematic reviews of Marchionni et al.33 and Smartt.34
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Although 9 of the 12 studies used a retrospective study design,79–88 other potential sources of bias 
were generally related to the following domains: sample of patients (inadequate description of 
diagnostic criteria, clinical/demographic characteristics not fully described and not including all 
eligible patients with tumour samples in the study), follow-up of patients, prognostic variables 
(not fully defined) and interventions subsequent to inclusion in the study (interventions were not 
described or standardised, thus precluding an unbiased assessment of the prognostic ability of 
the test).30
The assessment of study quality was further hampered by poor reporting of the following 
methodological items: whether or not sample of patients was representative and assembled at an 
early point in the course of their disease, whether or not outcomes were fully defined, objective 
and unbiased and whether or not appropriate statistical analyses were undertaken (continuous 
predictor variables analysed appropriately and statistical adjustment made for all prognostic 
factors). Overall, the risk of bias from the 12 included studies was judged to be moderate.
Results: OncotypeDX
In this section a summary of the clinical evidence for OncotypeDX is presented (Table 12) 
followed by a narrative summary of each study. Full data extraction tables are provided in 
Appendix 7.
Analytical validity
No new data examined analytical validity.
Clinical validity
Using 1231 tissue samples from the UK TransATAC (Arimidex, Tamoxifen, Alone or in 
Combination trial) trial, Dowsett et al.79 assessed postmenopausal, hormone receptor-positive 
and majority LN– patients. They demonstrated that a 50-point increase in RS in all LN– patients 
(e.g. RS = 55 vs. RS = 5) was significantly associated with an increased risk of distant recurrence 
[hazard ratio (HR) 3.92, 95% CI 2.08 to 7.39; p < 0.001] when adjusted for the effects of tumour 
size, local grade (grade derived from case record forms), age and treatment. They also reported 
that, when local grade was replaced with central grade (assessed using the Elston and Ellis 
system) in multivariate analysis, adjusted RS was also significantly associated with risk of distant 
recurrence (HR 5.25, 95% CI 2.84 to 9.73; p < 0.001). RS was also significantly associated with 
TTDR in both node-negative (HR 5.25, 95% CI 2.84 to 9.73; p < 0.001) and node-positive patients 
(HR 3.47, 95% CI 1.64 to 7.38; p < 0.002). Correlation between RS-predicted distant recurrence 
and Adjuvant! Online-predicted recurrence was low but statistically significant by central grade 
(Spearman rank correlation = 0.23; p < 0.001) or local grade (Spearman rank correlation = 0.22; 
p < 0.001). Only approximately 5% of the variability in the estimates of recurrence using either of 
these scores was explained by the other. The authors concluded that the findings demonstrated 
that RS is an independent predictor of distant recurrence in LN– and LN+ hormone 
receptor-positive patients treated with anastrozole, adding value to estimates with standard 
clinicopathological features. As the patients were recruited as part of a large-scale trial this study 
benefits from a large sample size of UK-based patients and has a relatively long follow-up time 
(9 years).
Yorozuya et al.88 reported a very small case–control study (10 cases, 30 control subjects) of ER+, 
LN– Japanese patients. The cases were those who had metastases after surgery; control subjects 
did not develop metastases. Significant differences were shown between the groups in terms of 
mean RS (cases: mean RS = 40.0, 95% CI 21.1 to 58.9; control subjects: mean RS = 17.8, 95% CI 
13.8 to 21.9; p < 0.001). The study found significant differences between cases and control subjects 
in the proportions assigned to different risk categories [low: 3 (30%) cases vs. 19 (63%) control 
subjects; intermediate: 1 (10%) vs. 8 (27%); high: 6 (60%) vs. 3 (10%); p = 0.005]. Multivariate 
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TABLE 12 Summary of evidence for the OncotypeDX test
Author (year) Evidence type
Overall 
quality Key findings
Ademuyiwa et 
al. (2011)82
Clinical utility – 
reclassification against 
existing prognostic 
variables – and 
changes in treatment 
recommendations
High 276 ER+, LN– patients from two cancer centres in the USA. Impact on clinical decision-
making in terms of recommending CT based on clinicopathological characteristics. 
37 fewer patients received CT using RS to help decide CT use. 38% of patients had a 
change in management as a result of the RS. Authors reported a significant association 
between RS risk group and NPI (p < 0.001). Conclusion: RS score had a significant 
impact on the receipt of adjuvant CT. Limitations: sample size relatively small, use of 
retrospective chart review
Albain et al. 
(2010)83
Clinical utility – 
predictive ability (benefit 
of chemotherapy)
Medium 367 postmenopausal ER+ and LN+ US and Canadian patients from the SWOG-9914 
trial. RS is prognostic for tamoxifen-treated patients with positive nodes and predicts 
significant benefit of CAF in tumours with a high RS. Conclusion: a low score identifies 
women who might not benefit from anthracycline-based chemotherapy, despite positive 
nodes. Limitations: moderate sample size, time over which tumour samples were 
collected not reported, therefore they may be differences in diagnostic criteria being 
applied
Cuzick et al.84 
(2011)
Clinical validity High 1125 patients, majority LN– and hormone receptor positive; multinational including UK. 
The authors reported the mean change in (likelihood ratio chi-squared) for the addition of 
the RS to the classical score (higher values indicate more added prognostic information) 
for TTDR and TR (all recurrences). For TTDR the (likelihood ratio chi-squared) for all 
patients was 25.3 (95% CI 25.2 to 25.9) and for LN– patients was 20.9 (95% CI 20.7 
to 21.6). For TR the LR-
X
2 for all patients was 25.6 (95% CI 25.2 to 25.9) and for LN– 
patients was 25.7 (95% CI 25.4 to 26.4). The authors report that the OncotypeDX RS 
adds prognostic information to traditional clinicopathological measures. This study has 
been rated as high quality and benefits from a large sample of patients
Dowsett et al. 
(2010)79
Clinical validity Medium 1231 UK, postmenopausal, hormone receptor-positive, LN– patients. Increase in RS 
significantly associated with an increased risk of distant recurrence. RS was also 
significantly associated with TTDR. Correlation between RS-predicted distant recurrence 
and Adjuvant! Online-predicted recurrence was low but statistically significant. 
Conclusion: RS is an independent predictor of distant recurrence in LN– and LN+ 
hormone receptor-positive patients treated with anastrozole, adding value to estimates 
using standard clinicopathological features. Large sample size, UK-based patients
Geffen et al. 
(2009)77
Clinical utility – 
changes in treatment 
recommendations
Medium 25 LN– Israeli patients. Each patient had a RS assay. Study reported findings on the 
impact of the OncotypeDX RS on clinical decision-making. Nine patients (36%) had 
their treatment recommendations changed based on the score, six from CT to no CT. 
Limitations: very small sample size
Holt et al. 
(2011)78
(Abstract 
only)
Clinical utility – 
changes in treatment 
recommendations
Medium 106 UK, ER+ and either LN– or N1 patients. 35 patients (33%) had their initial 
recommendation changed as a result of the RS; for 71 patients (67%) there was no 
change. RS added prognostic information beyond that from NPI alone. Conclusion: 
authors concluded that early results suggest that OncotypeDX is applicable and feasible 
to perform in the UK setting with a reduction in the use of adjuvant CT. Limitations: 
although UK based only conducted in one centre, small sample size, abstract data
Kelly et al. 
(2010)85
Clinical utility – 
reclassification against 
existing prognostic 
variables
Medium 309 hormone receptor-positive, LN– patients at clinically intermediate risk. Of these, 
52% were assigned a low risk on RS, 9% high risk and 39% intermediate risk. 
Conclusion: findings suggest that OncotypeDX has utility in reclassifying clinically 
intermediate patients into the three OncotypeDX risk groups. Employed recently 
diagnosed patients. Limitations: small sample size and a short follow-up time
Lo et al. 
(2010)76
Clinical utility – 
changes in treatment 
recommendations – 
and quality of life and 
patient anxiety
Medium 89 ER+, LN– patients. Prospective US-based study of RS effects on physician and patient 
adjuvant treatment selection and satisfaction, and quality of life. Changes in physician 
treatment recommendations for 28 patients (31.5%); 24 patients (27.0%) changed their 
own treatment decision. Most of the treatment changes were from CHT to HT alone for 
both physicians and patients. DCS score and state anxiety were significantly reduced 
across time points (pre and post RS), and the FACT-G score was marginally significantly 
reduced. Trait anxiety and the FACT-B score were not significantly different. Limitations: 
small sample size, only 16 physician self-reports
continued
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Author (year) Evidence type
Overall 
quality Key findings
Tang et al. 
(2011)81
Mamounas et 
al. (2010)80
Clinical validity 
(Mamounas et al.); 
clinical utility – 
predictive ability (benefit 
of chemotherapy) (Tang 
et al.)
High 1319 ER+, LN– patients from two large US trials (NSABP B14 and B20). Tang et al. 
– both RS and Adjuvant! Online provided strong independent prognostic information 
in tamoxifen-treated patients. In the B20 cohort RS was significantly predictive of CT 
benefit (for DRFI, OS and DFS) but Adjuvant! Online was not. In the larger B20 subcohort, 
Adjuvant! Online was significantly predictive of CT benefit for OS but not for DRFI or 
DFS. Conclusion: prognostic estimates can be optimised by combining RS and Adjuvant! 
Online. RS should be used for estimating relative CT benefit. Mamounas et al. – in the 
tamoxifen-treated patients, RS was a significant predictor of locoregional recurrence. 
Large sample size with a long follow-up. Limitation: relatively old tumour samples, may 
be differences in diagnostic criteria applied
Tang et al. 
(2010)86
(Abstract 
only) 
Clinical utility – 
predictive ability (benefit 
of chemotherapy)
Medium 625 ER+, LN–, US patients from the NSABP B20 trial. Examined the value of the SPC 
(integration of RS and clinicopathological factors) in the prediction of CT benefit in 
reducing risk of recurrence. Authors concluded that RS used alone remains the best 
predictor of CT benefit in ER+, LN– breast cancer. Large sample size. Limitations: 
abstract data, Tang et al.80 and Mamounas et al.79 also used the NSABP cohorts – 
limitations in using the same data because of risks of double counting in the evidence 
base as a whole
Toi et al. 
(2010)87 
Clinical validity Medium 200 ER+, LN–, Japanese patients. Patients categorised as low risk had a significantly 
lower risk of distant recurrence than patients in the high-risk category. Continuous RS 
was significantly associated with the risk of distant recurrence. Conclusion: OncotypeDX 
has value in providing prognostic information in Asian populations with ER+, LN– breast 
cancer. Limitation: small sample, Japanese patients so generalisability to UK practice 
may be limited
Yorozuya et 
al. (2010)88
Clinical validity Medium 40 ER+, LN–, Japanese patients. Compared those who had metastases after surgery 
with those who did not develop metastases. Significant differences were shown between 
the groups in terms of mean RS and there were significant differences in the proportions 
assigned to the different OncotypeDX risk categories. Conclusion: both histological grade 
and risk score classification were effective in identifying women at risk of developing 
distant metastases after initial therapy. Limitations: very small sample size, may not be 
generalisable to the UK setting
CAF, cyclophosphamide, doxorubicin and fluorouracil; CHT, chemotherapy plus hormone therapy; CI, confidence interval; CT, chemotherapy; DCS, 
Decisional Conflict Scale; DRFI, distant recurrence-free interval; FACT-B, Functional Assessment of Cancer Therapy breast cancer scale; FACT-G, 
Functional Assessment of Cancer Therapy general scale; HT, hormone therapy; TR, time to recurrence.
logistical regression analysis of age, ER score, PR score, RS, histological grade and lymphatic 
invasion compared with distant metastases showed that RS was not significant [RS ≥ 50 vs. RS 
< 50, p = 0.579, odds ratio (OR) 2.85, 95% CI 0.07 to 115.552] although the authors conclude that 
the OR indicates that it has value. The authors concluded that both histological grade and RS 
classification were effective in identifying women at risk of developing distant metastases after 
initial therapy for ER+, LN– stage I or IIA breast cancer. There are significant limitations in terms 
of the generalisation of the findings because of the extremely small sample size used in this study; 
furthermore, as the study was Japan based, generalisations to the UK setting are limited.
Toi et al.87 examined the prognostic ability of OncotypeDX in 200 ER+, LN– Japanese patients. 
They showed that patients categorised as low risk had a significantly lower risk of distant 
recurrence than patients in the high-risk category (p < 0.001, log-rank test). No recurrences were 
identified in the intermediate recurrence group. Continuous RS was significantly associated 
with the risk of distant recurrence for a 50-point increase in RS (HR 6.20, 95% CI 2.27 to 17.0). 
In multivariate analyses the continuous RS maintains statistical significance when adjusting 
for age and clinical tumour size (HR 6.03, 95% CI 2.17 to 16.7). For risk of recurrence the HR 
was 3.38 (95% CI 1.32 to 8.69), for risk of recurrence or death the HR was 2.09 (95% CI 0.84 to 
5.20) and for risk of death the HR was 2.67 (95% CI 0.93 to 7.62). The authors concluded that 
OncotypeDX has value in providing prognostic information in Asian populations with ER+, 
TABLE 12 Summary of evidence for the OncotypeDX test (continued)
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LN– breast cancer. This study had a small sample size and as it was conducted using Japanese 
patients generalisability to UK practice may be limited; however, the study does benefit from the 
fact that the tumour samples used were from patients who presented and were treated relatively 
recently (1992–8).
Cuzick et al.84 reported data that aimed to assess how much of the information in the RS is 
contained in standard IHC markers (data from this report relating to the IHC4 test is presented 
in IHC4 test). Patients comprised a retrospective cohort from the TransATAC trial (multinational 
including the UK). The 1125 patients were mainly LN– and hormone receptor positive, and there 
were a total of 195 recurrences of which 145 were distant recurrences. In LN– women there were 
101 recurrences of which 67 were distant recurrences. The authors reported the mean change 
in likelihood ratio chi-squared for the addition of GHI-RS (Genomic Health Recurrence Score)
v to the classical score in the validation halves of 100 random splits of the data (higher values 
indicate more added prognostic information) for TTDR and time to recurrence (all recurrences). 
For TTDR the likelihood ratio chi-squared for all patients was 25.3 (95% CI 25.2 to 25.9) and 
for LN– patients was 20.9 (95% CI 20.7 to 21.6). For time to recurrence the LR-X2 for all patients 
was 25.6 (95% CI 25.2 to 25.9), and for LN– patients was 25.7 (95% CI 25.4 to 26.4). The authors 
report that the OncotypeDX RS adds prognostic information to traditional clinicopathological 
measures. This study has been rated as high quality and benefits from a large sample of patients.
Mamounas et al.80 (and Tang et al.,81 reported in the following section) undertook a retrospective 
analysis of ER+, LN– patients who had been recruited into two large US trials (NSABP B14 
and B20). They showed a significant association between RS and the proportion of patients 
with locoregional recurrence at 10 years for 355 placebo-treated patients (NSABP B14), 895 
tamoxifen-treated patients (NSABP B14 and B20) and 424 tamoxifen plus chemotherapy-treated 
patients (NSABP B20). Multivariate Cox regression analysis in the cohort of 895 tamoxifen-
treated patients showed that RS was a significant predictor of locoregional recurrence (HR 
2.16, 95% CI 1.26 to 3.68; p < 0.005). The authors concluded that a significant association exists 
between RS and risk for locoregional recurrence. This information has biologic consequences and 
potential clinical implications relative to locoregional therapy decisions for patients with LN– and 
ER+ breast cancer. These studies appeared to be of reasonable quality and, as the patients were 
recruited as part of two large-scale trials, the studies benefit from a large sample size with a long 
follow-up. However, across the two trials tumour samples were collected as long ago as 1982 until 
1993. This means that there may be differences in diagnostic criteria applied and this may limit 
the generalisability of these findings to current practice.
Clinical utility
Predictive ability of the OncotypeDX test (benefit of chemotherapy) Tang et al.81 (and Mamounas et 
al.,80 as reported in the previous section) undertook a retrospective analysis of the NSABP B14 
and B20 trial data on ER+, LN– patients. They compared the prognostic and predictive utility of 
the OncotypeDX RS and Adjuvant! Online, with an end point of distant recurrence-free interval 
(DRFI). Cox proportional hazards models were used to compare the prognostic and predictive 
utility of RS and Adjuvant! Online. Both RS (p < 0.001) and Adjuvant! Online (p = 0.002) provided 
strong independent prognostic information in tamoxifen-treated patients. Combining RS and 
individual clinicopathological characteristics provided greater prognostic discrimination than 
combining RS and the composite Adjuvant! Online. In the B20 cohort with RS results (n = 651), 
RS was significantly predictive of chemotherapy benefit (interaction p = 0.031 for DRFI, p = 0.011 
for OS, p = 0.082 for DFS) but Adjuvant! Online was not. However, in the larger B20 subcohort 
(n = 1952), Adjuvant! Online was significantly predictive of chemotherapy benefit for OS 
(interaction p = 0.009) but not for DRFI or DFS. The authors concluded that prognostic estimates 
can be optimised by combining RS and Adjuvant! Online. RS should be used for estimating 
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36 Assessment of clinical effectiveness
relative chemotherapy benefit. As stated above, these studies appeared to be of reasonable quality 
and, as the patients were recruited as part of two large-scale trials, the studies benefit from a large 
sample size with a long follow-up. However, across the two trials tumour samples were collected 
as long ago as 1982 until 1993. This means that there may be differences in diagnostic criteria 
applied and this may limit the generalisability of these findings to current practice.
Albain et al.83 reported findings for 367 postmenopausal ER+ and LN+ US and Canadian patients 
from the SWOG-9914 trial. They aimed to investigate whether or not RS is prognostic in women 
treated with tamoxifen alone and whether or not it identified those who might not benefit from 
anthracycline-based chemotherapy despite higher risks of recurrence. RS was prognostic in the 
tamoxifen alone group (HR 2.64, 95% CI 1.33 to 5.27; p = 0.006) using a 50-point difference in 
RS as a threshold. There was no benefit of chemotherapy with cyclophosphamide, doxorubicin 
and 5-fluorouracil (CAF) in patients with a low RS but an improvement in DFS for those with 
a high RS (score ≥ 31) (HR 0.59, 95% CI 0.35 to 1.01; p = 0.033), after adjustment for number of 
positive nodes. The RS by treatment interaction was significant in the first 5 years (p = 0.029), 
with no additional prediction beyond 5 years, although cumulative benefit remained at 10 years. 
There were similar findings for OS and breast cancer-specific survival (BCSS). The authors 
concluded that RS is prognostic for tamoxifen-treated patients with positive nodes and predicts 
significant benefit of CAF in tumours with a high RS. A low score identifies women who might 
not benefit from anthracycline-based chemotherapy, despite positive nodes. This study employed 
a moderate sample size. The authors did not report the length of time over which tumour samples 
were collected; therefore, it is unclear whether or not it is likely that there were differences in the 
diagnostic criteria applied.
Tang et al.86 reported a study in abstract form that included 625 ER+, LN– US patients treated 
with tamoxifen with or without adjuvant chemotherapy from the NSABP B20 trial. They aimed 
to examine the value of the integration of RS and clinicopathological factors (RSPC) in the 
prediction of chemotherapy benefit in reducing risk of recurrence. They reported that in 60 
of the 625 patients distant recurrence occurred. The RS showed a significant interaction with 
chemotherapy treatment (p = 0.037) with a standardised HR of 0.836. The interaction of RSPC 
with treatment was not significant (p = 0.10) although there was a trend in the same direction 
as for RS (HR 0.833). The authors concluded that RS used alone remains the best predictor of 
chemotherapy benefit in ER+, LN– breast cancer. This study benefits from having a large sample 
size. However, there are significant limitations in making any interpretations from this evidence 
as it is derived only from an abstract. It has been shown that there may be discrepancies between 
data made available in abstracts and the reporting of results in subsequently published full-
length articles.89 Because of incomplete reporting the methodological quality of studies cannot 
be confidently assessed by systematic reviewers. It should also be noted that Tang et al.81 and 
Mamounas et al.80 also used the NSABP cohorts. There are limitations in using the same data 
because of the risks of double counting in the evidence base as a whole.
Reclassification of risk against existing prognostic variables Kelly et al.85 considered the correlation 
between OncotypeDX and Adjuvant! Online in a US population of 309 consecutive patients with 
hormone receptor-positive, majority LN– early breast cancer of clinically intermediate risk. They 
demonstrated a low correlation between Adjuvant! Online risk prediction and RS, and between 
death after 5 years of tamoxifen therapy and RS. Of these patients considered to be of clinically 
intermediate risk, 52% (n = 160) were assigned a low risk on RS, 9% (n = 27) a high risk and 39% 
(n = 122) an intermediate risk. The authors concluded that OncotypeDX yielded potentially 
informative risk assignments in patients who may be considered at indeterminate risk by routine 
clinical variables. However, 40% of the time they remain as intermediate risk using RS thresholds; 
this increases to 66% when using thresholds that have been revised for an ongoing trial of 
OncotypeDX [Trial Assigning Individualized Options for Treatment (TAILORx) – which will be 
described in Ongoing trial: the Trial Assigning Individualized Options for Treatment] (the revised 
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thresholds are as follows: low risk ≤ 10; intermediate risk 11–25; high risk ≥ 26). These findings 
suggest that OncotypeDX has utility in reclassifying clinically intermediate patients into the three 
OncotypeDX risk groups. The study benefits from the fact that all patients had been diagnosed 
relatively recently (2004–8), although it also has limitations, including a small sample size and 
a short follow-up time (actual follow-up time was not reported). The authors were not able to 
report recurrence and survival results because of the short follow-up time.
Ademuyiwa et al.82 reported a study on 276 ER+, LN– patients from two cancer centres in the 
USA. They reported a significant association between RS risk group and NPI (p < 0.001), although 
there were a number of discordant cases (comparisons are difficult because NPI and RS have 
two and three risk categories respectively). This was only a brief report and it therefore lacked 
the detail necessary to make adequate judgements about quality. Furthermore, the sample size 
was relatively small. Further data on clinical decision-making from this study are reported in the 
following section.
Changes in treatment recommendations Geffen et al.77 reported findings on the impact of 
the OncotypeDX RS on clinical decision-making in 25 LN– patients in Israel. Nine patients 
(36%) had their treatment recommendations changed based on the scores, six of these from 
chemotherapy to no chemotherapy. The generalisability of these findings is limited, primarily 
because of the very small sample size. Furthermore, as this study was conducted in Israel, 
generalisability to the UK is limited.
Lo et al.76 reported a prospective US-based study of 89 ER+, LN– patients to examine whether 
or not RS affects physicians’ and patients’ adjuvant treatment selection and satisfaction. They 
reported changes in physician treatment recommendations for 28 (31.5%) patients; 24 (27.0%) 
patients changed their own treatment decision. The largest change after RS results was conversion 
in 20 (22.5%) cases from physicians’ pretest recommendation of chemotherapy plus hormone 
therapy to a post-test recommendation of hormone therapy. Nine (10.1%) patients changed their 
treatment decision from chemotherapy plus hormone therapy to hormone therapy. The authors 
concluded that the RS assay impacts significantly on physician and patient adjuvant treatment 
decision-making. Most of the treatment changes were from a pretreatment recommendation of 
chemotherapy plus hormone therapy to hormone therapy alone, for both physicians and patients. 
In addition, Lo et al.75 reported, based on physician self-reports, that RS results have an enduring 
impact on physician confidence in their treatment recommendation. The generalisability of these 
findings is limited because of the very small sample size of 89 patients and only 16 physician 
self-reports.
Ademuyiwa et al.82 investigated the impact on the use of clinicopathological features (based on 
patient records with oncologists blind to RS) in decision-making for chemotherapy utilisation. 
The study included 276 ER+, LN– patients from two cancer centres in the USA. In total, 37 fewer 
patients received chemotherapy using RS to help decide chemotherapy use; 38% of the patients 
had a change in management as a result of RS. The authors reported a significant association 
between RS risk group and NPI (p < 0.001), although there were a number of discordant 
cases (comparisons are made difficult because NPI and RS have two and three risk categories 
respectively). They concluded that the RS had a significant impact on the receipt of adjuvant 
chemotherapy. This was only a brief report and therefore lacked the detail necessary to make 
adequate judgements about quality. Furthermore, the sample size was relatively small and there 
may also be significant limitations from the use of retrospective chart review.
In a conference poster Holt et al.78 reported a study investigating the impact of RS on clinical 
decision-making in Wales. The 106 patients included in the study were ER+ and either LN– or 
N1. The authors reported data on change in recommendations pre RS assay to post RS assay. 
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They demonstrated that 35 patients (33.0%) had their initial recommendation changed as a 
result of RS [change chemotherapy to no chemotherapy: 25 (23.6%); change no chemotherapy 
to chemotherapy: 10 (9.4%)] whereas for 71 patients (66.9%) there was no change [no change 
no chemotherapy: 49 (46.2%); no change chemotherapy: 22 (20.8%)]. The Spearman’s rank 
correlation comparing RS with individual components of the NPI showed that, of size, LN 
status and grade, only grade was significantly correlated. The authors concluded that early 
results suggest that OncotypeDX is applicable and feasible to perform in the UK setting, with a 
reduction in the use of adjuvant chemotherapy consistent with the findings of other studies. RS 
added prognostic information beyond that from NPI alone. Although the study was UK based 
it was conducted in only one centre with a very small sample size, making generalisations of 
the findings difficult. Furthermore, because more chemotherapy was given in the comparator 
arm, more benefits are likely to be derived from the use of OncotypeDX. In addition, there are 
significant limitations in making any interpretations from this evidence as it is derived only from 
an abstract. It has been shown that there may be discrepancies between data made available in 
abstracts and the reporting of results in subsequently published full-length articles.89 Because of 
incomplete reporting the methodological quality of studies cannot be confidently assessed by 
systematic reviewers.
Quality of life and patient anxiety Lo et al.76 also reported quality of life and patient anxiety data 
for 89 ER+, LN– patients. Patients were asked to complete standardised measures to assess 
decisional conflict and personal perceptions of decision-making [Decisional Conflict Scale 
(DCS)] pre and immediately post RS; anxiety – state anxiety refers to a transitory emotional state 
or condition and trait anxiety denotes relatively stable individual differences in anxiety proneness 
[State-Trait Anxiety Inventory (STAI)] pre RS, immediately post RS and 12 months post RS; and 
quality of life [Functional Assessment of Cancer Therapy (FACT)-B, which is specific to breast 
cancer, and FACT-G, which is the general scale] pre RS and 12 months post RS. The results 
showed that DCS score was significantly reduced post RS compared with pre-RS (p < 0.001); 
the STAI demonstrated that state anxiety was significantly reduced across the three time points 
(p = 0.007) whereas trait anxiety was not significantly different across the three time points. For 
quality of life the FACT-B score pre RS was not significantly different from the score at 12 months 
post RS; however, the FACT-G score was marginally significantly reduced at 12 months 
compared with pre RS (p = 0.49). The authors concluded that patient anxiety and decisional 
conflict were significantly lower after RS results. The small sample size used in this study limits 
the generalisability of the findings and further research in this area is necessary before definitive 
conclusions on quality of life improvements and reductions in patient anxiety can be formed.
Summary of evidence: OncotypeDX
Analytical validity of OncotypeDX
In the earlier systematic reviews evidence exists on the technical and operational aspects 
of the test and on assay variability and reproducibility. Studies showed reasonable 
within-laboratory replicability.
Our findings indicated no new evidence.
Clinical validity (prognostic ability) of OncotypeDX
In earlier systematic reviews the evidence shows that RS was significantly correlated with DFS 
and OS. RS alone was shown to be a better predictor of distant recurrence at 10 years than 
traditional clinicopathological predictors.42 Key gaps relate to the stability of risk categories in 
populations other then ER+, LN– patients.
Our findings indicate that further larger studies now exist which support the prognostic 
capability of OncotypeDX. In particular, a large UK study in 1231 postmenopausal women with 
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hormone receptor-positive, LN– early breast cancer concluded that an increase in risk score 
was significantly associated with an increased risk of distant recurrence.90 This study and the 
Mamounas et al.80 study provide new evidence on the clinical validity of OncotypeDX, which 
employs cohorts of patients from large-scale RCTs and is rated as high quality. Furthermore, 
the evidence base has been extended to include the LN+ population83 and there are the 
beginnings of an evidence base for the validity of OncotypeDX in different populations such as in 
Japanese patients.87,88
Clinical utility of OncotypeDX
In the earlier systematic reviews, evidence on clinical utility is limited. Paik et al.49 demonstrated 
a significant benefit from the use of chemotherapy in the OncotypeDX high-risk group, 
although the review highlighted that the study may have been subject to bias as some patients 
in the validation data set were also in the training data set. Clinical experts indicated that more 
effective chemotherapy regimes are currently used in the UK. In total, > 44% of patients were 
aged < 50 years. The benefit of chemotherapy (reduction in distant recurrence) was greater in this 
population than in women aged > 50 years. The HR for the benefit of chemotherapy (reduction in 
distant recurrence) in women aged > 50 years compared with younger women was 2.02 (95% CI 
0.75 to 5.47; p = 0.162).
Further supporting evidence was needed. Key gaps relate to the extent to which the test added 
to the management of patients and the proportion of patients who would benefit from the test. 
The role of the OncotypeDX test in guiding treatment of HER2-positive patients was unclear, as 
most of these patients were classified in the high-risk RS group in the initial trials. Prospective 
confirmation of the clinical utility of OncotypeDX was required.
Our findings indicate that there are no prospective studies reporting the impact of OncotypeDX 
on long-term outcomes such as OS. Four new studies76–78,82 presented further evidence on the 
impact of OncotypeDX on clinical decision-making. These indicate that the use of OncotypeDX 
leads to changes in decision-making for between 31.5% and 38% of patients. However, only one 
of these studies was UK based, and limitations in relation to study design were identified for this 
study. Specifically, these data were based on a small sample size (n = 106) and were derived from a 
conference poster,78 which was lacking the detail necessary to make judgements about the quality 
of the evidence. Two new studies (with three related citations81,83,86) provided evidence supporting 
the case that OncotypeDX predicts chemotherapy benefit. The Tang et al.81,86 studies were based 
on ER+, LN– patients and Albain et al.82 reported evidence for ER+, LN+ patients. These studies 
were based on trial data and the sample sizes were moderate in the case of Albain et al.83 (n = 367) 
and large in the Tang et al.81,86 analyses (n = 625–1319). These studies also had long follow-up 
times. Study quality was judged to be medium83,86 or high,81 although as Tang et al.86 was a 
conference abstract we were unable to access the detail necessary to make adequate judgements 
about the quality of the evidence.
The first evidence relating to improvements in quality of life and reductions in patient anxiety 
as a result of using the test have been reported, although generalisations should be made with 
caution because of the small sample sizes employed. Further research in this area is required.
Key gaps in the evidence remain:
 ■ Few of the studies were considered to be of high quality (n = 3). A number of studies in the 
current review were judged to provide medium-quality (although retrospective) evidence 
for OncotypeDX (n = 9). One of the most characteristic features of the studies was their 
heterogeneity. The studies varied considerably in their size, study design, patient populations 
and objectives. A large proportion of the OncotypeDX studies were small and retrospective. 
Many studies used old archived tumour samples and included the use of retrospective chart 
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review to elicit treatment recommendations before and after OncotypeDX testing. There was 
a lack of standardised decision-making tools both within and between studies, and non-
standardised methods of patient selection for OncotypeDX testing were used.
 ■ Further direct evidence of the clinical utility of OncotypeDX is still required. This will be 
addressed by the ongoing TAILORx trial.
 ■ The generalisability of the findings may be limited because of the small number of studies 
that were conducted in the UK setting and because a number of the studies were funded by 
the manufacturer, giving rise to possible conflicts of interest and publication bias.
Overall summary
The OncotypeDX evidence is the furthest along the validation pathway compared with other 
similar tests, and the evidence base, in particular in relation to the prognostic ability of the test, 
was reasonably sound. This review has identified further studies supporting the prognostic 
ability (clinical validity) of the test. These are generally of moderate to high quality. Our 
findings indicate that there are no prospective studies reporting the impact of OncotypeDX 
on long-term outcomes such as OS. Four additional studies on the impact of OncotypeDX on 
decision-making indicate that the use of OncotypeDX leads to changes in decision-making for 
31.5–38% of patients, but only one of these relates to the UK setting. Two further studies on the 
predictive benefit of the test were identified, one for LN+ patients. The first evidence relating to 
improvements in quality of life and reductions in patient anxiety as a result of using the test has 
been reported, but this is based on small patient numbers and further evidence is required.
Ongoing trial: the Trial Assigning Individualized Options for Treatment
The TAILORx trial commenced in April 2006 and is due to complete primary outcomes in April 
2014. It aims to demonstrate that endocrine treatment alone is non-inferior to chemoendocrine 
treatment in women with an intermediate OncotypeDX score (11–25). Patients aged 18–75 years 
with ER+ and/or PR+, HER2/neu-negative tumours who are LN– (and who will be treated with 
tamoxifen) are eligible for inclusion. All patients receive OncotypeDX profiling and are then 
allocated to risk groups. Those at low risk (≤ 10) will receive endocrine therapy alone and those at 
high risk (≥ 26) will receive endocrine therapy and adjuvant chemotherapy. Those at intermediate 
risk (11–25) will receive endocrine therapy and be randomly assigned to chemotherapy or no 
chemotherapy. The trial is closed for recruitment.91 Funding for the study is provided by the 
National Cancer Institute. Further details of this trial are included in Appendix 8.
MammaPrint
MammaPrint is based on microarray technology and uses a 70-gene expression profile. 
MammaPrint is intended as a prognostic test for women of all ages, LN– and LN+ (up to three 
nodes positive) with a tumour size of ≤ 5.0 cm. MammaPrint is used to determine the risk of 
distant recurrence of early breast cancer. Patients are stratified into two distinct groups – low risk 
(good prognosis) or high risk (poor prognosis) of distant recurrence. Further details are provided 
in Table 6.
Description of included studies
The present review identified an additional seven studies for the MammaPrint test. This included 
six full published peer-reviewed papers and one dissertation chapter.
The design and patient characteristics of the seven included studies are provided in Tables 13 and 
14 respectively. Most of the studies included retrospective analyses of archived tumour samples 
together with a database of patient characteristics and prognostic information. Only one study 
stated that the design was prospective.92 The populations used in the studies were somewhat 
heterogeneous, with some using only LN– patients and others using a mixture of LN– and LN+ 
patients. There was a similar pattern relating to ER status. The mean age was around 50 years. 
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TABLE 13 Study design characteristics of included studies: MammaPrint test (new data)
Author (year)
Country Study design Number of patients Follow-up Outcomes/end points Evidence type Funding
Bueno-de-
Mesquita et 
al. (2009)93
Netherlands
Consecutive 
cohort (1996–9)
Fresh frozen 
tumour samples 
(pT1–2, LN–)
Eligible sample: NR
Sample included: 
123
G1: 64 low-risk 
prognostic signature
G2: 59 high-risk 
prognostic signature
Median: 5.8 (range 
0.1–9.0) years
Time from surgery to 
distant metastasis as 
first event (counted as 
failures); OS (defined 
as time from surgery 
to death)
Clinical validity; 
clinical utility – 
reclassification 
against existing 
prognostic 
variables
NR
Gevensleben 
et al. (2010)94
Germany
Consecutive 
cohort (2005–8)
Frozen tumour 
samples 
(evaluates 
concordance)
Eligible sample: 170
Sample included: 
140
G1: 78 good 
prognosis signature
G2: 62 poor 
prognosis signature
Samples excluded 
because of 
inadequate RNA 
extraction (n = 30)
NR Comparison of risk 
prediction using the 
MammaPrint test with 
those of St Gallen 
criteria95 and Adjuvant! 
Online
Clinical utility – 
reclassification 
against existing 
prognostic 
variables; 
changes in 
treatment 
recommendations
NR
Ishitobi et al. 
(2010)96
Japan
Retrospective 
cohort (1998–
2001)
Frozen tumour 
samples
Eligible sample: 117
Sample included: 
102
G1: 20 low-risk 
prognostic signature
G2: 82 high-risk 
prognostic signature
Samples excluded 
because of failure of 
microarray profiling 
(n = 15)
Median: 7.1 (range 
0.5–9.8) years
DMFS (not defined); 
correlation between 
the MammaPrint test 
risk category and 
clinicopathological 
parameters (St Gallen 
criteria97,98)
Clinical validity; 
clinical utility – 
reclassification 
against existing 
prognostic 
variables
NR
Kok et al. 
(2010)99
Netherlands
Two datasets: 
G1: 1985–94; 
G2: 1982–96
Adjuvant 
tamoxifen (G1): 
retrospective, 
frozen tumour 
samples
No adjuvant 
systemic 
treatment (G2): 
consecutive 
series from 
van de Vijver63 
(n = 100) and 
Mook et al.64 
(n = 51), FFPE 
samples
Eligible sample: NR
Sample included: 
272
G1: 121 (83 low- 
risk, 38 high-risk 
prognostic signature)
G2: 151 (85 low-
risk, 66 high-risk 
prognostic signature)
Median: G1: 
9.6 years; G2: 
11.1 years
BCSS (defined as time 
from surgery to breast 
cancer-related death)
Clinical validity NR
Kunz et al. 
(2011)92
Germany
Prospective 
cohort (2004–8)
Fresh tumour 
samples (T1–3, 
NO-3) (evaluates 
concordance)
Eligible sample: 56
Sample included: 44
Samples excluded 
because of 
insufficient sample 
(n = 6); lost in 
transit, (n = 4); not 
eligible because of 
metastases (n = 2) 
NR Comparison of risk 
prediction using the 
MammaPrint test with 
that of the St Gallen 
guidelines97 (2007/9) 
and Adjuvant! Online
Clinical utility – 
reclassification 
against existing 
prognostic 
variables
NR
continued
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Most studies included a small number of participants (range 36–272). Follow-up was either short 
(< 10 years and in some cases < 5 years) or not reported for a number of studies.
Quality of included studies: MammaPrint
The methodological quality of the seven included studies75,92–94,96,99,100 is summarised in Figure 4 
(further details are provided in Appendix 9). Generally, only two studies75,93 performed well, 
receiving a positive assessment for at least 17 out of 21 methodological quality items. Although 
the majority of the studies (as reported by the authors) used a retrospective study design,75,96,99,100 
other potential sources of bias were generally related to the following domains: prognostic 
variable (inadequate reporting and justification of cut points used), statistical analysis (lack of 
statistical adjustment of all prognostic factors and inappropriate analysis of continuous predictor 
variables, for example categorising of continuous variables leads to loss of statistical power, 
and data-dependent categorisation leads to overoptimism)30 and interventions subsequent 
to inclusion in the study (interventions were not described or standardised). In the majority 
of studies, the assessment of study quality was hampered by poor reporting of the following 
methodological items: length of follow-up of patients, whether or not the sample of patients 
was representative and assembled at an early point in the course of the disease and whether 
or not outcomes were fully defined and appropriate (including whether or not the outcome 
assessment was unbiased). Overall, the risk of bias from the seven included studies was judged to 
be moderate.
Results: MammaPrint
A summary of the clinical evidence on MammaPrint is presented in Table 15, followed by a 
narrative summary of each study. Full data extraction tables are provided in Appendix 9.
Author (year)
Country Study design Number of patients Follow-up Outcomes/end points Evidence type Funding
Mook et al. 
(2010)75
Netherlands
Consecutive 
series (1984 –6)
Frozen tumour 
samples (T1–2, 
LN–)
Eligible sample: 173
Sample included: 
148
G1: 91 good 
prognosis signature
G2: 57 poor 
prognosis signature
Samples excluded 
because of 
insufficient sample 
(n = 22); poor RNA 
quality, (n = 3)
Median: 
11.6 years
DMFS (defined as 
time from surgery to 
distant metastasis as 
first event: counted 
as failures); BCSS 
(defined as time from 
surgery to breast 
cancer-related death); 
comparison of risk 
prediction using the 
MammaPrint test 
with that of Adjuvant! 
Online
Clinical validity; 
clinical utility – 
reclassification 
against existing 
prognostic 
variables
European 
Commission 
Framework 
Program VI-
TRANSBIG; 
Dutch National 
Genomics 
Initiative 
Cancer 
Genomics 
Center; 
Agendia BV
Na et al. 
(2011)100
Republic of 
Korea
Retrospective 
cohort (2008–9)
Fresh tumour 
samples 
(T1–2, LN–, 
M0) (evaluates 
concordance)
Eligible sample: 48
Sample included: 36
G1: 5 low-risk 
prognostic signature
G2: 31 high-risk 
prognostic signature
Samples excluded 
because of sampling 
failure (n = 10); not 
eligible because of 
metastases (n = 2)
NR Comparison of risk 
prediction using the 
MammaPrint test 
with those of the 
St Gallen criteria,95 
National Institutes of 
Health guideline101 and 
Adjuvant! Online
Clinical utility – 
reclassification 
against existing 
prognostic 
variables
NR
NR, not reported.
TABLE 13 Study design characteristics of included studies: MammaPrint test (new data) (continued)
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TABLE 15 Summary of evidence for the MammaPrint test
Author (year) Evidence type
Overall 
quality Key findings
Bueno-de-
Mesquita et al. 
(2009)93
Clinical validity; clinical 
utility – reclassification 
against existing prognostic 
variables
High 123 LN–, majority ER+ patients from the Netherlands. The rates of discordance 
between MammaPrint and four different standard clinicopathological measures 
were relatively high (38%, 41%, 26%, 30%). OS probability was 97% for good and 
82% for poor prognosis signature patients with an estimated HR of 3.4 (95% CI 
1.2 to 9.6; p = 0.021). The probability of remaining free of distant metastasis (as 
first event) was 98% for good and 78% for poor prognosis signature patients with 
an estimated HR of 5.7 (95% CI 1.6 to 20; p = 0.007). MammaPrint was shown to 
be a strong independent prognostic factor in multivariate analyses, outperforming 
the clinicopathological risk indexes. Limitations: small sample size, follow-up 
limited to 5 years
Gevensleben et 
al. (2010)94
Clinical utility – 
reclassification 
against existing 
prognostic variables; 
changes in treatment 
recommendations
Moderate 140 LN– and ER+ patients from Germany. MammaPrint and Adjuvant! Online 
were concordant in 83 cases and discordant in 57 cases (41%). A retrospective 
analysis of treatment given (where available) compared with treatment indication 
by MammaPrint was performed showing that, according to MammaPrint, 40% of 
patients had been either undertreated or overtreated. Limitation: small sample size
Ishitobi et al. 
(2010)96
Clinical validity; clinical 
utility – reclassification 
against existing prognostic 
variables
Moderate 102 LN–, majority ER+ patients from Japan. NPV for time to distant metastasis 
was high (100%), indicating that all patients were correctly classified, whereas 
PPV was low (9.8%), indicating that many of the cases classified as high risk were 
incorrectly classified. The relatively young patient population and 5-year follow-up 
may also explain why the probability of DMFS was also very high for the high-risk 
group. Limitations: small sample size, particularly in the low-risk group, findings 
may not be generalisable to the UK setting
Kok et al. 
(2010)99
Clinical validity Moderate 272, all ER+ patients from the Netherlands. Inpatients treated with adjuvant 
tamoxifen (mainlyLN+), both MammaPrint and the endocrine response categories 
were associated with BCSS at 10 years. Inpatients treated with tamoxifen, 
combined analysis of MammaPrint and ER/PR revealed additional value. Inpatients 
who did not receive tamoxifen, only MammaPrint was associated with outcome. 
Limitation: small sample size
Kunz et al. 
(2011)92
Clinical utility – 
reclassification against 
existing prognostic 
variables
Moderate 44 LN– and majority ER+ patients from Germany. Comparison of numbers 
of patients classified into risk groups using St Gallen,97 Adjuvant! Online and 
MammaPrint. The authors concluded that gene expression analysis as an 
additional tool can accurately separate patients with an intermediate clinical risk 
into low- and high-risk groups. Limitation: very small sample size
Mook et al. 
(2010)75
Clinical validity; clinical 
utility – reclassification 
against existing prognostic 
variables
High 148 ER+, LN−, postmenopausal patients from the Netherlands. Distant 
metastasis-free survival at 5 years was 93% in the low-risk group and 72% in 
the high-risk group (p = 0.07) with an associated HR of 4.6 (95% CI 1.8 to 12.0; 
p = 0.001). At 10 years the difference was not significant. BCSS at 5 years was 
99% in the low-risk group and 80% in the high-risk group (p = 0.036) with an 
associated HR of 19.1 (95% CI 2.5 to 148; p = 0.005). At 10 years the difference 
was not significant. MammaPrint and Adjuvant! Online were concordant in 107 
cases and discordant in 41 cases. The authors concluded that the MammaPrint 
signature can accurately select postmenopausal patients at low risk of breast 
cancer in terms of related death within 5 years of diagnosis and can be of clinical 
use in selecting postmenopausal women for adjuvant chemotherapy. Limitations: 
small sample size, assessed only postmenopausal women
Na et al. 
(2011)100
Clinical utility – 
reclassification against 
existing prognostic 
variables
Moderate 36 LN–, majority ER+ patients from Republic of Korea. Clinical risk concordant 
with the prognostic signature for 29 (81%) patients according to the St Gallen 
guidelines;95 30 (83%) patients according to the National Institutes of Health 
guidelines and 23 (64%) patients according to Adjuvant! Online. Limitations: very 
small sample size, no follow-up data, may not be generalisable to the UK setting
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Analytical validity
Our searches did not reveal any studies that examined analytical validity.
Clinical validity (prognostic ability)
Kok et al.99 assessed whether or not analysing both MammaPrint score and hormone receptors 
provides superior prediction of outcome than hormone receptors alone in 272 Dutch patients. 
One group comprised LN+, ER+, tamoxifen-treated patients and a second group comprised 
LN–, ER+ patients who had received no adjuvant systemic treatment. Hormone receptors were 
evaluated using the St Gallen consensus recommendations102 (highly endocrine responsive: 
ER and PR ≥ 50%; incompletely endocrine responsive: ER and/or PR low or with either one 
absent). In patients treated with adjuvant tamoxifen (mainly LN+), both MammaPrint (adjusted 
for endocrine response categories, HR 2.78; 95% CI 1.30 to 5.94) and the endocrine response 
categories (adjusted for MammaPrint, HR 7.22; 95% CI 2.17 to 24.0) were associated with BCSS 
at 10 years. Also, in patients treated with tamoxifen for metastatic disease, combined analysis 
of MammaPrint and ER/PR revealed additional value (multivariate Cox regression; p = 0.013). 
In patients who did not receive tamoxifen, only MammaPrint was associated with outcome. 
The authors concluded that both methods provide independent information on outcome after 
tamoxifen for LN+ breast cancer. There are a number of limitations to this study: the second 
patient group comprised patients included in two previously reported evaluations, the overall 
sample size was small and tumour samples had been collected over a number of years (1982–97), 
which has implications for changes in diagnosis, treatment and standards of care. The study did 
benefit from an adequate follow-up time of 10 years.
Ishitobi et al.96 examined risk classification using MammaPrint and disease outcome for 102 
LN–, majority ER+, relatively young breast cancer patients in Japan. The results relating to 
clinical validity are presented here and the results relating to clinical utility are presented in 
the relevant section below. Among the 102 patients, 20 (20%) were classified as low risk and 82 
(80%) as high risk. The authors reported that the probability of DMFS at 5 years was 100% for 
the low-risk group and 94% for the high-risk group. They did not report a HR. The NPV for time 
to distant metastasis was high (100%, 20/20), whereas the PPV was quite low (9.8%, 8/82). The 
NPV indicates the proportion of patients classified as low risk who were correctly classified using 
MammaPrint, whereas the small PPV indicates that many of the cases classified as high risk were 
incorrectly classified. The authors concluded that the 70-gene prognosis signature accurately 
identified Japanese breast cancer patients as being at low risk of developing recurrences, as 
100% of the individuals in the low-risk group remained metastasis free for the duration of the 
observation period. The authors suggest that the low number of individuals in the low-risk group 
is consistent with previous findings on patient groups of ≤ 54 years. However, these low numbers 
make any generalisations of the findings limited. The young patient population may also explain 
why the probability of DMFS was also very high for the high-risk group, together with the fact 
that this was assessed at only 5 years, given that the majority of distant recurrences and deaths 
from breast cancer occur > 5 years after diagnosis. This study employed a very small sample size 
and, furthermore, as this study was performed in a Japanese population any generalisations to the 
UK population are significantly limited.
In a Netherlands-based study, Bueno-de-Mesquita et al.93 assessed 123 LN–, majority ER+ 
patients who had been assigned MammaPrint risk categories. They reported risk classification 
and probability of disease outcome (time from surgery to distant metastasis and OS). OS 
probability was 97% (±2%) for good and 82% (±5%) for poor prognosis signature patients 
(p-value not reported) with an estimated HR of 3.4 (95% CI 1.2 to 9.6; p = 0.021). The probability 
of remaining free of distant metastasis (as first event) was 98% (±2%) for good and 78% (±6%) 
for poor prognosis signature patients (p-value not reported) with an estimated HR of 5.7 (95% 
CI 1.6 to 20; p = 0.007). In multivariate analysis, the authors demonstrated that MammaPrint 
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was a strong independent prognostic factor, outperforming the clinicopathological risk indexes. 
They concluded that the 70-gene prognosis signature is also an independent prognostic factor in 
LN – breast cancer patients for women diagnosed in recent years. Again, as this study used a small 
sample size and the follow-up assessment was limited to 5 years, generalisations of the findings 
are limited. This study also reported reclassification findings, which are detailed in the relevant 
section below.
Mook et al.75 examined 148 LN– and majority ER+, specifically postmenopausal patients. 
The study, conducted in the Netherlands, investigated disease outcome (DMFS and BCSS at 
5 years), and prediction of early breast cancer-specific death (BCSD) using MammaPrint risk 
categories. The authors also assessed reclassification and these findings will be presented below. 
DMFS at 5 years was 93% in the low-risk group and 72% in the high-risk group (p = 0.07) with 
an associated HR of 4.6 (95% CI 1.8 to 12.0; p = 0.001). At 10 years it was 80% in the low-risk 
group and 67% in the high-risk group (HR not reported, p-value not reported). Over the entire 
follow-up period the HR was 1.8 (95% CI 0.9 to 3.5; p = 0.07). BCSS at 5 years was 99% in the 
low-risk group and 80% in the high-risk group (p = 0.036) with an associated HR of 19.1 (95% 
CI 2.5 to 148, p = 0.005). At 10 years it was 90% for the low-risk group and 69% for the high-risk 
group (HR not reported, p-value not reported). Over the entire follow-up period the HR was 2.0 
(95% CI 1.0 to 4.0; p = 0.04). In terms of the prediction of early BCSD, the HR for BCSS at 5 years 
was 14.4 (95% CI 1.7 to 122.2; p = 0.01) and at 10 years was 4.4 (95% CI 1.4 to 13.6; p = 0.01). 
Subgroup analyses showed that the HR for BCSS in hormonal therapy-naive patients (untreated) 
at 5 years was 10.8 (95% CI 1.2 to 94.7; p = 0.03). The authors concluded that the MammaPrint 
signature can accurately select postmenopausal patients at low risk of breast cancer in terms 
of related death within 5 years of diagnosis, although not at 10 years, and can be of clinical use 
in selecting postmenopausal women for adjuvant chemotherapy. Again this study employed a 
very small sample size and was based on postmenopausal women, limiting the applicability of 
the findings.
Clinical utility
Reclassification against existing prognostic variables Kunz et al.92 compared the MammaPrint 
result with St Gallen criteria97 and Adjuvant! Online and conducted risk assessment using 
MammaPrint according to nodal status in 44 women in Germany. The majority of patients 
were LN– and ER+. MammaPrint classified 29 patients as low risk and 15 patients as high 
risk. St Gallen criteria classified four patients as low risk, 34 patients as intermediate risk and 
six patients as high risk. In the group of women with intermediate risk according to St Gallen, 
MammaPrint assigned 23 patients to low risk and 11 to high risk. Adjuvant! Online classified 19 
patients as low risk and 25 patients as high risk (for Adjuvant! Online, patients were classified as 
having low clinical risk when the 10-year OS rate as predicted by Adjuvant! Online was > 88% 
for ER+ tumours and > 92% for ER– tumours). MammaPrint classified 13 patients with LN+ 
disease as low risk and five as high risk. For those with LN– disease, 17 were classified as low 
risk and nine as high risk. The authors concluded that, by using gene expression analysis as 
an additional tool, patients with an intermediate clinical risk can be accurately separated into 
low- and high-risk groups. Follow-up data would be required to verify the authors’ conclusions 
that the gene expression analysis provides more accurate information on recurrence risk than 
conventional clinicopathological criteria. This was a reasonable quality study with a prospective 
design although the interpretation of the findings is limited because of the very small sample size. 
Studies on larger sample sizes would be required to verify these conclusions.
Na et al.100 compared MammaPrint with the St Gallen criteria,95 the National Institutes of Health 
(NIH) guidelines101 and Adjuvant! Online in 36 LN– and majority ER+ Korean patients. The 
70-gene prognosis signature identified 5 (14%) patients with a low-risk prognosis signature 
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and 31 (86%) patients with a high-risk prognosis signature. Clinical risk was concordant with 
the prognostic signature for 29 (81%) patients according to the St Gallen guidelines, 30 (83%) 
patients according to the NIH guidelines and 23 (64%) patients according to Adjuvant! Online. 
The authors concluded that the 70-gene prognostic signature gave somewhat different results in 
Korean patients with breast cancer from those in European patients. They suggested that further 
studies should assess whether or not a gene disparity between Asians and Europeans influenced 
the results. Further large-scale studies with a follow-up evaluation are required to assess whether 
or not the use of the 70-gene prognostic signature can predict the prognosis of Korean patients 
with breast cancer. (Note that as St Gallen has three risk categories and MammaPrint has two, a 
calculation of concordance is not possible.) This study had a very small sample size and, as the 
results could have been influenced by a gene disparity between European and Asian patients, 
any generalisations to the UK population are significantly limited. Furthermore, as there was no 
follow-up evaluation, no conclusions regarding the prognostic value of MammaPrint compared 
with clinicopathological guidelines can be made.
Ishitobi et al.96 examined risk classification using MammaPrint and disease outcome for breast 
cancer in 102 LN–, majority ER+ patients in Japan. The results relating to clinical validity have 
been presented in the previous section. Among the 102 patients, 20 (20%) were classified as low 
risk and 82 (80%) as high genomic risk. Based on the 1998 St Gallen criteria,103 all patients were 
classified as intermediate or high risk. The 2009 St Gallen criteria97 use more refined criteria to 
define the low-risk group and they classified 7 (of 100) patients as low risk compared with 20 (of 
102) patients identified as low risk by MammaPrint (p = 0.009). The authors concluded that the 
70-gene prognosis signature accurately identified Japanese breast cancer patients at low risk of 
developing recurrences, as 100% of the individuals in the low-risk group remained metastasis 
free for the duration of the observation period. Overall, this study employed a very small sample 
size; furthermore, as this study was performed using a Japanese population, any generalisations 
to the UK population are significantly limited.
Bueno-de-Mesquita et al.93 made a comparison between MammaPrint risk categories and risk 
assessment based on Adjuvant Online!, St Gallen guidelines,103,104 NPI and Dutch Institute for 
Healthcare Improvement (CBO) guidelines (2004)105,106 in 123 LN– and majority ER+ Dutch 
patients. Discordance between the measures was 38% (47/123), 41% (50/123), 26% (32/123) and 
30% (37/123) respectively. These rates of discordance appear relatively high although we do not 
know which predictor is classifying correctly. Again, as this study used a small sample size and 
the follow-up assessment was limited to 5 years, generalisations of the findings are limited.
Mook et al.75 examined 148 LN– and majority ER+, specifically postmenopausal patients. 
The study, conducted in the Netherlands, investigated classification using MammaPrint and 
disease outcome (the results of the latter are presented in the earlier section). MammaPrint risk 
categories of high and low were compared with Adjuvant! Online categories of high and low 
(low clinical risk: predicted 10-year BCSS > 88% for ER+ tumours and > 92% for ER– tumours). 
MammaPrint and Adjuvant! Online were concordant in 107 cases and discordant in 41 cases, 
although again we cannot make any assertions regarding which indicator is more accurate. The 
authors concluded that the 70-gene prognosis signature can accurately select postmenopausal 
patients at low risk of breast cancer. Again, these findings were based on a very small sample 
size and assessed only postmenopausal women, limiting the applicability of the findings to 
younger women.
A German-based study95 investigating 140 majority LN– and ER+ patients was reported by 
Gevensleben et al.94 The authors made a comparison between risk prediction using the 70-gene 
prognostic signature and risk prediction using the St Gallen criteria95 and Adjuvant! Online 
(Adjuvant! Online risk classification according to Ravdin et al.107). MammaPrint and Adjuvant! 
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Online were concordant in 83 cases and discordant in 57 cases (41%). The authors concluded 
that MammaPrint provides improved prediction of recurrence risk compared with currently 
used guidelines. The generalisability of the findings is limited because of the small sample 
size employed.
Changes in treatment recommendations Gevensleben et al.94 in their study investigating 140 
LN– and ER+ German patients, also examined treatment advice. For 59 patients (out of 62) 
with poor prognosis identified by the 70-gene prognosis signature, the clinical treatment was 
recorded. In total, 19 (32%) of these patients did not receive adjuvant systemic treatment other 
than endocrine therapy and were potentially undertreated. In contrast, 35 (out of 77) patients 
who were classified as having a good prognosis by the 70-gene prognosis signature, and for whom 
treatment was known, received chemotherapy and were potentially overtreated. As a result, the 
authors concluded that the 70-gene prognosis signature would have resulted in altered treatment 
advice in 40% of the patients, based on the assumption that all high-risk patients would receive 
chemotherapy and all low-risk patients would not. There are limitations to this study, including 
that it was based on a small sample of patients and that the data relating to changes in treatment 
recommendations are retrospective and relate only to potential and not actual changes.
Supplementary evidence: MammaPrint
Four further citations108–111 were excluded from the review as they did not meet the inclusion 
criteria on the basis that they are pooled analyses of existing data. This evidence was not in the 
form of meta-analyses of the separate studies. This approach is methodologically inappropriate. 
However, because of the paucity of data on the clinical utility of MammaPrint, a number of these 
studies have been used to inform the economic model and therefore they will be summarised 
here for completeness.
These studies suffer from several major limitations. First, they are based on pooled analyses and 
it is unclear how individual patient data have been combined from the various primary studies 
incorporated. Furthermore, there is likely to be significant heterogeneity in the chemotherapy 
used, standards of care and diagnosis as patients were recruited over a period of > 20 years 
(1984–2006). This makes any generalisability of the conclusions to current practice difficult.
Knauer et al.112 evaluated the predictive value of the 70-gene prognostic signature for response 
to chemotherapy. They created a pooled database of patients from six previous studies, including 
541 women with unilateral stage T1–3, N-1, M0 invasive breast cancer diagnosed between 
1984 and 2006. Each tumour had been classified as having a high- or low-risk signature using 
the MammaPrint test: 252 (47%) as low risk and 289 (53%) as high risk. Median follow-up was 
7.1 years, but all analyses were censored at 5 years. The signature was prognostic: women with 
a low-risk tumour signature had a 5-year BCSS of 97% and a 5-year DMFS of 95% whereas 
women with a high-risk tumour signature had a 5-year BCSS of 87% and a 5-year DMFS of 
82%. However, women in both risk categories appeared to benefit from chemotherapy, although 
the estimates were not statistically significant in the low-risk group. For BCSS the unadjusted 
HR for chemotherapy was 0.58 (95% CI 0.07 to 5.0) in the low-risk group and 0.21 (95% CI 
0.07 to 0.59) in the high-risk group. The p-value for interaction between use of chemotherapy 
and the risk signature was not statistically significant (p = 0.45). For DMFS the unadjusted HR 
for chemotherapy was 0.26 (95% CI 0.03 to 2.0) in the low-risk group and 0.35 (95% CI 0.17 to 
0.71) in the high-risk group. The p-value for the interaction was not reported, but in this case the 
trend was towards greater relative benefit from chemotherapy in the low-risk group. This study, 
however, has some major statistical flaws. For instance, data were truncated arbitrarily at 5 years, 
despite that fact that the median follow-up was 7.1 years. Censoring the follow-up at 5 years 
biased the results in favour of the utility of the prognostic signature because the association 
between the 70-gene signature and recurrent disease falls quickly after 5 years of follow-up.113 As 
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the majority of distant recurrences and deaths from breast cancer occur > 5 years after diagnosis, 
this is a significant limitation.113
Knauer et al.110 investigated whether or not MammaPrint identifies HER2-positive patients with 
a favourable outcome. A total of 168 T1–3, N-1, HER2-positive patients were identified from 
a pooled database, classified by the MammaPrint test as having a good or a poor prognosis, 
and correlated with long-term outcome. A total of 89 of these patients did not receive adjuvant 
chemotherapy. In these patients, after a median follow-up of 7.4 years, 35 (39%) distant 
recurrences and 29 (33%) BCSDs occurred. The test classified 20 (22%) patients as having a 
good prognosis, with 10-year distant disease-free survival (DDFS) of 84%, compared with 69 
(78%) poor prognosis patients with a 10-year DDFS of 55%. The estimated HRs were 4.5 (95% 
CI 1.1 to 18.7, p = 0.04) and 3.8 (95% CI 0.9 to 15.8, p = 0.07) for DDFS and BCSS respectively. 
In multivariate analysis adjusted for known prognostic factors and hormone therapy, HRs 
were 5.8 (95% CI 1.3 to 26.7, p = 0.03) and 4.7 (95% CI 1.0 to 21.7, p = 0.05) for DDFS and 
BCSS respectively. The authors concluded that the test is an independent prognostic indicator 
that identified a subgroup of HER2-positive early breast cancer patients with a favourable 
long-term outcome.
Mook et al.108 aimed to evaluate the accuracy of MammaPrint in T1 breast cancer. They selected 
964 patients with pT1 tumours (≤ 2 cm) from a pooled database. The samples had been previously 
analysed and classified as having good or poor prognosis. The median follow-up was 7.1 years. 
The 10-year DMFS and BCSS probabilities were 87% [standard error (SE) 2%] and 91% (SE 
2%), respectively, for the good prognosis group (n = 525) and 72% (SE 3%) and 72% (SE 3%), 
respectively, for the poor prognosis group (n = 439). The signature was an independent prognostic 
factor for BCSS at 10 years (multivariate HR 3.25; 95% CI 1.92 to 5.51; p < 0.001]). Moreover, 
the test predicted DMFS at 10 years for 139 patients with pT1ab cancers (HR 3.45; 95% CI 1.04 
to 11.50; p = 0.04). The authors concluded that the test is an independent prognostic factor in 
patients with pT1 tumours and can help to individualise adjuvant treatment recommendations.
Bueno-de-Mesquita et al.109 evaluated the additional prognostic value of MammaPrint compared 
with a combination of established prognostic guidelines. A total of 701 patients from a pooled 
database with an existing MammaPrint result were evaluated. Only 6% (10/156) of ER– tumours 
had a good prognosis signature. The signature was not useful for ER+ tumours with a concordant 
high Adjuvant! Online, high St Gallen and/or high NPI risk (n = 139). The 10-year OS estimate 
for the good prognosis group with these characteristics was < 80% and adjuvant systemic 
treatment (AST) would therefore be appropriate irrespective of the signature result. In contrast, 
for patients with a concordant low Adjuvant! Online, low St Gallen and/or low NPI risk and in 
discordant clinical risk patients, the signature identified low-risk patients in whom AST could 
be safely withheld (10-year OS < 90%). The authors concluded that the MammaPrint signature 
provides additional prognostic information, especially in ER+, LN– breast cancer patients with 
a predominantly low or discordant clinical risk on the basis of Adjuvant! Online, the St Gallen 
guidelines and/or NPI.
Summary of evidence: MammaPrint
Analytical validity of MammaPrint
In the earlier systematic reviews limited data are available on variability and reproducibility, with 
a limited number of patients and a moderate number of replications. The only validation study 
using the MammaPrint assay (rather than the underlying 70-gene signature) showed that only 
about 80% of fresh-frozen specimens were analysable.
Our review identified no new evidence.
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Clinical validity (prognostic ability) of MammaPrint
Earlier systematic reviews identified a range of studies providing evidence on the prognostic 
ability of the test in heterogeneous populations. The evidence relating to the clinical validity 
of MammaPrint was not always conclusive nor supportive of the prognostic value of the test. 
Four studies suggested that the test could predict prognosis, one study failed to verify the 
prognostic utility of the test and in another the methods and results were at variance with those 
of other studies.
The current review identified four additional studies that contain data on clinical validity. Of 
these, two were rated as high quality and two as moderate quality. These studies demonstrated 
that the MammaPrint score is a strong independent prognostic factor and may provide additional 
value to standard clinicopathological measures. The majority of the evidence suggests that the 
test is reliable at predicting outcome at 5 years.74 However, the population in all of these studies 
was relatively small, ranging between 102 and 272 patients. One of the studies was conducted in 
a Japanese population, making generalisation to UK practice difficult. Follow-up was limited to 
only 5 years in two of the studies.
Clinical utility of MammaPrint
Earlier systematic reviews identified one study on clinical utility, which demonstrated that 
MammaPrint had an impact on clinical decision-making. The addition of MammaPrint to the 
standard Dutch clinical assessment of risk (modified by patient preference) in a cohort of 427 
patients increased the number of patients receiving adjuvant systemic therapy by 20. However, 
the follow-up was not long enough to provide evidence of its effect on clinical end points such as 
DMFS or its utility in predicting treatment benefit.
The current review identified six studies that contained data on the clinical utility of 
MammaPrint. Of these, two were rated as high quality and four as moderate quality. Five of the 
six studies reported on how the MammaPrint test reclassifies patients into high- and low-risk 
groups compared with the risk assigned in current practice. None of these was based in a UK 
setting. These studies reported that there was a high level of discordance between MammaPrint 
and current practice, although the studies did not demonstrate how this would impact on 
treatment decisions. One study reported that the use of MammaPrint would result in altered 
treatment advice for 40% of patients, but this was based on the assumption that all patients 
classified as high risk would receive chemotherapy and no patients classified as low risk would 
receive chemotherapy rather than by providing evidence of actual changes in practice. A study 
on the benefits of chemotherapy by MammaPrint risk group was identified but omitted from the 
systematic review because it was based on a pooled analysis of six primary studies (which were 
included in the review in their own right). This study reports findings on chemotherapy benefit 
for MammaPrint high-and low-risk groups but the findings are not considered to be robust as the 
authors do not reanalyse the tumour samples and it is unclear how individual patient data were 
combined. All of the studies on clinical utility were based on small sample sizes.
Key gaps in the evidence base remain:
 ■ Robust evidence of clinical utility is needed. It is not yet clear whether or not the use of the 
MammaPrint test will change the management of patients, for example reduce the number 
of patients unnecessarily treated with chemotherapy or improve patient outcomes through 
increases in DFS and OS. The ongoing Microarray In Node-negative Disease may Avoid 
ChemoTherapy (MINDACT) trial, which is summarised in Ongoing randomised trial: the 
Microarray In Node-negative Disease may Avoid ChemoTherapy trial (see Appendix 8 for 
further detail of the MINDACT trial), will provide this evidence.
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 ■ Only two studies were considered to be of high quality. The rest of the studies in the current 
review were judged to provide moderate-quality (although retrospective) evidence for 
MammaPrint. All of the included studies employed very small sample sizes. One of the 
most characteristic features of the studies was their heterogeneity, particularly with respect 
to patient populations. All but one92 of the MammaPrint studies were retrospective, and 
many used old archived tumour samples and non-standardised methods of patient selection. 
In addition to patient heterogeneity, there is likely to be significant heterogeneity in the 
chemotherapy treatment as patients were diagnosed with breast cancer over a period of 
> 20 years (1984–2006) and the standards of care have changed considerably.
 ■ Further issues that may limit the extent to which we can generalise the findings include 
publication bias and the fact that no studies were conducted in the UK setting.
Overall summary
The evidence base, in particular in relation to the prognostic ability of the test, is developing 
but is based on small sample sizes (≤ 272). None of the studies used UK-based patients and the 
data were all based on cohort studies. The test appears to be prognostic at 5 years although the 
validity of the test to predict longer-term outcomes does not seem to have been established. 
Robust evidence of clinical utility is needed as it is not yet clear to what extent the use of the 
MammaPrint test will change the management of patients and to what extent chemotherapy 
would be offered to patients classified as having a good or a poor prognosis with MammaPrint. 
It is also unclear to what extent MammaPrint risk groups are predictive of chemotherapy benefit 
or how the use of MammaPrint will improve patient outcomes through increases in DFS and 
OS. The evidence for MammaPrint to date is mainly derived from premenopausal women, but 
younger women are more likely to be classified as having a poor prognosis using MammaPrint, 
which might overestimate the benefit of the test.
Ongoing randomised trial: the Microarray In Node-negative Disease 
may Avoid ChemoTherapy trial
The MINDACT trial started recruiting patients in 2006 and has an estimated completion date of 
2019. It is a partially randomised, open-label, prospective, multicentre clinical trial that aims to 
assess the value of the 70-gene prognostic signature in predicting which patients would benefit 
from chemotherapy compared with Adjuvant! Online, which is based on clinical characteristics. 
Women > 18 years (the upper age limit of 70 years was recently removed) with histologically 
confirmed unilateral invasive breast cancer, T1–3 operable disease, up to three positive lymph 
nodes and no distant metastases are eligible for enrolment. The target for enrolment recently 
increased to 6600 from 6000. This is predicted to result in 55% of patients assessed as high risk 
by both methods, who will go on to have chemotherapy, and 13% of patients assessed as low risk 
by both methods, who will go on to have no chemotherapy. The 32% who are assessed as high 
risk by one method and low risk by the other will then be randomised to follow the treatment 
indicated by MammaPrint or the treatment indicated by Adjuvant! Online. Two further 
objectives of the trial relating to the efficacy of different chemotherapy agents and endocrine 
treatment strategies are addressed by two further stages of randomisation. Regardless of previous 
randomisation and risk categorisation, patients who are to receive chemotherapy are randomised 
to docetaxel or capecitabine regimens and patients who are hormone receptor-positive are 
randomised to a single-agent upfront aromatase inhibitor (letrozole) for 7 years or tamoxifen for 
2 years followed by letrozole for 5 years. The primary outcome measures are DMFS at 5 years and 
DFS, followed up for a minimum of 15 years. As of October 2012, the study had enrolled 6700 
patients. Further details of this trial are included in Appendix 8.
MammaPrint and BluePrint
BluePrint is used in addition to MammaPrint for molecular subtyping. It is an 80-gene 
microarray and the target population is patients with early-stage (stage I or II), LN– or LN+ 
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(up to three nodes), ER+ or ER– breast cancer. BluePrint provides information on breast cancer 
subtype using three categories: basal-type, luminal-type and ERBB2-type cancers.
Description of included studies
The searches did not identify any full peer-reviewed papers relating to the BluePrint test; 
however, one meeting abstract by Stork-Sloots et al.114 met the inclusion criteria. This study 
related to clinical validity, the design was retrospective and the sample size was moderate 
(n = 469). No further details of the design or the study populations were reported.
Quality of the included study: MammaPrint and Blueprint
Although the assessment of study quality was hindered by poor reporting in the domains of 
outcome, prognostic variable, analysis and interventions subsequent to inclusion in the cohort, 
the overall methodological quality of the included study114 was judged to be low, indicating a 
high risk of bias (the study received a positive assessment of at least two out of 21 methodological 
quality items).
Results: MammaPrint and Blueprint
Full data extraction tables are provided in Appendix 10.
Analytical validity
No available evidence.
Clinical validity
Stork-Sloots et al.114 compared BluePrint directly with the intrinsic subtyping using the original 
intrinsic gene set as developed by Perou et al.,26 from which the PAM50 gene set has originated. 
Using 469 independent samples and two publicly available data sets (n = 215, n = 159), the authors 
reported 5-year survival estimates for the subtypes and for the groups further separated by high- 
and low-risk MammaPrint categories. They reported that samples with a ERBB2-like or basal-like 
gene profile showed equally poor 5-year survival rates of ~65%. However, the ERBB2-like subset 
of MammaPrint low-risk patients (15%) showed an 89% (95% CI 71% to 100%) survival rate 
without trastuzumab treatment. When the luminal-like subtype was separated into high and low 
risk by MammaPrint the survival rate was 56% (95% CI 46% to 68%) for high-risk luminal-like 
samples and 94% (95% CI 90% to 99%) for low-risk luminal-like samples. The authors concluded 
that the developed multigene profile can classify breast tumours into luminal-, ERBB2- and basal-
like subgroups. By combining this molecular subtyping with MammaPrint risk classification, 
specific groups of patients can be recognised that are at high risk of recurrence. The low-risk 
patients within the luminal- and ERBB2-like subclasses have a very low risk of recurrence. There 
are significant limitations in making any interpretations from this evidence as it is derived only 
from an abstract. It has been shown that there may be discrepancies between data made available 
in abstracts and the reporting of results in subsequently published full-length articles.89 Because 
of incomplete reporting the methodological quality of studies cannot be confidently assessed by 
systematic reviewers.
Clinical utility
No available evidence.
Summary of evidence: MammaPrint and BluePrint
Because of the limited available data (reported in abstract form only), no firm conclusions can 
be drawn about the clinical validity (prognostic ability) of the MammaPrint and BluePrint test, 
although it does appear that the test has been validated in an independent cohort. No published 
evidence is yet available on the clinical utility of the test in combination with MammaPrint. 
Further evidence for this test is required.
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PAM50 test
The PAM50 gene expression assay identifies the major intrinsic biological subtypes of breast 
cancer. The current version of the test provides classification of breast cancer subtype and 
quantitative values for (gene/protein) ESR1/ER, PGR/PR, ERBB2/HER2, proliferation score and 
luminal score (ER pathway). The current version does not provide a risk of recurrence score 
or category. The PAM50 Breast Cancer Intrinsic Classifier test is recommended for all patients 
diagnosed with invasive breast cancer, regardless of stage or ER status. Further details are 
provided in Table 6.
Description of included studies
The searches identified six studies for the PAM50 test. This included two full peer-reviewed 
papers,115,116 three meeting abstracts117–120 and an unpublished manuscript provided by 
the manufacturer.121
The design and patient characteristics of the six included studies are provided in Tables 16 and 
17 respectively. All of the reported studies had a retrospective design analysing archived tumour 
samples. The populations used in the studies were somewhat heterogeneous, although in most 
studies more patients were LN+ and ER+ than LN– and ER–. The ages of the patients varied 
across the studies, from a median age of 47.5 years in one paper121 to a median of 67 years in 
another.116 Most studies included a moderate number of tumour samples. Follow-up was not 
reported for a number of studies but was around a median of 10 years in those that did report a 
follow-up time.
Quality of included studies: PAM50
The methodological quality of the six included studies (seven citations)115–121 is summarised in 
Figure 5 (further details are provided in Appendix 11). Of these, two studies performed well,117,121 
receiving a positive assessment for at least 17 out of 21 methodological quality items. Although 
all studies used a retrospective study design, other potential sources of bias were generally related 
to the following domains: sample of patients (all eligible patients were not included), outcomes 
(not fully defined) and interventions subsequent to inclusion in the cohort (interventions were 
not fully described or standardised). Overall, the risk of bias from these studies was judged to 
be moderate.
Results: PAM50
A summary of the clinical evidence for PAM50 is presented in Table 18 followed by a narrative 
summary of each study. Full data extraction tables are provided in Appendix 11.
Analytical validity
Ebbert et al.118 reported an analytical validity study using 171 tumour samples from US patients. 
They reported that within-platform cross-validation of the clinical subtype predictor showed 
91.6% concordance. There was 100% reproducibility in subtype predictions across 46 runs 
testing different subtypes. Subtype predictions across platforms showed 88.1% concordance. 
Dilution experiments, introducing ‘normal’ breast tissue RNA into breast cancer RNA, showed a 
systematic switch towards the ‘normal’ signature, with luminal A and luminal B subtypes being 
most susceptible. The authors concluded that the PAM50 Breast Cancer Intrinsic Classifier 
is highly reproducible within and across platforms and that the clinical test has utility in the 
management of ER+ and ER– invasive breast cancer of all stages. The quality of this report was 
judged as low. Furthermore, the study was based on a small number of tumour samples and 
full details of the patient characteristics were not provided. In addition, there are significant 
limitations in making any interpretations from this evidence as it is derived only from an 
abstract. It has been shown that there may be discrepancies between data made available in 
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abstracts and the reporting of results in subsequently published full-length articles.89 Because of 
incomplete reporting the methodological quality of studies cannot be confidently assessed by 
systematic reviewers.
TABLE 18 Summary of evidence for the PAM50 test
Author (year) Evidence type Overall quality Key findings
Bernard et al. 
(2011)119 (abstract) 
and Martin et al.120 
(abstract)
Analytical validity; clinical utility 
– predictive ability (benefit of 
chemotherapy)
Comparison of PAM50 by RT-
qPCR with IHC and identification 
of potential predictive markers 
of taxane clinical benefit
Low 793 LN+ patients from the GEICAM 9906 randomised trial. 
Bernard et al. reported agreement between RT-qPCR gene 
expression and IHC scoring for clinical markers. They showed 
that there was good agreement between (gene/protein) ESR1/
ER, PGR/PR and ERBB2/HER2. The accuracy was significantly 
lower for MKI67/Ki-67, EGFR/EGFR and KRT5/CK5/6. The authors 
concluded that calling cut-points based on RT-qPCR expression 
across subtypes is reproducible across data sets and has good 
agreement with expression by IHC for clinically used biomarkers. 
Martin et al. reported (AIC information has been removed). The 
authors concluded that (AIC information has been removed). 
Limitations: abstract data
Cheang et al. 
(2011)117 (AIC 
information has been 
removed)
Clinical validity; clinical utility 
– predictive ability (benefit of 
chemotherapy)
(AIC information has been 
removed)
High (AIC information has been removed)
Chia et al. (2011)121 Clinical validity; clinical utility 
– predictive ability (benefit of 
tamoxifen)
(AIC information has been 
removed)
High (AIC information has been removed)
Ebbert et al. (2011)118 
(abstract) 
Analytical validity Low 171 US patients. Reported that within-platform cross-validation of 
the clinical subtype predictor showed 91.6% concordance. There 
was 100% reproducibility of subtype predictions across 46 runs 
testing different subtypes. Subtype predictions across platforms 
showed 88.1% concordance. The authors concluded that the 
PAM50 Breast Cancer Intrinsic Classifier is highly reproducible 
within and across platforms. Limitations: small sample size, 
abstract data
Nielsen et al. 
(2010)116 (additional 
data from 
unpublished version 
of the manuscript)
Clinical validity
Comparison of clinical, IHC and 
GEP models of prognosis
Moderate 786 LN+ or higher-risk LN–, ER+ Canadian patients. Assessed 
numbers of patients assigned to each intrinsic subtype and risk of 
relapse score against IHC (ER, PR, HER2, Ki-67). Reported that the 
included patients were considered to be high risk with overall 10-
year RFS of 62% and DSS of 72%. Those assigned to luminal A 
tumours had significantly better outcomes (10-year RFS 74%; DSS 
83%) than those assigned to luminal B, HER2-enriched and basal-
like tumours. The authors concluded that IHC approaches do work 
and provide significant prognostic information; however, PAM50 
is superior to these in terms of adding significant additional 
information and in its capacity to identify a particularly low-risk 
group. Incorporated a relatively large sample
Parker et al. (2009)115 Clinical validity Moderate 950 majority LN–, ER+ Canadian and US patients. Reported that 
the intrinsic subtypes showed prognostic significance (for RFS) 
in untreated (no systemic therapy) patients (p < 0.0001) and 
remained significant in multivariable analyses that incorporated 
clinical covariates (ER status, histological grade, tumour size and 
LN status) (p < 0.0001). The authors concluded that the intrinsic 
subtype and risk predictors based on the PAM50 gene set add 
significant prognostic and predictive value to pathological staging, 
histological grade and standard clinical molecular markers
DSS, disease-specific survival; RFS, recurrence-free survival; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.
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Bernard et al.,119 using a cohort of 793 LN+ tumour samples from the GEICAM 9906 randomised 
trial, reported agreement between reverse transcription-quantitative polymerase chain reaction 
(RT-qPCR) gene expression and IHC scoring for clinical markers. They showed that there was 
good agreement between (gene/protein) ESR1/ER, PGR/PR and ERBB2/HER2. The accuracy 
was significantly lower for MKI67/Ki-67, EGFR/EGFR and KRT5/CK5/6. Discrepancies 
between the Hercep test and chromogenic in situ hybridisation (CISH) procedure for 2+ and 
3+ staining-intensity samples showed that RT-qPCR agreed better with the Herceptest [area 
under the curve (AUC): 0.95 vs. 0.93). The authors concluded that calling cut-points based on 
RT-qPCR expression across subtypes is reproducible across data sets and has good agreement 
with expression by IHC for clinically used biomarkers. The quality of this report was judged as 
low. Although the study benefits from a relatively large sample size, as these data were reported in 
abstract form only there are significant limitations in using these results to make generalisations.
Clinical validity
Parker et al.115 investigated the distribution of intrinsic subtypes in comparison with clinical 
marker status and risk of relapse models for prognosis in a cohort of 950 Canadian and US 
majority LN–, ER+ breast cancer patients. They reported that the intrinsic subtypes showed 
prognostic significance (for recurrence-free survival, RFS) in untreated (no systemic therapy) 
patients (p < 0.0001) and remained significant in multivariable analyses that incorporated 
clinical covariates (ER status, histological grade, tumour size and node status) (p < 0.0001). The 
authors concluded that the intrinsic subtype and risk predictors based on the PAM50 gene set 
add significant prognostic and predictive value to pathological staging, histological grade and 
standard clinical molecular markers. The quality of this study was judged to be moderate and the 
sample size was relatively large.
Nielsen et al.116 used a cohort of 786 LN+ or higher-risk LN–, ER+ Canadian patients with 
tumours collected between 1986 and 1992 to assess the numbers of patients assigned to each 
intrinsic subtype and risk of relapse score against IHC (ER, PR, HER2, Ki67). Adjuvant! Online 
was used to generate breast cancer recurrence-free survival and disease-specific survival 
estimates for each patient. They reported that the included patients were considered to be high 
risk, with overall 10-year RFS of 62% and disease-specific survival of 72%. Those assigned to 
luminal A tumours had significantly better outcomes (10-year RFS 74%; disease-specific survival 
83%) than those assigned to luminal B, HER2-enriched and basal-like tumours. In Cox models 
incorporating standard prognostic variables, HRs for breast cancer disease-specific survival over 
the first 5 years of follow-up, relative to the most common luminal subtype, were 1.99 (95% CI 
1.09 to 3.64) for the luminal B subtype, 3.65 (95% CI 1.64 to 8.16) for the HER2-enriched subtype 
and 17.71 (95% CI 1.71 to 183.33) for the basal-like subtype (p = 0.0018). The authors concluded 
that IHC approaches do work and provide significant prognostic information; however, PAM50 
is superior to these in terms of adding significant additional information and in its capacity 
to identify a particularly low-risk group. This study was judged to be of moderate quality and 
incorporated a relatively large sample size.
Chia et al.121 (AIC information has been removed).
Cheang et al.117 (AIC information has been removed).
Clinical utility
In addition to the clinical validity data reported above, Chia et al.121 (AIC information has 
been removed).
(AIC information has been removed.) Using the same data reported by Bernard et al.119 for a 
cohort of 793 LN+ tumour samples, Martin et al.120 (AIC information has been removed). The 
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quality of this report was judged as low. Although the study benefits from a relatively large sample 
size, as these data were reported in abstract form only there are significant limitations in using 
these results to make generalisations.
Cheang et al.117 (AIC information has been removed).
Summary of evidence: PAM50
Analytical validity of PAM50
Two abstracts118,119 reported data on analytical validity, both rated as low quality. One118 employed 
a relatively small sample (n = 171) whereas the other119 was based on a much larger sample 
(n = 793). These studies provide a comparison of PAM50 against standard IHC measurements. 
There are significant limitations in making any interpretations from this evidence as it is derived 
only from abstracts. It has been shown that there may be discrepancies between data made 
available in abstracts and the reporting of results in subsequently published full-length articles.89 
Because of incomplete reporting the methodological quality of studies cannot be confidently 
assessed by systematic reviewers.
Clinical validity (prognostic ability) of PAM50
Four studies,115–117,121 two rated as high quality and two rated as low quality, were identified that 
contain data on clinical validity. Two of these are as yet unpublished. These studies demonstrate 
that the intrinsic subtypes are significantly associated with outcome, provide additional 
information to IHC approaches and standard clinicopathological measures and can identify 
a particularly low-risk group. They demonstrate that prognostic ability has been validated in 
external cohorts. However, the population in most of the studies was LN+, with the exception 
of that by Parker et al.,115 who assessed LN– patients; therefore, the generalisability of these 
findings to LN–, ER+ patients is limited. Furthermore, no studies were UK based, limiting the 
generalisation of the findings to UK practice. Finally, as two of these studies were unpublished 
there are significant limitations in drawing conclusions from this evidence.
Clinical utility of PAM50
(AIC information has been removed).
Key gaps in the evidence base remain and are summarised below:
 ■ The evidence base to date is still immature as the majority of the evidence presented here is 
in abstract or unpublished form only. Only two studies were considered to be of high quality 
(these presented clinical validity and clinical utility data), two were of moderate quality 
and two were of low quality, although it should be noted that only two studies were full 
peer-reviewed papers.
 ■ Further evidence around analytical validity is required as the current evidence is based on 
abstracts only.
 ■ Robust evidence of clinical utility is needed. It is not yet clear whether or not the use of 
the PAM50 test will change the management of patients, for example reduce the number 
of patients unnecessarily treated with chemotherapy or improve patient outcomes through 
increases in DFS and OS.
 ■ The fact that no studies were conducted in a UK setting may limit the extent to which we can 
generalise the findings.
Overall summary
The evidence base, in particular in relation to the prognostic ability of the test, is developing.
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None of the studies used UK-based patients and the data were all based on cohort studies. Most 
of the evidence is in LN+ patients. The main limitation is that currently most of the evidence is 
unpublished or is in abstract form only. Robust evidence of clinical utility is needed as it is not yet 
clear to what extent the use of the PAM50 test will change the management of patients, to what 
extent PAM50 subtypes are predictive of chemotherapy benefit or how the use of PAM50 will 
improve patient outcomes through increases in DFS and OS.
Breast Cancer Index
The BCI is a RT-PCR assessment of the ratio of expression of two genes, HOXB13 and IL17BR, 
combined with the MGI and gives an indication of recurrence risk. The target population is those 
with ER+ and LN– early breast cancer. The BCI RS ranges from 0 to 10 and divides patients into 
three risk groups. Low risk is defined as a score < 5; intermediate risk as a score of 5–6.3; and high 
risk as a score ≥ 6.4. Further details are included in Table 6.
Description of included studies
The searches identified one full peer-reviewed study relating to the BCI.122 The design and patient 
characteristics of the included study are provided in Tables 19 and 20.
Quality of included studies: Breast Cancer Index
Although the assessment of study quality was hindered by poor reporting of whether or not 
outcomes were unbiased, the overall methodological quality of the included study was judged 
to be high, indicating a low risk of bias (received a positive assessment for at least 19 out of 21 
methodological quality items).
TABLE 19 Study design characteristics of the included study: BCI
Author (year)
Country Study design Number of patients 
Follow-up 
(years)
Outcomes/end 
points
Evidence 
type Funding
Jerevall et al. 
(2011)122
Sweden
Retrospective cohort 
(1976–1990) from 
the randomised, 
prospective 
Stockholm trial
FFPE
RT-PCR
Eligible sample: 808
Sample included: 588
G1: 314; G2: 274
Samples excluded 
because of insufficient 
tumour (n = 37); failure 
of RT-PCR, (n = 2); ER– 
cases (n = 181) (exclusion 
criterion of study)
Mean: 17 Time to distant 
metastasis; 
DMFS; BCSD
Clinical 
validity
Swedish Cancer Society, 
Swedish Research 
Council, King Gustaf V 
Jubilee Fund, National 
Cancer Institute, 
Avon Foundation and 
bioTheranostics
TABLE 20 Patient characteristics of the included study: BCI
Author 
(year)
Age (years), 
mean (SD)
LN 
status
ER 
status Tumour size Grade HER2 status
Mean NPI 
score Treatment 
Jerevall et 
al. (2011)122
NR (all 
postmenopausal)
All LN– All ER+ G1: ≤ 2 cm: 256 
(82%); > 2 cm: 
55 (18%); 
unknown: 3 (1%)
G2: ≤ 2 cm: 223 
(81%); > 2 cm: 
49 (18%); 
unknown: 2 (1%).
G1: I: 67 (21%); 
II: 209 (67%); 
III: 38 (12%)
G2: I: 67 (24%); 
II: 172 (63%); 
III: 35 (13%)
G1: +/–/unknown: 
14 (4%)/272 
(87%)/28 (9%)
G2: +/–/unknown: 
13 (5%)/238 
(87%)/23 (8%)
NR G1: 
tamoxifen
G2: 
systemically 
untreated
NR, not reported; SD, standard deviation.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62 Assessment of clinical effectiveness
Results: Breast Cancer Index
Full data extraction tables are presented in Appendix 12.
Analytical validity
No available evidence.
Clinical validity (prognostic ability)
Jerevall et al.122 reported a retrospective analysis of (a subcohort of) a randomised prospective 
trial cohort. The 588 patients were all postmenopausal, LN– and ER+. The authors reported the 
development and testing of HOXB13:IL17BR plus MGI as a continuous index (BCI) in a training 
set (G1) and a test set (G2) of the same trial data. In the training set (G1) BCI classified 59% of 
patients as low risk. The rate of distant recurrence for the low-risk group was 7.1% (95% CI 0% 
to 3.5%) and the rate of death was 1.1% (95% CI 0% to 2.6%). In total, 22% were classified as 
intermediate risk, with a rate of distant recurrence of 17.8% (95% CI 7.6% to 26.8%) and a rate 
of death of 14.5% (95% CI 5.2% to 22.9%), and 18.4% were classified as high risk, with a rate of 
distant recurrence of 20.0% (95% CI 8.7% to 30.0%) and a rate of death of 14.7% (95% CI 4.7% to 
23.6%). In the test set (G2) 53% of patients were classified as low risk (rate of distant recurrence 
8.3%, 95% CI 4.7% to 14.4%; rate of death 5.1%, 95% CI 1.3% to 8.7%), 27% were intermediate 
risk (rate of distant recurrence 22.9%, 95% CI 14.5% to 35.2%; rate of death 19.8%, 95% CI 10.0% 
to 28.6%) and 20% were high risk (rate of distant recurrence 28.5%, 95% CI 17.9% to 43.6%; 
rate of death 28.8%, 95% CI 15.3% to 40.2%). The authors concluded that the BCI was a strong 
prognostic factor for distant recurrence and BCSD, independent of tumour size, grade, HER2 
status and PR status (although tumour size did contribute prognostic value to distant recurrence). 
The prognostic utility of the BCI was also assessed compared with Adjuvant! Online for the 
test set (G2). Both BCI and Adjuvant Online were significant predictors of BCSD (BCI: HR 2.3, 
95% CI 1.5 to 3.7, p < 0.001; Adjuvant Online: HR 1.4, 95% CI 1.0 to 1.8, p = 0.04) and distant 
recurrence (BCI: HR 2.0, 95% CI 1.3 to 3.1, p = 0.001; Adjuvant! Online: HR 1.4, 95% CI 1.0 to 
1.8, p 0.03). The authors concluded that the retrospective analysis of this randomised, prospective 
trial cohort validated the prognostic utility of HOXB13:IL17BR plus MGI and it was used to 
develop and test a continuous risk model that enables prediction of distant recurrence risk at the 
patient level. The study had a long mean follow-up time and a moderate sample size. The study 
used tumour samples that dated back to 1976, introducing differences in the diagnostic criteria 
applied to patients.
Clinical utility
No available evidence.
Summary of evidence: Breast Cancer Index
Based on the limited available data, no firm conclusions can be made about the BCI. Further 
evidence on analytical validity, clinical validity and clinical utility is required. The test has also 
not been validated in an external cohort.
Randox Breast Cancer Array
The Randox BCA is a cDNA-based expression biochip assay that aims to accurately define the 
clinical subtype of breast cancer tumour before initiating treatment. The target population is all 
individuals with diagnosed breast cancer.
Description of included studies
The searches did not identify any relevant full peer-reviewed papers or meeting abstracts relating 
to the Randox assay. Supplementary evidence was provided by the manufacturer of the test.
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Results: the Randox assay
Supplementary evidence
The manufacturer submitted a description of the data gathered on the Randox assay up to August 
2011.123 A summary of this information is provided here.
The objective of the study was to improve the discrimination, to include basal and unclassified 
(triple-negative) types, subdivide luminal groups into A and B and assign samples to an ERBB2 
group. The main indicator of correct typing is whether the samples are correctly typed as 
ER+ or ER–. A total of 150 archived tumour samples were collected and used on the Randox 
biochip array. Exclusion criteria included a lack of ER status information or one or both of the 
housekeeping genes failing to reach adequate expression levels, preventing normalisation of the 
remaining gene set on the chip. The sample set included information on the following: DFS, OS 
ER status, PR status and other standard clinical measurements. However, HER2 (ERBB2) status 
was not available for any patients; thus, hormonal status was either luminal positive or negative. 
The initial summary, using a patient cohort of 78 individuals, shows an overall agreement of 79% 
between hormonal status (primarily ER) and the multiplex biochip assay. The authors concluded 
that these findings were encouraging.
Methodological detail was lacking for the summarised study and the sample size was very small. 
Quality assessment could not be undertaken because of the limited detail available. It should also 
be noted that, although Randox separates luminal A and luminal B groups, the overall reported 
agreement of 79% was based on luminal A and B combined and hormonal status, and did not 
differentiate between the subtypes.
Summary of evidence: the Randox assay
No conclusions can be drawn from this evidence. Further evidence is required.
Mammostrat test
The Mammostrat test uses five IHC markers (SLC7A5, HTF9C, p53, NDRG1 and CEACAM5) to 
stratify patients into risk groups to inform treatment decisions. These markers are independent 
of one another and do not directly measure either proliferation or hormone receptor status. 
The current version of the test provides classification into one of five breast cancer subtypes, 
and quantitative values for (gene/protein) ESR1/ER, PGR/PR, ERBB2/HER2, proliferation, and 
luminal score (ER pathway), along with a RS and category (low, moderate and high). For further 
information see Table 7.
Description of included studies
The searches identified three full peer-reviewed studies relating to the Mammostrat test.124–126 All 
studies contained data relating to clinical validity. Ross et al.126 also reported on clinical utility 
in terms of the predictive ability of the test by risk group. The studies are described in Tables 21 
and 22.
Quality of included studies: Mammostrat
The methodological quality of the three included studies124–126 is summarised in Figure 6 (further 
details are provided in Appendix 13). Of these, two studies performed well,124,126 receiving a 
positive assessment for at least 17 out of 21 methodological quality items. Although all studies 
used a retrospective study design, other potential sources of bias were generally related to the 
following domains: sample of patients (clinical/demographic characteristics not fully described) 
and interventions subsequent to inclusion in the cohort (interventions were not fully described or 
standardised). The assessment of study quality was generally hampered by poor reporting of the 
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TABLE 21 Study design characteristics of included studies: Mammostrat test
Author (year)
Country Study design Number of patients 
Follow-up 
(years)
Outcomes/end 
points Evidence type Funding
Bartlett et al. 
(2010)124
UK
Retrospective, 
consecutive sample 
series (1981–98)
Microarray
Eligible sample: 1540
Sample included: 1540
G1 (all ER+): 1189; G2 (ER+, 
tamoxifen only): 831; G3 (ER+, 
N–, tamoxifen only): 657
Minimum 9 DRFS; RFS; OS Clinical validity Sarah Percy 
Endowment 
Fund
Ring et al. 
(2006)125
[Commercial-in-
confidence (CIC) 
information has 
been removed]
USA
Retrospective cohort 
(G1: 1989–2002; 
G2: 1995–6; G3: 
1974–95)
Eligible sample: NR
Sample included: 1109
G1: 466 (also training cohort); 
G2: 299; G3: 344
G1: NR; G2: 
5; G3: mean 
11.7
DFS at 5 years Clinical validity NR
Ross et al. 
(2008)126
NR
Retrospective 
cohort (dates not 
specified) from 
the randomised, 
prospective NSABP 
B14 and B20 trials
Eligible sample: NR
Sample included: 1267
Placebo: 287; B14 tamoxifen: 
550; B20 tamoxifen: 161; B20 
chemotherapy: 269
Minimum 
10 
Recurrence-free 
interval; DRFI; 
BCSD
Clinical validity; 
clinical utility 
– predictive 
ability (benefit of 
chemotherapy)
NR
NR, not reported.
following methodological items: whether or not all eligible patients were included, representative 
and assembled at an early point in the course of their disease and whether or not outcomes were 
unbiased and known for all or a high proportion of patients. Overall, the risk of bias from these 
studies was judged to be low.
Results: Mammostrat
A summary of the clinical evidence for the Mammostrat test is presented in Table 23 followed by 
a narrative summary of each study. Full data extraction tables are provided in Appendix 13.
Analytical validity
No available evidence.
Clinical validity
Bartlett et al.124 investigated assignment to risk groups using Mammostrat for 1540 UK patients 
with LN– tumours. They demonstrated that significantly more cases were assigned to high-
risk groups for ER– than for ER+ cases (45% vs. 16%; p < 0.001), but there were no differences 
between other groups. They also looked at associations between risk scores and DRFS, RFS and 
OS across the different groups: all cases, all ER+ cases, all ER+ cases treated with tamoxifen 
only and ER+, LN– cases treated with tamoxifen only. For all groups there were significant 
associations between risk score and RFS, DRFS and OS (with the exception of the ER+, LN– 
treated with tamoxifen only group for which there was a trend only for OS). Multivariate analyses 
for each of the four groups showed that risk score was a significant independent predictor of RFS, 
DRFS and OS, along with clinicopathological predictors, for all cases and all ER+ cases. Risk 
score was a significant independent predictor of DRFS and OS with a trend for RFS for ER+ cases 
treated with tamoxifen only, and there was a trend towards significance for Mammostrat score 
to predict RFS and DRFS in ER+, LN– cases treated with tamoxifen only. The authors concluded 
that Mammostrat can act as an independent prognostic tool for ER+, tamoxifen-treated breast 
cancer and that there is a possible association with outcome regardless of LN status and ER– 
tumours. This study was rated as being of high quality on the basis of the quality assessment 
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employed here. It also benefits from a large sample size overall, although it should be noted that 
the subsets analysed had relatively small numbers of patients within each. It had a relatively long 
follow-up of 9 years, and as it employed UK patients the findings should be applicable to UK 
practice. The samples used in these analyses were relatively old, dating back to 1981; therefore, 
there may be differences between the patients in terms of stage at presentation and diagnosis.
In a US-based study, Ring et al.125 assessed 1109 majority LN–, ER+ patients. Using a training 
cohort the authors demonstrated that a Cox model identified a group of patients as having either 
poor or moderate prognosis, with a 5-year DFS rate of approximately 75%, as opposed to patients 
classified as having good prognosis, who had a 5-year DFS rate of approximately 95% (p < 0.001). 
In the first independent cohort the model identified poor prognosis patients with a 5-year 
DFS rate of 50%, compared with approximately 70% for patients classified as having moderate 
prognosis and 87% for patients classified as having good prognosis (p = 0.008). In the second 
independent cohort the model distinguished ER+ patients classified as having poor prognosis 
with OS rates of 55%, compared with 75% for patients classified as having moderate prognosis 
and 90% for patients classified as having good prognosis (p = 0.0039). In both independent 
cohorts the model was independent of stage, grade and LN status. In the combined independent 
cohort, for patients with poor or good prognosis (82%), sensitivity for poor prognosis in 
predicting disease progression was 38%, whereas specificity was 88%. The PPV of poor prognosis 
was 38% (95% CI 32% to 44%), whereas the NPV was 88% (95% CI 84% to 92%). The authors 
concluded that the test can significantly improve on traditional prognosticators in predicting 
outcome for ER+ breast cancer patients. The quality assessment indicated that this study was of 
moderate quality and it used a large sample of patients. The test was also validated in an external 
cohort. However, there are limitations in that the tumour samples used in these analyses date 
TABLE 23 Summary of evidence for the Mammostrat test
Author 
(year) Evidence type
Overall 
quality Key findings
Bartlett et 
al. (2010)124
Clinical validity High 1540 LN– UK patients. Also looked at associations between risk score and outcomes across 
the different groups: all cases, all ER+, all ER+ treated with tamoxifen only and ER+, LN– 
treated with tamoxifen only. For all cases and across the three groups there were significant 
associations between risk score and RFS, DRFS and OS (with the exception of the ER+, 
LN– treated with tamoxifen only group for which there was only a trend for OS). The authors 
concluded that Mammostrat can act as an independent prognostic tool for ER+, tamoxifen-
treated breast cancer and that there is a possible association with outcome regardless of node 
status and ER– tumours. This study had a large sample size overall, a relatively long follow-up of 
9 years and employed UK patients. Limitations: subsets analysed had relatively small numbers 
of patients within each; the samples used in these analyses were relatively old, dating back 
to 1981, and therefore there may be differences between the patients in terms of stage at 
presentation and diagnosis
Ring et al. 
(2006)125
Clinical validity Moderate 1109 majority LN–, ER+ US patients. Cox model was able to identify patients classified in 
different risk categories based on outcomes. In both independent cohorts the model was 
independent of stage, grade and LN status. The authors concluded that the test can significantly 
improve on traditional prognosticators in predicting outcome for ER+ breast cancer patients. 
Large sample of patients. Validated in an external cohort. Limitation: tumour samples used in 
these analyses dated back as far as 1974 and therefore there may be differences between the 
patients in terms of stage at presentation and diagnosis
Ross et al. 
(2008)126
Clinical validity; 
clinical utility 
– predictive 
ability (benefit of 
chemotherapy)
High 711 ER+, LN–, tamoxifen-treated patients taken from the NSABP B14 and B20 trials. In 
multivariate analyses the Mammostrat test had significant prognostic power independent of 
age and tumour size (HR 1.3; 95% CI 1.1 to 1.6; p = 0.007). Concluded that the risk index was 
significantly associated with clinical outcome among the ER+, LN–, tamoxifen-treated patients. 
Clinical utility: in terms of recurrence-free interval, patients in the low-risk group improved by 
5% from 86% to 91% (HR 0.4; 95% CI 0.2 to 0.8) and patients in the high-risk group improved 
by 21% from 64% to 85% (HR 0.4; 95% CI 0.2 to 0.9), showing that these groups benefited 
from chemotherapy, whereas the patients in the intermediate risk group did not. Limitation: data 
from two trials were used but it was unclear how the data were combined
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back as far as 1974; therefore, there may be differences between the patients in terms of stage at 
presentation and diagnosis.
Ross et al.126 examined the association between the clinical outcomes recurrence-free interval 
(RFI), DRFI and BCSD and stratification by the Mammostrat test in 711 ER+, LN– tamoxifen-
treated patients taken from the NSABP B14 and B20 trials. Of this group approximately 58% 
were classified as low risk, 21% as moderate risk and 21% as high risk. There was a significant 
association between patients stratified by the Mammostrat test and RFI (HR 1.3; 95% CI 1.1 to 
1.6; p = 0.006). This was not significant in the low-risk group compared with the moderate-risk 
group (log-rank, p = 0.05) but was significant in the low-risk group compared with the high-risk 
group (HR 1.8; 95% CI 1.2 to 2.6). The authors reported a significant association between patients 
stratified by the test and DRFI (HR 1.4, 95% CI 1.1 to 1.7; p = 0.001). In the low-risk group 
compared with the moderate-risk group this was not significant whereas in the high-risk group 
compared with the low-risk group it was significant (HR 2.1, 95% CI 1.4 to 3.1; p = 0.0004). They 
also reported a significant association between patients stratified by the test and BCSD (HR 1.5, 
95% CI 1.2 to 1.9; p = 0.0003). In the low-risk group compared with the moderate-risk group 
this was not significant whereas in the high-risk group compared with the low-risk group it was 
significant (HR 2.3; 95% CI 1.5 to 3.5; p < 0.0001). The Kaplan–Meier estimate of the proportion 
of patients recurrence free after 10 years was 82% (95% CI 79% to 85%) for the group overall, 
85% (95% CI 81% to 88%) for the low-risk group, 85% (95% CI 80% to 91%) for the moderate-
risk group and 73% (95% CI 65% to 80%) for the high-risk group. In multivariate analyses the 
Mammostrat test had significant prognostic power independent of age and tumour size (HR 
1.3; 95% CI 1.1 to 1.6; p = 0.007). The authors concluded that the risk index was significantly 
associated with clinical outcome among the ER+, LN– tamoxifen-treated patients. Ross et al.126 
also reported data relating to clinical utility, which are detailed in the following section.
Clinical utility
Predictive ability (benefit of chemotherapy) Ross et al.126 also presented evidence on the ability 
of the test to identify patients who have greater absolute benefit from adjuvant chemotherapy 
compared with unstratified patient populations. These analyses were based on the tamoxifen- and 
cytotoxic chemotherapy-treated patients (n = 269) and the B20 tamoxifen only-treated patients 
(n = 161) from the trial data. In terms of RFI patients in the low-risk group improved by 5% 
from 86% to 91% (HR 0.4; 95% CI 0.2 to 0.8) and patients in the high-risk group improved by 
21% from 64% to 85% (HR 0.4; 95% CI 0.2 to 0.9), showing that these groups benefited from 
chemotherapy, whereas the patients in the intermediate-risk group did not. This study was rated 
as high quality although data from two different trials were used and it was unclear how the data 
were combined.
Supplementary evidence
(CIC information has been removed.)
Summary of evidence: Mammostrat
Analytical validity of Mammostrat
No evidence was found on the analytical validity of the test.
Clinical validity (prognostic ability) of Mammostrat
The three studies identified suggest that Mammostrat can act as an independent prognostic tool 
for ER+, tamoxifen-treated breast cancer. Two of the studies were rated as high quality and one as 
moderate quality. The test has been validated in an external cohort. Although the evidence base 
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for Mammostrat is relatively immature, these initial studies include a large sample size, appear to 
be of reasonable quality and, in the case of Bartlett et al.,127 use a UK-based population.
Clinical utility of Mammostrat
One study reported on clinical utility and was rated as high quality. Initial evidence suggests 
that low- and high-risk groups benefited from chemotherapy, with high-risk patients benefitting 
more than low-risk patients. The moderate-risk group did not appear to benefit. There was no 
published evidence on reclassification of risk groups compared with conventional risk classifiers, 
and no evidence on the impact of the test on decision-making. Further evidence is required.
Overall summary
The evidence base, in particular in relation to the prognostic ability of the test, was of reasonably 
high quality. Further evidence of analytical validity and clinical utility is required.
IHC4 test
IHC4 assesses the levels of four key proteins (ER, PR, HER2 and Ki-67) in a breast cancer sample. 
The IHC4 score is calculated based on the percentage of cells positive for Ki-67 and PR (0–100%); 
the Histoscore for ER status (a measure of the percentage of cells positive multiplied by the 
intensity, range 0–300); and the tumour HER2 status, expressed as a binary measure (positive/
negative). The final algorithm for IHC4 calculates a risk score for distant recurrence based on ER, 
PR, HER2 and Ki-67 in addition to classical clinical and pathological variables (composite risk 
score IHC4 + clinical). No risk category is given. Further details are included in Table 7.
Description of included study
The searches did not identify any relevant full peer-reviewed papers relating to IHC4. One 
relevant meeting abstract was identified, but had been superseded by a full paper.83 The study 
design and patient characteristics are detailed in Tables 24 and 25 respectively. The investigators 
also provided further information on the test (Professor Mitch Dowsett, Royal Marsden Hospital, 
London, September 2011, personal communication) and this information is detailed in the 
supplementary evidence section.
Quality of included studies: IHC4
Although the assessment of study quality was hindered by poor reporting of whether or not 
outcomes were fully defined and unbiased, the overall methodological quality of the included 
study was judged to be high, indicating a low risk of bias (received a positive assessment for at 
least 19 out of 21 methodological quality items).
Results: IHC4
Full data extraction tables are presented in Appendix 14.
Clinical validity
Cuzick et al.83 reported a study assessing the prognostic value of IHC4. The IHC4 score was 
created and validated in one cohort (G1) and further validated in an independent cohort (G2). 
G1 was a retrospective cohort comprising patients from the TransATAC trial (a multinational 
trial, including the UK). The majority of the 1125 patients in G1 were LN– and hormone receptor 
positive. In this cohort there was a total of 195 recurrences of which 145 were distant recurrences. 
In LN– women there were 101 recurrences of which 67 were distant recurrences. The authors 
determined the value of each of the four IHC markers in three ways: univariately, as an addition 
to a model containing the classical variables, and when added to a model containing the classical 
variables and the other three IHC markers; this was carried out for all women and separately 
for LN– women only. They found that each of the four variables added a significant amount of 
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information. Ki-67 was the most powerful univariately, but not in multivariate analyses because 
of its correlation with grade. For the multivariate models PR was most prognostic overall, but less 
so in LN– patients, in whom ER, HER2 and Ki-67 had similar values. The overall contribution 
of the IHC measurements for distant recurrence was highly significant [χ2 (4 degrees of freedom, 
df) = 39.1; p < 0.0001], and it was reported that the median IHC4 score for all patients was –4.2 
and the interquartile range (IQR) –29.9 to 29.9. The HR for a change from the 25th to the 75th 
percentile of the IHC4 score for all patients was 5.7 (95% CI 3.4 to 9.7) in univariate analysis and 
3.9 (95% CI 2.4 to 6.7) when added to clinical score. In a second validation cohort of 786 ER+ 
younger patients treated in the UK (G2), the authors demonstrated that IHC4 score was highly 
significantly predictive of outcome (HR 4.8; 95% CI 2.2 to 10.2) for a change from the 25th to the 
75th percentile in univariate analysis, and gave similar results when added to clinical score (HR 
4.4; 95% CI, 2.0 to 9.3; p < 0.0001). The authors concluded that they have created a prognostic 
model that integrates IHC information with classical clinical and pathological variables and 
may prove helpful in managing early ER+ breast cancer in postmenopausal patients, but that 
additional studies are needed to determine the general applicability of the IHC4 score. This study 
was rated as high quality on the basis of the quality assessment checklist. It has employed a large 
sample size and the test has been validated in an external cohort of UK patients.
Supplementary information
Supplementary data were provided by the co-investigators of this study84 after request by the 
External Assessment Group (EAG) (Professor Mitch Dowsett, Royal Marsden Hospital, London, 
September 2011, personal communication). Two analyses were conducted in the TransATAC 
trial – among women with LN–, ER+, HER2– early breast cancer (n = 707) and among all 
women (n = 1117).
Discussion with the co-investigators of the study (Professor Mitch Dowsett, Royal Marsden 
Hospital, London, July 2011, personal communication) indicated that the test was meant to 
be used in conjunction with clinicopathological parameters and therefore data for the final 
algorithm (using age, grade and tumour size) were used in the economic model. They provided 
data on the reclassification and risk of distant recurrence of patients using IHC4 plus clinical 
score (for simplicity the term IHC4 will be used in the report but the data refer to the use of the 
test in conjunction with clinicopathological parameters). Although cut-offs are not available 
for IHC4, for the purpose of the economic assessment investigators provided risk classification 
evidence of IHC4 based on low, intermediate and high risk of distant recurrence. Cut-offs were 
defined using a similar approach to the classification with OncotypeDX (< 10%, 10–20% and 
> 20% risk of distant recurrence). The cut-offs used for IHC4 are, however, exploratory and were 
defined only to populate the economic model. More details are available in Chapter 3.
Among the 707 women with LN–, ER+, HER2– early breast cancer, 85.3% of patients (n = 603) 
were classified as having a low risk of distant recurrence using IHC4. The proportions of patients 
classified as having an intermediate and a high risk of distant recurrence were 9.9% (n = 70) and 
4.8% (n = 34). The risk of distant recurrence for patients classified as low, intermediate or high 
risk of distant recurrence by IHC4 is shown in Figure 7.
The reclassification of the three IHC4 risk groups against the two NPI risk groups used in the 
economic model (NPI ≤ 3.4 and NPI > 3.4) is presented in Table 26.
Summary of evidence: IHC4
Analytical validity of IHC4
We found no evidence on analytical validity. Although the use of IHC4 may be extended for 
use in other laboratories, the included paper suggests that there may be a lack of reproducibility 
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of the test in relation to Ki-67. The authors suggest that, because IHC4 offers the possibility of 
carrying out the test in local laboratories, full validation would require evaluation of the IHC4 
score when carried out in a range of local laboratories. Reproducibility of the test would need to 
be confirmed and quality assurance programmes put in place.
Clinical validity (prognostic ability) of IHC4
One study on the clinical validity of IHC4 was available, which claims that the IHC4 score is a 
highly significant predictor of distant recurrence. This initial study included a large sample size 
and detailed the development of the test in one cohort and the external validation of the test 
in an independent cohort. The study has been rated as high quality on the basis of the quality 
assessment employed.
Clinical utility of IHC4
There is currently no evidence on the clinical utility of IHC4 in terms of its ability to 
change treatment decisions or its ability to predict chemotherapy benefit. Although there 
are no published data on clinical utility, unpublished data were obtained to populate the 
economic model.
Overall summary
The evidence base for IHC4 is currently limited to clinical validity (prognostic ability), although 
the evidence for clinical validity is relatively strong given that the test has been developed using a 
large cohort of patients and has been validated in an external cohort. Further evidence is required 
on the analytical validity and clinical utility of IHC4.
Nottingham Prognostic Index plus
NPI+ is a biomarker-based prognostic assay that integrates 10 predictive biomarkers of long-term 
survival and therapeutic response with existing clinical and molecular pathology knowledge to 
support individualised clinical decision-making. This test is under development and outputs/
presentation are not yet finalised. Further details are provided in Table 7.
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FIGURE 7 Time to distant recurrence by IHC4 + clinical score group for patients who were LN–, ER+, HER2–.
TABLE 26 Reclassification of ER+, LN–, HER2– patients from the TransATAC trial by IHC4 + clinical score and NPI group 
(Professor Mitch Dowsett, Royal Marsden Hospital, London, UK, September 2011, personal communication)
Low risk IHC4, n (%) Intermediate risk IHC4, n (%) High risk IHC4, n (%) Total, n (%)
NPI ≤ 3.4 437 (97.3) 12 (2.7) 0 449 (100)
NPI > 3.4 166 (64.6) 58 (22.6) 33 (12.8) 257 (100)
Total 603 (85.4) 70 (9.9) 33 (4.7) 706 (100)
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Description of included studies
The searches did not identify any relevant full peer-reviewed papers or meeting abstracts relating 
to NPI+. Supplementary evidence was provided by the manufacturer of the test.
Supplementary evidence
The manufacturers submitted two draft full papers based on the same data and one draft abstract 
(of a full paper). The study design and patient characteristics included in these documents are 
presented in Tables 27 and 28.
Quality of included studies: Nottingham Prognostic Index plus
The overall methodological quality of the two (unpublished) included studies is provided in 
Appendix 15. Both studies were deemed to be of (AIC information has been removed).
Results: Nottingham Prognostic Index plus
A summary of the evidence provided is present in Table 29 followed by a narrative summary. Full 
data extraction tables are presented in Appendix 15.
TABLE 27 Study design characteristics of included studies: NPI+ test (information submitted by the manufacturer)
Author (year)
Country
Study 
design Number of patients 
Follow-up 
(years)
Outcomes/
end points
Evidence 
type Funding
Green et al. (unpublished) 
and Nottingham Prognostics 
(2011)128 (AIC information has 
been removed)
(AIC 
information 
has been 
removed)
Eligible sample: (AIC information 
has been removed)
Sample included: (AIC 
information has been removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
Nottingham Prognostics (2011) 
(abstract)128 (AIC information 
has been removed)
(AIC information has been 
removed)
(AIC 
information 
has been 
removed)
Eligible sample: (AIC information 
has been removed)
Sample included: (AIC 
information has been removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
TABLE 28 Patient characteristics of included studies: NPI+ test (information submitted by manufacturer)
Author 
(year)
Age (years), 
mean (SD) LN status ER status Tumour size Grade HER2 status
Mean NPI 
score Treatment 
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
(AIC 
information 
has been 
removed)
SD, standard deviation.
TABLE 29 Summary of evidence for the NPI+ test
Author (year) Evidence type Overall quality Key findings
(AIC information has been removed) (AIC information has been removed) Moderate (AIC information has been removed)
(AIC information has been removed) (AIC information has been removed) Low (AIC information has been removed)
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(AIC information has been removed.)
Summary of evidence: Nottingham Prognostic Index plus
The evidence base for NPI+ is currently insufficient to draw any firm conclusions regarding the 
analytic and clinical validity of the test, and as yet there is no available evidence on the clinical 
utility of the test. Further evidence on the prognostic ability of the test is required. According to 
the unpublished abstract from the manufacturers of the test, validation in an external cohort is 
ongoing but as yet results are not available.
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Chapter 3 
Economic analysis
Asystematic review of existing cost-effectiveness evidence is reported in the following section. This is followed by reviews of the economic evaluations submitted by two of the 
manufacturers/sponsors of the tests in response to the request for information issued by NICE 
at the start of the assessment process. The relevance of existing cost-effectiveness evidence for 
NICE decision-making is then summarised. This is followed by a description of the independent 
economic model and its results, and a comparison of the independent economic model with the 
evaluations from the two manufacturers/sponsors. Finally, the independent economic model 
results are discussed.
Systematic review of existing cost-effectiveness evidence
This section of the report describes a review of the existing published evidence on the cost-
effectiveness of GEP and expanded IHC (or protein expression profiling) tests to guide the use of 
adjuvant chemotherapy in breast cancer management.
Methods
A systematic search of the existing literature evaluating the cost-effectiveness of the nine 
GEP and expanded IHC tests identified by NICE (OncotypeDX, MammaPrint, Mammostrat, 
PAM50, BluePrint in combination with MammaPrint, IHC4, Randox BCA, BCI and NPI+) to 
guide adjuvant chemotherapy treatment decision-making in the management of early breast 
cancer was undertaken. Only full economic evaluations published in English addressing the 
cost-effectiveness of those tests compared with NPI, Adjuvant! Online or any adaptations of 
these tools in clinical practice were included in the review. Cost-effectiveness studies that used 
St Gallen, the National Comprehensive Cancer Network (NCCN)129 and NIH guidelines101 were 
excluded from the review because of time and resource constraints as these comparators are not 
directly relevant to the UK context, but such studies were scanned by the reviewers to inform the 
model development.
The following databases were searched for relevant published literature: MEDLINE, MEDLINE 
In-Process & Other Non-Indexed Citations (Ovid), CINAHL, EMBASE, NHS Economic 
Evaluation Database and HTA (via the Cochrane Library), Web of Science (which includes the 
Science Citation Index) and BIOSIS. In addition, literature searches were undertaken for the 
clinical effectiveness review (see Chapter 2, Methods for reviewing effectiveness) and relevant cost 
papers were identified from these searches. In addition, the reference lists of relevant articles were 
hand searched. Full details of the search strategies used in MEDLINE are presented in Appendix 1 
(these have been adapted for use in other databases). Searches were not restricted by language.
Studies were selected for inclusion through a two-stage process. Titles and abstracts were 
examined for inclusion by one reviewer. Full manuscripts of selected citations were then retrieved 
and assessed by the same reviewer. The quality of the cost-effectiveness studies was assessed using 
a critical appraisal checklist adapted from the Drummond and Jefferson130 and Eddy131 checklists.
The aim of the review was to identify published economic evaluations and summarise the main 
limitations of the existing models. Because of time constraints it was not possible to provide a 
detailed direct comparison of the models.
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Results
Identified studies
The search retrieved 72 citations relating to cost-effectiveness (Figure 8) and two additional 
references were known by the authors. Fifty-six articles were excluded at title stage and four 
articles were excluded at abstract level. Thirteen studies (corresponding to 14 references) were 
examined at full-text level and four studies (corresponding to five references) were identified 
as meeting the inclusion criteria of the systematic review of economic evaluations.132–136 
This included an economic evaluation developed as part of the Ontario Health Technology 
Assessment (OHTA) described in a report134 and PowerPoint presentation slides.136
Nine articles were excluded after retrieving the full text because there were insufficient details 
to assess the validity of assumptions,137 the economic evaluation was available only in abstract 
form,138–140 the study used a different comparator141 or for other reasons.143–145 Klang et al.141 was 
excluded from the review as the exact nature of the comparator defined as clinical practice in 
Israel was unclear.
Of the four identified economic studies (corresponding to five references), two compared 
MammaPrint against Adjuvant! Online132,133 and two compared OncotypeDX against Adjuvant! 
Online.134–136 None of the four published economic evaluations was conducted in a UK setting.
Description of published cost-effectiveness studies evaluating the 
use of MammaPrint
Two economic evaluations compared treatment guided using the MammaPrint test with 
treatment guided using Adjuvant! Online and used a health-care payer perspective.132,133 A 
Markov approach was employed in both economic evaluations but the populations considered 
in the models differed slightly. Retel et al.133 addressed the cost-effectiveness of MammaPrint in 
Potentially relevant papers
identified through the
literature search
(n = 72)
Studies included based on the
title
(n = 18)
Potentially appropriate studies
included based on the abstract
Full papers retrieved (n = 14)
Reference included:
(five references)
Corresponding to four studies
Studies excluded based on
the title
(n = 56)
Studies excluded based on
the abstract
(n = 4)
Studies excluded after review
of the full paper
(n = 9)
Additional papers/report
known by the authors
(n = 2)
FIGURE 8 Flow diagram of economic evaluation selection/exclusion.
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women with LN–, ER+, HER2+/– early breast cancer. Chen et al.132 included ER– early breast 
cancer but excluded HER2+ early breast cancer.
A tabulated summary of the key features and data sources and a quality assessment for the two 
studies included in the cost-effectiveness review of MammaPrint are presented in Appendices 16 
and 17 respectively. It was not possible for the EAG to check the economic models as only the 
publications were available in the public domain.
A narrative description and assessment of each economic evaluation is presented in the 
following sections.
Description and critique of Retel et al.:146 cost-effectiveness of the 
70-gene signature compared with St Gallen guidelines and Adjuvant! 
Online for early breast cancer
Brief overview The aim of the study was to estimate the cost-effectiveness of MammaPrint 
compared with that of the St Gallen guidelines and Adjuvant! Online to guide adjuvant treatment 
decisions in Dutch women with LN–, ER+, HER2 +/– early breast cancer.
The model used a Markov approach and followed women over 20 years in four possible health 
states: disease free, relapse (local, regional or contralateral relapse), distant metastasis and death. 
The study adopted the perspective of the Dutch health-care payer and costs and QALYs were 
discounted at 4.0% and 1.5% per annum respectively. The mean age of patients entering the 
model was 50 years.
Summary of effectiveness data For the strategy using MammaPrint and Adjuvant! Online, the 
sensitivity and specificity were calculated and patients were classified into four risk groups of 
developing distant metastasis: true high, true low, false high and false low. The sensitivity and 
specificity were calculated from a pooled analysis of three validation studies60,63,93 using 10-year 
BCSS as a final outcome (thus, patients were classified as low or high risk according to the 
probability of survival rather than the probability of developing distant metastasis).
The study classified patients as low risk with Adjuvant! Online if the predicted 10-year survival 
was > 88%. MammaPrint classified patients into two categories: low (good prognosis) and high 
(poor prognosis) risk of developing distant recurrence. Patients classified as high risk either 
by MammaPrint or by Adjuvant! Online were assumed to receive chemotherapy in addition to 
endocrine therapy. Low-risk patients were assumed to receive endocrine therapy alone.
Patients classified as true low and false high had a zero probability of relapse and distant 
metastasis. The probability of relapse and distant metastasis for true high-risk patients was 
based on an analysis conducted in a sample of 20,624 Swedish breast cancer patients derived 
from Lidgren et al.,147 with a constant risk within three time periods: 1–5, 5–10 and 10–20 years. 
Patients classified as false low were assumed to have a 100% probability of developing 
distant metastases.
Patients could have only one relapse (and then possibly move to distant metastasis). In total, 
10% of high-risk patients were assumed to be HER2+, with a risk twice as high as observed for 
HER2– patients. A relative risk reduction with a HR of 0.64 (95% CI 0.54 to 0.76) was applied for 
patients treated with trastuzumab. Adverse events associated with chemotherapy were included 
for chronic heart failure only.
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Finally, utilities (see Appendix 16) were measured using the European Quality of Life-5 
Dimensions (EQ-5D).148
Summary of resource utilisation and cost data The costs of the health states (see Appendix 16) 
were based on Lidgren et al.148 Drug costs for chemotherapy and hormonal therapies were 
based on Dutch sources. Chemotherapy costs included drug costs, day-care costs (including 
administration), laboratory and diagnostic imaging costs (mammography, tumour markers) 
and prevention. The cost of MammaPrint was assumed to be €2675. Costs were expressed in 
2005 euros.
Summary of cost-effectiveness The results for the base case are presented in Table 30. Treatment 
guided using MammaPrint was associated with a cost per QALY gained of €4614 compared with 
Adjuvant! Online.
The impact of key model parameters was examined in one-way univariate sensitivity analysis 
and probabilistic sensitivity analysis (PSA) and showed that the results were sensitive to data 
used to calculate the sensitivity and specificity of the tests (5-year risk of distant metastasis 
instead of 10-year risk of BCSS, and using data for each individual validation study) and the cost 
of chemotherapy.
Comments Based on the description of the model, this appears to be a reasonably well-conducted 
cost-effectiveness analysis, although it has a number of limitations. The generalisability of the 
results from this study to the UK context is limited.
The study used sensitivity/specificity of the tests to reclassify patients into risk group categories. 
Patients were classified according to their risk of developing distant metastasis, but the 
sensitivity/specificity were calculated using the 10-year BCSS risk in the base-case analysis. Using 
the 5-year risk of distant metastasis instead of the 10-year of risk of BCSS was tested in sensitivity 
analysis. An assumption has also been made when calculating the sensitivity/specificity of 
the tests that low-risk patients cannot die from breast cancer. Although low-risk patients are 
less likely to die from breast cancer, they could still die from their cancer. There are also some 
limitations associated with the use of the sensitivity/specificity for tests providing a continuous 
risk score (especially for Adjuvant! Online).
The evaluation assumes that the decision to receive chemotherapy will be based on the test results 
for MammaPrint and Adjuvant! Online alone. However, it is likely that MammaPrint would be 
used in conjunction with other clinical parameters to inform the treatment recommendation. 
The assumption that the prognostic test results and treatment guidelines would be followed in all 
cases (patients and physicians are 100% compliant) is simplistic. Furthermore, it is unclear if the 
cut-off of ≤ 88% used to identify high-risk patients with Adjuvant! Online reflects actual clinical 
practice. Discussions with clinical experts indicated that the risk score estimated using Adjuvant! 
Online on its own is less informative than the complete output, which includes estimates of 
reduction in risk at 10 years of breast cancer-related death or relapse for selected treatments.
TABLE 30 Base-case results for the cost-effectiveness of MammaPrint compared with Adjuvant! Online estimated by 
Retel et al.146a
Life-years QALYs Cost (€) Cost/QALY gained (€) Cost/life-year gained (€)
Adjuvant! Online 15.68 12.20 26,915
MammaPrint 15.88 12.44 28,045 4614 5736
a Results for the cost-effectiveness of MammaPrint compared with the St Gallen guidelines are not presented here but are available in the 
original paper.146
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The test was assumed to be administered to women with both HER2+ and HER2– early breast 
cancer; however, UK clinical opinion indicated that the vast majority of patients with HER2+ 
early breast cancer are typically offered chemotherapy and the MammaPrint test may therefore be 
considered unnecessary.
The authors also assumed that patients classified as low risk (true low or false high) have a 
zero probability of having a relapse or distant metastasis. This seems to be a very simplistic 
assumption. Furthermore, the authors modelled only one relapse but acknowledge that about 
30% of patients develop more than one relapse.
Many assumptions have also been made about the probability of moving between health states, 
and the impact of chemotherapy is unclear. The risk of recurrence for patients treated with 
endocrine therapy was extracted from studies of patients receiving tamoxifen only; however, 
more effective agents are now available, potentially reducing the risk of recurrence. The starting 
age of the cohort was low (50 years) given that the majority of breast cancers are diagnosed 
in women > 50 years of age. Finally, the use of fresh tissue samples for MammaPrint will have 
service configuration implications for UK pathology laboratories.
Description and critique of Chen et al.:132 cost-effectiveness of the 
70-gene MammaPrint signature in node-negative breast cancer
Overview The aim of the study was to estimate the cost-effectiveness of MammaPrint compared 
with Adjuvant! Online to guide the adjuvant treatment decision in US patients aged ≤ 60 years 
with ER+/–, T1 or T2, LN–, HER2– breast cancer. The model used a Markov approach and 
followed patients over their lifetime in three possible health states: disease free, death from cancer 
and death from other causes. The study adopted the perspective of the US payer, and costs and 
QALYs were discounted at 3.0% per annum.
Summary of effectiveness data Two separate models were constructed using effectiveness data 
from a validation study61 and Surveillance, Epidemiology and End Results (SEER) data149 to 
reflect US clinical practice (the alternative model). This was carried out as no low-risk patients 
with ER– tumours were included in the Buyse et al.61 study.
In the base-case model, the risk classification and 10-year OS were extracted from Buyse et al.61 
In the alternative model, the risk reclassification was adapted from SEER and Buyse et al.,61 
assuming the same rate of cross-classification between high- and low-risk patients as observed 
in the Buyse et al. study, as data for MammaPrint were unavailable. A range of assumptions was 
necessary to use the SEER data.
Patients with ER+ early breast cancer were assumed to receive endocrine therapy (tamoxifen) 
whereas ER– patients were not; chemotherapy was given to patients classified as high risk only. 
The benefit of chemotherapy was extracted from a meta-analysis of RCTs (EBCTCG 1998),150 
applying a reduction in all-cause deaths of 26% in ER+ and 32% in ER– patients.
Utilities used to calculate quality of life were extracted from the published literature.46,151 A utility 
of 0.70 was applied for patients undergoing chemotherapy for 6 months and 0.98 for patients after 
completion of chemotherapy or disease free. The authors did not report the valuation method or 
the quality of life instrument used to estimate the utility values.
Summary of resource utilisation and cost data Costs are presented in 2007 US dollars. Costs 
included the costs of endocrine therapy, chemotherapy, administration, treatment-related toxic 
effects and breast cancer surveillance. The cost of recurrence and terminal care (with cancer) was 
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included for women dying from cancer. A cost of terminal care was included for women dying 
from other causes.
The cost of chemotherapy was derived from insurance claims152 and included the costs of 
chemotherapy medication, hospitalisation and emergency room for chemotherapy adverse events 
or all causes, ambulatory encounters and prescription. The study included patients receiving 
alkylating agents (58%), anthracyclines (51%), taxanes (25%) and antimetabolites (18%). The cost 
of the MammaPrint test was $4200.
Summary of cost-effectiveness Results for the base-case and alternative model are presented 
in Table 31. The incremental cost-effectiveness ratio (ICER) was also presented by ER status 
subgroup – US$5908 per QALY gained (US$6167 per life-year) for ER+ patients. MammaPrint 
was dominated in ER– patients in the base-case model.
The impact of the main model parameters was examined in one-way univariate sensitivity 
analysis, which showed that the results were mostly sensitive to the proportion of ER+ patients 
classified as high risk by MammaPrint, the estimate of OS, the cost of MammaPrint and the cost 
of chemotherapy.
Comments Based on the description of the model, this appears to be a reasonable cost-
effectiveness analysis. The generalisability of the results from this study is limited given that it is 
based on the US health-care system.
The model is simplistic – patients either stay alive or die. The impact of recurrence is 
incorporated only in terms of the cost for patients dying from breast cancer. This ignores the 
health effect. Furthermore, a proportion of patients will have a relapse but not die from breast 
cancer. The authors also did not discuss the selected cut-off for Adjuvant! Online. It was unclear 
how the benefit of chemotherapy was applied to breast cancer deaths.
The benefit of chemotherapy was extracted from a meta-analysis and was assumed to be the same 
whether patients were classified as low or high risk with MammaPrint or Adjuvant! Online.
Furthermore, there were limitations in the data used. As highlighted by the authors, no low-
risk patients with ER– early breast cancer were included in the Buyse et al. study.61 Therefore, 
an alternative model was constructed using SEER data. However, a series of assumptions 
were necessary in order to make use of the SEER data, increasing the uncertainty relating to 
these results.
The authors stated that patients can experience local, regional or distant recurrence before 
death. It is unclear what the relative contribution of each of the types of relapse was on breast 
TABLE 31 Base-case results for the cost-effectiveness of MammaPrint compared with Adjuvant! Online estimated by 
Chen et al.132
Life-years QALYs Cost ($) Cost/QALY gained ($) Cost/life-year gained ($)
Base-case model
Adjuvant! Online 21.596 21.065 162,140
MammaPrint 21.739 21.218 163,580 9428 10,059
Alternative model
Adjuvant! Online 20.659 21.191 163,108
MammaPrint 21.230 21.751 163,509 702 716
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cancer survival. This can have implications in terms of costs and health effects if included in the 
economic model. Likewise, the authors report neither the valuation method nor the quality of life 
instrument used to estimate utilities. No PSA was conducted.
Furthermore, the risk of recurrence for patients treated with endocrine therapy was extracted 
from patients receiving tamoxifen only; however, more effective agents are now available, 
reducing the risk of recurrence. The use of fresh tissue samples associated with MammaPrint will 
have service configuration and cost implications for UK pathology laboratories.
The health-state utility value for the recurrence-free health state was high (0.98). Evidence 
indicates that the utility in the general population for a similar age cohort would be lower.153 Less 
gain would be accrued in the model by preventing a recurrence if a lower value was used.
The mean age of patients entering the model is unclear. The economic evaluation considered only 
patients aged ≤ 60 years. MammaPrint is now licensed for both younger and older women with 
breast cancer; however, the cost-effectiveness of the test in an older population is not known.
Description of published cost-effectiveness studies evaluating the 
use of OncotypeDX
Two economic evaluations134–136 compared treatment guided using OncotypeDX with that guided 
using Adjuvant! Online and used a health-care perspective. The same model structure was used 
in both studies, with the model developed by Tsoi et al.135 being made available to the OHTA and 
adapted.134,136 Both studies addressed the cost-effectiveness of OncotypeDX in Canada in women 
with LN–, ER+, HER2– early breast cancer. The mean age of women entering the model was 
50 years.
A tabulated summary of the key features and data sources and a quality assessment for the two 
studies included in the cost-effectiveness review of OncotypeDX are presented in Appendix 18. 
It was not possible for the EAG to check the economic models as only the publications were 
available in the public domain.
A narrative description and assessment of each economic evaluation is presented in the 
following sections.
Description and critique of Tsoi et al.:135 cost-effectiveness analysis 
of recurrence score-guided treatment using a 21-gene assay in early 
breast cancer
Overview The aim of the study was to estimate the cost-effectiveness of OncotypeDX compared 
with Adjuvant! Online to guide the adjuvant treatment decision in Canadian patients with LN–, 
ER+, HER2 early breast cancer. The model used a Markov approach using a monthly cycle and 
followed patients over their lifetime in four possible health states: chemotherapy, recurrence 
free, distant recurrence and death. The study adopted the perspective of Canadian health care, 
and costs and QALYs were discounted at 5.0% per annum. The mean age of patients entering the 
model was 50 years.
Summary of effectiveness data The probability of reclassification was based on Bryant et al.45 
High and intermediate risks defined by OncotypeDX were grouped together. High-risk patients 
according to Adjuvant! Online were defined as patients with a 10-year mortality ≤ 91%. Patients 
were first classified according to Adjuvant! Online (low vs. high). For the strategy including 
OncotypeDX, patients classified as low or high risk using Adjuvant! Online were further 
reclassified into low and intermediate/high risk using OncotypeDX. Patients were assumed 
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to receive chemotherapy if they were considered at intermediate/high risk and entered the 
chemotherapy state for 6 months during which they might experience toxicity. The probability 
of developing toxicity (major and minor) was obtained from the literature.154,155 Patients in the 
recurrence-free state received tamoxifen for 5 years. Patients could develop distant metastases, 
remain disease free or die. Death from other causes than breast cancer was included.
The 10-year risk of recurrence was obtained from Paik et al.49 for each risk group category (for 
both the Adjuvant! Online and OncotypeDX arms). A relative risk reduction of 30%, taken from 
a meta-analysis conducted by the EBCTCG,29 was applied for patients classified in the high-risk 
group to represent the effect of chemotherapy. The median survival after distant metastasis was 
assumed to be 21 months. The probabilities were assumed to follow an exponential distribution.
Utility values were extracted from the published literature and were estimated using different 
approaches, including standard gamble and a visual analogue scale.
Summary of resource utilisation and cost data Costs were reported in 2008 Canadian dollars. 
The cost of chemotherapy was obtained from the Sunnybrook Odette Cancer Centre pharmacy, 
Toronto, Ontario. In the base case, patients were assumed to receive four cycles of doxorubicin 
and cyclophosphamide (AC). Other chemotherapy regimes were considered in sensitivity 
analysis [four cycles of docetaxel and cyclophosphamide (TC) and six cycles of 5-flurouracil, 
epirubicin and cyclophosphamide-docetaxel (FEC-D)]. The costs of chemotherapy included 
the costs of the chemotherapeutic agent, supportive medications, laboratory evaluation and 
human resources.
No costs were assumed for minor toxicities as it was assumed that they were already included 
in the cost of supportive medication. The cost of major toxicities included the cost for the 
management of febrile neutropenic complications and growth factor support. The model 
included the cost of fatal toxicities. The cost of hormonal treatment was applied to all patients for 
5 years or until death. In addition to the costs of the health state (recurrence free and recurrence), 
the model included the cost for terminal care.
The cost of OncotypeDX was assumed to be C$4404.
Summary of cost-effectiveness Results for the base-case analysis are presented in Table 32.
The impact of changes in the main model parameters was examined in one-way univariate 
sensitivity analysis, which showed that the results were sensitive to the reclassification 
probabilities, recurrence rates used, discounting, baseline age and cost of OncotypeDX.
Comments Based on the description of the model, this appears to be a reasonably well-conducted 
cost-effectiveness analysis. The generalisability of the results from this study to the UK context is, 
however, limited.
TABLE 32 Base-case results for the cost-effectiveness of OncotypeDX compared with Adjuvant! Online estimated by 
Tsoi et al.135
Life-years QALYs Cost (C$) Cost/QALY gained (C$) Cost/life-year gained (C$)
Adjuvant! Online 13.933 13.573 15,645
OncotypeDX + Adjuvant! Online 13.997 13.638 19,747 63,064 (approx. £39,917a) 63,911 (approx. £40,466a)
a 1C$ = £0.632967 (www.xe.com, accessed 22 September 2011).
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The study assumed that the decision to receive chemotherapy will be based on OncotypeDX or 
Adjuvant! Online alone; however, it is likely that both tools will be used in clinical practice to 
inform the treatment recommendation. It is also assumed that the prognostic test results and 
treatment guidelines would be followed in all cases (patients and physician are 100% compliant). 
This is unlikely to be the case in clinical practice.
High- and intermediate-risk group patients identified by OncotypeDX were grouped together 
and assumed to receive chemotherapy. However, it is unclear from existing studies whether or not 
patients classified in the intermediate-risk group would benefit from chemotherapy. Furthermore, 
the benefit of chemotherapy was assumed to be the same irrespective of OncotypeDX risk score. 
There is some evidence to suggest that high-risk patients gain a greater proportionate benefit, 
although this evidence has a number of weaknesses.
There was also an issue with the definition of risk groups. Bryant et al.45 rank order outputs from 
Adjuvant! Online so that a similar proportion of cases would be categorised as low risk (50%) as 
for OncotypeDX. This is arbitrary and therefore may introduce biases into the analysis.
Local and regional recurrences were not included in the model. No long-term adverse events 
were included.
The risk of recurrence for patients treated with endocrine therapy was extracted from data on 
patients receiving tamoxifen only; however, more effective agents are now available, reducing the 
risk of local and systemic recurrence.
Finally, utilities were extracted from a variety of sources using different valuation methods. 
This might bias the cost-effectiveness results. The starting age of the cohort was low (50 years) 
compared with the average age of patients presenting with early breast cancer in the UK.
Description and critique of OHTA analysis:134,136 gene expression 
profiling for guiding adjuvant chemotherapy decisions in women 
with breast cancer
Overview The aim of the study was to estimate the cost-effectiveness of Adjuvant! Online in 
combination with OncotypeDX compared with Adjuvant! Online alone to guide the adjuvant 
treatment decision in Canadian patients (Ontario) with LN–, ER+, HER2– early breast cancer. 
The analysis was built on the economic model developed by Tsoi et al.135
Compared with the original model,135 the OHTA analysis classified patients into low, intermediate 
and high risk using OncotypeDX or Adjuvant! Online, analysed all possible combination to give 
OncotypeDX to specific group of patients according to the Adjuvant! Online score (all patients, 
low, intermediate or high only, intermediate and high), modelled different chemotherapy 
regimens and conducted a PSA.
The majority of costs have been inflated from Tsoi et al.135 to reflect 2010 prices. The cost of 
OncotypeDX was updated to C$4191. The authors also stated that the cost of chemotherapy was 
updated but this was not reported. The benefit of chemotherapy was assumed to be different 
between risk group categories, based on evidence from the Paik et al. study.48 As in the original 
analysis, the risk reclassification and the probability of distant recurrence were derived from 
Bryant et al.45 and Paik et al.49
Summary of cost-effectiveness Incremental analysis was conducted comparing the most effective 
strategy with the next most effective strategy (Table 33). Assuming that OncotypeDX was 
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provided only to high-risk patients classified by Adjuvant! Online resulted in an estimated ICER 
of C$518 per QALY gained compared with not using OncotypeDX. The ICER was C$795 per 
QALY gained if OncotypeDX was given to intermediate- and high-risk patients compared with 
high-risk patients only classified by Adjuvant! Online. Finally, giving OncotypeDX to all patients 
is associated with higher benefit and costs. The ICER comparing this strategy (OncotypeDX to 
all patients) with OncotypeDX given only to patients classified as high and intermediate risk by 
Adjuvant! Online was C$23,983 per QALY gained.
Univariate sensitivity analysis was performed. PSA was also performed using Monte Carlo 
simulation. The PSA indicated that, at the willingness-to-pay threshold of $75,000 per QALY 
gained, the probability that OncotypeDX is cost-effective is 83.5% for patients identified as 
Adjuvant! Online low risk, 99.8% for patients identified as Adjuvant! Online intermediate risk 
and 65.8% for patients identified as Adjuvant! Online high risk.
Comments Based on the description of the model, this appears to be a reasonably well-conducted 
cost-effectiveness analysis. The generalisability of the results from this study to the UK context 
are, however, limited.
The description of the model and its assumptions is minimal in the report, but this is explained 
by the fact that this is an adaptation of a previously published cost-effectiveness evaluation. 
The authors were also contacted and a greater description of the model and results are due for 
publication soon. Despite the adaptations, key limitations remain regarding the data used to 
reclassify patients and for utility estimates, the probability of distant metastases, the type of 
relapse modelled, long-term adverse events after chemotherapy and the benefit of chemotherapy.
Assessment of the economic evaluation submitted by 
Genomic Health
An economic evaluation was submitted by Genomic Health27 comparing the use of OncotypeDX 
with current clinical practice in the UK and included a full report and an electronic model 
submitted in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). The economic 
model was reviewed to check that the parameters presented in the report corresponded to those 
used in the economic model and assessed using a critical appraisal checklist adapted from the 
Drummond and Jefferson130 and Eddy131 checklists (Table 34).
TABLE 33 Base-case results for the cost-effectiveness of OncotypeDX compared with Adjuvant! Online estimated by 
the OHTA analysis (2010)134,136
Cost (C$) QALYs ICER (C$)
No patients 13,298 13.34
Adjuvant! Online high risk 13,660 14.04 518 (approx. £328a)
Adjuvant! Online intermediate/high risk 13,961 14.42 795 (approx. £503a)
All patients 17,466 14.64 23,983 (approx. £15,179a)
a 1C$ = £0.632967 (www.xe.com, accessed 22 September 2011).
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Description of the economic model submitted by Genomic Health
Overview
The economic model submitted by Genomic Health27 used a Markov approach with individuals 
moving between three possible health states: recurrence free, distant recurrence and death 
(from breast cancer or other causes) (Figure 9). The model compared the cost-effectiveness of 
the addition of OncotypeDX to clinical and pathological parameters (using NPI and Adjuvant! 
Online; termed usual care in the economic model submitted by Genomic Health) with that of 
clinical and pathological parameters alone in women with ER+ and LN– or single node-positive 
early breast cancer in the UK. The starting age in the model was 60.55 years and patients were 
followed up for 30 years. The study adopted the perspective of the UK NHS, with costs and 
QALYs discounted at 3.5%. A tabulated summary of the key features and data sources of the 
economic model submitted by Genomic Health is presented in Table 35.
The structure was based on an original model by Hornberger et al.46 Patients with ER+ and LN– 
or single node-positive [pN1(mic)] early breast cancer with no contraindications for adjuvant 
chemotherapy are assigned adjuvant therapy based on:
 ■ clinical and pathological parameters alone (using NPI and Adjuvant! Online) or
 ■ the addition of OncotypeDX RS to usual care [terminology used in the Sponsor 
submission (SS)].
Patients are categorised as low, intermediate or high risk according to the OncotypeDX 
classification. Among each risk group category patients are further divided according to the 
treatment they received (either hormonal therapy alone or hormonal therapy in addition 
to chemotherapy). In each cycle of the model, the risk of recurrence was evaluated for each 
TABLE 34 Critical appraisal of the economic model submitted by Genomic Health27
Modelling assessments should include:
Economic evaluation 
submitted by Genomic Health26
1 A statement of the problem Yes
2 A discussion of the need for modelling vs. alternative methodologies Yes
3 A description of the relevant factors and outcomes Yes
4 A description of the model including reasons for this type of model and a specification of the scope, 
including time frame, perspective, comparators and setting. Note: n = number of health states within 
submodel
Yes
5 A description of data sources (including subjective estimates) with a description of the strengths and 
weaknesses of each source, with reference to a specific classification or hierarchy of evidence
Yes
6 A list of assumptions pertaining to the structure of the model (e.g. factors included, relationships and 
distributions) and the data
Yes
7 A list of parameter values that will be used for a base-case analysis and a list of the ranges in those 
values that represent appropriate confidence limits and which will be used in a sensitivity analysis
Yes
8 The results derived from applying the model for the base case Yes
9 The results of the sensitivity analyses: unidimensional, best/worst case, multidimensional (Monte Carlo/
parametric), threshold
Yes
10 A discussion of how the modelling assumptions might affect the results, indicating both the direction of 
the bias and the approximate magnitude of the effect
Yes
11 A description of the validation undertaken including concurrence of experts, internal consistency, external 
consistency, predictive validity
Unclear
12 A description of the settings to which the results of the analysis can be applied and a list of factors that 
could limit the applicability of the results 
Unclear
13 A description of research in progress that could yield new data that could alter the results of the analysis Unclear
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simulated patient based on their RS-defined category of low, intermediate or high risk as 
reported for the NSABP B20 cohort.49 The risk was then adjusted for patients who received 
chemotherapy, based on whether or not patients received chemotherapy as per the initial 
recommendation (in the arm termed usual care) and based on the recommendation following 
the additional information provided by the OncotypeDX RS. The benefit of chemotherapy 
varied by OncotypeDX risk group, based on Paik et al.49 For PSA, recurrence risks and relative 
risk reductions for chemotherapy were sampled from normal distributions, with the assumed 
variance derived from published data. Non-breast cancer death was captured as a competing risk 
in the model, based on UK life tables for women in 2007–9.156 For patients experiencing distant 
recurrence, the median survival was assumed to be 3.3 years.157
Summary of effectiveness data
The impact of OncotypeDX on treatment recommendations was obtained from the preliminary 
results from a Welsh cohort study by Holt et al.78 reporting on the first 107 patients.27 The 
study considered the treatment recommendations made based on usual care (chemotherapy 
or no chemotherapy) and then the treatment recommendations made following the additional 
knowledge of the OncotypeDX test result. In this study, 33% of patients had their initial 
treatment recommendations changed following OncotypeDX testing.27,78 Not all treatment 
decisions were directly influenced by the high- or low-risk category from the report, that is, some 
high-risk patients did not receive chemotherapy and vice versa (Table 36).
The risk of recurrence for patients in the low-, intermediate- and high-risk groups assessed by 
OncotypeDX and the impact of chemotherapy on risk of recurrence by risk group was taken 
from Paik et al.49 The risk of recurrence was assumed to be constant over time, modelled by an 
exponential distribution. All patients within each OncotypeDX risk category were assumed to 
have the average risk of recurrence for that group.
No recurrence
Recurrence
free
RecurrenceUsual care
ODX testing
All patients
As aboveM
M
Dead
Recurrence free
Recurrence
Recurrence
Dead
Dead
Recurrence
Non-ESBC death
Survive
Die
FIGURE 9 Overview of the OncotypeDX cost-effectiveness model structure submitted by Genomic Health (reproduction 
of figure 6–2 in the report submitted by Genomic Health).27
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The probability of dying from distant metastasis was derived from Thomas et al.,157 assuming a 
median life expectancy of 3.3 years. Again, this was assumed to be the same for all risk groups.
Utilities were extracted from the published literature. The quality of life associated with 
recurrence (0.60) was taken from Milne et al.,158 who reported an analysis in New Zealand 
women with advanced breast cancer and assumed treatment with endocrine therapy. The 
disutility associated with chemotherapy (–0.07) was taken from Peasgood et al.159 The health 
utility associated with 1 year in the recurrence-free state (0.78) was assumed to be the same 
during and after endocrine therapy.160
Summary of resource utilisation and cost data
All drug costs were taken from the British National Formulary (BNF).161 Five endocrine therapy 
regimes were considered in line with NICE guidelines: (1) tamoxifen for 5 years, (2) anastrozole 
for 5 years, (3) letrozole for 5 years, (4) tamoxifen for 2 years plus exemestane for the final 3 years 
TABLE 35 Tabulated summary of the key features and data of the economic model submitted by Genomic Health27
Parameter Key features/data
Country UK 
Perspective (costs) NHS and PSS
Comparators (NPI, 
Adjuvant Online!)
Usual care (NPI and Adjuvant Online!)
Starting age in the 
model
60.55 years
Population ER+, LN– (or single node-positive) early breast cancer
Model structure (type, 
health states)
Markov model with three health states (recurrence free, distant recurrence and death)
Definition of relapse Distant recurrence only
Time horizon 30 years
Endocrine therapy 
regime
Mixed – tamoxifen and aromatase inhibitors – according to NICE guidance (see text) 
Chemotherapy regime Six cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC75)
Benefit of 
chemotherapy by RS 
risk group
Low-risk group: no benefit (assumed); intermediate group: 39%; high risk: 74% 
Adverse events Short-term adverse events included in the cost and disutility associated with chemotherapy
Other assumptions The probability of dying after distant metastases was the same irrespective of risk classification. Transitional probabilities 
are assumed to be exponential
Definition of high risk In the usual care arm patients were offered chemotherapy based on the treatment decision taken using NPI and Adjuvant 
Online! In the OncotypeDX arm patients were offered chemotherapy based on the treatment decision taken using NPI and 
Adjuvant Online! and knowledge of the OncotypeDX test result. Note that the results of the test were not always followed
Quality of life Different sources, valuation methods. Recurrence free = 0.78; decrement from chemotherapy = 0.07; distant 
recurrence = 0.6
Costs and resources 
used
2010 UK pounds
OncotypeDX test: £2580; chemotherapy (all cycles): £3194 (chemotherapy) + £4534 (adverse events associated with 
chemotherapy and use of G-CSF); recurrence free (yearly): £0; endocrine therapy (mixed): £853 (first 5 years) + £40 
(adverse events first 5 years) + £123 (adverse events 6–8 years); DM (3.3 years): £916 monthly; terminal care (last 
3 months): £0
Discounting (per 
annum)
3.5% for both costs and benefits
Uncertainty One-way and probabilistic sensitivity analysis
% of HER2+ Unclear from the submission
Cost per QALY £6232
DM, distant metastasis; G-CSF, granulocyte colony-stimulating factor; PSS, Personal Social Services.
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and (5) tamoxifen for 5 years followed by extended therapy with letrozole for a further 3 years. 
The probability that a patient was treated with each regime was taken from NICE TA112.162 The 
annual cost over the first 5 years was £669.03 and the annual cost over the following 3 years was 
£108.40. All patients were assumed to be 100% compliant with endocrine therapy. Adverse event 
probabilities and costs of adverse events associated with endocrine therapies were derived from 
Hind et al.163 and inflated to 2010 prices.
Patients treated with chemotherapy were assumed to receive six cycles of FEC75 (5-fluorouracil, 
epirubicin and cyclophosphamide) based on the regime description of FEC75 given by 
Avon, Somerset and Wiltshire Cancer Services in its chemotherapy protocol documents.27 
Administration costs were taken from the National Schedule of Reference Costs 2009–10164 
for NHS trusts on an outpatient basis. The costs of adverse events and the probability of their 
occurrence was taken from Wolowacz et al.165 for patients treated with CAF in the absence of 
sufficient evidence for FEC. The model did not include long-term adverse events associated 
with chemotherapy.
Finally, it was assumed that all patients were treated with granulocyte colony-stimulating factor 
(G-CSF) in order to prevent neutropenia.
Summary of cost-effectiveness
The base-case analysis is presented in Table 37. The addition of OncotypeDX to current practice 
(clinical and pathological parameters) resulted in an ICER of £6231.91 per QALY gained.
One-way sensitivity analysis showed that the base-case outcomes were most sensitive to 
variation in patient age, the cost of OncotypeDX testing and the change in chemotherapy 
recommendations for low-risk patients. The PSA results indicated that, at a willingness-to-pay 
threshold of £20,000 per QALY, there was a 99.6% probability that OncotypeDX would be cost-
effective compared with current clinical practice (Figure 10).
A scenario analysis was also presented for node-positive patients using data from treatment 
decisions in node-positive patients in the German setting.166 (Commercial in-confidence 
information has been removed.)
TABLE 36 Proportions of patients in the preliminary analysis of the Holt et al.78 study receiving chemotherapy before 
and after OncotypeDX testing (by RS)27
Initial recommendation Post ODX
RS Group HT CT RS Group HT
Low 30.5% 23.8% Low 30.5%
Int. 16.2% 10.5% Int. 16.2%
High 8.6% 10.5% High 8.6%
All 55.24% 44.76% All 55.24%
CT, chemotherapy; HT, hormonal therapy; int., intermediate.
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Critique of the economic evaluation submitted by Genomic Health
The EAG has reviewed the economic model and report submitted by Genomic Health. A detailed 
critique is presented below. In summary, the model was considered to be of a good standard 
given the evidence available; however, there are a number of limitations with the model structure, 
assumptions and data inputs that need further consideration.
Impact of OncotypeDX on chemotherapy decision-making in the UK
The economic model used data from Holt et al.78 to reflect current practice in England and Wales 
and the impact of OncotypeDX on treatment recommendations.27 The study was conducted in a 
Welsh cohort and is the only identified evidence of the impact of the test on UK decision-making.
The EAG have several concerns regarding the use of the Holt et al. study. These concerns have 
been discussed in Chapter 3, Results: OncotypeDX and are further detailed in Model inputs: test-
specific parameters. Briefly:
 ■ Data used to populate the economic model were taken from a preliminary analysis 
conducted in a small sample of 106 patients.
 ■ The study was conducted in Wales in two centres and it is unclear to what extent results are 
generalisable to the rest of England and Wales.
 ■ It is unclear how the decision to recommend chemotherapy was made.
 ■ There are concerns that patients may not be representative of patients seen in clinical practice 
in England and Wales. In Model inputs: test-specific parameters, the NPI distribution of 
patients included in the Holt et al. study78 is compared with the NPI distribution of patients 
TABLE 37 Base-case result for the cost-effectiveness of OncotypeDX compared with current clinical practice in the UK 
estimated by Genomic Health (reproduction of table 6–13 in the report submitted by Genomic Health)27
Usual care OncotypeDX testing Difference
Cost (£) 11,847.24 12,734.93 887.69
QALYs 11.39 11.54 0.14
Life expectancy (years) 14.73 14.89 0.16
ICER (£/QALY gained) 6231.91
ICER (£/life-year gained) 5633.30
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FIGURE 10 Cost-effectiveness acceptability curve for the probability of OncotypeDX being cost-effective at various 
willingness-to-pay thresholds estimated by Genomic Health.27
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from two registries [Eastern Cancer Registration and Information Centre (ECRIC) and West 
Midland Cancer Intelligence Unit (WMCIU)], which shows that patients included in the 
Holt et al. study were more severe – with larger tumours and a higher proportion of grade II 
and III tumours (analysis conducted by the EAG).
 ■ The proportion of patients recommended for chemotherapy under current practice in the 
Holt et al. study appears to be overestimated when compared with the proportion of patients 
who are actually offered chemotherapy, based on data from two cancer registries in England 
and Wales (see Model inputs: test-specific parameters). If this is the case, use of these data 
in the model may increase the predicted benefits derived from the use of OncotypeDX, 
resulting in a potential overestimation of the ICER.
Because of these limitations, the EAG did not consider the Holt et al. study to be an appropriate 
study to reflect current practice in England and Wales.
Risk of recurrence
In the absence of follow-up in the Holt et al. study,27,78 a separate data source was used to 
estimate the risk of recurrence for patients classified as being of low, intermediate or high risk 
of distant recurrence with OncotypeDX. The 10-year risk of distant recurrence used in the 
model for patients on endocrine therapy (tamoxifen) was 3.2% for the low RS group, 9.1% for 
the intermediate RS group and 39.5% for the high RS group.49 The EAG expresses three main 
concerns with these data:
 ■ Data were taken from a US cohort of women prior to 2006 and therefore the results might 
not be transferable to current treatment practice for women in England and Wales.
 ■ The Paik et al. study49 is based on pre- and postmenopausal women who received tamoxifen 
only; however, a mixture of different endocrine therapies is now used in the UK.
 ■ Biases could have been introduced because two separate sources of data were used for the 
risk classification and risk of recurrence. Although the EAG acknowledges the rationale 
of the manufacturer to use two separate data sources, the EAG considers this approach 
to be inappropriate because of the high correlation between the two parameters. This is 
particularly important as the ICER is likely to be sensitive to these assumptions. Data from 
a previous US study indicated a 10-year risk of distant recurrence of 6.8%, 14.3% and 30.5% 
for the low, intermediate and high RS groups, respectively, in women treated with tamoxifen 
only. The TransATAC trial conducted in the UK79 showed a 10-year risk of recurrence of 
4.0%, 12.0% and 25.0% for women classified in the low, intermediate and high RS groups, 
respectively, based on postmenopausal, LN–, HER2+/– women treated with tamoxifen and 
anastrozole. In sensitivity analyses, the manufacturer shows that using data for the risk of 
recurrence from the TransATAC trial increases the ICER from £6232 to about £9160 per 
QALY gained.
In addition, the manufacturer assumed the risk of recurrence to be constant over time. Evidence 
shows that the hazard of distant recurrence declines with time, with a plateau after approximately 
15 years.167 Assuming a reduction in recurrences over time, and certainly beyond 15 years, would 
have resulted in a higher ICER as the use of OncotypeDX would prevent fewer recurrences.
Finally, the risk of recurrence was applied according to the OncotypeDX classification, that 
is, patients recommended chemotherapy or not using current clinical practice have the same 
risk of recurrence. However, it seems likely that patients who are recommended chemotherapy 
within current clinical practice (based on the use of the NPI and/or Adjuvant Online) have a 
higher risk of recurrence than patients who are not recommended chemotherapy (even within 
the same RS group). For example, as shown in Model inputs: test-specific parameters, the risk of 
distant recurrence for patients classified using OncotypeDX is different from the risk of distant 
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recurrence for patients classified by NPI. Ignoring the prognostic value of the treatment decision 
using clinicopathological parameters is likely to produce a more favourable ICER.
Patients who are offered the test
The model assumes that OncotypeDX is given to all women with ER+ and LN– or single node-
positive early breast cancer. However, clinical opinion indicates that in the UK only a subgroup 
of patients might be offered OncotypeDX – those patients at intermediate risk for whom 
the decision for adjuvant treatment is uncertain. Assuming that all women receive the test is 
considered to be a conservative assumption and the ICER is likely to be more favourable if only 
selected patients receive the test.
Benefit of chemotherapy
Data from the Paik et al. study49 were used to determine the benefit of chemotherapy. Although 
the study showed a consistent benefit in women classified as being of intermediate or high 
risk of distant recurrence with OncotypeDX, there are some concerns with the study design. 
Indeed, data from the training set (used to develop the test) were used to estimate the benefit 
of chemotherapy. This is likely to positively bias the observed effect of chemotherapy. More 
discussion is available in Chapter 2, OncotypeDX test. Given that the Paik et al. study is based on 
patients who received tamoxifen only, it is not clear how this evidence relates to women in the 
UK who currently receive a mixture of different endocrine therapies. This impact is not, however, 
expected to be large as the use of different endocrine therapies does not generate large differences 
in OS. In addition, the study included women with HER2+ early breast cancer. Those women are 
likely to have a high risk of distant recurrence (and are more likely to be classified with a high RS) 
and derive a greater benefit from chemotherapy.
The chemotherapy regimen used to define the impact of chemotherapy by risk group in Paik 
et al.49 was CMF (cyclophosphamide, methotrexate and 5-fluorouracil) or MF (methotrexate and 
5-fluorouracil). Discussion with clinical experts indicated that newer and more effective regimens 
are used in the UK. The economic model assumes the use of FEC75 in the UK. The impact of 
this assumption (on both efficacy and cost) has not been discussed. It is not known how this will 
influence the impact of chemotherapy on distant recurrence.
Time between recurrence and death
The economic model submitted by Genomic Health assumed that the time between distant 
recurrence and death was the same irrespective of the risk group. Discussion with clinical experts 
indicated that it is likely that the time between recurrence and death may be shorter for patients 
at high risk. This has not been discussed by the manufacturer and it is unclear how this would 
affect the ICER.
Exclusion of local and regional recurrences
The economic model submitted by Genomic Health included only distant metastases. The 
omission of local and regional recurrences is likely to produce a less favourable ICER as 
additional benefits might be accrued by the use of the new test with no additional cost.
Cost and utility associated with recurrence
The cost of recurrence was taken from the study by Thomas et al.,157 which was conducted in 
a mixture of patients, some with ER–, HER2+ and LN– early breast cancer. The manufacturer 
discussed the limitations of using data from this study.
There are concerns that the cost of recurrence is applied as a one-off cost, which has implication 
when discounting costs. It is further assumed that patients remain in the recurrence health state 
for 3.3 years, whether they are aged 60 years or 90 years. However, in reality, older women are 
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likely to spend less time in the recurrence health state. It is unclear how this would affect the 
ICER as it potentially results in an overestimation of the cost of distant recurrence but also of the 
QALYs gained whilst in the recurrence health state.
Adverse events
Long-term adverse events associated with chemotherapy, such as cardiotoxicity and secondary 
cancers, are not captured in the model. This is likely to produce a less favourable ICER if the 
use of OncotypeDX reduces the proportion of patients receiving chemotherapy, as it does in the 
Genomic Health model.
Short-term adverse events were included in the model. Costs relating to the use of G-CSF to 
prevent neutropenia were considered to be overestimated as it was assumed that all patients 
receive G-CSF for each of the six cycles. This is a concern given the high cost of G-CSF in the 
model. The cost of G-CSF accounts for £4118 (53%) of the total cost of chemotherapy (drug, 
administration, monitoring, adverse events) in the model (£7728). Discussion with clinical 
experts indicated that in the UK G-CSF is typically used for the secondary prevention of febrile 
neutropenia (i.e. after an event or following a dose delay due to neutropenia); it is given only to 
a proportion of patients (approximately 25%) as secondary prophylaxis for all subsequent cycles 
(five or fewer) following an episode of febrile neutropenia or dose delay. This assumption used in 
the Genomic Health model is likely to produce a lower (more favourable) ICER.
Cost of endocrine therapy and chemotherapy
Finally, the economic model submitted by Genomic Health assumed no wastage and a dosage 
per body surface area (BSA) of 1.8 mg/m2. A UK study reported that the mean dosage per BSA 
for women with breast cancer in the UK was 1.75 mg/m2.168 This is likely to overestimate the drug 
cost based on the BSA, such as the cost of chemotherapy or endocrine therapy, and therefore 
produce a more favourable ICER.
Probabilistic sensitivity analysis
Finally, the EAG had some concerns about the PSA conducted by the manufacturer. The benefit 
of chemotherapy for patients classified as low risk with OncotypeDX was not varied in the PSA. 
Although no benefit (reduction in distant recurrence) was observed for this group of patients 
(HR 1.31), the CI was wide enough (95% CI 0.46 to 3.78) that a benefit is not impossible.49 Costs 
were varied in the PSA assuming a normal distribution and an arbitrary SE of 10% around the 
mean. Neither the proportion of patients receiving chemotherapy under clinical practice nor 
the classification of patients was varied in the PSA. The change in treatment allocation after 
knowledge of the OncotypeDX result was, however, varied using a normal distribution using 
an arbitrary SE of 10%. The EAG did not consider this approach appropriate as this ignores the 
correlation between the risk reclassification used for both the comparator and the intervention 
arms and the change in treatment allocation for the intervention arm.
Assessment of the economic evaluation submitted by Clarient
An economic evaluation for the use of Mammostrat in the UK (report only) was submitted by 
Clarient late in the appraisal process shortly before the finalisation of the EAG report.169 Because 
of its direct relevance to the UK, the EAG felt it useful to report the method and main finding. 
Because of the late submission and time constraints, only a brief description and critique is 
reported thereafter.
The submission169 included a full report only and therefore it was not possible for the EAG to 
check the economic model.
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Brief description of the economic model submitted by Clarient
Description of the method and data inputs
The model compared the cost-effectiveness of treatment guided using Mammostrat with that 
of treatment guided using the NPI in women with ER+, LN– early breast cancer in the UK, 
including both pre- and postmenopausal women. Patients were followed up for 10 years and 
the study adopted the perspective of the UK NHS, with costs and QALYs discounted at 3.5%. 
The economic model used a Markov approach with individuals moving between three possible 
health states: recurrence free, recurrence (all recurrences) and death (from breast cancer or 
other causes).
(CIC information has been removed.)
Summary of results
(CIC information has been removed.)
(CIC information has been removed.)
Critique of the economic evaluation submitted by Clarient
It was not possible for the EAG to check the economic model as only the report was provided 
by the manufacturer. Based on the description of the model alone the robustness of the model 
cannot be verified. A large number of assumptions were made to link the evidence available and 
it is not possible to fully assess the impact of this. Therefore, the results from this study should be 
interpreted with caution.
Because of time and resource constraints and the absence of the Microsoft Excel model, it was 
not possible to provide a detailed critique of the economic evaluation submitted by Clarient; 
however, the main limitations/concerns are highlighted below:
 ■ The model uses a 10-year time horizon. This is believed to be very short given that 
recurrences can usually occur after 10 years.
 ■ (CIC information has been removed.)
(CIC information has been removed.)
Relevance of existing cost-effectiveness evidence for NICE 
decision-making
The existing cost-effectiveness evidence has limited relevance for the UK setting. Only two of 
the nine tests (OncotypeDX and MammaPrint) have any published cost-effectiveness evidence 
TABLE 38 Base-case results for the cost-effectiveness of Mammostrat compared with the NPI estimated by Clarient 
(reproduction of table 17 in the report submitted by Clarient169)
(CIC information has been removed) (CIC information has been removed) (CIC information has been removed)
(CIC information has been removed) (CIC information has been removed) (CIC information has been removed)
(CIC information has been removed) (CIC information has been removed) (CIC information has been removed)
(CIC information has been removed) (CIC information has been removed) (CIC information has been removed)
(CIC information has been removed) (CIC information has been removed) (CIC information has been removed)
(CIC information has been removed) (CIC information has been removed) (CIC information has been removed)
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to date132,134–136,146 and each presented a number of limitations (see Systematic review of existing 
cost-effectiveness evidence).
Genomic Health and Clarient each submitted an economic evaluation considering the cost-
effectiveness of OncotypeDX26 and Mammostrat169 in the UK, respectively, and the submitted 
economic evaluations are therefore potentially more relevant for UK decision-making. However, 
there were a number of issues in the evaluations that require further consideration:
 ■ the assumption about the baseline level of chemotherapy in clinical practice in England 
and Wales
 ■ the assumption about the risk of distant recurrence in a UK population
 ■ the assumption about the proportion of patients who would be offered chemotherapy after 
reclassification with the new test in England and Wales
 ■ the assumption about who would be offered the test in England and Wales
 ■ the assumptions about the cost of chemotherapy and the treatment of adverse events 
generated by the chemotherapy in England and Wales.
Independent economic model: methods
This section of the report describes the development of the de novo economic model. The 
following sections describe the population under assessment, the interventions to be modelled, 
the comparators and the subgroups of interest. The economic model is described in Description of 
the de novo economic model. This gives an overview of the model and a more detailed description 
of the model structure, followed by a description of the model input parameters – first, those 
common to all models (including costs and utilities) and, second, those that are test specific 
(clinical parameters).
The key objective of the economic assessment is to address the cost-effectiveness of the use of 
GEP and expanded IHC tests compared with current practice to guide adjuvant chemotherapy 
decision-making in women with early breast cancer in England and Wales. Only two of the tests, 
OncotypeDX and MammaPrint, have published evidence about their economic value134–136,146 but 
these evaluations are not UK specific. Two UK economic evaluations were submitted by Genomic 
Health (OncotypeDX)27 and Clarient (Mammostrat)169 as part of the NICE request for additional 
information to the manufacturers. The review of the published cost-effectiveness evidence and 
the critique of the economic evaluations submitted by the manufacturers for this appraisal 
revealed a number of limitations that need to be addressed.
Therefore, a de novo economic model was constructed to address these limitations where 
possible and to estimate the cost-effectiveness of a wider range of GEP and expanded IHC tests. 
Notably, the EAG economic assessment uses UK-specific data and addresses limitations over 
the proportion of patients who currently receive chemotherapy in England and Wales and the 
risk of distant recurrence in a UK population; carries out a subgroup analysis offering the test to 
patients who are considered the most likely to benefit from the test; and seek to undertake a more 
accurate estimation of the cost of chemotherapy in England and Wales.
The economic model considers the selection of patients for chemotherapy using the new 
tests (intervention arm) compared with the selection of patients for chemotherapy using 
current prognostic tools (comparator arm). Patients who receive chemotherapy are assumed 
to experience a reduction in the risk of recurrence (and subsequent deaths) compared with 
those patients who receive endocrine therapy only. The costs of chemotherapy, along with the 
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costs and the reduction in quality of life resulting from the adverse events associated with the 
chemotherapy, are taken into account within the model.
Population under assessment
The NICE scope25 identifies the population under assessment as people diagnosed with early 
breast cancer. However, most of the GEP and expanded IHC tests have been developed for use 
in a specific subpopulation or have evidence of efficacy only within a specific subpopulation (see 
Chapter 2, Results). The economic assessment focuses on women with ER+, LN–, HER2– early 
breast cancer. This subgroup was selected after review of the evidence available (see Chapter 2, 
Results) and the indications of the tests (see Tables 6 and 7), discussion with clinical experts and 
the perceived likelihood of the use of the test resulting in a change in current clinical practice.170 
This was considered to be the population for which the new tests had the most robust evidence 
base and the population in which the tests were most likely to be used in the first instance in 
England and Wales. Patients with HER2+ early breast cancer or with positive nodes were not 
considered in this assessment because of time and resource constraints and lack of evidence, but 
they should be the subject of future research. Of particular note, the role and cost-effectiveness 
of GEP and expanded IHC tests in LN+ women may be explored as part of the planned Optimal 
Personalised Treatment of breast cancer using Multi-parameter Analysis (OPTIMA) trial, 
although funding for this trial is not yet confirmed. The proposed aim of the OPTIMA trial is to 
identify an effective method, using multiparameter analysis, to target women with ER+, HER2 
normal primary breast cancer who are likely to benefit or not from chemotherapy. A health 
economic evaluation is planned as part of the study (Dr Peter Hall, Clinical Research Fellow, 
University of Leeds, July 2011, personal communication).
Interventions
Nine tests were identified by NICE in the scope25 (OncotypeDX, MammaPrint, Mammostrat, 
IHC4, PAM50, BCI, Randox BCA, NPI+ and BluePrint). These tests are described in detail in 
Chapter 1, Description of technologies under assessment. Our systematic review of the evidence 
(see Chapter 2, Results) indicated considerable differences in the level, quality and reporting of 
evidence between tests. Although some of the included tests have a relatively well-developed 
evidence base, some tests are still under development or have a relatively immature evidence base 
(e.g. NPI+, Randox BCA). Furthermore, there are differences in the output of the tests. Many of 
the tests predict the likelihood of distant recurrence, providing either a risk of recurrence score 
(as a continuous scale) or a risk category (e.g. high/low), but three of the tests (Randox BCA, 
current version of the PAM50 test and BluePrint) provide information about subtyping alone. 
The impact of information on subtype on the management of patients with early breast cancer 
is not yet clearly understood. No evidence on the impact of subtype information on clinical 
decision-making in early breast cancer in England and Wales was identified. This makes the 
potential comparison between tests particularly difficult.
To allow a sensible comparison between tests based on the available evidence, and given the 
time and resource constraints of the project, the EAG defined four minimum criteria that a test 
had to fulfil to be included in the economic evaluation. These criteria have been defined after 
consideration of the NICE scope,25 discussion with clinical experts and consideration of the 
review of the existing cost-effectiveness evidence:
1. The test has been validated in an external cohort (clinical validity).
2. There is evidence about risk reclassification against one of the comparators defined by NICE 
within the scope (i.e. NPI, Adjuvant! Online or clinical practice in the UK).25 In other words, 
there is evidence on how the new test reclassifies patients into risk groups relative to their 
initial risk group as defined by current practice.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96 Economic analysis
3. The test provides an estimate of risk of recurrence in the form of a risk score or risk 
category. Following discussion with clinical experts tests that provide only information 
about subtyping were excluded as it is not yet clear how this knowledge will impact on the 
treatment decision-making process.
4. The outputs of the test, which will be used to inform the decision about whether or not to 
offer chemotherapy, are well defined.
A summary of these criteria for each of the nine tests considered for this appraisal is presented in 
Table 39.
Overall, only a subset of these tests met the criteria for inclusion in the economic evaluation 
defined by the EAG: OncotypeDX, MammaPrint, IHC4 and Mammostrat.
Although the PAM50 test has evidence about risk reclassification against OncotypeDX and 
Adjuvant! Online,171 this test was excluded for the following reasons:
 ■ PAM50 was not available in the UK at the time of writing of the report. Furthermore, the 
current version of the commercialised test (not available in the UK) does not provide a risk 
score but only information about subtyping. Following discussion with clinical experts it 
remained unclear how subtyping would be used to inform treatment decisions. An in vitro 
diagnostic version of the test is expected to be commercialised and this version will calculate 
a risk score; however, this is still under development.
 ■ The evidence for risk reclassification was derived from a cohort in which the majority 
of women had positive nodes and therefore fall outside the subgroup of interest for 
this assessment.
The evidence base for NPI+ is developing. External validation of the test in an independent 
cohort is currently underway but has not yet been published. At the time of writing this report 
there was no published evidence on risk reclassification with NPI+.
There is no published evidence on risk reclassification against any of the comparators defined 
in the scope for BluePrint, Randox BCA and BCI. Furthermore, BluePrint and Randox BCA 
provide subtyping only.
TABLE 39 Summary of the inclusion/exclusion criteria for the economic evaluation
Test
External validation 
of the test in an 
independent cohort
Evidence about risk 
reclassification
Final version of the 
test provides risk of 
recurrence
Clear use 
of the test Other comments
In
cl
ud
ed
OncotypeDX P P	Adjuvant! Online, NPI, 
clinical practice 
P P
MammaPrint P P	Adjuvant! Online, NPI P P
Mammostrat P P	NPI P P
IHC4 P P	NPI (OncotypeDX) P P
Ex
cl
ud
ed
PAM50 P P	OncotypeDX, Adjuvant! 
Online
7	In vitro diagnostic 
version in 
development
P Reclassification evidence 
in a mix of LN+/–
BluePrint 7 7 7 P
NPI+ 7 Nearing completion P	Unpublished P 7
Randox CA 7 7 7 7
BCI 7 7 P P
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Interventions to be assessed in the economic evaluation
Four tests were evaluated: OncotypeDX, MammaPrint, IHC4 and Mammostrat. These tests 
are described in detail in Chapter 1, Description of technologies under assessment. However, as 
indicated in the systematic review of the literature conducted as part of this project, the level and 
quality of evidence for these tests varies considerably.
The primary analysis evaluated the cost-effectiveness of adjuvant chemotherapy guided using 
OncotypeDX and IHC4. The systematic review of the evidence indicated that OncotypeDX is the 
furthest along the validation pathway compared with other similar tests, and the evidence base, in 
particular in relation to the prognostic ability of the test, was considered to be reasonably sound. 
The evidence for IHC4 is less developed; however, there is evidence relating to the performance 
of IHC4 compared with OncotypeDX and this allowed both tests to be modelled within the same 
model structure. A number of additional assumptions were, however, necessary to evaluate the 
cost-effectiveness of IHC4.
The final algorithm for IHC4 calculates a risk score for distant recurrence based on ER, PR, 
HER2 and Ki-67 in addition to classical clinical and pathological variables (composite risk score 
IHC4 + clinical score). This version of the algorithm was considered in the economic analysis 
(the term IHC4 will be used for simplicity but it refers to the composite risk score IHC4 + clinical 
score). Of note, an online calculator is expected to be made available (Professor Mitch Dowsett, 
Royal Marsden Hospital, London, July 2011, personal communication).
Analyses were performed for MammaPrint and Mammostrat but these were considered to be 
exploratory as there were significant gaps and/or limitations in the evidence base available for 
both tests (see Model inputs: test-specific parameters).
Comparators
Description of potentially relevant comparators
NICE CG807 indicates that adjuvant therapy should be considered for all patients with early 
invasive breast cancer after surgery, based on assessment of the prognostic and predictive factors 
alongside the potential benefits and side effects of the treatment. The guidelines recommend 
consideration of the use of Adjuvant! Online to support estimation of individual prognosis 
and the absolute benefit of adjuvant treatment for patients with early invasive breast cancer.7 
In addition, guidelines based on NPI are widely used in England and Wales. Clinical opinion 
suggests that there is wide variation in clinical practice between centres in the UK, with some 
centres using Adjuvant! Online, some using NPI-based guidelines and some using a combination 
of the two.
Adjuvant! Online
Despite NICE recommendations to use Adjuvant! Online,7 clinical experts indicated that it is not 
comprehensively used in the UK for a number of reasons:
 ■ It is based on a US population and there are some difficulties in applying the Adjuvant! 
Online data to the UK population.
 ■ Although it is a useful aid for discussing risk of recurrence and benefits of 
chemotherapy with patients, it is viewed by some as complex to use and interpret for 
decision-making purposes.
 ■ It cannot be used by all NHS trusts as access is blocked by some trusts for information 
technology security reasons.
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The published evidence reports outcomes based only on the risk of recurrence estimated using 
Adjuvant! Online. However, both the risk of recurrence and predicted impact of adjuvant 
treatments would be used to inform treatment decisions.
Nottingham Prognostic Index
Nottingham Prognostic Index-based guidelines are widely used in some parts of the UK to 
inform decisions about adjuvant chemotherapy. The NPI forms part of the National Cancer 
Dataset for breast cancer so the NPI score should be given in the report of every invasive breast 
cancer case in the UK. It is simple to use although it may be considered to be less informative and 
therefore potentially less useful than Adjuvant! Online, particularly when discussing prognosis 
and potential treatments with patients.
Comparator used in the economic model
The comparator used in the model was current clinical practice. Clinical opinion indicated that, 
although NPI and Adjuvant Online! are used to aid the decision-making process, the decision 
whether or not to offer adjuvant chemotherapy to a specific patient is complex and includes 
other demographic and pathological parameters. Consequently, the EAG economic assessment 
used cancer registry data to reflect current clinical practice in England and Wales in terms of 
the proportion of women who currently receive chemotherapy. Summary data from ECRIC and 
WMCIU were obtained to populate the economic model (West Midland Cancer Intelligence 
Unit, July 2011, personal communication; Eastern Cancer Registration and Information Centre, 
July 2011, personal communication). The use of registry data reflects decision-making based on 
actual clinical practice, using NPI and/or Adjuvant! Online or other prognostic information.
The ECRIC registers all malignant tumours and some precancerous lesions occurring in people 
resident in the East of England at the time of diagnosis. Analyses for this assessment were 
constrained to women with ER+, LN–, HER2– early breast cancer (stage I or II) aged < 75 years at 
diagnosis. An age cut-off was applied to reflect the fact that older women are likely to benefit less 
from the test (with a high proportion ineligible or unwilling to undergo chemotherapy because of 
frailty, comorbidities, etc.). It is acknowledged that there is no specific age cut-off but in practice 
the proportion of women receiving chemotherapy falls significantly for women aged ≥ 70 years 
and is very low for women aged ≥ 75 years.172 Overall, 4475 patients were included in the analysis 
from 2007 onwards. Of these, around 800 had unknown HER2 status. The mean (median) age 
of included patients was 58.3 (60.0) years. The mean (median) tumour size of included patients 
was 16.9 (14.0) mm and 23.7% had grade I breast cancer, 56.0% grade II breast cancer and 20.2% 
grade III breast cancer.
The WMCIU registers all malignant tumours and some precancerous lesions occurring in 
people resident in the West Midlands. Again, analyses were constrained to women with ER+, 
LN–, HER2– invasive breast cancer and who were aged < 75 years at diagnosis. The WMCIU 
had incomplete information on stage; therefore, early breast cancer was defined as women with 
no metastases and having had surgery (mastectomy or breast-conserving surgery). Data for the 
years 2007 and 2008 were available but data from 2007 only were used in the economic model as 
this was believed to be more accurate as the data were supplemented by national audit data (West 
Midland Cancer Intelligence Unit, July 2011, personal communication). Overall, 1214 patients 
with ER+, LN–, HER2– early breast cancer, who were diagnosed in 2007, were included. The 
mean (median) age of included patients was 58.0 (60.0) years. The mean (median) tumour size 
of included patients was 17 (15) mm and 26.6% had grade I breast cancer, 56.5% grade II breast 
cancer and 16.5% grade III breast cancer.
Cancer registry data from ECRIC and WMCIU were combined by the EAG and used in the 
base-case analysis to reflect the current levels of chemotherapy in England and Wales for women 
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with ER+, LN–, HER2– early breast cancer. Data were obtained for patients with a NPI score 
≤ 3.4 and patients with a NPI score > 3.4 to allow a subgroup analysis to be performed and to take 
account of the prognostic value of the current treatment decision based on clinicopathological 
parameters. Registry data reflect how both NPI or Adjuvant! Online are used currently in the 
decision-making process; however, it is not known which particular tools/guidelines (e.g. NPI 
or Adjuvant! Online, both, other tools) were used to inform adjuvant treatment decisions in the 
trusts within these cancer registry areas. For the purposes of the economic model it is assumed 
that data from these two areas are representative of all trusts in England and Wales. The term 
‘clinical practice’ is used to define the comparator selected for this appraisal (i.e. current levels of 
adjuvant chemotherapy, based on the use of current prognostic tools, such as NPI and Adjuvant! 
Online).
Subgroups for whom the new tests are most likely to be used
Previous economic evaluations have typically assumed that the new tests will be offered to all 
women with ER+, LN–, HER2– early breast cancer. However, after discussion with clinical 
experts, it seems likely that, in England and Wales, the new tests may be targeted at a subgroup 
of this population – those at intermediate risk (and typically those aged < 75 years) for whom 
the decision about whether or not to give chemotherapy is most uncertain. The definition of this 
‘intermediate group’ is not clear-cut (see Chapter 1, Identification of important subgroups) but 
clinical advice suggested that usually typically patients with a NPI score of ≤ 3.4 are unlikely to 
receive chemotherapy (except for a few very young women with aggressive early breast cancer).
Consequently, two analyses are presented:
 ■ The new test is given to all women with ER+, LN–, HER– breast cancer.
 ■ The new test is given only to women with a NPI score > 3.4 (based on the assumption that the 
vast majority of women with a NPI score ≤ 3.4 would not be considered for chemotherapy).
Of note, this subgroup is a proxy for the intermediate-risk group that might benefit the most 
from the test, but this may subgroup also include patients at the top end of the NPI distribution 
for whom the decision of chemotherapy is more certain. This subgroup was used as it was not 
possible, because of data restrictions, to create an intermediate-only group by separating out the 
high NPI risk group. However, because our population is ER+, LN–, HER2– it is rare to have 
a patient with a NPI score > 5.4 and therefore the number of high-risk patients is expected to 
be low.
Finally, the EAG acknowledges that the cut-off is arbitrary and, although NPI is used in clinical 
practice to guide treatment decisions in some centres in England and Wales, treatment decision 
will not be based on NPI alone.
Description of the de novo economic model
Overview
A probabilistic decision-analytic model was developed to estimate the costs and QALYs of 
adjuvant chemotherapy guided by GEP and expanded IHC tests compared with current 
clinical practice (using cancer registry data) in England and Wales. The economic model was 
programmed using Microsoft Excel software (2011) and used a 6-monthly cycle length and 
followed patients over a lifetime horizon (100 years as the upper age limit) in the base case. 
Shorter time horizons were examined in sensitivity analyses. In accordance with NICE’s interim 
methods guide for diagnostics,32 the economic model adopted the perspective of the UK NHS 
and Personal Social Services (PSS) with costs and benefits discounted at 3.5% per annum.
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No prospective studies that follow patients from initial diagnosis through to final health 
outcomes have been identified for any of the tests. Two prospective studies, MINDACT 
(MammaPrint) and TAILORx (OncotypeDX), are ongoing but not due to report for several years 
(see Chapter 2, Results). The economic model therefore needed to combine clinical data from 
several different sources in order to model how the results from the new tests translated into final 
outcomes in the form of QALYs.
Four tests were selected for the economic evaluation (OncotypeDX, IHC4, MammaPrint and 
Mammostrat). It is envisaged that these tests will be used as an addition to existing prognostic 
tools. As indicated in the systematic review, there are differences in the level and quality of 
evidence supporting each of the tests. Three separate analyses were performed using the best 
direct sources of data available for each test and these should not be directly compared. This was 
carried out because the EAG considered that combining evidence from different studies, based 
on different methodologies and with different patient characteristics (see Chapter 2, Results), 
limited the conclusions that could be drawn from the analyses and, in particular, the comparisons 
that could be made between the analyses.
The primary analysis compared current clinical practice with the adjuvant treatment decision 
based on the addition of OncotypeDX to current clinical practice and the addition of IHC4 
to current clinical practice. Two exploratory analyses were undertaken to compare current 
clinical practice with the addition of MammaPrint and Mammostrat to current clinical practice. 
These analyses were considered to be exploratory only because of significant limitations in the 
evidence base.
Model structure
The key objective of the economic assessment is to address the cost-effectiveness of the use of 
GEP and expanded IHC tests to guide adjuvant chemotherapy decisions in women with early 
breast cancer in England and Wales. The model takes into account the reduction in the risk of 
relapses (and subsequent deaths) associated with the use of adjuvant chemotherapy. It also takes 
into account the costs and reduction in quality of life resulting from the adverse events associated 
with the chemotherapy.
All patients in the model are assumed to receive endocrine therapy. A proportion of patients in 
the comparator arm (current practice) received chemotherapy, based on cancer registry data. In 
the intervention arm (addition of new test) patients were assigned into a risk category using the 
new test and this additional information influenced the decision to prescribe chemotherapy.
The economic model comprises three key components:
1. Patients were assigned to risk categories according to the assigned risk score/group using the 
new test.
2. Women who would receive chemotherapy, as well as endocrine therapy, were identified, 
using the additional knowledge of the assigned risk group.
3. The natural history of breast cancer for patients treated with endocrine therapy alone or with 
the addition of chemotherapy was then simulated using a state transition model.
These three components are described in detail in the following sections.
Assignment of patients into different risk groups
OncotypeDX, MammaPrint and Mammostrat assign women into risk groups – high, 
intermediate and low risk (OncotypeDX and Mammostrat) or good and poor prognosis 
(MammaPrint). The IHC4 test provides a risk score only; however, patients have been allocated 
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into risk groups, similar to the OncotypeDX risk groups, for the purposes of this assessment (see 
Model inputs: test-specific parameters for more details).
In the economic model, women were first stratified into two NPI groups (women with a NPI 
score ≤ 3.4 and women with a NPI score > 3.4). This was carried out to allow the use of the test 
with different subgroups of patients to be explored and to allow adjustment of non-UK clinical 
evidence to reflect the NPI distribution in the UK population. This also takes into account the 
prognostic value of the treatment decision using clinicopathological parameters. Indeed, within 
the current treatment decision-making process based on clinicopathological parameters, it is 
possible to identify patients who are at a higher risk of distant recurrence. Within these two NPI 
groups, patients were further reclassified into low, intermediate or high risk (or low and high risk 
in the case of MammaPrint) of recurrence according to the outputs of the new tests.
In simple terms, patients are assigned into different boxes, each with a different prognosis. 
Patients are assigned to the same boxes for the comparator (current practice) arm or the 
intervention arm (GEP and expanded IHC tests) as the diagnostic tool does not affect the 
prognosis of those patients if there is no change in the adjuvant treatment.
Identification of women receiving adjuvant chemotherapy on the 
basis of the test results
Once women have been assigned into the different boxes (with different prognosis) the next step 
is to identify which women would receive adjuvant chemotherapy.
The aim of categorising patients into risk groups based on distant recurrence with the GEP and 
expanded IHC tests is to identify patients who have a greater chance of developing a distant 
recurrence/recurrence. The risk groups identified by the new tests are therefore expected to 
influence the targeting of chemotherapy. However, other factors will also influence the decision 
regarding chemotherapy, including clinical and pathological factors, along with patient choice. 
In clinical practice a proportion of women classified as low risk of distant recurrence using 
GEP and expanded IHC tests may still receive chemotherapy; similarly, a proportion of women 
considered to be at high risk may not receive chemotherapy, as shown in Spain173 or in the USA174 
for OncotypeDX.
In the intervention arm of the economic model the proportion of patients who would receive 
chemotherapy is based on the expected interpretation of the test, for example women categorised 
as high risk of recurrence are more likely to receive chemotherapy than women categorised as 
low risk. Some previous analyses have assumed that chemotherapy is received based on the risk 
group only. For instance, all women defined as high risk receive chemotherapy. However, in 
clinical practice other issues are likely to impact on this decision (clinicopathological factors, 
age of patient, patient choice, etc.) and it is unlikely that 100% of high-risk patients will receive 
chemotherapy. An adjustment for such factors was therefore used in the model.
In the comparator (current practice) arm, the proportion of women receiving chemotherapy is 
based on cancer registry data. Two subgroups are considered: women with a NPI score ≤ 3.4 and 
women with a NPI score > 3.4. Because the model categorised women into boxes (defined by 
the new test a posteriori) and the oncologist is blind to the results of the new test, we assumed 
that the probability of receiving chemotherapy was the same in the current practice arm whether 
patients were reclassified as low, intermediate or high using GEP and expanded IHC tests. 
However, it is likely that patients who are classified as high risk by the new test are more likely 
to have been identified as high risk under current practice and, therefore, are more likely to have 
received chemotherapy than those patients classified as low or intermediate risk by the new test. 
To further explore this assumption, data from the Holt et al. study78 were analysed by the EAG 
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to approximate the proportion of patients who were recommended chemotherapy by RS group 
before knowledge of the OncotypeDX score (analysis conducted by the EAG using individual 
patient-level data submitted by Genomic Health).
Overall, 30.43%, 30.30% and 68.42% of patients with a low, intermediate and high RS score were 
recommended chemotherapy before knowledge of the OncotypeDX test results. Preliminary 
analyses suggested that the proportion is likely to be higher for patients with a high RS, but the 
sample size was too small (69 in low RS, 33 in intermediate RS and 19 in high RS) to draw any 
definitive conclusion. While preliminary, this analysis suggested that our assumption (that the 
probability of receiving chemotherapy in the comparator is constant irrespective of the RS group) 
might be conservative as current practice using clinicopathological parameters does appear to 
add some prognostic value.
Natural history of breast cancer
The final part of the model was a Markov model. Patients were able to move between five possible 
health states: recurrence free (A), distant recurrence (B), local recurrence (C), long-term adverse 
events after chemotherapy (D) and death (from breast cancer, long-term adverse events or 
general causes – E).
As shown in Figure 11, patients enter the model in the recurrence-free survival health state 
(A) and remain in that health state until they develop a distant recurrence (B), have an adverse 
event after chemotherapy (D) or die from breast cancer or general causes or from their adverse 
event (E). After a distant recurrence (B), patients remain in this health state until they die from 
either breast cancer or general causes (E) or develop an adverse event for women treated with 
chemotherapy (D). Patients developing an adverse event after chemotherapy can remain in 
that health state, die from their adverse event or die from general causes (E). The estimation of 
long-term adverse events is simplistic. No distinction was made between patients developing 
long-term adverse events after a recurrence (B) and patients developing long-term adverse events 
in the recurrence-free health state (A). Furthermore, patients with a long-term adverse event 
were assumed to remain in that health state (D) until death (E) and were not allowed to move to 
other health states.
Local/regional recurrences have been modelled by considering the costs and quality of life 
decrements (disutility) assuming that a proportion of patients entering the distant recurrence 
state (B) have previously experienced a local recurrence (C). No transition probabilities were 
used between this health state and death or adverse events. This is simplistic but justified by the 
fact that the risk categories (used in the economic model) defined by the new tests (OncotypeDX, 
Distant
recurrence (B)
Recurrence free
(A)
Death from general causes/breast
cancer or adverse event (E)
Long-term AE
(D)
Local
recurrence (C)
FIGURE 11 Schematic of the model structure.
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MammaPrint, IHC4) have been defined according to the risk of developing distant recurrence 
and there is no robust evidence to accurately model the development of local recurrence and the 
different transitions between health states for patients reclassified as low, intermediate or high 
risk with GEP and expanded IHC tests.
Model inputs: general
Model inputs that were common to the assessment of each of the four tests are described below. 
Model inputs that are test specific, such as clinical parameters, are described in Model inputs: 
test-specific parameters.
Mean age of patients entering the model
The EAG economic assessment focuses on women with ER+, LN–, HER2– who are aged 
≤ 75 years. Patients were assumed to enter the economic model at a mean age of 58.3 years based 
on the average age in the ECRIC dataset of women with ER+, LN–, HER2– aged < 75 years 
(Eastern Cancer Registration and Information Centre, July 2011, personal communication). 
Although patient age is not used to determine treatment selection, experts suggested that women 
aged > 70–75 years are much less likely to be offered chemotherapy because of issues of frailty and 
comorbidities. Sensitivity analysis was conducted varying the mean baseline age.
Of note, the model does not separate pre- and postmenopausal women but most of the evidence 
was taken from postmenopausal women. In addition, it was not possible to explore different age 
thresholds as we did not have access to patient-level data.
Baseline Nottingham Prognostic Index distribution in England 
and Wales
The economic assessment separates women with a NPI score ≤ 3.4 and women with a NPI 
score > 3.4. The baseline NPI distribution was extracted from the combined (EAG analysis) 
ECRIC (2007 onwards) and WMCIU (2007 only) data (West Midland Cancer Intelligence Unit, 
July 2011, personal communication; Eastern Cancer Registration and Information Centre, 
July 2011, personal communication). Approximately two-thirds of patients had a NPI score ≤ 3.4 
(Table 40).
For the scenario assuming that the test is given to all women with ER+, LN–, HER2– early 
breast cancer, we modelled patients with a NPI score of ≤ 3.4 and patients with a NPI 
score > 3.4 separately to account for the prognostic value of the treatment decision using 
clinicopathological parameters.
Additional sources of evidence for the baseline distribution of NPI were considered in sensitivity 
analysis (Table 41). These included women with ER+, LN–, HER2– early breast cancer from 
the TransATAC trial (Professor Mitch Dowsett, Royal Marsden Hospital, London, September 
2011, personal communication) and the ER+, LN–, HER2– population from the Holt et al. 
study78 (analysis conducted by the EAG using individual patient-level data submitted by 
Genomic Health).
TABLE 40 Distribution of the NPI score observed in the ECRIC and WMCIU data and used in the economic model 
Cohort NPI ≤ 3.4, n (%) NPI > 3.4, n (%) Total, n 
ECRICa (2007 onwards) 2602 (65.6) 1365 (34.4) 3967
WMCIU (2007 only) 819 (68.2) 382 (31.8) 1201
Combined data used in the economic model 3421 (66.2) 1747 (33.8) 5168
a Includes HER2 equivocal and unknown.
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Proportion of patients receiving chemotherapy in current clinical 
practice in England and Wales
As described in Comparator used in the economic model, cancer registry data were used to 
reflect the proportion of women with ER+, LN–, HER2– early breast cancer who currently 
receive chemotherapy in England and Wales. Data from ECRIC (2007 onwards; Eastern Cancer 
Registration and Information Centre, July 2011, personal communication) and WMCIU (2007 
only) (West Midland Cancer Intelligence Unit, July 2011, personal communication; Eastern 
Cancer Registration and Information Centre, July 2011, personal communication) were 
combined (EAG analysis) and showed that overall about 14.4% of women aged < 75 years with 
ER+, LN–, HER2– early breast cancer received chemotherapy. When separating patients with 
a NPI score of ≤ 3.4 and a NPI score > 3.4, 4.6% and 33.6% of women received chemotherapy 
respectively (Table 42).
Death from breast cancer causes after a distant recurrence
In the base case, the hazard rate of death after a distant recurrence was taken from Thomas et 
al.157 Thomas et al.157 analysed the time to death from relapse among 77 relapsed breast cancer 
patients. The first site of relapse was distant in 51 patients (66%) with the remaining patients 
having locoregional recurrences. The study included a mix of patients with regard to ER status 
(55% ER+), nodal involvement (66% LN–) and HER2 status (75% HER2–). The study reported a 
median survival of 40.1 months (equating to an annual hazard rate of about 0.30) and this value 
was used in the base case. Sensitivity analyses were conducted varying the time spent in the 
distant recurrence health state within the reported CI in this study.155
In the base case we assumed that the risk of death after a recurrence was independent of the 
prognosis of the patient, because of the lack of more informative data. Discussion with clinical 
experts indicated that it is likely that low- and high-risk patients will spend a different amount of 
time in the distant recurrence health state. High-risk patients are likely to have more aggressive 
cancer and are likely to spend less time in recurrence before death. A scenario analysis was 
therefore explored assuming different times in recurrence between risk groups. Because there are 
no published data to our knowledge on survival after distant metastasis for patients with different 
prognosis, assumptions were made to examine the impact of this assumption on the ICER.
Costs
All costs are in 2010 prices.
Costs of the different tests No costs were assumed for treatment guided by current clinical 
practice as pathological parameters that are currently used to guide the adjuvant treatment 
decision will continue to be collected after the introduction of the new tests. The new tests are 
considered to be add-ons to the existing tests.
The costs of performing the OncotypeDX, MammaPrint and Mammostrat tests in the UK 
were assumed to be £2580, £2675 and £1120–1620 (£1135 was used in the economic model) 
respectively (data received from the respective manufacturers) (Table 43). The IHC4 algorithm 
TABLE 41 Distribution of the NPI score from the TransATAC trial (Professor Mitch Dowsett, Royal Marsden Hospital, 
London, September 2011, personal communication) and the Holt cohort (EAG analysis) in women with ER+, LN–, 
HER2– early breast cancer used in sensitivity analysis
Source NPI ≤ 3.4, n (%) NPI > 3.4, n (%)
TransATAC 449 (63.6) 257 (36.4)
Holt (EAG analysis) 70 (57.8%) 51 (42.2%)
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is free; therefore, the only costs will be the additional time required for analysis of Ki-67 and 
PR (measured in some centres) and quantitative H scoring (a immunohistochemical approach 
used in the assessment of markers for breast cancer prognosis, by assessing the intensity and 
distribution of positive staining) of ER. The investigators of IHC4 were contacted to provide an 
estimate of the likely additional cost to the NHS. Although no formal costings have been made 
it was estimated that the additional cost of IHC4 would range between £100 and £200, including 
the pathologist’s time for scoring (Professor Mitch Dowsett, Royal Marsden Hospital, London, 
July 2011, personal communication). In the base case we assumed that it cost an additional £150 
to the NHS to run an IHC4 test (see Table 43). This figure is varied in the sensitivity analysis.
The MammaPrint test can be performed on fresh tissue preserved in RNARetain® (Asuragen, 
Austin, TX) or fresh frozen tissue (note: use of FFPE to be introduced in 2012). In addition to 
the cost of the test, we assumed an additional cost of £250 per patient for MammaPrint for the 
cost of handling fresh tissue. A sensitivity analysis was conducted assuming no additional cost. 
Fresh tissue collection is not routine in the NHS (only a few research centres currently have 
this working arrangement) so there will be additional costs, which would be considerable at 
hospitals where the dissection facilities are running at capacity (which is likely to be a significant 
proportion of hospitals) and where explicit staffing for collection of fresh tissue is not in place. 
Discussion with local clinicians indicates that capital costs could be at least £75,000 per hospital 
if new dissection tables are required, which is likely to be the case in many hospitals where 
routine fresh tissue sampling is not in place, and additional staff costs for biomedical scientists 
and histopathologists will be incurred. If a full fresh tissue service is required and needed to 
cover all theatre time then additional staff costs could be £20,000–50,000 per year (Simon Cross, 
Reader and Honorary Consultant, Royal Hallamshire Hospital, Sheffield, July 2011, personal 
communication). Experts indicated that a charge of about £250 per sample would be necessary 
to take a fresh tissue sample for a research study because of the time-critical staff-intensive work 
required. However, this assumes that a fresh tissue sample is collected only in a small number 
of patients under the current service configuration. A reconfiguration of the entire pathology 
service would be necessary if fresh tissue samples had to be collected routinely for all patients, 
which would incur additional costs.
TABLE 42 Proportion of patients currently receiving chemotherapy in ECRIC and WMCIU (women with ER+, LN–, 
HER2– early breast cancer aged < 75 years)
Cohort Entire cohort (%) NPI ≤ 3.4 (%) NPI > 3.4 (%)
ECRICa (2007 onwards) 13.97 4.23 32.53
WMCIU (2007) 15.90 5.86 37.43
Combined data used in the economic model 14.42 4.62 33.60
a Includes HER2 equivocal and unknown.
TABLE 43 Costs of the new tests used in the economic model
Cost of the new test (£) Cost of the additional NHS time (£) Cost of handling fresh tissue (£)
OncotypeDX 2580
IHC4 100–200
Mammostrat 1135
MammaPrint 2675 250
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We did not incorporate the additional cost associated with the failure of a test. This was 
considered to be minimal as contact with the manufacturers indicated that another sample could 
be sent for free or a refund issued in case of failure of the test.
Endocrine therapy costs
The economic model considers only women with ER+ early breast cancer and assumes that 
all patients receive endocrine therapy. Five endocrine therapy regimens were considered as 
per NICE Technology Appraisal 112:162 (1) tamoxifen for 5 years, (2) anastrozole for 5 years, 
(3) letrozole for 5 years, (4) tamoxifen for 2 years plus exemestane for the final 3 years and (5) 
tamoxifen for 5 years followed by extended therapy with letrozole for a further 3 years.
Drug costs were taken from BNF 61.161 It was assumed that each endocrine therapy was given 
once daily at a 20-mg, 1-mg, 2.5-mg and 25-mg dosage for tamoxifen, anastrozole, letrozole and 
exemestane respectively. The annual cost for each drug is presented in Table 44.
The probability that a patient will be treated with each regimen was taken from the costing 
template accompanying TA112.162 It was assumed that 40% of patients received tamoxifen for 
5 years, 20% anastrozole for 5 years, 20% letrozole for 5 years and 20% tamoxifen for 2 years plus 
exemestane for the final 3 years. It was further assumed that 10% of patients received tamoxifen 
for 5 years followed by extended therapy with letrozole for a further 3 years. After weighting, the 
annual drug cost was calculated to be £668.90 for the first 5 years and £110.70 for the remaining 
3 years.
In addition to drug costs, monitoring cost were included. We assumed that patients treated 
with endocrine therapy have two follow-up appointments in the first year and one follow-up 
appointment every subsequent year (£129 based on NHS reference costs 2009/10,175 370 Medical 
Oncology). We further assumed that patients had one mammogram every year (£46.37 based on 
Campbell et al.176) for a maximum of 5 years.
Chemotherapy costs
It was assumed that all patients received FEC75 as clinical opinion indicated that this is 
the most commonly used chemotherapy regime for this population (ER+, LN–, HER2–). 
Sensitivity analysis was carried out varying the cost to explore the sensitivity of the results to this 
assumption. Note that the choice of chemotherapy (FEC75) in the economic model impacts on 
cost only as the effect of chemotherapy was taken from a separate source of data49 that uses CMF/
MF regimes. No effectiveness data were available for FEC75 for this group of patients.
The cost of the chemotherapy drugs was calculated according to the regime description of 
FEC75 given by Avon, Somerset and Wiltshire Cancer Services in their chemotherapy protocol 
documents.177 All drug costs are taken from BNF 61.161 We also assumed a dosage per BSA of 1.75 
mg/m2 based on the value reported by Sacco et al.,168 estimated in women with breast cancer in 
the UK.
The chemotherapy drug cost per cycle is summarised in Table 45. No drug wastage was assumed.
TABLE 44 Costs of endocrine therapy drugs used in the economic model
 Dose (mg) Tablets per pack Price per pack (£) Annual cost (£)
Tamoxifen 20 30 2.09 25.45
Anastrozole 1 28 68.56 894.34
Letrozole 2.5 28 84.86 1106.97
Exemestane 25 30 88.80 1081.14
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Discussion with clinical experts indicated that FEC75 is usually given for six cycles. The number 
of cycles was varied in sensitivity analysis. In addition to drug costs, we assumed an additional 
pharmacy cost of £38162 per cycle to account for the chemopharmacy/aseptic costs.
Furthermore, administration costs were assumed to be £270.60 for the first cycle of treatment 
(NHS reference costs 2009/210,175 S13Z: Deliver more complex Parenteral Chemotherapy at 
first attendance) and £284.50 for the remaining cycles (NHS reference costs 2009/10,175 SB15Z: 
Deliver subsequent elements of a Chemotherapy cycle). Patients were also assumed to have a 
separate outpatient appointment before administration of each cycle of the chemotherapy (NHS 
reference costs 2009/10,175 370 Medical Oncology – £129).
Patients were also assumed to be monitored and to receive one liver function test (£12.68), a test 
of urea and electrolytes (£12.30) and a full blood count (£5.81) at each cycle based on 2008/9 
data from the Sheffield Teaching Hospital (Sheffield Teaching Hospital Trust, 2007–8, personal 
communication), uplifted to 2010 prices.178 Finally, it was further assumed that 25% of patients 
would have an echocardiogram before starting chemotherapy (NHS reference costs 2009/10,175 
RA60Z – £59).
The total cost of chemotherapy including drug acquisition cost, administration and monitoring 
was calculated to be £4099 for the entire course of chemotherapy (six cycles of treatment).
Costs of short-term adverse events associated with chemotherapy
Short-term adverse events were included for patients receiving chemotherapy.
The probability of short-term grade 3 and grade 4 adverse events was extracted from the PACS-01 
clinical trial for patients treated with FEC100 as no data were available for FEC75.179 This 
included anaemia, thrombocytopenia, neutropenic infection, nausea/vomiting and stomatitis. 
Short-term grade 3 and grade 4 adverse events were costed using the NHS reference costs where 
appropriate.175 The total cost of treating short-term adverse events was estimated to be £275.61 
per patient (Table 46). This excluded the cost associated with the secondary prevention of febrile 
neutropenia using G-CSF prophylaxis, included separately (see next section).
Costs of the secondary prevention of febrile neutropenia
We assumed that G-CSF prophylaxis was given for the secondary prevention of neutropenia to 
women receiving chemotherapy only. In the base case it was assumed that about 25% of patients 
would receive G-CSF prophylaxis (Dr Matthew Winter, Consultant in Medical Oncology, 
Sheffield Teaching Hospitals NHS Foundation Trust, September 2011, personal communication) 
and that G-CSF would be given for an average of three cycles. Patients were assumed to receive 
filgrastim at a dose of 500,000 units/kg daily for six days after each cycle of chemotherapy 
(maximum three cycles). A mean weight of 66 kg was assumed and the drug cost per injection 
of 30 million units was assumed to be £59.161 Filgrastim was assumed to be administrated by 
a district nurse (£39 per injection) using the cost from the Personal Social Services Research 
Unit (PSSRU).178
TABLE 45 Costs of chemotherapy drugs used in the economic model
Dose (mg) Total dose per cycle (mg) Cost per cycle (£)
Fluorouracil 600 1050 16.00
Epirubicin 75 131 168.78
Cyclophosphamide 600 1050 16.32
Total 201.10
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Overall, the cost associated with the secondary prevention of adverse event for patients receiving 
chemotherapy was estimated to be £485.30 per patient.
Costs associated with long-term adverse events
Potential long-term adverse events include secondary malignancies and congestive heart failure 
(CHF). Although CHF is more common than secondary malignancies, the development of 
cancer is likely to have more serious consequences and to be associated with a higher impact on 
health-care resources than the management of CHF.
The base-case economic model included acute myeloid leukaemia (AML) as a long-term 
adverse event after chemotherapy. The probability of developing AML was based on the 8-year 
cumulative probability of developing AML in women treated with epiribucin extracted from a 
meta-analysis of 19 trials conducted in early breast cancer.180
The meta-analysis showed that the 8-year cumulative probability of AML was 0.37% (95% CI 
0.13 to 0.61%) in women receiving a cumulative dose of cyclophosphamide < 6300 mg/m2 and a 
cumulative dose of epirubicin < 720 mg/m2 (n = 4760).180
We further assumed that patients spend 8 months on average in the AML health state at a mean 
cost of £11,500 based on the approximate mean life-years and mean costs estimated by the 
manufacturer for the NICE technology appraisal of azacitidine for myelodysplastic syndromes.181 
These assumptions were varied in sensitivity analysis.
Costs associated with the management of distant recurrence
The costs associated with distant recurrence were derived from Thomas et al.157 using a sample 
of 77 patients with relapsed breast cancer. Costs included active supportive care and end-of-life 
care. Costs specifically associated with terminal care were removed to avoid double counting as 
these were included separately in the economic model. (Note that only cost items described as 
supportive/terminal care were removed.)
After removing cost items that were specific to terminal care, we estimated the 6-monthly cost 
to be approximately £4082 (uplifted to 2010 prices).178 We assumed that the cost was constant 
over time. This is very simplistic as evidence shows that the cost is higher in the first 2 years and 
decreases thereafter.182 However, the impact of this assumption is likely to be minimal because 
this affects both the comparator arm and the intervention arm in the model.
TABLE 46 Costs of short-term adverse events from chemotherapy used in the economic model 
Proportion of grade 3/4 
adverse events (%)
HRG 
code175 HRG
Cost of 
HRG (£)
Cost per  
patient (£)
Anaemia 1.4 SA09F Other Red Blood Cell Disorders without CC 1529 21.41
Thrombocytopenia 0.3 SA12F Thrombocytopenia without CC 1355 4.06
Neutropenic infection 1.6 2286 36.58
Nausea/vomiting 24.2 FZ48C Malignant General Abdominal Disorders 
with length of stay 1 day or less
588 142.34
Stomatitis 4.0 CZ24Q Complex/Major Head, Neck and Ear 
Disorders without CC
1781 71.22
Cost of adverse event 
per patient
   275.61
CC, Complications and Comorbidities ; HRG, Healthcare Resource Group.
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Costs associated with the management of local recurrence
The cost of local recurrence was taken from Karnon et al.182 and was estimated at £14,132 
(uplifted to 2010 prices).178
Costs associated with the management of death from breast cancer
Finally, the cost associated with terminal care/end of life was taken from Campbell et al.176 and 
was assumed to be about £4038. This cost was applied as a one-off in the economic model, 
immediately before death from breast cancer.
Health-state utilities
Quality of life utility scores were identified from a recent systematic review of utility values in 
breast cancer.159 The utility values used in the model are given in Table 47.
Utility values for patients in the recurrence-free and distant recurrence health states were 
extracted from Lidgren et al.148 These were EQ-5D values and using this study allowed values 
for recurrence free (0.824) and distant recurrence (0.685) to be taken from the same study for 
consistency (see Table 47). The study followed 361 breast cancer patients attending the breast 
cancer outpatient clinic at Karolinska University Hospital Solna between April and May 2005. 
The decrement in utility per patient experiencing a local recurrence was taken from Campbell 
et al.176 and assumed to be –0.108 in the base case. We assumed that patients with AML have 
a utility value of 0.26 based on the value used in a previous economic evaluation conducted in 
Canada.183 We further assumed that patients receiving chemotherapy have a disutility of 0.038, 
taken from Campbell et al.176 for women treated with E-CMF (epirubicin, cyclophosphamide, 
methotrexate and 5-fluorouracil)/FEC60 in the first year. This is believed to capture the 
decrement in utility associated with the administration of chemotherapy and related adverse 
events. Finally, a decrement in utility was applied for patients dying from breast cancer, derived 
from Campbell et al.176 and Lidgren et al.148 Utility values were varied in sensitivity analysis.
Death from causes other than breast cancer
The mortality rate from causes other than breast cancer was extracted from UK life tables 
(2007–9) for women184 after adjustment to remove death attributable to breast cancer.
Proportion of patients with distant recurrence who have previously 
experienced a local recurrence
In the base case we assumed that 10.5% of patients entering the distant recurrence state have 
previously experienced a local recurrence. This is based on an analysis conducted in 3601 
women with early breast cancer enrolled in previous European Organisation for Research and 
Treatment in Cancer (EORTC) trials (10801, 10854 and 10902), which showed that the presence 
of locoregional recurrence was a significant prognostic risk factor for the occurrence of distant 
TABLE 47 Utility values used in the model 
 Mean utility score Duration Source
Recurrence free 0.824 (95% CI 0.785 to 0.857) 1 year Lidgren et al.148
Distant recurrence 0.685 (95% CI 0.62 to 0.735) 1 year Lidgren et al.148
Local recurrence (decrement per patient) –0.108 NA Campbell et al.176
AML 0.26 1 year Younis et al.183
Chemotherapy (decrement per patient) –0.038 NA Campbell et al.176
Utility for patients dying from breast cancer (final 3 months of life) 0.159 (SE 0.04) 3 months Campbell et al.176
NA, not applicable.
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recurrence.185 The analysis showed that, among the 1224 patients who developed a distant 
recurrence, 129 patients had a distant recurrence after a locoregional recurrence.
We did not make any assumptions about the time spent in the local recurrence health state. 
Local/regional recurrences have been modelled by considering the cost and quality of life 
decrements (disutility), assuming that a proportion of patients entering the distant recurrence 
state have previously experienced a local recurrence.
Model inputs: test-specific parameters
Clinical parameters specific to each test are described below. For each test clinical parameters 
relating to the three main components of the model are described in turn.
Clinical parameters: OncotypeDX and IHC4
The systematic review of evidence indicated that the OncotypeDX test is the furthest along the 
validation pathway compared with other similar tests, and the evidence base, in particular in 
relation to the prognostic ability of the test, was reasonably sound. The evidence base for IHC4 
is less developed but there is direct evidence relating to the performance of IHC4 compared with 
that of OncotypeDX and so the clinical evidence relating to these two tests is described together.
The primary analysis compared current clinical practice with treatment guided using 
OncotypeDX or IHC4 in addition to current practice. This was carried out using evidence that 
directly compared the test results for OncotypeDX and IHC4. An overview of this evidence was 
presented in Cuzick et al.84 However, the specific data used in the economic model for IHC4 were 
unpublished and were made available to the EAG for the purpose of this assessment (Professor 
Mitch Dowsett, Royal Marsden Hospital, London, September 2011, personal communication).
Assignment of patients into risk category: OncotypeDX and IHC4 Most of the evidence on the 
ability of OncotypeDX to classify patients into the low, intermediate or high risk group is derived 
from US studies (see Chapter 2, OncotypeDX test). The systematic review did, however, identify 
two UK studies78,79 that presented classification evidence. Data from one of these studies, the 
TransATAC trial (Professor Mitch Dowsett, Royal Marsden Hospital, London, September 2011, 
personal communication), were used in the base-case analysis. The second study, the Holt et al. 
study78 included a small sample of patients recruited in Wales and reported how the test classified 
patients by OncotypeDX RS and how this influenced clinical decision-making. However, the 
systematic review of evidence showed that there are limitations with using data from this study 
(see Chapter 2, OncotypeDX test results). Likewise, discussion with clinical experts indicated 
some concerns that the patients included might not be representative of patients seen in clinical 
practice. To further explore this point, we compared the baseline characteristics of women 
with ER+, LN–, HER2– early breast cancer included in the final analysis of the Holt et al. study 
(n = 121) (EAG analysis) with the baseline characteristics of cohorts of patients from the cancer 
registry data provided by ECRIC (2007 onwards) and WMCIU (2007 only) (West Midland 
Cancer Intelligence Unit, July 2011, personal communication; Eastern Cancer Registration and 
Information Centre, July 2011, personal communication) (Table 48). Overall, the Holt cohort was 
generally more severe with a higher distribution of Grade 2 and 3 tumours and larger tumour size 
(20.4 mm vs 17.0 mm). There was also a higher proportion of patients classified as intermediate 
or high risk according to NPI (NPI > 3.4) in the Holt study (42.15%) compared with patients 
included in the ECRIC (34.4%) or WMCIU (31.8%) cohort.
The impact of using data from the Holt et al. study was explored in a scenario analysis using data 
used in the economic model submitted by Genomic Health (see Comparison of assumptions and 
results with the economic models submitted by Genomic Health and Clarient).
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The TransATAC trial evaluated the efficacy and safety of 5 years of anastrozole, tamoxifen or 
the combination of both treatments in postmenopausal women with localised breast cancer in 
the UK.79,84 The study included a much larger sample size. Furthermore, data on both the risk of 
distant recurrence and risk classification were available in the TransATAC trial from the same 
cohort for patients using OncotypeDX and IHC4, making it the most robust source to use to 
populate the economic model. Clinical experts supported the view that patients included in this 
study were more likely to be representative of patients seen in clinical practice. However, the 
inherent limitations of the generalisability of such trial data, such as the fact that women with 
comorbidities would have been excluded from the trial, need to be taken into consideration.
Data from the TransATAC trial were reanalysed by the investigators of the trial to exclude 
women with HER2+ cancer, to stratify patients by NPI score (≤ 3.4 and > 3.4) and to provide 
additional data relating to IHC4 (Professor Mitch Dowsett, Royal Marsden Hospital, London, 
September 2011, personal communication). Reclassification using the OncotypeDX and IHC4 
tests compared with NPI group for women with ER+, LN–, HER2– is presented in Tables 49 and 
50 respectively. The IHC4 + clinical score test provides a continuous risk score. Selected cut-offs 
for three IHC4 risk groups have been defined specifically to populate the economic model (using 
the same methodology as for OncotypeDX) and therefore this might not reflect how the test will 
be used in clinical practice.
Among patients with a NPI score ≤ 3.4 (n = 449), significantly more patients were reclassified 
as intermediate/high using OncotypeDX (n = 126) than with IHC4 (n = 12). Among patients 
with a NPI score > 3.4 (n = 257), more patients were reclassified as having a low risk using IHC4 
(n = 166) than with OncotypeDX (n = 133).
TABLE 48 Comparison of patients included in the Holt et al. study78 (EAG analysis) and cohorts of patients from the 
ECRIC and WMCIU cancer registry data (West Midland Cancer Intelligence Unit, July 2011, personal communication; 
Eastern Cancer Registration and Information Centre, July 2011, personal communication) 
Baseline characteristic Holt et al.78 (n = 121)a ECRIC cohort (n = 3245) WMCIU cohort (n = 1214)
Age (years)
 Mean 55.88 58.30 58
 First interquartile 50.00 51.00 51
 Third interquartile 63.00 66.00 66
 Median 55.00 60.00 60
Grade distribution (%)
 I 19.01 23.7 26.6
 II 63.64 56.0 56.5
 III 17.36 20.2 16.5
Tumour size (mm)
 Mean 20.39 16.90 17
 First interquartile 13.00 10.00 10
 Third interquartile 23.00 20.00 20
 Median 18.00 14.00 15
NPI score (%)
 Low (≤ 3.4) 57.85 65.59 68.19
 Intermediate/high (> 3.4) 42.15 34.41 31.81
a Analysis conducted by the EAG.
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For the purposes of the economic assessment, patients classified using OncotypeDX were 
reclassified according to IHC4. Reclassification data for patients with a NPI score ≤ 3.4 and a NPI 
score > 3.4 used in the EAG economic model are presented in Tables 51 and 52 respectively.
The impact of using data from Holt27 was examined in Comparison with the economic model 
submitted by Genomic Health.
Note that the approach of classifying patients into risk categories has some limitations:
 ■ It was assumed that the new tests categorised patients into risk categories; however, both 
OncotypeDX and IHC4 provide a continuous risk score.
 ■ Although cut-offs are available for OncotypeDX to identify patients at low, intermediate or 
high risk of distant recurrence, these are informative and not definitive. In the economic 
model, patients were classified according to the original cut-offs defined by the manufacturer 
of the technology: low – RS < 18; intermediate – RS between 18 and 30; and high – RS ≥ 31. 
However, the definition of low, high and mid-range RS was modified in the TAILORx trial 
for OncotypeDX. A cut-off of ≤ 10 was used instead of the original < 18 to define patients at 
low risk of distant recurrence. The cut-off for high risk of distant recurrence was modified 
from ≥ 31 to ≥ 26.
 ■ The IHC4 test does not present cut-offs. The test is intended to be used as a continuous 
risk score and interpretation is at the discretion of the physician. For the purpose of the 
economic assessment, investigators provided risk classification evidence of IHC4 based on 
low, intermediate and high risk of distant recurrence. Cut-offs were defined using a similar 
approach to that for OncotypeDX (< 10%, 10–20% and > 20% predicted risk of distant 
recurrence). The cut-offs used for IHC4 are therefore exploratory and were defined only to 
populate the economic model.
Risk of distant recurrence for patients receiving endocrine therapy only: OncotypeDX and IHC4 The 
TransATAC trial reported the risk of distant recurrence in patients treated with anastrozole or 
tamoxifen. The advantage of using data from this trial is that it was possible to extract the risk 
of distant recurrence for patients classified using OncotypeDX and further reclassified using 
IHC4 from the same source of data as the reclassification data used above (see Tables 51 and 
52). The proportions of patients without distant recurrence at 10 years used in the economic 
model for patients with a NPI score ≤ 3.4 and a NPI score > 3.4 are presented in Tables 53 and 
54 respectively (Professor Mitch Dowsett, Royal Marsden Hospital, London, September 2011, 
TABLE 49 Reclassification of ER+, LN–, HER2– patients from the TransATAC trial by OncotypeDX and NPI group 
(Professor Mitch Dowsett, Royal Marsden Hospital, London, September 2011, personal communication)
 Low RS, n (%) Intermediate RS, n (%) High RS, n (%) Total, n (%)
NPI ≤ 3.4 323 (71.94) 109 (24.28) 17 (3.79) 449 (100)
NPI > 3.4 133 (51.75) 76 (29.57) 48 (18.68) 257 (100)
Total 456 (64.59) 185 (26.20) 65 (9.21) 706 (100)
TABLE 50 Reclassification of ER+, LN–, HER2– patients from the TransATAC trial by IHC4 + clinical score and NPI group 
(Professor Mitch Dowsett, Royal Marsden Hospital, London, September 2011, personal communication)
 Low IHC4, n (%) Intermediate IHC4, n (%) High IHC4, n (%) Total, n (%)
NPI ≤ 3.4 437 (97.33) 12 (2.67) 0 449 (100)
NPI > 3.4 166 (64.59) 58 (22.57) 33 (12.84) 257 (100)
Total 603 (85.41) 70 (9.92) 33 (4.67) 706 (100)
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personal communication). Note that inconsistencies can be observed because of the small sample 
size of patients within each box (in bold for sample size < 10).
We assumed that the risk of distant recurrence was constant over the first 10 years, using an 
exponential distribution. This was done in the absence of the Kaplan–Meier data for each 
subgroup and is acknowledged as a limitation as the risk of recurrence may vary over time.
We also assumed that the risk was reduced by half after 10 years as clinical experts indicated that 
patients who had not experienced a distant recurrence before 10 years have a lower risk of distant 
recurrence beyond 10 years. We further assumed that no recurrences would occur after 15 years. 
Discussion with clinical experts indicated that only a minority of recurrences are likely to occur 
beyond this date. This assumption was tested in sensitivity analysis.
Patients offered chemotherapy based on the result of the test: OncotypeDX and IHC4 The risk 
groups identified by the new tests are expected to influence the targeting of chemotherapy. 
However, other factors will also influence the decision regarding chemotherapy, including clinical 
TABLE 53 Proportion of patients free of distant recurrence at 10 years in patients with a NPI score ≤ 3.4 – classified 
using OncotypeDX and then reclassified using IHC4 + clinical score (n = 449)
Low RS (%) Intermediate RS (%) High RS (%)
Low IHC4 98 92 91
Intermediate IHC4 100 100 100
High IHC4  –  –  – 
TABLE 54 Proportion of patients free of distant recurrence at 10 years in patients with a NPI score > 3.4 – classified 
using OncotypeDX and then reclassified using IHC4 + clinical score (n = 257)
Low RS (%) Intermediate RS (%) High RS (%)
Low IHC4 92 89 93
Intermediate IHC4 100 75 76
High IHC4 63 89 60
TABLE 51 Risk classification using OncotypeDX followed by reclassification using IHC4 + clinical score for patients with 
a NPI score ≤ 3.4 (n = 449)
 Low RS, n (%) Intermediate RS, n (%) High RS, n (%) Total, n (%)
Low IHC4 321 (71.49) 103 (22.94) 13 (2.90) 437 (97.33)
Intermediate IHC4 2 (0.45) 6 (1.34) 4 (0.89) 12 (2.67)
High IHC4 0 0 0 0
Total 323 (71.94) 109 (24.28) 17 (3.79) 449 (100)
TABLE 52 Risk classification using OncotypeDX followed by reclassification using IHC4 + clinical score for patients with 
a NPI score > 3.4 (n = 257)
 Low RS, n (%) Intermediate RS, n (%) High RS, n (%) Total, n (%)
Low IHC4 111 (43.19) 39 (15.18) 16 (6.23) 166 (64.59)
Intermediate IHC4 13 (5.06) 28 (10.89) 17 (6.61) 58 (22.57)
High IHC4 9 (3.50) 9 (3.50) 15 (5.84) 33 (12.84)
Total 133 (51.75) 76 (29.57) 48 (18.68) 257 (100)
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and pathological factors, along with patient choice. In clinical practice, a proportion of women 
classified as having a low risk of distant recurrence may receive chemotherapy; similarly, a 
proportion of women classified at high risk may not receive chemotherapy, as shown in previous 
studies for OncotypeDX undertaken in Spain173 or in the USA.174
To populate our economic model, data from the only identified UK study was used for 
OncotypeDX in the base case.78 The Holt et al. study reported the OncotypeDX RS and the 
chemotherapy decision based on knowledge of the RS combined with traditional clinical and 
pathological parameters. Individual patient-level data were made available to the EAG and were 
reanalysed by NPI group. Results are presented in Table 55 (analysis conducted by the EAG using 
individual patient-level data submitted by Genomic Health). This study, however, has a number 
of limitations, discussed previously, and these assumptions were tested in sensitivity analysis.
No data exist on the proportion of women who are given chemotherapy according to the 
results of the IHC4 test. Discussion with clinical experts indicated that interpretation of the 
OncotypeDX and IHC4 results is likely to be similar. We therefore assumed the same proportions 
for IHC4 as for OncotypeDX. This is, however, a limitation of the analysis and the assumption 
was tested in sensitivity analysis.
Benefit of chemotherapy (reduction in the risk of distant recurrence): OncotypeDX and IHC4 The 
systematic review of evidence identified one study, the Paik et al. study, evaluating the benefit 
of chemotherapy for LN– patients receiving chemotherapy in addition to tamoxifen compared 
with tamoxifen alone and classified using OncotypeDX.49,86 In the overall population, the 
addition of chemotherapy compared with tamoxifen alone was estimated to reduce the risk of 
distant recurrence by 44% (HR 0.56, 95% CI 0.34 to 0.91). No chemotherapy benefit (reduction 
in distant recurrence) was found for women classified as low risk of distant recurrence with 
OncotypeDX (HR 1.31, 95% CI 0.46 to 3.78, p = 0.61). A reduction of 39% (HR 0.61, 95% CI 
0.24 to 1.59, p = 0.39) and 74% (HR 0.26, 95% CI 0.13 to 0.53, p < 0.001) was found for the risk 
of distant recurrence for women receiving chemotherapy in addition to tamoxifen compared 
with tamoxifen alone and classified as intermediate and high risk of distant recurrence with 
OncotypeDX respectively. The limitations of this study are described in Chapter 2, Results: 
OncotypeDX test.
The base-case analysis used data from the Paik et al. study,49 assuming the test to be predictive of 
the benefit of chemotherapy. This may be an optimistic assumption as the effect of chemotherapy 
might be lower than that reported (as the Paik et al. study included younger women and women 
with HER2+ early breast cancer). However, this study is based on a less effective regimen than 
is currently used and it is unclear what the overall impact of these factors would be. Univariate 
sensitivity analyses were conducted varying the benefit of chemotherapy. In addition, because 
of the limitations of this study (see Chapter 2, Results: OncotypeDX test), the EAG explored a 
scenario assuming that all women receiving chemotherapy derive the same benefit in terms of 
reduction in distant recurrence (i.e. that the test is prognostic only). However, not all clinical 
TABLE 55 Proportion of patients receiving chemotherapy after knowledge of the OncotypeDX results:78 final analysis 
including 121 patients with ER+, LN–, HER2– breast cancer (EAG analysis)
Entire cohort NPI ≤ 3.4 NPI > 3.4
Low RS 1.45% 0.00% 4.55%
Moderate RS 42.42% 38.10% 50.00%
High RS 89.47% 50.00% 94.12%
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Ward et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced 
for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated 
with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha 
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
115 Health Technology Assessment 2013; Vol. 17: No. 44DOI: 10.3310/hta17440
experts supported this assumption and recommended the use of the predictive evidence available 
despite the limitations noted above.
No studies were identified for the benefit of chemotherapy in women reclassified using IHC4; 
therefore, we used indirect evidence. Patients classified as low, intermediate or high risk with 
OncotypeDX were assumed to derive the same benefit from chemotherapy irrespective of their 
further reclassification as low, intermediate or high with IHC4. The benefit of chemotherapy 
for a particular risk group for IHC4 was therefore derived from the known mix of patients with 
OncotypeDX RS of low, intermediate and high within the IHC4 group. In simple terms, because 
we know the RS classification of patients reclassified by IHC4, it is possible to apply the benefit of 
chemotherapy from the RS risk group. This assumes that the reclassification with IHC4 does not 
provide any additional benefit in terms of identifying patients who would benefit the most from 
chemotherapy. This may be a conservative assumption; however, it is not possible to ascertain the 
potential bias of such an assumption.
Clinical parameters: Mammostrat
Compared with OncotypeDX, the evidence base for Mammostrat was less developed and some 
gaps were identified by the systematic review of the literature (see Chapter 2, Quality of included 
studies: Mammostrat test). Most of the evidence available for Mammostrat related to the clinical 
validity (prognostic ability) of the test. No published analyses of reclassification against Adjuvant! 
Online or NPI or the impact of the test on decision-making were identified.
Because of the gaps and uncertainties in the data available, an exploratory analysis was carried 
out to assess the cost-effectiveness of Mammostrat in addition to current clinical practice 
compared with current clinical practice in England and Wales.
Clinical parameters relating to the three main components of the model are described in turn.
Assignment of patients into risk category and risk of (all) recurrence: Mammostrat Unpublished 
data from a subset of women with ER+, LN– breast cancer included in the Ring et al. study169 
were used to populate the economic model for the risk reclassification against NPI (Table 56). 
(CIC information has been removed.)
The number of recurrences in the same subset of patients (n = 245) was also obtained for patients 
classified by Mammostrat and NPI (Table 57).169
The fraction of patients who recur was calculated by the EAG for patients classified using 
Mammostrat and NPI to provide an indication of the risk of recurrence (mean follow-up of 
11.7 years) for each prognostic group (Table 58).
TABLE 56 Risk reclassification by Mammostrat and by NPI group for a subset of 245 patients included in the  
Ring et al. study169
(CIC information has 
been removed)
(CIC information has 
been removed)
(CIC information has 
been removed)
(CIC information has 
been removed)
(CIC information has 
been removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
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(CIC information has been removed.)
Data from this subset of patients were used in the economic model in the absence of 
other evidence.
Furthermore, because this study was conducted outside the UK, the risk was adjusted by 
calculating the ratio of the risk between patients with a NPI score < 3.4 and for patients with a 
NPI score > 3.4 for patients classified as low, intermediate or high using Mammostrat. The ratio 
was then applied to the risk of recurrence (DFS) estimated from the TransATAC trial for patients 
with a NPI score ≤ 3.4 and patients with a NPI score > 3.4 with ER+, LN–, HER2– breast cancer. 
The estimated adjusted 10-year risk of being free of distant recurrence used in the economic 
model is presented in Table 59. A sensitivity analysis was conducted using the direct data 
without adjustment.
Patients offered chemotherapy based on the results of the test: Mammostrat There is no published 
evidence on how Mammostrat will influence treatment decisions in the UK, or elsewhere. In the 
base case we assumed that the interpretation of the Mammostrat test would be the same as for 
patients categorised as low, intermediate or high risk of recurrence with OncotypeDX, using data 
from the Holt et al. study78 (see Table 55). A sensitivity analysis was conducted assuming that no 
patients classified as low risk, 50% of patients classified as intermediate risk and 100% of patients 
classified as high risk received chemotherapy.
Benefit of chemotherapy (reduction in the risk of all recurrence): Mammostrat One study has been 
identified by the systematic review reporting the effect of chemotherapy for patients reclassified 
TABLE 57 Number of recurrences by Mammostrat and by NPI group for a subset of 245 patients included in the 
Ring et al. study169
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
TABLE 58 Estimated proportions of patients free of recurrence (EAG calculation)
(CIC information has 
been removed)
(CIC information has 
been removed)
(CIC information has 
been removed)
(CIC information has 
been removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
TABLE 59 Proportions of patients free of recurrence at 10 years used in the economic model for the 
Mammostrat analysis
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
(CIC information has been 
removed)
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as low, intermediate or high risk using Mammostrat.126 This study showed that patients with a low 
Mammostrat risk (HR 0.4, 95% CI 0.2 to 0.8) and a high Mammostrat risk (HR 0.4, 95% CI 0.2 to 
0.9) benefited from chemotherapy whereas patients in the intermediate-risk group did not. The 
limitations of this study are described in Chapter 2, Quality of included studies: Mammostrat test.
Data from this study by Ross et al.126 were used in the base case. Sensitivity analyses were 
undertaken using the 95% CIs of this study.
Clinical parameters: MammaPrint
Compared with OncotypeDX, the evidence base for MammaPrint is less well developed and gaps 
were identified by the systematic review of the literature (see Chapter 2, Results: MammaPrint 
test). The systematic review of the literature indicated that the evidence base, in particular in 
relation to the prognostic ability of the test, is developing but is based on cohort studies with 
small sample sizes. None of the studies is based on UK patients and studies are mainly derived 
from premenopausal women and so are not representative of the population of women with ER+, 
LN–, HER2– early breast cancer. No robust evidence on clinical utility was identified. The one 
study identified that considered chemotherapy benefit by MammaPrint risk group had significant 
limitations.111 No UK studies of the impact of the test on clinical decision-making were identified.
Because of the gaps and uncertainties in the data available, an exploratory analysis was carried 
out looking at the cost-effectiveness of adjuvant chemotherapy guided using MammaPrint 
in addition to current clinical practice compared with current clinical practice in England 
and Wales.
Clinical parameters relating to the three main components of the model are described in turn.
Assignment of patients into risk category and risk of recurrence: MammaPrint Risk classification 
data from Bueno de Mesquita et al.109 were used in the economic model as this study contained a 
relatively large sample size (Table 60). The study included Dutch women only. In this study, data 
from previous cohorts were pooled and reanalysed. Women included in this study were mainly 
premenopausal and included ER– women. Premenopausal women and ER– women are more 
likely to be classified as poor prognosis with MammaPrint and this raises concerns relating to the 
generalisability of the reclassification data to the population considered in the economic model.
The systematic review of evidence did not identify any studies that presented the risk of 
recurrence in a UK population for patients classified using MammaPrint. The risk of distant 
recurrence for patients receiving endocrine therapy was therefore derived using data from the 
same non-UK study as the risk reclassification data but from a different subset of patients.105 This 
study reported the risk of recurrence (distant metastases as first event) for patients stratified by 
NPI, Adjuvant! Online and MammaPrint. This evidence relates to premenopausal women in a 
non-UK cohort and is based on patients receiving tamoxifen only. The study separated patients 
into those with a low NPI/low Adjuvant! Online score, an intermediate NPI/high Adjuvant! 
Online score or discordant results, rather than just low and intermediate NPI only (Table 61).
TABLE 60 Risk reclassification of patients using MammaPrint by NPI group
 Good prognosis using MammaPrint, n (%) Poor prognosis using MammaPrint, n (%) All, n (%)
NPI ≤ 3.4 259 (71.75) 102 (28.25) 361 (100)
NPI > 3.4 84 (24.71) 256 (75.29) 340 (100)
All 343 (48.93) 358 (51.07) 701 (100)
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This study also showed, from a different subset of patients, that 94% of the discordances between 
NPI and Adjuvant! Online occurred in patients with a NPI ≤ 3.4. Consequently, the EAG pooled 
data for patients with a low NPI and low Adjuvant! Online score and patients with a discordant 
result between the two prognostic tools.
This non-UK study presented the risk of distant recurrence as first event (rather than time to 
any distant recurrence) in predominantly premenopausal women. We therefore adjusted the 
risk using data from the TransATAC trial to more closely reflect the expected risk within a UK 
population. The ratio of the risk between the good and poor prognosis groups was calculated for 
patients with a NPI score ≤ 3.4 and a NPI score > 3.4. This ratio was then applied to the 10-year 
risk of distant recurrence for patients with a NPI score ≤ 3.4 and a NPI score > 3.4 estimated from 
the TransATAC trial (Professor Mitch Dowsett, Royal Marsden Hospital, London, September 
2011, personal communication) in a UK population with ER+, LN–, HER2– early breast cancer. 
This is acknowledged to be a limitation of the analysis.
The estimated adjusted 10-year risk of being free of distant recurrence used in the economic 
model is presented in Table 62.
Patients offered chemotherapy based on the results of the test: MammaPrint No UK studies were 
identified on the proportion of patients who receive chemotherapy based on the MammaPrint 
test results (see Chapter 2, Results: MammaPrint test). A Dutch study (the MircoarRAy 
PrognoSTics in Breast CancER study or RASTER)186 was identified that provided information 
on the number of patients who have been recommended and/or offered chemotherapy based 
on poor or good outcome classification according to the CBO105 and subsequently following 
knowledge of the MammaPrint test result.
The study showed that, overall, out of the 273 and 208 patients classified as having good and 
poor prognosis by MammaPrint, respectively, chemotherapy advice was given to 13.55% and 
87.50% respectively. Among patients considered to be at low risk according to the CBO,105 1.80% 
and 68.42% were classified as having good and poor prognosis using MammaPrint, respectively, 
and were recommended chemotherapy. The figures for patients considered to be at high risk 
according to the CBO were 32.08% and 98.48% respectively.
Data from this study were used in the base-case analysis in the absence of other evidence, 
assuming that the NPI category was a proxy for the risk group defined using the CBO 
TABLE 61 Proportion of patients free of recurrence at 10 years (distant metastases as first event) for patients 
reclassified using MammaPrint and NPI/Adjuvant! Online
Low NPI/ 
low Adjuvant! Online score (%)
Intermediate NPI/ 
high Adjuvant! Online score (%) Discordant results (%)
Good prognosis using MammaPrint 87 77 92
Poor prognosis using MammaPrint 69 45 59
All 82 53 83
TABLE 62 Proportions of patients free of recurrence at 10 years used in the economic model for the 
MammaPrint analysis
Good prognosis using MammaPrint (%) Poor prognosis using MammaPrint (%)
NPI ≤ 3.4 97.7 91.3
NPI > 3.4 94.3 83.7
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guidelines.105 This is a limitation. Furthermore, the study included ER– patients and the 
MammaPrint test classified most ER– patients as having poor prognosis. Furthermore, there 
were some concerns with the study design as there were some amendments to the protocol and 
patients from different cohorts had been pooled. In total, 84% of patients were aged < 55 years 
and the population included women with ER+ and ER– early breast cancer. It was unclear how 
representative patients were compared with those seen in clinical practice in the UK and how this 
study would relate to UK clinical practice.
Benefit of chemotherapy (reduction in the risk of distant recurrence): MammaPrint A study was 
identified providing data on the benefit of chemotherapy for ER+, LN– patients reclassified 
as having a good or a poor prognosis with MammaPrint.112 This study showed that patients 
with both a poor and a good prognosis benefited from chemotherapy (compared with no 
chemotherapy) in terms of a reduction in distant metastasis, but the benefit was not significant 
for patients with a good prognosis. The limitations of this study are described in Chapter 2, 
Results: MammaPrint test.
Summary of inputs used
To summarise, we assign patients into different boxes according to the risk group predicted by 
the new test (Figure 12). A proportion of these patients are assumed to receive chemotherapy. 
In the current practice arm, the proportion is informed by registry data and is assumed to be 
independent of the risk group (as oncologists are blind to the results of the new test). For the 
intervention arm, the proportion is linked to the risk group assigned by the new test. Patients are 
then at risk of developing a recurrence, and die from breast cancer or other causes.
A summary of the main inputs is presented in Table 63.
The main assumptions used in the base-case economic model are summarised below:
 ■ The population assessed was all women with ER+, LN–, HER2– early breast cancer.
 ■ A subgroup analysis was carried out in women with ER+, LN–, HER2– early breast cancer 
with a NPI score > 3.4 only.
 ■ Interventions assessed were OncotypeDX, MammaPrint, IHC4 and Mammostrat.
 ■ The comparator was current clinical practice in England and Wales. We used registry data 
from the ECRIC and WMCIU to reflect current clinical practice. We assumed that data from 
these two registries were representative of all trusts in England and Wales.
 ■ Women were separated by NPI score (≤ 3.4 and > 3.4) to conduct subgroup analysis but 
also to capture the prognostic value of the treatment decision using clinicopathological 
parameters based on NPI, that is, women with a low NPI score are likely to have a lower risk 
than women with a NPI score > 3.4 but are also less likely to receive chemotherapy under 
current clinical practice.
 ■ The NPI score distribution was taken from data from two registries (ECRIC and WMCIU).
 ■ The starting age of the cohort was 58.3 years.
 ■ We assumed that the new test will not be considered in women aged > 75 years as the 
decision for chemotherapy might be limited because of frailty and comorbidities.
 ■ The model used a lifetime horizon.
 ■ The model used a 6-monthly cycle length.
 ■ The model adopted the perspective of the UK NHS and PSS.
 ■ Costs and benefits were discounted at 3.5% annually.
 ■ A primary analysis was carried out comparing current clinical practice alone, OncotypeDX 
in addition to current clinical practice and IHC4 in addition to current clinical practice as 
this presented the most robust evidence to populate the economic model (mainly derived 
from UK sources).
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High risk
Moderate risk
Low risk
Chemo
No chemo
Recurrence
No recurrence Death other causes
Death other causes
Death from breast cancer
FIGURE 12 Schematic diagram showing how the inputs were assembled.
TABLE 63 Summary of inputs
Parameter Base-case value Distribution Source
Baseline age (years) 58.3 ECRIC (West Midland Cancer Intelligence Unit, 
July 2011, personal communication; Eastern 
Cancer Registration and Information Centre, 
July 2011, personal communication)
Dosage per BSA (mg/m2) 1.75 Normal (SE 0.01) Sacco et al.168
Cost of the tests
OncotypeDX £2580
IHC4 £150 Personal communication and assumption 
(Professor Mitch Dowsett, Royal Marsden 
Hospital, London, September 2011)
MammaPrint £2675
Mammostrat £1135
Handling fresh tissue £250 Personal communication (Simon Cross, 
Reader and Honorary Consultant, Royal 
Hallamshire Hospital, Sheffield, July 2011)
Endocrine therapy cost (6-monthly cost)
First 5 years £334 Normal BNF161 plus NICE guidance162 and assumption
Remaining 3 years £65
Cost of monitoring in recurrence-free state (6-monthly cost) (£)
First year £151 Normal NHS reference costs 2010/11175 and 
assumptionRemaining 4 years £87
Chemotherapy cost (one-off)
Drug, administration and monitoring £4099 Normal BNF,161 NHS reference costs 2010/11175 and 
assumption
Short-term adverse events £276 NHS reference costs 2010/11175 and 
assumptionG-CSF £485
Long-term adverse events after chemotherapy
8-year probability of AML 0.37% Beta (129,1095) Praga et al.180
Time spent in AML health state 8 months Assumption based on NICE STA18181
Lifetime cost £11,500 Assumption based on NICE STA18181
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Parameter Base-case value Distribution Source
Recurrence cost (6-monthly) £4082 Normal Derived from Thomas et al.157
End-of-life cost (one-off) – after death 
from breast cancer
£4038 Normal (SE £454) Campbell et al.176
Local recurrence cost – one-off £14,132 Normal (SE £1853) Derived from Karnon et al.182 and PSSRU178
Health state utilities
Recurrence-free state 0.824 Beta (353,75) Lidgren et al.148
Distant recurrence 0.685 Beta (171,79) Lidgren et al.148
Local recurrence (decrement per patient) –0.108 Normal (SE 0.04) Campbell et al.176
AML 0.26 Younis et al.183
Chemotherapy (decrement per patient) –0.038 Campbell et al.176
Terminal care cost (final 3 months) 0.159 Normal (SE 0.04) Campbell et al.176
Baseline NPI score distribution
≤ 3.4 66.2% Beta (2602,819) ECRIC and WMCIU (West Midland Cancer 
Intelligence Unit, July 2011, personal 
communication; Eastern Cancer Registration 
and Information Centre, July 2011, personal 
communication)
> 3.4 33.8%
Proportion of patients receiving chemotherapy under current clinical practice
NPI ≤ 3.4 4.6% Beta (3263,158) ECRIC and WMCIU (West Midland Cancer 
Intelligence Unit, July 2011, personal 
communication; Eastern Cancer Registration 
and Information Centre, July 2011, personal 
communication)
NPI > 3.4 33.6% Beta (1160, 587) ECRIC and WMCIU (West Midland Cancer 
Intelligence Unit, July 2011, personal 
communication; Eastern Cancer Registration 
and Information Centre, July 2011, personal 
communication)
Proportion of patients receiving 
chemotherapy after knowledge of the 
result of the new test (Holt et al. study78)
See Table 55 EAG analysis
Risk reclassification
OncotypeDX and IHC4 See Tables 51 
and 52
Beta TransATAC trial (personal communication)
MammaPrint See Table 60 Beta Bueno-de-Mesquita et al.109
Mammostrat See Table 56 Beta Subset of the Ring et al. study125 (Clarient169)
Risk of recurrence
OncotypeDX and IHC4 See Tables 53 
and 54
TransATAC trial (Professor Mitch Dowsett, 
Royal Marsden Hospital, London, September 
2011, personal communication)
MammaPrint See Table 62 Derived from Bueno-de-Mesquita et al.109 and 
the TransATAC trial (Professor Mitch Dowsett, 
Royal Marsden Hospital, London, September 
2011, personal communication)
Mammostrat See Table 59 Derived Professor Mitch Dowsett, Royal 
Marsden Hospital, London, September 
2011, from a subset of the Ring et al. 
study125 (Clarient169) and the TransATAC trial 
(Professor Mitch Dowsett, Royal Marsden 
Hospital, London, September 2011, personal 
communication)
continued
TABLE 63 Summary of inputs (continued)
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 ■ Two exploratory analyses were carried out comparing current clinical practice alone against 
MammaPrint or Mammostrat in addition to current clinical practice.
 ■ We assumed that the diagnostic tool does not affect the prognosis of patients if there is no 
change in the adjuvant treatment.
 ■ In the comparator arm (current clinical practice), the probability of receiving chemotherapy 
was taken from data from two registries (ECRIC and WMCIU). It was assumed that the 
probability of receiving chemotherapy was the same irrespective of the reclassification of 
patients with the new test in the low-, intermediate- or high-risk group. This is likely to be a 
conservative assumption.
 ■ The probability of receiving chemotherapy in the intervention arm was based on the assigned 
risk group, with a greater likelihood of receiving chemotherapy for patients classified as high 
risk of recurrence/distant recurrence than for patients classified as low risk.
 ■ The economic model used distant recurrence as the primary outcome.
 ■ Only locoregional recurrence that led to a distant recurrence was included, by considering 
the cost and quality of life decrement associated with locoregional recurrence. We assumed 
that 10.5% of distant recurrences were preceded by a local recurrence.
 ■ We assumed that patients treated with chemotherapy can develop long-term adverse events. 
The model included the development of AML only.
 ■ The risk of recurrence was assumed to be constant in the first 10 years and to be halved 
between 10 and 15 years; no recurrence was assumed after 15 years.
 ■ Median survival after a distant recurrence was assumed to be 40.1 months.
 ■ We assumed that all patients receive endocrine therapy. Five regimens were considered: 
tamoxifen for 5 years, anastrozole for 5 years, letrozole for 5 years, tamoxifen for 2 years plus 
exemestane for the final 3 years and tamoxifen (or other endocrine therapy regimens) for 
5 years followed by extended therapy with letrozole for a further 3 years.
 ■ Patients were assumed to have two follow-up appointments in the first year and one 
follow-up appointment every subsequent year. Patients were assumed to have one 
mammogram every year for a maximum of 5 years.
Parameter Base-case value Distribution Source
Benefit of chemotherapy (HR)
OncotypeDX Log-normal Paik et al.49
Low RS: 1.31 Low RS: 95% CI 0.46 to 3.78
Intermediate RS: 
0.61
Intermediate RS: 95% CI 0.24 
to 1.59
High RS: 0.26 High RS: 95% CI 0.13 to 0.53
MammaPrint Log-normal Knauer et al.110
Good prognosis: 
0.26
Good prognosis: 95% CI 0.03 
to 2.02
Poor prognosis: 
0.35
Poor prognosis: 95% CI 0.17 
to 0.71
Mammostrat Log-normal Ross et al.126
Low: 0.4 Low: 95% CI 0.2 to 0.8
Intermediate: 1 Intermediate: 95% CI NA
High: 0.4 High: 95% CI 0.2 to 0.9
NA, not applicable; STA, Single Technology Appraisal.
TABLE 63 Summary of inputs (continued)
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 ■ Patients treated with chemotherapy receive six cycles of FEC75. We assumed that patients 
have a separate outpatient appointment before drug administration. Monitoring includes a 
liver function test, urea and electrolytes tests and a full blood count. It was further assumed 
that 25% of patients have an echocardiogram before starting chemotherapy.
 ■ Short-term adverse events after chemotherapy were included based on the probability of 
patients treated with FEC100 suffering from short-term adverse events, as no data were 
available for FEC75.
 ■ We assumed that 25% of patients treated with chemotherapy receive G-CSF (maximum of 
three cycles) for the secondary prevention of febrile neutropenia.
 ■ A decrement in utility was assumed for patients receiving chemotherapy and for patients 
dying from breast cancer-specific causes.
Assumptions specific to each test are described in Table 64.
Independent economic model: results
The primary analysis compared current clinical practice with treatment guided using 
OncotypeDX and IHC4. This involved using data from a direct comparison between 
OncotypeDX and IHC (Professor Mitch Dowsett, Royal Marsden Hospital, London, 
September 2011, personal communication).
In addition to the primary analysis, exploratory analyses were undertaken for Mammostrat 
and MammaPrint. These analyses were exploratory because of the significant limitations in the 
evidence base, and results need to be interpreted with consideration of the assumptions made 
and the robustness of the evidence used.
All analyses assumed that the new tests were used in addition to current prognostic tools. Base-
case analyses assumed the tests to have predictive ability, that is, patients in the high-risk group 
benefit relatively more from reduction in recurrences following chemotherapy than patients in 
the lower-risk groups; this assumption was tested in sensitivity analysis.
Cost-effectiveness of treatment guided using OncotypeDX and IHC4
Two analyses are presented:
1. The tests were given to all women with ER+, LN–, HER2– early breast cancer.
2. The tests were given only to women with ER+, LN–, HER2– early breast cancer with a NPI 
score > 3.4. This subgroup analysis was undertaken to explore the impact of targeting the 
tests at patients with intermediate risk. It is considered likely that the majority of women with 
a NPI score ≤ 3.4 would be considered low risk and would not receive chemotherapy under 
current practice or using the new tests and therefore the tests would have a limited impact on 
the management of these women.
The new tests were offered to all women with ER+, LN–, HER2– early 
breast cancer
Deterministic results
Assuming that the tests were offered to all women with ER+, LN–, HER2– early breast cancer, 
treatment guided using OncotypeDX was predicted to lead to an increase in the proportion of 
patients receiving chemotherapy compared with current clinical practice under our base-case 
assumptions (19.11% vs. 14.42%). On the contrary, treatment guided using IHC4 was predicted 
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to lead to a reduction in the proportion of patients receiving chemotherapy compared with 
current clinical practice under our base-case assumptions (9.57% vs. 14.42%). More women were 
classified as high or intermediate risk with OncotypeDX than with IHC4, and were therefore 
more likely to receive chemotherapy.
For a cohort of 1000 women with ER+, LN–, HER2– early breast cancer, we predicted that 
76 distant recurrences would occur under current clinical practice. Treatment guided using 
TABLE 64 List of assumptions specific to each test
OncotypeDX IHC4 Mammostrat MammaPrint
 ■ OncotypeDX used as a 
discrete variable (low, 
intermediate, high RS) 
instead of continuous RS
 ■ Original RS groups are used: 
low (RS < 18), intermediate 
(RS between 18 and 30), 
high (RS ≥ 31)
 ■ Reclassification evidence 
from the TransATAC trial 
(UK population) by NPI, by 
OncotypeDX and by IHC4
 ■ Risk of recurrence from 
the TransATAC trial (UK 
population) by NPI, by 
OncotypeDX and by IHC4
 ■ Holt et al. study (UK 
population)78 used to 
inform the proportion 
of patients classified as 
low, intermediate or high 
(receiving chemotherapy)
 ■ The benefit of chemotherapy 
in terms of reduction 
of distant recurrence 
was taken from the Paik 
et al. study49 of a US 
cohort treated with CMF/
CM. The study included 
a large proportion of 
premenopausal women and 
some women with HER2+. 
No benefit was assumed 
for women with a low 
OncotypeDX RS
 ■ Composite score of IHC4 in 
addition to clinicopathological 
parameters
 ■ The test was assumed to be 
reproducible (notably Ki-67 
element)
 ■ IHC4 used as a discrete variable 
(low, intermediate, high) instead 
of continuous risk of distant 
recurrence
 ■ Patients with low, intermediate 
and high risk of distant 
recurrence were defined as 
patients with a predicted 
risk of distant recurrence of 
< 10%, 10–20% and > 20% 
respectively (same approach as 
for OncotypeDX)
 ■ Reclassification evidence 
from the TransATAC trial 
(UK population) by NPI, by 
OncotypeDX and by IHC4
 ■ Risk of recurrence from the 
TransATAC trial (UK population) 
by NPI, by OncotypeDX and by 
IHC4
 ■ We assumed that physicians 
interpret OncotypeDX and IHC4 
in the same way. The Holt et 
al. study (UK population)78 was 
used to inform the proportion of 
patients receiving chemotherapy 
classified as low, intermediate 
or high
 ■ The benefit of chemotherapy 
in terms of reduction of distant 
recurrence was applied from 
the RS risk group (using 
OncotypeDX – Paik et al. 
study49) as no specific data 
for IHC4. This assumes that 
reclassification with IHC4 does 
not provide any additional 
benefit (possibly conservative 
assumption)
 ■ We assumed that it cost an 
additional £100–200 to perform 
the IHC4 test
 ■ Reclassification evidence 
from a subset of patients 
from the Ring et al. study 
(USA).125 We assumed that 
the reclassification holds for 
the UK
 ■ The risk of recurrence was 
derived from the same 
subset of the Ring et al. study 
(USA)125 with adjustment for 
the UK population using data 
from the TransATAC trial
 ■ We assumed that physicians 
interpret OncotypeDX and 
Mammostrat in the same 
way. The Holt study (UK 
population)78 was used 
to inform the proportion 
of patients receiving 
chemotherapy classified as 
low, intermediate or high
 ■ Health and cost outcomes 
after a recurrence were 
assumed to be the same as 
for distant recurrence as the 
EAG used distant recurrence 
as a primary outcome
 ■ The benefit of chemotherapy 
in terms of reduction of 
recurrence (any) was taken 
from the Ross et al. study126 of 
a US cohort treated with CMF/
CM. No benefit was assumed 
for women with a moderate 
Mammostrat risk
 ■ Reclassification from 
Bueno-de-Mesquita et al.109 
from a pooled analysis 
of Dutch women (mainly 
premenopausal and including 
ER–). We assumed that the 
reclassification hold for the UK
 ■ The risk of recurrence was 
derived from a different subset 
of patients from the Bueno-
de-Mesquita et al. study109 
of Dutch women (mainly 
premenopausal and including 
ER–), with adjustment for the 
UK population using data from 
the TransATAC trial
 ■ We used data from the 
RASTER study186 (Dutch 
women) to estimate the 
probability of chemotherapy 
for patients classified as 
having good or poor prognosis 
with MammaPrint. The study 
separated patients using the 
CBO guidelines102 instead of 
NPI (we therefore assumed 
that CBO is a proxy for NPI). 
The study also included a mix 
of ER+/–, HER2 +/– women. 
Data from this study were 
assumed to hold for the UK in 
the absence of other evidence
 ■ The benefit of chemotherapy 
in terms of reduction of 
distant recurrence was taken 
from the Knauer et al. study110 
of a Dutch cohort treated 
with CMF or anthracycline 
+/– taxane regimens (pooled 
analysis of previous cohort). 
The study had several flaws. 
We assumed that women 
with a good prognosis had a 
greater benefit (although non-
significant) than women with a 
poor prognosis
 ■ MammaPrint offers three 
optional tests for no additional 
cost. This was not considered
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OncotypeDX and IHC4 was predicted to reduce the number of distant recurrences to 64 and 71, 
respectively, under the assumptions used for the base-case analysis.
The mean discounted cost of treatment guided using current clinical practice, OncotypeDX and 
IHC4 was estimated to be £6519, £9094 and £6340 per patient respectively. The breakdown of 
costs by category is presented in Table 65. Treatment guided using OncotypeDX was estimated to 
reduce the costs associated with the management of recurrences (distant and local recurrences, 
terminal care) but incurred additional costs to perform the test (£2580) compared with current 
clinical practice. IHC4 also reduced the costs associated with recurrences, but also reduced the 
costs associated with chemotherapy, for an additional test cost of £150 per patient compared with 
current clinical practice.
The mean discounted QALYs were 13.44, 13.54 and 13.49 for current clinical practice, 
OncotypeDX and IHC4 respectively.
Compared with current clinical practice, the incremental cost for treatment guided using 
OncotypeDX was estimated to be £26,940 per QALY gained. Chemotherapy treatment guided 
using IHC4 was dominant (i.e. provided more QALYs at a lower cost) compared with current 
clinical practice. These results are based on the assumption that OncotypeDX has predictive 
ability. This assumption was tested in sensitivity analysis.
Treatment guided using OncotypeDX, IHC4 and current clinical practice was also compared 
using incremental analysis, that is, the least effective strategy was compared with the next least 
effective strategy that was neither dominated nor extendedly dominated. The base-case costs and 
QALYs are shown in Table 66. Treatment guided using OncotypeDX provided the most benefit 
(13.54 QALYs) at the highest cost (£9094). The ICER for treatment guided using OncotypeDX 
compared with treatment guided using IHC4 was £55,406 per QALY gained.
TABLE 65 Breakdown of costs for the primary analysis: current clinical practice compared with OncotypeDX and IHC4 
Cost categories Current clinical practice (£) OncotypeDX (£) IHC4 (£)
Recurrence free 926 928 927
Distant recurrence 1277 1081 1199
Terminal care 222 188 209
Local recurrence 92 78 87
Endocrine therapy 3298 3307 3302
Chemotherapy 591 783 392
Short-term adverse events 110 145 73
Long-term adverse events 3 4 2
Cost of test 0 2580 150
Total cost 6519 9094 6340
TABLE 66 Deterministic ICER for the primary analysis comparing OncotypeDX and IHC4 with current clinical practice 
assuming that the test is given to all women with ER+, LN–, HER2– early breast cancer in England and Wales
Mean cost (£) Mean QALYs ICER (£) Incremental analysis (£)
OncotypeDX 9094 13.54 26,940 55,406
IHC4 6340 13.49 Cost saving
Current clinical practice 6519 13.44 
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Probabilistic results
The results of PSA using 2500 iterations are shown in Table 67. Treatment guided using IHC4 
remained dominant (i.e. provided more QALYs at a lower cost) compared with current clinical 
practice. The incremental cost for treatment guided using OncotypeDX was £29,503 per QALY 
gained compared with current clinical practice and £64,111 per QALY gained compared with 
IHC4 (see Table 67).
Figure 13 shows the cost-effectiveness acceptability curve (CEAC) using results generated over 
a lifetime horizon. The curve shows the probability of each test being cost-effective for different 
monetary values that the decision-maker may be willing to pay for an additional QALY. The 
CEAC shows that treatment guided by IHC4 was the most cost-effective strategy compared with 
current clinical practice and OncotypeDX when using a willingness-to-pay threshold of £20,000 
per QALY gained (in 99.48% of cases). The probability that treatment guided using OncotypeDX 
was cost-effective at a £20,000 threshold was 0.40% in the incremental analysis and 12.44% 
compared with current clinical practice alone.
The new tests were offered only to women with ER+, LN–, HER2– 
early breast cancer with a Nottingham Prognostic Index score > 3.4
Deterministic results
Assuming that the tests were offered only to women with ER+, LN–, HER2– early breast cancer 
with a NPI score > 3.4, a greater proportion of patients were predicted to receive chemotherapy 
when using OncotypeDX (under our base-case assumptions) and a lower proportion were 
TABLE 67 Probabilistic ICER (2500 iterations) for the primary analysis comparing OncotypeDX and IHC4 with current 
clinical practice assuming that the test is given to all women with ER+, LN–, HER2– early breast cancer in England 
and Wales
Mean cost (£) Mean QALYs ICER (£) Incremental analysis (£)
OncotypeDX 9100 13.52 29,503 64,111
IHC4 6332 13.48 Cost saving 
Current clinical practice 6507 13.44 
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FIGURE 13 Cost-effectiveness acceptability curve for the primary analysis comparing OncotypeDX and IHC4 with 
current clinical practice assuming that the test is given to all women with ER+, LN–, HER2– early breast cancer in 
England and Wales.
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predicted to receive chemotherapy when using IHC4 compared with current clinical practice 
(34.72% vs. 26.31% vs. 33.60% respectively).
Treatment guided using IHC4 was dominant (i.e. provided more QALYs at a lower cost) 
compared with current clinical practice. The incremental cost for treatment guided using 
OncotypeDX was £9007 per QALY gained compared with current clinical practice and £26,859 
per QALY gained compared with IHC4 (Table 68). This is based on the assumption that 
OncotypeDX has predictive ability. This assumption was tested in sensitivity analysis.
Probabilistic results
The results of PSA using 2500 iterations are shown in Table 69. Treatment guided using IHC4 
remained dominant (i.e. provided more QALYs at a lower cost) compared with current clinical 
practice. The incremental cost for treatment guided using OncotypeDX was £9774 per QALY 
gained compared with current clinical practice and £31,125 per QALY gained compared with 
IHC4 (see Table 69).
The CEAC (Figure 14) shows that treatment guided by IHC4 was the most cost-effective 
strategy when using a willingness-to-pay threshold of £20,000 per QALY gained (in 81.24% of 
cases). The probability that treatment guided using OncotypeDX was cost-effective at a £20,000 
threshold was 18.60% in the incremental analysis and 91.56% compared with current clinical 
practice alone.
Univariate sensitivity analyses: parameters
A range of univariate sensitivity analyses were carried out to explore the impact of varying the 
main model parameters. Results of the univariate sensitivity analysis assuming that the tests 
were offered to all women with ER+, LN–, HER2– early breast cancer are presented in Table 70. 
Results for the univariate sensitivity analysis assuming that the tests were offered only to women 
with a NPI score > 3.4 are presented in Table 71.
OncotypeDX
The main model parameters were varied within reasonable ranges. The ICER for OncotypeDX 
compared with current clinical practice was mainly sensitive (defined as changes in the ICER 
by ≥ ±10%) to the assumptions about the time horizon, the starting age of the cohort, the risk of 
recurrence, the proportion of patients receiving chemotherapy after reclassification with the new 
test, the benefit of chemotherapy and the NPI score distribution (see Tables 70 and 71).
TABLE 68 Deterministic ICER for the primary analysis comparing OncotypeDX and IHC4 with current clinical practice 
assuming that the test is given only to women with a NPI score > 3.4
Mean cost (£) Mean QALYs ICER (£) Incremental analysis (£)
OncotypeDX 10,911 13.06 9007 26,859
IHC4 8318 12.97 Cost saving
Current clinical practice 8816 12.83 
TABLE 69 Probabilistic ICER for the primary analysis comparing OncotypeDX and IHC4 with current clinical practice 
assuming the test to be given to women with a NPI > 3.4 only
Mean cost (£) Mean QALYs ICER (£) Incremental analysis (£)
OncotypeDX 10,924 13.05 9774 31,125
IHC4 8305 12.96 Cost saving
Current clinical practice 8797 12.83
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The ICER was sensitive to the assumed benefit of chemotherapy. The ICER increased (less 
favourable to OncotypeDX) assuming a lower benefit of chemotherapy (–20% to –40%). The 
ICER also deteriorated (less favourable to OncotypeDX) significantly assuming that the test was 
prognostic only, that is, the same relative reduction in the risk of distant recurrence following 
chemotherapy was applied whether patients were classified as low, intermediate or high risk 
according to the OncotypeDX RS classification.
The ICER increased (less favourable to OncotypeDX) as the time horizon decreased or the age 
increased, given that less benefit can be accrued over time.
A reduction in the risk of distant recurrence increased the ICER (less favourable to OncotypeDX) 
whereas an increase in the risk of distant recurrence improved the ICER in favour of 
OncotypeDX. Given that more recurrences can be avoided if there is an increase in the risk of 
distant recurrence, more of the cost of the test can be offset.
Furthermore, the ICER was sensitive to the assumptions about the proportion of patients who 
received chemotherapy depending on the results of the test (interpretation of the test). If we 
assumed that chemotherapy was guided solely by the test results, so no women classified as low 
risk, 50% of women classified as intermediate risk and 100% of women classified as high risk 
with OncotypeDX receive chemotherapy (for women with both a NPI score ≤ 3.4 and a NPI score 
> 3.4), the ICER improved (more favourable to OncotypeDX) because chemotherapy is targeted 
to patients who, according to the test, are likely to benefit the most from it. In addition, the ICER 
was very sensitive to the assumption about the probability of chemotherapy in patients classified 
as intermediate risk with OncotypeDX. The ICER ranged from £22,812 to £35,629 if the test was 
given to all women and from £8371 to £10,022 if the test was given only to women with a NPI 
score > 3.4, assuming that the probability of receiving chemotherapy was the same as for patients 
classified as low and high risk respectively.
The ICER improved (more favourable to OncotypeDX) when using the NPI distribution from the 
Holt et al. study77 in the model as more patients were classified with a NPI score > 3.4. This group 
of patients was shown to derive a greater benefit from the new test.
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FIGURE 14 Cost-effectiveness acceptability curve for the primary analysis comparing OncotypeDX and IHC4 with 
current clinical practice assuming that the test is given only to women with a NPI score > 3.4.
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TABLE 70 Results of the univariate sensitivity analysis for the primary analysis assuming that the new tests are offered 
to all women with ER+. LN–, HER2– early breast cancer in England and Wales
OncotypeDX IHC4 Clinical practice ICER (£)
QALYs Cost (£) QALYs Cost (£) QALYs Cost (£)
OncotypeDX 
vs. clinical 
practice
IHC4 vs. 
clinical 
practice
Base case 13.54 9094 13.49 6340 13.44 6519 26,940 Cost saving
Time horizon = 5 years 4.11 7947 4.11 5093 4.10 5209 632,318 Cost saving
Time horizon = 10 years 7.05 8680 7.04 5883 7.03 6036 120,123 Cost saving
Time horizon = 20 years 11.08 9080 11.04 6324 11.01 6502 39,368 Cost saving
Starting age = 50 years 15.51 9166 15.45 6416 15.39 6597 21,632 Cost saving
Starting age = 60 years 12.97 9066 12.93 6310 12.88 6487 28,932 Cost saving
Starting age = 70 years 9.83 8792 9.80 6017 9.77 6184 47,796 Cost saving
Reduction in the risk of 
recurrence by 10%
13.59 8975 13.54 6207 13.50 6379 29,960 Cost saving
Reduction in the risk of 
recurrence by 20%
13.64 8853 13.60 6073 13.56 6236 33,784 Cost saving
Increase in the risk of 
recurrence by 10%
13.49 9212 13.43 6471 13.38 6656 24,494 Cost saving
Increase in the risk of 
recurrence by 20%
13.44 9328 13.37 6599 13.32 6791 22,473 Cost saving
Recurrence up to 20 years 13.50 9229 13.45 6488 13.40 6673 25,298 Cost saving
No changed in the risk of 
distant recurrence between 10 
and 15 years 
13.48 9277 13.42 6541 13.37 6728 24,342 Cost saving
Reduction in the risk of distant 
recurrence by 75% between 
10 and 15 years
13.57 9002 13.52 6238 13.48 6411 28,520 Cost saving
Proportion of local 
recurrence before a distant 
recurrence = 5%
13.54 9053 13.49 6294 13.44 6470 27,034 Cost saving
Proportion of local 
recurrence before a distant 
recurrence = 20%
13.54 9165 13.49 6418 13.44 6602 26,780 Cost saving
Proportion of local 
recurrence before a distant 
recurrence = 30%
13.54 9239 13.49 6500 13.44 6689 26,611 Cost saving
Time in distant recurrence 
health state different by 
prognosis group
13.56 9359 13.51 6648 13.46 6772 26,793 Cost saving
Time in distant recurrence 
– LCI
13.51 8809 13.46 6023 13.41 6181 26,248 Cost saving
Time in distant recurrence 
– UCI
13.56 9354 13.51 6628 13.47 6825 27,629 Cost saving
Proportion of patients receiving 
chemotherapy under current 
clinical practice = ECRIC only
13.54 9094 13.49 6340 13.44 6493 26,830 Cost saving
Proportion of patients receiving 
chemotherapy under current 
clinical practice = WMCIU only
13.54 9094 13.49 6340 13.45 6605 27,428 Cost saving
Proportion of patients receiving 
chemotherapy under current 
clinical practice = Holt et al. 
study77
13.54 9094 13.49 6340 13.48 7230 35,951 Cost saving
continued
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OncotypeDX IHC4 Clinical practice ICER (£)
QALYs Cost (£) QALYs Cost (£) QALYs Cost (£)
OncotypeDX 
vs. clinical 
practice
IHC4 vs. 
clinical 
practice
Increase by 20% in the 
proportion of patients receiving 
chemotherapy under current 
clinical practice
13.54 9094 13.49 6340 13.45 6632 28,346 Cost saving
Increase by 30% in the 
proportion of patients receiving 
chemotherapy under current 
clinical practice
13.54 9094 13.49 6340 13.45 6688 29,182 Cost saving
Reduction by 20% in the 
proportion of patients receiving 
chemotherapy under current 
clinical practice
13.54 9094 13.49 6340 13.43 6405 25,810 Cost saving
Reduction by 30% in the 
proportion of patients receiving 
chemotherapy under current 
clinical practice
13.54 9094 13.49 6340 13.43 6348 25,326 Cost saving
Assumption about who would 
receive chemotherapy with the 
new tests
(CiC 
information 
has been 
removed)
(CiC 
information 
has been 
removed)
13.49 6308 13.44 6519 23,765 Cost saving
Reduction in the benefit of 
chemotherapy by 10%
(CiC 
information 
has been 
removed)
(CiC 
information 
has been 
removed)
13.48 6350 13.44 6525 28,416 Cost saving
Reduction in the benefit of 
chemotherapy by 20%
13.52 9128 13.48 6359 13.43 6532 29,945 Cost saving
Reduction in the benefit of 
chemotherapy by 30%
13.51 9144 13.47 6368 13.43 6538 31,529 Cost saving
Reduction in the benefit of 
chemotherapy by 40%
13.51 9158 13.47 6376 13.43 6543 33,169 Cost saving
Assuming the same benefit 
of chemotherapy for 
everyone = 40%
13.49 9200 13.47 6374 13.45 6498 64,940 Cost saving
Assuming the same benefit 
of chemotherapy for 
everyone = 30%
13.46 9264 13.45 6421 13.43 6535 91,274 Cost saving
NPI distribution from the Holt 
et al. study77
13.48 9323 13.42 6589 13.36 6808 22,281 Cost saving
NPI distribution from the 
TransATAC trial
13.52 9169 13.47 6421 13.42 6613 25,251 Cost saving
Cost for IHC4 = £100 13.54 9094 13.49 6290 13.44 6519 26,940 Cost saving
Cost for IHC4 = £200 13.54 9094 13.49 6390 13.44 6519 26,940 Cost saving
Cost for IHC4 = £300 13.54 9094 13.49 6490 13.44 6519 26,940 Cost saving
Cost for IHC4 = £400 13.54 9094 13.49 6590 13.44 6519 26,940 1557
G-CSF is given to all patients 
receiving chemotherapy
13.54 9373 13.49 6479 13.44 6728 27,655 Cost saving
Five cycles of G-CSF (instead 
of three)
13.54 9156 13.49 6371 13.44 6565 27,099 Cost saving
Five cycles of chemotherapy 
(instead of three)
13.54 8964 13.49 6275 13.44 6420 26,604 Cost saving
100% echocardiogram 
(instead of 25%)
13.54 9103 13.49 6344 13.44 6525 26,961 Cost saving
TABLE 70 Results of the univariate sensitivity analysis for the primary analysis assuming that the new tests are offered 
to all women with ER+. LN–, HER2– early breast cancer in England and Wales (continued)
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OncotypeDX IHC4 Clinical practice ICER (£)
QALYs Cost (£) QALYs Cost (£) QALYs Cost (£)
OncotypeDX 
vs. clinical 
practice
IHC4 vs. 
clinical 
practice
Increase in the cost of 
chemotherapy by 25%
13.54 9290 13.49 6438 13.44 6666 27,443 Cost saving
Reduction in the cost of 
chemotherapy by 25%
13.54 8899 13.49 6242 13.44 6371 26,437 Cost saving
Increase in the cost of 
endocrine therapy by 25%
13.54 9921 13.49 7166 13.44 7343 26,964 Cost saving
Reduction in the cost of 
endocrine therapy by 25%
13.54 8268 13.49 5515 13.44 5694 26,916 Cost saving
Increase in the cost of distant 
metastases by 25%
13.54 9365 13.49 6640 13.44 6838 26,427 Cost saving
Reduction in the cost of distant 
metastases by 25%
13.54 8824 13.49 6040 13.44 6199 27,453 Cost saving
Cost of local recurrence – LCI 13.54 9070 13.49 6313 13.44 6490 26,986 Cost saving
Cost of local recurrence – UCI 13.54 9123 13.49 6372 13.44 6552 26,886 Cost saving
Terminal care cost – LCI 13.54 9053 13.49 6294 13.44 6470 27,018 Cost saving
Terminal care cost – UCI 13.54 9136 13.49 6386 13.44 6568 26,861 Cost saving
Utility values – LCI 12.89 9094 12.84 6340 12.80 6519 28,061 Cost saving
Utility values – UCI 14.08 9094 14.03 6340 13.98 6519 26,034 Cost saving
Increase of 25% in the 
decrement in utility for patients 
dying from breast cancer
13.53 9094 13.48 6340 13.44 6519 26,862 Cost saving
Decrease of 25% in the 
decrement in utility for patients 
dying from breast cancer
13.54 9094 13.49 6340 13.44 6519 27,018 Cost saving
Increase of 25% in the 
decrement in utility for patients 
receiving chemotherapy
13.53 9094 13.49 6340 13.44 6519 27,066 Cost saving
Decrease of 25% in the 
decrement in utility for patients 
receiving chemotherapy
13.54 9094 13.49 6340 13.44 6519 26,815 Cost saving
Utility for patients with 
AML = 0.5
13.54 9094 13.49 6340 13.44 6519 26,936 Cost saving
Utility for patients with 
AML = 0.6
13.54 9094 13.49 6340 13.44 6519 26,934 Cost saving
Risk of long-term adverse 
events multiplied by 2
13.52 9096 13.48 6340 13.43 6519 27,954 Cost saving
Risk of long-term adverse 
events multiplied by 3
13.51 9097 13.47 6340 13.42 6520 29,034 Cost saving
Proportion of patients 
classified as intermediate 
with the new test undergoing 
chemotherapy = low-risk value
13.50 8683 13.46 6215 13.44 6519 35,629 Cost saving
Proportion of patients 
classified as intermediate 
with the new test undergoing 
chemotherapy = high-risk 
value
13.56 9323 13.52 6434 13.44 6519 22,812 Cost saving
LCI, lower confidence interval; UCI, upper confidence interval.
TABLE 70 Results of the univariate sensitivity analysis for the primary analysis assuming that the new tests are offered 
to all women with ER+. LN–, HER2– early breast cancer in England and Wales (continued)
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TABLE 71 Results of the univariate sensitivity analysis for the primary analysis assuming that the new tests are offered 
only to women with a NPI score > 3.4
OncotypeDX IHC4 Clinical practice ICER (£)
QALYs Cost (£) QALYs
Cost 
(£) QALYs
Cost 
(£)
OncotypeDX 
vs. clinical 
practice
IHC4 vs. 
clinical 
practice
Base case 13.06 10,911 12.97 8318 12.83 8816 9007 Cost saving
Time horizon = 5 years 4.07 9012 4.07 6245 4.06 6544 170,573 Cost saving
Time horizon = 10 years 6.94 10,170 6.92 7501 6.88 7918 39,573 Cost saving
Time horizon = 20 years 10.75 10,884 10.69 8289 10.59 8784 13,108 Cost saving
Starting age = 50 years 14.93 11,019 14.81 8434 14.64 8941 7203 Cost saving
Starting age = 60 years 12.53 10,868 12.44 8272 12.32 8765 9686 Cost saving
Starting age = 70 years 9.56 10,456 9.50 7828 9.42 8286 16,152 Cost saving
Reduction in the risk of recurrence 
by 10%
13.16 10,700 13.07 8085 12.94 8559 10,087 Cost saving
Reduction in the risk of recurrence 
by 20%
13.25 10,485 13.17 7846 13.06 8296 11,440 Cost saving
Increase in the risk of recurrence 
by 10%
12.98 11,117 12.87 8547 12.72 9066 8125 Cost saving
Increase in the risk of recurrence 
by 20%
12.89 11,319 12.77 8770 12.62 9311 7392 Cost saving
Recurrence up to 20 years 13.00 11,146 12.90 8577 12.76 9095 8389 Cost saving
No changed in the risk of distant 
recurrence between 10 and 
15 years 
12.96 11,230 12.85 8670 12.71 9195 8055 Cost saving
Reduction in the risk of distant 
recurrence by 75% between 10 and 
15 years
13.12 10,747 13.03 8138 12.90 8619 9585 Cost saving
Proportion of local recurrence 
before a distant recurrence = 5%
13.07 10,836 12.97 8235 12.83 8723 9086 Cost saving
Proportion of local recurrence 
before a distant recurrence = 20%
13.06 11,039 12.97 8459 12.83 8973 8872 Cost saving
Proportion of local recurrence 
before a distant recurrence = 30%
13.06 11,174 12.97 8609 12.83 9139 8729 Cost saving
Time in distant recurrence health 
state different by prognosis group
13.08 11,118 12.99 8587 12.84 8932 9091 Cost saving
Time in distant recurrence – LCI 13.02 10,391 12.92 7743 12.78 8175 9116 Cost saving
Time in distant recurrence – UCI 13.11 11,383 13.01 8840 12.88 9396 8900 Cost saving
Proportion of patients receiving 
chemotherapy under current clinical 
practice = ECRIC only
13.06 10,911 12.97 8318 12.83 8775 9019 Cost saving
Proportion of patients receiving 
chemotherapy under current clinical 
practice = WMCIU only
13.06 10,911 12.97 8318 12.85 8959 8967 Cost saving
Proportion of patients receiving 
chemotherapy under current clinical 
practice = Holt et al. study77
13.06 10,911 12.97 8318 12.97 10,037 8818 Cost saving
Increase by 20% in the proportion 
of patients receiving chemotherapy 
under current clinical practice
13.06 10,911 12.97 8318 12.86 9066 8938 Cost saving
Increase by 30% in the proportion 
of patients receiving chemotherapy 
under current clinical practice
13.06 10,911 12.97 8318 12.87 9191 8907 Cost saving
Reduction by 20% in the proportion 
of patients receiving chemotherapy 
under current clinical practice
13.06 10,911 12.97 8318 12.81 8564 9082 Cost saving
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OncotypeDX IHC4 Clinical practice ICER (£)
QALYs Cost (£) QALYs
Cost 
(£) QALYs
Cost 
(£)
OncotypeDX 
vs. clinical 
practice
IHC4 vs. 
clinical 
practice
Reduction by 30% in the proportion 
of patients receiving chemotherapy 
under current clinical practice
13.06 10,911 12.97 8318 12.79 8438 9121 Cost saving
Assumption about who would 
receive chemotherapy with the new 
tests
13.09 10,799 12.98 8192 12.83 8816 7761 Cost saving
Reduction in the benefit of 
chemotherapy by 10%
13.05 10,950 12.96 8347 12.82 8834 9459 Cost saving
Reduction in the benefit of 
chemotherapy by 20%
13.03 10,987 12.94 8374 12.82 8851 9923 Cost saving
Reduction in the benefit of 
chemotherapy by 30%
13.02 11,022 12.93 8399 12.81 8867 10,400 Cost saving
Reduction in the benefit of 
chemotherapy by 40%
13.00 11,055 12.92 8423 12.80 8882 10,890 Cost saving
Assuming the same benefit of 
chemotherapy for everyone = 40%
(CiC 
information 
has been 
removed)
(CiC 
information 
has been 
removed)
12.93 8419 12.85 8766 28,833 Cost saving
Assuming the same benefit of 
chemotherapy for everyone = 30%
(CiC 
information 
has been 
removed)
(CiC 
information 
has been 
removed)
12.87 8557 12.81 8867 39,579 Cost saving
NPI distribution from the Holt et al. 
study77
13.06 10,911 12.97 8318 12.83 8816 9007 Cost saving
NPI distribution from the TransATAC 
trial
13.06 10,911 12.97 8318 12.83 8816 9007 Cost saving
Cost for IHC4 = £100 13.06 10,911 12.97 8268 12.83 8816 9007 Cost saving
Cost for IHC4 = £200 13.06 10,911 12.97 8368 12.83 8816 9007 Cost saving
Cost for IHC4 = £300 13.06 10,911 12.97 8468 12.83 8816 9007 Cost saving
Cost for IHC4 = £400 13.06 10,911 12.97 8568 12.83 8816 9007 Cost saving
G-CSF is given to all patients 
receiving chemotherapy
13.06 11,416 12.97 8701 12.83 9305 9077 Cost saving
Five cycles of G-CSF (instead of 
three)
13.06 11,023 12.97 8403 12.83 8924 9023 Cost saving
Five cycles of chemotherapy 
(instead of three)
13.06 10,674 12.97 8139 12.83 8586 8974 Cost saving
100% echocardiogram (instead of 
25%)
13.06 10,926 12.97 8330 12.83 8830 9009 Cost saving
Increase in the cost of 
chemotherapy by 25%
13.06 11,267 12.97 8588 12.83 9160 9056 Cost saving
Reduction in the cost of 
chemotherapy by 25%
13.06 10,555 12.97 8049 12.83 8471 8958 Cost saving
Increase in the cost of endocrine 
therapy by 25%
13.06 11,727 12.97 9132 12.83 9627 9031 Cost saving
Reduction in the cost of endocrine 
therapy by 25%
13.06 10,094 12.97 7504 12.83 8005 8984 Cost saving
Increase in the cost of distant 
metastases by 25%
13.06 11,403 12.97 8862 12.83 9421 8519 Cost saving
Reduction in the cost of distant 
metastases by 25%
13.06 10,419 12.97 7774 12.83 8210 9495 Cost saving
continued
TABLE 71 Results of the univariate sensitivity analysis for the primary analysis assuming that the new tests are offered 
only to women with a NPI score > 3.4 (continued)
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OncotypeDX IHC4 Clinical practice ICER (£)
QALYs Cost (£) QALYs
Cost 
(£) QALYs
Cost 
(£)
OncotypeDX 
vs. clinical 
practice
IHC4 vs. 
clinical 
practice
Cost of local recurrence – LCI 13.06 10,867 12.97 8269 12.83 8761 9051 Cost saving
Cost of local recurrence – UCI 13.06 10,963 12.97 8375 12.83 8879 8956 Cost saving
Terminal care cost – LCI 13.06 10,835 12.97 8235 12.83 8723 9082 Cost saving
Terminal care cost – UCI 13.06 10,986 12.97 8402 12.83 8908 8932 Cost saving
Utility values – LCI 12.44 10,911 12.35 8318 12.21 8816 9378 Cost saving
Utility values – UCI 13.59 10,911 13.49 8318 13.35 8816 8707 Cost saving
Increase of 25% in the decrement 
in utility for patients dying from 
breast cancer
13.06 10,911 12.97 8318 12.83 8816 8982 Cost saving
Decrease of 25% in the decrement 
in utility for patients dying from 
breast cancer
13.07 10,911 12.97 8318 12.84 8816 9032 Cost saving
Increase of 25% in the decrement 
in utility for patients receiving 
chemotherapy
13.06 10,911 12.97 8318 12.83 8816 9011 Cost saving
Decrease of 25% in the decrement 
in utility for patients receiving 
chemotherapy
13.07 10,911 12.97 8318 12.84 8816 9003 Cost saving
Utility for patients with AML = 0.5 13.06 10,911 12.97 8318 12.83 8816 9007 Cost saving
Utility for patients with AML = 0.6 13.07 10,911 12.97 8318 12.83 8816 9007 Cost saving
Risk of long-term adverse events 
multiplied by 2
13.04 10,913 12.95 8318 12.81 8817 9061 Cost saving
Risk of long-term adverse events 
multiplied by 3
13.02 10,915 12.93 8318 12.79 8818 9112 Cost saving
Proportion of patients classified 
as intermediate with the new test 
undergoing chemotherapy = low 
risk value
13.00 10,450 12.88 8045 12.83 8816 10,022 Cost saving
Proportion of patients classified 
as intermediate with the new test 
undergoing chemotherapy = high 
risk value
13.14 11,351 13.06 8565 12.83 8816 8371 Cost saving
LCI, lower confidence interval; UCI, upper confidence interval.
TABLE 71 Results of the univariate sensitivity analysis for the primary analysis assuming that the new tests are offered 
only to women with a NPI score > 3.4 (continued)
IHC4
The ICER for IHC4 was sensitive to a greater number of assumptions than the ICER for 
OncotypeDX, such as the time spent in the distant recurrence health state, the proportion of 
patients receiving chemotherapy under clinical practice and the cost of chemotherapy, but 
remained dominant compared with current clinical practice (i.e. provided more QALYs at a 
lower cost) except when the cost of IHC4 was raised to £400 (ICER of £1557 per QALY gained 
compared with current clinical practice).
Univariate sensitivity analyses: structural assumptions
In addition to input parameter values, we also examined the impact of two structural 
assumptions; the exclusion of IHC4 from the model and the impact of modelling patients as a 
single group (instead of as two separate subgroups: NPI score ≤ 3.4 and NPI score > 3.4)
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Assuming no further reclassification using IHC4 (exclusion of IHC4)
In this scenario we used data for OncotypeDX only (Table 49 presents data for the risk 
classification) from the TransATAC trial, assuming no further reclassification with IHC4. 
Therefore, we calculated the ICER only for OncotypeDX compared with current clinical practice. 
Patients were split into six possible risk categories (by NPI and OncotypeDX RS) compared with 
18 risk categories in the base-case model (by NPI, RS and IHC4).
The impact on the ICER was minimal: a reduction in the ICER from £26,940 (base case) to 
£25,574 per QALY gained assuming that the test is given to all women with ER+, LN–, HER2– 
early breast cancer or an increase in the ICER from £9007 (base case) to £10,218 per QALY 
gained assuming that the test is given only to women with a NPI score > 3.4.
The results of this scenario analysis suggested that our base-case ICER for OncotypeDX was 
minimally affected by our choice of model structure to accommodate the evaluation of IHC4.
Assuming no further reclassification using IHC4 (exclusion of IHC4) 
and modelling the entire cohort as a single group (not split by 
Nottingham Prognostic Index score)
A second structural assumption was tested, to examine to what extent not separating patients 
into two subgroups (by NPI score) affected the ICER. This assumes that patients with a NPI score 
≤ 3.4 and patients with a NPI score > 3.4 within the same risk group (defined by the new test) 
have the same prognosis.
Again, in this scenario analysis we used data for OncotypeDX only (Table 49 present data for the 
risk classification) from the TransATAC trial, assuming no further reclassification with IHC4. 
Therefore, we calculated the ICER only for OncotypeDX compared with current clinical practice. 
In this scenario analysis, the model separated patients into three possible risk categories (by RS 
only) compared with 18 risk categories in the base-case model (by NPI, RS and IHC4).
As expected, this assumption had a positive impact on the ICER (more favourable to 
OncotypeDX), with the ICER decreasing from £26,940 (base case) to £18,859 per QALY gained 
assuming that the test is given to all woman with ER+, LN–, HER2– early breast cancer.
By modelling the entire cohort as a single group, the prognostic value of current decision-making 
using clinicopathological parameters is ignored (i.e. that patients with a low NPI score have a 
lower risk of recurrence but are also less likely to receive chemotherapy compared with patients 
with a NPI score > 3.4 under current clinical practice). This is more favourable to OncotypeDX. 
This scenario assumes that patients within the defined RS risk group are homogeneous; however, 
it seems more likely that patients with a low RS and low NPI score would have a better prognosis 
than patients with a low RS and high NPI score.
Exploratory analysis: cost-effectiveness of treatment guided using Mammostrat
An exploratory analysis was carried out to assess the cost-effectiveness of Mammostrat compared 
with current clinical practice in England and Wales. The evidence base for Mammostrat is less 
well developed and a number of gaps were identified by the systematic review of the literature.
The EAG economic model was repopulated using the evidence for Mammostrat on 
reclassification (unpublished) and on the benefit of chemotherapy by risk group, but many 
assumptions were necessary because of limitations in the evidence available, especially on the 
impact of the test on decision-making and the extent to which the reclassification data used in 
the model were generalisable to the UK population. Further uncertainty is introduced given that 
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the EAG economic model uses distant recurrence as an outcome whereas most of the evidence 
for Mammostrat was drawn from analyses of DFS and therefore included all recurrences.
Data from a subset of the Ring et al. study125 were used in the economic model; however, (CIC 
information has been removed). There is major uncertainty regarding the robustness of the 
reclassification data from the subset of the Ring et al. study.125
Because of the limitations of the evidence base, any conclusions drawn from this analysis are 
subject to significant uncertainty.
Deterministic results
The proportion of women receiving chemotherapy was estimated to increase slightly with the 
use of Mammostrat compared with current clinical practice under our base-case assumptions 
(21.16% vs. 14.42% in all women; 34.27% vs. 33.60% in women with a NPI score > 3.4 with ER+, 
LN–, HER– early breast cancer).
Compared with current clinical practice, the incremental cost for treatment guided using 
Mammostrat was £26,598 per QALY gained under our base-case assumptions, assuming that the 
test is given to all women with ER+, LN–, HER– early breast cancer (Table 72).
If Mammostrat was given only to women with a NPI score > 3.4, the Mammostrat test was 
dominated (i.e. provided less benefits for a higher cost). (CIC information has been removed.) 
Probabilistic sensitivity analysis
The results of the PSA using 2500 iterations are shown in Table 73. Treatment guided using 
Mammostrat had a cost per QALY gained of £27,731 compared with current clinical practice 
if the test was offered to all women with ER+, LN–, HER2– early breast cancer. If the test was 
TABLE 72 Deterministic ICER for the exploratory analysis comparing Mammostrat with current clinical practice in 
women with ER+, LN–, HER– early breast cancer in England and Wales
 Mean cost (£) Mean QALYs ICER (£)
All patients
Mammostrat 9040 12.91 26,598
Current clinical practice 7699 12.86 
Patients with a NPI score > 3.4
Mammostrat 10,985 12.29 Dominated
Current clinical practice 9717 12.34 
TABLE 73 Probabilistic ICER (2500 iterations) for the exploratory analysis comparing Mammostrat with current clinical 
practice in women with ER+, LN–, HER2– early breast cancer in England and Wales
Mean cost (£) Mean QALYs ICER (£)
All patients
Mammostrat 9028 12.90 27,731
Current clinical practice 7683 12.85 
Patients with a NPI score > 3.4
Mammostrat 10,958 12.29 Dominated
Current clinical practice 9685 12.34 
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offered only to women with a NPI score > 3.4, Mammostrat was dominated (i.e. provided less 
QALYs at a higher cost).
The CEAC shows that treatment guided by Mammostrat score is a cost-effective strategy in 36.0% 
of cases when using a willingness-to-pay threshold of £20,000 per QALY gained (Figure 15) if the 
test were to be given to all women with ER+, LN–, HER2- early breast caner. The probability of 
treatment guided using Mammostrat being cost-effective at a £20,000 threshold was 18.0% if the 
test were to be offered only to women with a NPI score > 3.4 (Figure 16).
Univariate sensitivity analysis
The impact of key parameters was tested in univariate sensitivity analysis (Tables 74 and 75).
The ICER was very sensitive to the assumption about the proportion of patients who would 
receive chemotherapy based on the result of the new test if the test was offered to all women 
with ER+, LN–, HER2– early breast cancer (see Table 74). Assuming that no patients classified 
as low risk, 50% of patients classified as intermediate risk and 100% of patients classified as 
high risk would receive chemotherapy improved the ICER (more favourable to Mammostrat). 
Furthermore, the ICER was very sensitive to the assumption about the probability of 
chemotherapy in patients classified as intermediate risk with Mammostrat. The ICER ranged 
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FIGURE 15 Cost-effectiveness acceptability curve for the exploratory analysis comparing Mammostrat with current 
clinical practice assuming that the test is given to all women with ER+, LN–, HER2– early breast cancer in England 
and Wales.
FIGURE 16 Cost-effectiveness acceptability curve for the exploratory analysis comparing Mammostrat with current 
clinical practice assuming that the test is given only to women with a NPI score > 3.4.
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TABLE 74 Results of the univariate sensitivity analysis for the exploratory analysis assuming that the Mammostrat test 
is offered to all women with ER+, LN–, HER2– early breast cancer in England and Wales
Current clinical 
practice Mammostrat
ICER (£)QALYs Cost (£) QALYs Cost (£)
Base case 12.86 7699 12.91 9040 26,598
No adjustment for risk of recurrence 13.18 6995 13.23 8333 25,729
Interpretation based on assumption 12.86 7699 12.99 9115 10,407
Chemotherapy benefit = LCI 12.89 7626 12.96 8927 18,879
Chemotherapy benefit = UCI 12.78 7863 12.77 9329 Dominated
Time in DM = 50 months 12.91 8279 12.96 9593 27,324
Time in DM = 60 months 12.95 8820 13.00 10,110 28,071
Time in DM = 70 months 13.00 9319 13.04 10,586 28,830
Utility value in recurrence = 0.7 12.86 7699 12.91 9040 26,696
Utility value in recurrence = 0.75 12.87 7699 12.92 9040 27,028
Reduction in cost of DM of 20% 12.86 7216 12.91 8579 27,037
Reduction in cost of DM of 40% 12.86 7457 12.91 8810 26,817
Proportion of patients classified as intermediate with the new test undergoing 
chemotherapy = low-risk value
12.86 7699 12.92 8616 15,500
Proportion of patients classified as intermediate with the new test undergoing 
chemotherapy = high-risk value
12.86 7699 12.90 9287 34,959
DM, distant metastasis; LCI, lower confidence interval; UCI, upper confidence interval.
TABLE 75 Results of the univariate sensitivity analysis for the exploratory analysis assuming that the Mammostrat test 
is offered only to women with a NPI score > 3.4
Current clinical 
practice Mammostrat
ICER (£) QALYs Cost (£) QALYs Cost (£)
Base case 12.34 9717 12.29 10,985 Dominated
No adjustment for risk of recurrence 13.15 7962 13.12 9193 Dominated
Interpretation based on assumption 12.34 9717 12.28 10,955 Dominated
Chemotherapy benefit = LCI 12.43 9523 12.37 10,815 Dominated
Chemotherapy benefit = UCI 12.15 10,146 12.10 11,401 Dominated
Time in DM = 50 months 12.41 10,528 12.37 11,819 Dominated
Time in DM = 60 months 12.48 11,286 12.43 12,597 Dominated
Time in DM = 70 months 12.54 11,984 12.50 13,314 Dominated
Utility value in recurrence = 0.7 12.35 9717 12.30 10,985 Dominated
Utility value in recurrence = 0.75 12.37 9717 12.32 10,985 Dominated
Reduction in cost of DM of 20% 12.34 9040 12.29 10,291 Dominated
Reduction in cost of DM of 40% 12.34 9379 12.29 10,638 Dominated
Proportion of patients classified as intermediate with the new test undergoing 
chemotherapy = low-risk value
12.34 9717 12.30 10,471 Dominated
Proportion of patients classified as intermediate with the new test undergoing 
chemotherapy = high-risk value
12.34 9717 12.28 11,484 Dominated
DM, distant metastasis; LCI, lower confidence interval; UCI, upper confidence interval.
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from £15,500 to £34,959 if the test was given to all women assuming that the probability of 
receiving chemotherapy was the same as for patients classified as low and high risk respectively.
The ICER ranged from £18,879 to being dominated, using the lower and upper CIs from the 
Ross et al. study,126 for the impact of chemotherapy in terms of reduction in risk of recurrences if 
the test was offered to all women with ER+, LN–, HER2– early breast cancer. The ICER was not 
sensitive to the assumptions about utility values, management costs and the time spent in the 
recurrence health state (see Table 74).
The ICERs for the use of Mammostrat remained dominated under the assumptions examined in 
sensitivity analysis if the test was offered only to women with a NPI score > 3.4 (see Table 75).
Exploratory analysis: cost-effectiveness of treatment guided using MammaPrint
Finally, a second exploratory analysis was carried out assessing the cost-effectiveness of 
MammaPrint. Although there was a greater volume of evidence for MammaPrint than for 
Mammostrat, there were significant gaps in the evidence available and data that were used to 
populate the economic model were not considered to be robust. Therefore, any conclusions that 
can be drawn from this analysis are subject to considerable uncertainty.
Of note, particular concerns exist about the existing evidence on the benefit of chemotherapy as 
this is likely to have a significant influence on the ICER. Other issues include the lack of UK data 
and the fact that the data available were derived mainly from premenopausal women, limiting 
generalisability to the UK population. Because of these issues, the EAG was not sufficiently 
confident to provide a single ICER but presented a range of ICERs within the CIs for the benefit 
of chemotherapy, as this was considered to be the main uncertainty in the model. Note that, 
although a range of ICERs is presented, there were also significant concerns relating to the design 
of studies in the evidence base, and this range does not capture this uncertainty in study design.
More assumptions have been made within this analysis than within the other analyses and the 
results are highly uncertain.
Only a limited number of univariate sensitivity analyses were carried out because of the nature of 
the analysis. A sensitivity analysis was conducted assuming no additional costs for the NHS for 
the use of fresh tissue. A second sensitivity analysis was conducted assuming that 5% of patients 
classified as having good prognosis and 95% of patients classified as having poor prognosis 
received chemotherapy.
In addition to the univariate sensitivity analyses, we performed a multivariate sensitivity analysis 
examining different values for the benefit of chemotherapy.
No PSA was conducted as there was considered to be significant uncertainties in the studies used 
that could not be adequately captured in the economic model (for instance limitations in study 
design, differences in population included in the studies being younger and at higher risk than 
the population in the economic model, uncertainties that could not be adequately captured by the 
parameter uncertainty within the PSA).
MammaPrint offers the option of three complementary tests at no additional cost. ER, PR and 
HER2 status can be provided in the TargetPrint report. The impact of this has not been captured 
in the economic model.
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Deterministic results
Compared with current clinical practice, the incremental cost for treatment guided using 
MammaPrint was estimated to range between £12,240 and £53,058 per QALY gained, when 
the benefit of chemotherapy was varied by the upper and lower CI limits from the Knauer et al. 
study,110 assuming that the test was given to all women with ER+, LN–, HER2– early breast 
cancer. If MammaPrint was given only to women with a NPI score > 3.4, the ICER ranged 
between £6053 and £29,569 per QALY gained (Table 76).
Of note, the proportion of patients receiving chemotherapy increased significantly with the use 
of MammaPrint compared with current practice under our base-case assumptions: 44.18% vs. 
14.42% in all women and 90.31% vs. 33.60% in women with a NPI score > 3.4.
Univariate sensitivity analysis
As expected, assuming no additional cost for the NHS for the use of fresh tissue samples 
improved the ICER (more favourable to MammaPrint) (Table 77).
Assuming that 5% and 95% of patients classified as having good and poor prognosis with 
MammaPrint, respectively, received chemotherapy improved the ICER (more favourable to 
MammaPrint) (Table 78).
Multivariate sensitivity analysis examining the benefit of 
chemotherapy for risk of distant recurrence
An exploratory multivariate sensitivity analysis was conducted examining the effect of different 
values for the benefit of chemotherapy by risk group in terms of reduction in the risk of distant 
recurrence, assuming that MammaPrint is given to all women with ER+, LN–, HER2– early 
breast cancer (Table 79).
TABLE 76 Deterministic ICER for the exploratory analysis comparing MammaPrint with current clinical practice in 
women with ER+, LN–, HER2– early breast cancer in England and Wales
Mean QALYs Mean cost (£) ICER (£)
All patients
Current practice 13.49–13.39 6408–6629 12,240–53,058
MammaPrint 13.78–13.47 10,017–10,748
Patients with a NPI score > 3.4
Current practice 13.07–12.81 8281–8872 6053–29,569
MammaPrint 13.73–12.99 12,278–14,014
TABLE 77 Sensitivity analysis assuming no additional cost for the NHS for the use of fresh tissue samples
Mean QALYs Mean cost (£) ICER (£)
All patients
Current practice 13.49–13.39 6408–6629 11,392–49,838
MammaPrint 13.78–13.47 9767–10,498
Patients with a NPI score > 3.4
Current practice 13.07–12.81 8281–8,872 5675–28,131
MammaPrint 13.73–12.99 12,028–13,764
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This analysis suggested that, under base-case assumptions about the risk classification, risk of 
recurrence and interpretation of the test (i.e. which patients would receive chemotherapy), the 
ICER was < £20,000 per QALY gained if the relative risk reduction in the risk of recurrence was 
at least 60% for patients with a poor prognosis. However, the conclusions are likely to change if 
different assumptions are used for the risk classification or the proportion of patients who would 
receive chemotherapy according to MammaPrint.
Comparison of assumptions and results with the economic 
models submitted by Genomic Health and Clarient
Comparison with the economic model submitted by Genomic Health
The base-case ICER estimated by Genomic Health for treatment guided using OncotypeDX 
compared with current clinical practice was £6232 per QALY gained assuming that the test was 
given to all women with ER+, LN– or single node-positive and HER2+/– early breast cancer 
(Table 80).
The ICER estimated by the EAG was £26,940 (deterministic) assuming that the test was offered to 
all women with ER+, LN–, HER2– early breast cancer (see Table 80).
The main differences between the EAG’s economic assessment and the economic model 
submitted by Genomic Health for OncotypeDX are:
 ■ A shorter time horizon was used in the economic evaluation submitted by Genomic Health 
(30 years compared with lifetime in the EAG economic assessment). The starting age of 
the cohort was also different (58.3 years in the EAG economic assessment compared with 
60.6 years in the Genomic Health economic model). This partly explains the differences in 
the mean life-years and QALYs.
 ■ There were differences in the populations under assessment (LN–, HER– only in the EAG 
economic assessment compared with LN– or single positive node and HER2+/– in the 
economic model submitted by Genomic Health).
 ■ The risk of distant recurrence was taken from the TransATAC trial in the EAG economic 
model of a UK population treated with tamoxifen and anastrozole. Data from Paik et al.48 
from a US cohort treated with tamoxifen only was used in the Genomic Health economic 
model. Of note, the manufacturer examined a scenario using the risk of distant recurrence 
from the TransATAC trial and showed that the ICER increased from about £6232 to about 
£9160 per QALY gained.
 ■ The EAG assumed that the risk of distant recurrence was halved after 10 years and that no 
distant recurrences occurred after 15 years. The Genomic Health economic model assumed 
TABLE 78 Sensitivity analysis assuming that chemotherapy is given to 5% and 95% of patients classified as having 
good and poor prognosis with MammaPrint respectively
Mean QALYs Mean cost (£) ICER (£)
All patients
Current practice 13.49–13.39 6408 –6629 12,369–48,322
MammaPrint 13.78–13.48 10,045 –10,756
Patients with a NPI score > 3.4
Current practice 13.07–12.81 8281 –8872 6115–23,939
MammaPrint 13.63–12.99 11,705 –13,189
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TABLE 79 Multivariate sensitivity analysis varying the benefit of chemotherapy for patients classified as having a good 
or a poor prognosis with MammaPrint
ICER (£)
Reduction in the risk of distant recurrence in patients classified with a poor prognosis using MammaPrint
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0% Dominated Dominated 679,644 169,516 95,893 66,391 50,493 40,552 33,748 28,799 25,037 22,081 19,696 17,732 16,087 14,688 13,485 12,438 11,519 10,707 9983
5% Dominated Dominated 620,556 165,504 94,569 65,740 50,107 40,298 33,568 28,665 24,933 21,998 19,629 17,677 16,040 14,648 13,450 12,408 11,493 10,683 9962
10% Dominated Dominated 570,873 161,673 93,280 65,102 49,728 40,046 33,389 28,531 24,830 21,916 19,562 17,621 15,993 14,608 13,415 12,377 11,466 10,659 9940
15% Dominated Dominated 528,515 158,013 92,024 64,474 49,353 39,797 33,213 28,399 24,728 21,834 19,495 17,566 15,946 14,568 13,381 12,347 11,440 10,636 9920
20% Dominated Dominated 491,972 154,510 90,800 63,858 48,983 39,552 33,037 28,268 24,626 21,753 19,429 17,511 15,900 14,528 13,346 12,317 11,413 10,613 9899
25% Dominated Dominated 460,125 151,156 89,607 63,254 48,619 39,309 32,864 28,138 24,525 21,672 19,363 17,456 15,854 14,489 13,312 12,287 11,387 10,589 9878
30% Dominated Dominated 432,123 147,941 88,444 62,659 48,260 39,068 32,692 28,009 24,425 21,592 19,298 17,401 15,808 14,449 13,278 12,258 11,361 10,566 9857
35% Dominated Dominated 407,310 144,857 87,309 62,076 47,905 38,831 32,522 27,881 24,325 21,513 19,233 17,347 15,762 14,410 13,244 12,228 11,334 10,543 9836
40% Dominated Dominated 385,170 141,896 86,202 61,502 47,556 38,595 32,353 27,755 24,226 21,434 19,168 17,293 15,716 14,371 13,210 12,198 11,308 10,520 9816
45% Dominated Dominated 365,293 139,051 85,121 60,938 47,211 38,363 32,186 27,629 24,128 21,355 19,104 17,240 15,671 14,332 13,177 12,169 11,282 10,496 9795
50% Dominated Dominated 347,349 136,314 84,067 60,384 46,870 38,133 32,020 27,504 24,031 21,277 19,040 17,186 15,626 14,293 13,143 12,140 11,256 10,473 9774
55% Dominated Dominated 331,070 133,681 83,036 59,840 46,534 37,906 31,856 27,380 23,934 21,199 18,976 17,133 15,581 14,255 13,110 12,110 11,231 10,451 9754
60% Dominated Dominated 316,233 131,145 82,030 59,304 46,203 37,680 31,694 27,257 23,838 21,122 18,913 17,080 15,536 14,216 13,076 12,081 11,205 10,428 9733
65% Dominated Dominated 302,656 128,701 81,047 58,778 45,876 37,458 31,532 27,135 23,742 21,045 18,850 17,028 15,491 14,178 13,043 12,052 11,179 10,405 9713
70 Dominated Dominated 290,185 126,343 80,086 58,260 45,553 37,238 31,373 27,014 23,648 20,969 18,787 16,975 15,447 14,140 13,010 12,023 11,154 10,382 9693
75% Dominated Dominated 278,689 124,069 79,147 57,751 45,234 37,020 31,215 26,894 23,553 20,893 18,725 16,923 15,403 14,102 12,977 11,994 11,128 10,360 9672
80% Dominated Dominated 268,059 121,872 78,229 57,250 44,920 36,804 31,058 26,775 23,460 20,818 18,663 16,871 15,359 14,064 12,944 11,966 11,103 10,337 9652
85% Dominated Dominated 258,200 119,750 77,330 56,757 44,609 36,591 30,902 26,657 23,367 20,743 18,601 16,820 15,315 14,027 12,912 11,937 11,078 10,315 9632
90% Dominated Dominated 249,032 117,698 76,451 56,272 44,303 36,380 30,748 26,540 23,275 20,669 18,540 16,768 15,271 13,989 12,879 11,908 11,052 10,292 9612
95% Dominated Dominated 240,484 115,714 75,591 55,795 44,000 36,171 30,596 26,423 23,183 20,595 18,479 16,717 15,228 13,952 12,847 11,880 11,027 10,270 9592
100% Dominated Dominated 232,496 113,793 74,750 55,325 43,701 35,964 30,444 26,308 23,092 20,521 18,418 16,667 15,185 13,915 12,814 11,852 11,002 10,247 9572
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TABLE 79 Multivariate sensitivity analysis varying the benefit of chemotherapy for patients classified as having a good 
or a poor prognosis with MammaPrint
ICER (£)
Reduction in the risk of distant recurrence in patients classified with a poor prognosis using MammaPrint
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40% Dominated Dominated 385,170 141,896 86,202 61,502 47,556 38,595 32,353 27,755 24,226 21,434 19,168 17,293 15,716 14,371 13,210 12,198 11,308 10,520 9816
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60% Dominated Dominated 316,233 131,145 82,030 59,304 46,203 37,680 31,694 27,257 23,838 21,122 18,913 17,080 15,536 14,216 13,076 12,081 11,205 10,428 9733
65% Dominated Dominated 302,656 128,701 81,047 58,778 45,876 37,458 31,532 27,135 23,742 21,045 18,850 17,028 15,491 14,178 13,043 12,052 11,179 10,405 9713
70 Dominated Dominated 290,185 126,343 80,086 58,260 45,553 37,238 31,373 27,014 23,648 20,969 18,787 16,975 15,447 14,140 13,010 12,023 11,154 10,382 9693
75% Dominated Dominated 278,689 124,069 79,147 57,751 45,234 37,020 31,215 26,894 23,553 20,893 18,725 16,923 15,403 14,102 12,977 11,994 11,128 10,360 9672
80% Dominated Dominated 268,059 121,872 78,229 57,250 44,920 36,804 31,058 26,775 23,460 20,818 18,663 16,871 15,359 14,064 12,944 11,966 11,103 10,337 9652
85% Dominated Dominated 258,200 119,750 77,330 56,757 44,609 36,591 30,902 26,657 23,367 20,743 18,601 16,820 15,315 14,027 12,912 11,937 11,078 10,315 9632
90% Dominated Dominated 249,032 117,698 76,451 56,272 44,303 36,380 30,748 26,540 23,275 20,669 18,540 16,768 15,271 13,989 12,879 11,908 11,052 10,292 9612
95% Dominated Dominated 240,484 115,714 75,591 55,795 44,000 36,171 30,596 26,423 23,183 20,595 18,479 16,717 15,228 13,952 12,847 11,880 11,027 10,270 9592
100% Dominated Dominated 232,496 113,793 74,750 55,325 43,701 35,964 30,444 26,308 23,092 20,521 18,418 16,667 15,185 13,915 12,814 11,852 11,002 10,247 9572
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that the risk of distant recurrence was constant and ongoing over time. Therefore, there is the 
potential to avoid more recurrences in the Genomic Health economic model, resulting in a 
more favourable ICER.
 ■ The distribution of patients reclassified using OncotypeDX was derived from the TransATAC 
trial and cancer registry data in the UK in the EAG economic model, compared with 
the reclassification from the Holt et al. study78 in the Genomic Health economic model. 
However, the EAG had concerns regarding the representativeness of patients included in the 
Holt et al. study (discussed in Chapter 2, Results: OncotypeDX test).
 ■ The proportion of patients receiving chemotherapy under clinical practice was extracted 
from registry data in the EAG economic model, whereas in the Genomic Health economic 
model the proportion observed in the Holt et al. study78 was used. About 44% of women 
received chemotherapy in the manufacturer’s model under current clinical practice. Registry 
data (used in the EAG economic model) suggested that about 14.4% of women with ER+, 
LN–, HER2– breast cancer received chemotherapy (4.6% among women with a NPI score 
≤ 3.4 and 33.6% among women with a NPI score > 3.4). In the Genomic Health model, 
43.86% of patients subsequently classified as low risk by OncotypeDX received chemotherapy 
under current clinical practice. Because those patients have a low risk of distant recurrence 
and derive limited benefit from chemotherapy, this high estimate of the proportion of 
patients receiving chemotherapy in the comparator arm in this subgroup is favourable 
to OncotypeDX.
 ■ There were also structural differences between the models. The EAG modelled patients 
with a NPI score ≤ 3.4 and patients with a NPI score > 3.4 separately in order to conduct a 
subgroup analysis but also to account for the prognostic value of current decision-making 
based on clinicopathological parameters. Indeed, as shown in cancer registry data, patients 
with a low NPI score are less likely to receive chemotherapy than patients with a NPI score 
> 3.4. But at the same time, patients with a low NPI score have a lower risk of recurrence than 
patients with a NPI score > 3.4. The economic model submitted by Genomic Health assumed 
that the risk of recurrence was constant within each OncotypeDX RS group and used the 
Holt et al. study78 to estimate the proportion of patients who would receive chemotherapy. 
The Genomic Health approach ignores the prognostic value of current treatment 
decision-making using clinicopathological parameters and is therefore more favourable 
to OncotypeDX.
 ■ The EAG economic model further reclassified patients according to the IHC4 test results to 
also evaluate the cost-effectiveness of IHC4. A scenario analysis was conducted and showed 
that the impact of this structural assumption was minimal.
TABLE 80 Comparison of the EAG and Genomic Health estimates of the ICER for OncotypeDX compared with current 
clinical practice
Genomic Health 
economic model
EAG economic 
model
Cost (£) 12,735 9094
QALYs 11.54 13.54 
Life expectancy (years) 14.89 16.47 
Current clinical practice
Cost (£) 11,847 6519
QALYs 11.39 13.44 
Life expectancy (years) 14.73 16.35 
ICER (£) 6232 26,940
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 ■ The costs of chemotherapy and associated short-term adverse events were lower in the EAG 
economic assessment (£4866) than in the Genomic Health economic assessment (£7728).
 ■ There were also differences between the EAG economic assessment and the Genomic Health 
economic assessment in the utility estimates for the recurrence-free (0.824 vs. 0.78) and 
distant recurrence (0.685 vs. 0.60) health states. There were therefore more gains associated 
with the prevention of a distant recurrence in the Genomic Health economic model than in 
the EAG model (0.18 vs. 0.14).
 ■ Finally, the EAG economic model also included local recurrences and long-term adverse 
events due to chemotherapy.
To understand the differences in the results produced by the two models, the EAG economic 
model was repopulated using the same data inputs and assumptions as in the Genomic Health 
economic model. The results of this analysis are presented in Table 81. Each row shows the 
impact of introducing a new assumption in addition to the assumptions considered in the 
rows above.
Using a similar model structure as the Genomic Health economic model reduced the ICER in the 
EAG model from £26,960 to £18,859 per QALY gained (i.e. modelling three groups of patients 
according to the OncotypeDX RS classification, with no split by NPI score). When we further 
assumed a constant risk of recurrence over time using data from the Paik et al. study,49 the ICER 
decreased to £8311 per QALY gained. Finally, using similar assumptions/data inputs for the 
proportion of patients receiving chemotherapy, starting age, time horizon, utility values and costs 
as in the Genomic Health economic model reduced the ICER further to £6276 (compared with 
£6232 in Genomic Health economic model).
This analysis suggests that the differences in the results are mainly explained by the choice 
of model structure, assumptions about the risk of recurrence over time and data on risk 
reclassification and the proportion of patients receiving chemotherapy in clinical practice and 
after using the new tests.
TABLE 81 Changes in the ICER using Genomic Health assumptions in the EAG model
Assumption ICER (£)
Base case 26,940
Using data for OncotypeDX only (excluding IHC4) 25,574
Using data for OncotypeDX only (excluding IHC4) and modelling the entire cohort as a single group (no split by NPI score) 18,859
Assuming the risk of distant recurrence to be constant and ongoing 13,874
10-year risk of recurrence extracted from the Paik et al. study49 8311
Using the classification of patients from the Holt et al. study78 3953
Using the proportion of patients receiving chemotherapy from the Holt et al. study78 7032
Starting age = 60.55 years as per the Genomic Health model 7887
Time horizon = 30 years as per the Genomic Health model 8431
No long-term adverse events 8883
No local recurrences 9067
Cost of chemotherapy as per the Genomic Health model 6534
Utility values as per the Genomic Health model 6607
No terminal care cost or decrement in utility 7091
Cost of distant recurrence as per the Genomic Health model 6276
Note: Each row shows the impact of introducing a new assumption in addition to the assumptions considered in the rows above.
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Comparison with the economic model submitted by Clarient
(CIC information has been removed.)
Both analyses had to use a large number of assumptions given the gap in the evidence available 
and therefore need to be interpreted with caution. The EAG economic assessment also showed 
that the use of Mammostrat in women with a NPI score > 3.4 is dominated (i.e. provided less 
benefit at a higher cost). This may reflect limitations in the reclassification data used.
(CIC information has been removed.) Because of time and resource constraints, the late 
submission and the nature of this analysis (exploratory), only a brief comparison of the 
differences is presented for completeness:
 ■ Time horizon: 10 years in the Clarient economic assessment compared with lifetime in the 
EAG economic assessment.
 ■ Model structure: the EAG economic assessment is simple and assumes that patients enter the 
recurrence state and remain in that health state until death (using data from Thomas et al.155). 
The Clarient economic model is more complex and models recurrence-free survival and OS 
separately; however, a large number of assumptions have been made and inconsistencies 
were reported by the manufacturer.
 ■ (CIC information has been removed.)
 ■ (CIC information has been removed.)
Discussion of the independent economic model results
The four tests with the most well-developed clinical evidence base were considered within 
the economic evaluation. The EAG presented a primary analysis that compared OncotypeDX 
and IHC4 with current clinical practice in England and Wales. Based on the EAG model the 
incremental cost for adjuvant chemotherapy guided using OncotypeDX was estimated to be 
£29,503 per QALY gained compared with current clinical practice, assuming that the test 
was offered to all woman with ER+, LN–, HER2– early breast cancer under our base-case 
assumptions. This assumes that the test has predictive ability, that is, patients in the high-risk 
group benefit relatively more proportionally from chemotherapy than patients in the lower-risk 
groups. The IHC4 test was dominant compared with current clinical practice, providing more 
QALYs at a lower cost. The ICER for OncotypeDX increased substantially if the test was assumed 
to be prognostic only, that is, assuming the same relative reduction in the risk of recurrence 
from chemotherapy for all patients irrespective of the OncotypeDX RS classification. IHC4 
remained dominant under this assumption. In incremental analysis, when the treatment decision 
using OncotypeDX was compared with the treatment decision using IHC4, the ICER increased 
to £64,111 per QALY gained. In a second scenario, assuming that the test was offered only to 
women with a NPI score > 3.4, treatment guided using IHC4 remained dominant (i.e. provided 
more QALYs at a lower cost) compared with current clinical practice. The incremental cost 
for treatment guided using OncotypeDX was £9774 per QALY gained compared with current 
clinical practice and £31,125 per QALY gained compared with IHC4 (assuming that the test 
has predictive ability). However, it should be noted that the evidence base for IHC4 is less well 
developed and therefore the results should be interpreted with consideration of the additional 
assumptions used in the evaluation. One-way sensitivity analyses indicated that the ICER was 
most sensitive to the assumptions about the benefit reduction associated with chemotherapy, the 
time horizon of the model, the starting age of the cohort, the risk of recurrence and who would 
receive chemotherapy depending on the result of the test. A key area of uncertainty is whether 
the new tests are prognostic only or offer predictive ability.
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The economic analyses suggested that treatment guided using IHC4 has the greatest potential 
to be cost-effective at a willingness-to-pay threshold of £20,000. However, the evidence base for 
IHC4 is less well developed than the evidence base for OncotypeDX and a number of additional 
assumptions were needed to model the IHC4 test. The IHC4 test provides only a continuous risk 
score and so it was necessary to derive risk categories solely for the purposes of the analysis. No 
evidence exists on the predictive ability of the IHC4 test. The benefits of chemotherapy by IHC4 
risk group were based on indirect evidence, using the OncotypeDX classification; no additional 
benefit was assumed for IHC4. In the absence of evidence it was assumed that the likelihood 
of receiving chemotherapy based on the IHC4 risk classification would be the same as for 
OncotypeDX RS group, that is, that physicians would interpret the results from OncotypeDX and 
IHC4 in the same way.
For MammaPrint and Mammostrat there were significant gaps/limitations in the evidence 
available and data that have been used were not considered to be robust by the EAG. For this 
reason the analyses that were carried out evaluating the cost-effectiveness of MammaPrint and 
Mammostrat compared with current clinical practice in England and Wales were considered 
to be exploratory. Any conclusions that are drawn from these analyses are limited and further 
clinical evidence will be needed to make the findings more robust. The exploratory analyses 
suggested that the ICER for Mammostrat was around £28,000 per QALY gained compared with 
current clinical practice under our base-case assumptions, assuming that the test was offered to 
all women with ER+, LN–, HER2– early breast cancer, but Mammostrat was dominated if the test 
was given only to women with a NPI score > 3.4 (i.e. provided less QALYs at a higher cost). The 
second exploratory analysis indicated that MammaPrint has the potential to be cost-effective, but 
there were too many uncertainties in the data used and the design of the clinical studies to draw 
any definitive conclusions. Additionally, MammaPrint offers the option of three complementary 
tests at no additional cost. Notably, ER, PR and HER2 status can be provided in the TargetPrint 
report. This has not been captured in the economic model.
We did not perform an incremental analysis including the four tests evaluated because of the 
heterogeneity in the data used to populate the models and the differences in the quality of 
evidence between the tests. These differences are not adequately reflected in the PSA. Although 
this may be considered a limitation, we considered that including MammaPrint and Mammastrat 
within an incremental analysis could potentially be misleading given the gaps in the evidence 
base and significant issues relating to the quality of the data used to populate the economic 
models for these two tests.
No prospective studies that follow patients from initial diagnosis through to final health 
outcomes have been identified for any of the tests. Two prospective studies, MINDACT186 
(MammaPrint) and TAILORx187 (OncotypeDX), are ongoing but not due to report for several 
years. The economic model therefore needed to combine data from different sources to model 
how the results from the new tests translated into final outcomes in the form of QALYs. This 
resulted in significant limitations – data used in the model were not always based on UK 
populations and were not always specifically based on the ER+, LN–, HER2– population of 
interest. Differences in the ages of study populations and the endocrine and chemotherapy 
regimens used in the studies compared with those in the model introduced further uncertainty. 
In addition to the uncertainty in the data derived from each study, there are uncertainties 
introduced by using separate studies to represent different elements in the model.
These tests will have an impact on the health of patients only if the management of the patients 
changes. Evidence on how the results of tests change treatment decisions in practice in the UK 
is limited. We conducted two analyses, one assuming that the test was given to all women and 
one assuming that the test was given only to women with a NPI score > 3.4, as a proxy for those 
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at intermediate risk. This group reflects patients for whom the decision whether or not to given 
chemotherapy is most uncertain. The definition of the subgroup is relatively simplistic, because 
of data limitations, and may include women at the top end of the NPI distribution who are likely 
to receive chemotherapy despite the result of the test. It does, however, suggest that generally the 
cost-effectiveness may be improved by focusing the test in these women (although this was not 
the case in the exploratory analysis for Mammostrat).
Our analysis focused on women with ER+, LN–, HER2– early breast cancer as this population is 
supported by the most robust clinical evidence. Other populations, such as women with a small 
number of positive nodes, might also benefit from the tests, and results are likely to change if the 
population appraised is extended to women with ER– cancer or with positive nodes.
Evidence used in the model was generally identified from the systematic review of the literature 
on the clinical validity and utility of each of the tests. However, for the purpose of the economic 
analysis of patients with ER+, LN–, HER2– early breast cancer in a UK population the published 
data were sometimes not available in the right format for use within the economic model or 
the necessary data were not presented. Therefore, on occasion, once we had identified the most 
relevant data source from the review, we sought additional data to populate the economic 
model. For instance, data on the risk reclassification and risk of recurrence for patients treated 
with endocrine therapy in the UK for the main analysis were taken from a reanalysis of a study 
(TransATAC trial79) identified through the systematic review of the literature, as the published 
data were not specific to the population of interest (ER+, LN–, HER2– early breast cancer). 
Similarly, data on the impact of OncotypeDX on decision-making were taken from a reanalysis 
of the Holt et al. study78 (identified through the systematic review), to provide data specific to 
the population of interest, that is, ER+, LN–, HER2– early breast cancer. On occasion, data 
outside the systematic review were used, such as UK registry data to inform the current level of 
chemotherapy in the UK.
Despite the strength of the analysis, there were a number of significant limitations, mostly 
because of the gaps in the evidence base, the quality of the evidence base in some instances 
(e.g. issues with trial design) and the necessity to use data taken from non-UK populations 
when UK data were not available. There were particular concerns with the data used to reflect 
the benefit associated with chemotherapy by risk group for the new tests. Methodological flaws 
have been highlighted for the study on the benefits of chemotherapy by MammaPrint risk 
group. Limitations were identified with the data for OncotypeDX and Mammostrat in terms 
of how this evidence should be generalised to the UK population and potential biases in the 
evidence base. In addition, the evidence base on the proportion of patients who would receive 
chemotherapy after classification with the new tests had limitations or was lacking (in the case 
of IHC4 and Mammostrat). OncotypeDX was the only test for which there was evidence from a 
UK setting; however, there were concerns relating to this study, notably the small sample size and 
the possibility that patients were not representative of typical patients seen in clinical practice 
in England and Wales. Univariate sensitivity analyses indicated that the ICER was sensitive to 
the assumptions about the benefit reduction associated with chemotherapy and the proportion 
of patients who would be offered chemotherapy after categorisation with the new test. There are 
particular uncertainties relating to whether or not physicians would recommend chemotherapy 
to patients classified as intermediate risk with the new tests, as the evidence for the benefit of 
chemotherapy (reduction in the risk of recurrence) in these patients is less clear. Data from 
the TransATAC trial show that about 26% and 10% of ER+, LN–, HER– women were classified 
as intermediate risk with OncotypeDX and IHC4 respectively (predicted risk of recurrence 
between 10% and 20%). The ICER for Mammostrat was very sensitive to the assumption about 
the proportion of patients who would receive chemotherapy in the intermediate-risk group. 
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The ICER for OncotypeDX improved if more chemotherapy was given to this intermediate-risk 
group. In addition, in the evaluation of OncotypeDX and IHC4, the data on risk classification 
using OncotypeDX followed by further reclassification using IHC4 relied on a very small number 
of patients and therefore biases could have been introduced.
The exploratory analyses were subject to further uncertainties in the data. The exploratory 
analysis for Mammostrat used data from a subset of patients included in the Ring et al. 
study;125 however, the tests (CIC information has been removed). The exploratory analysis for 
MammaPrint used a wide range of assumptions and it was not possible for the EAG to present an 
ICER with confidence given the lack of robustness of the data that have been used to populate the 
economic model.
No direct comparison between tests was possible because of the differences in quality of the 
evidence. This therefore limits the conclusions that can be drawn from the analysis.
Further uncertainties were introduced into the analysis because of the wide range of assumptions 
needed in the EAG model. These include:
 ■ The use of UK cancer registry data to inform the proportion of patients receiving 
chemotherapy in the current practice arm. The registry data allowed us to capture decision-
making based on real clinical practice, using current methods (a mix of the NPI, Adjuvant! 
Online and/or other prognostic tools). It should be noted that NPI was not used as a 
comparator in the economic model. NPI was used only to separate patients into two groups 
– those with a NPI score ≤ 3.4 and those with a NPI score > 3.4. This was to allow a subgroup 
analysis to be conducted and to allow the model to take into account, at least in part, the 
prognostic value of the treatment decision using clinicopathological parameters. This is a 
limitation given that it may be less discriminatory than current practice. The decision was 
taken to model current practice in this way as the evidence available for each test did not 
reflect the current level of chemotherapy given in the UK. Furthermore, data from only two 
registries were used (WMCIU and ECRIC), the results are generalisable only if the centres 
included in these two regions are considered to be representative of the centres across 
England and Wales.
 ■ The original RS groups were used for OncotypeDX to define patients who are at low, 
intermediate or high risk of distant recurrence. However, cut-offs have been modified in the 
ongoing TAILORx trial. The impact of these revised cut-offs cannot be assessed.
 ■ It was assumed that the IHC4 test was reproducible; however, there are issues relating to the 
reproducibility of the Ki-67 element of the test, which would need to be addressed in the UK 
before this test could be used by local laboratories in clinical practice.
 ■ The risk of distant recurrence was assumed to be constant over the first 10 years. It is likely 
that the risk increases over the first few years and then decreases with time. Likewise, we 
assumed that the risk reduced after 10 years and that no recurrence would occur after 
15 years. This is a simplifying assumption.
 ■ The impact of locoregional recurrences was included in the model by applying a one-off cost 
and a decrement in utility to a proportion of patients developing distant recurrence. This is 
simplistic but this approach was used because of data limitations.
 ■ Long-term adverse events were modelled using simplifying assumptions. Only AML was 
included as a long-term adverse event after chemotherapy. The prevalence of CHF following 
chemotherapy with FEC may be higher but clinical opinion suggested that modelling CHF is 
complex as some patients remain asymptomatic or have a reversible disease and this would 
have added further uncertainty into the model.
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 ■ A significant proportion of the total cost of chemotherapy (including treatment of adverse 
events and prevention of febrile neutropenia) is made up of the cost of treatment to prevent 
febrile neutropenia, which is more uncertain than the cost of the drug or the administration 
costs. We assumed that 25% of women receive G-CSF for the secondary prevention of 
neutropenia after chemotherapy in the UK based on clinical opinion.
 ■ In the comparator arm (current clinical practice), the probability of receiving chemotherapy 
was based on registry data. It was assumed that the probability of receiving chemotherapy 
was the same irrespective of the reclassification of patients with the new test into the low-, 
intermediate- or high-risk group. This is likely to be conservative.
In addition, there are potentially some limitations relating to the structure of the model. 
The model is static in that individuals are separated into risk groups and are assumed to be 
homogeneous with similar characteristics on average within these groups. For the main analysis, 
we separated individuals according to NPI, OncotypeDX and IHC4 to allow us to model IHC4 
using direct evidence against OncotypeDX. Revised structural assumptions were examined in 
sensitivity analysis: removing IHC4 from the analysis and therefore separating patients according 
to NPI and OncotypeDX only or assuming no further reclassification using IHC4 (exclusion 
of IHC4) and modelling the entire cohort as a single group (no split by NPI). Results of the 
scenario analysis suggested that our base-case ICER for OncotypeDX was minimally affected 
by our choice of model structure to accommodate the evaluation of IHC4. Results were more 
affected when modelling the entire cohort as a single group (no split by NPI and IHC4) as the 
prognostic value of current decision-making using clinicopathological parameters is ignored (i.e. 
that patients with a low NPI score have a lower risk of recurrence but are also less likely to receive 
chemotherapy than patients with a NPI score > 3.4 under clinical practice). It is unclear how the 
ICER would be affected if a different NPI cut-off was selected or if patients were separated using 
Adjuvant! Online or other prognostic tools. Additional limitations are imposed as we assumed 
that tests categorised patients into risk groups and that the groups are homogeneous. However, 
we did not have access to individual patient-level data to explore the heterogeneity within the risk 
groups or to explore using different thresholds to define the risk groups.
Finally, the model structure for the exploratory analyses for MammaPrint and Mammostrat was 
driven by the OncotypeDX analysis, which imposed some constraints in the data that have been 
used. No economic assessment was provided for PAM50, NPI+, Randox BCA, BluePrint and BCI 
because of significant gaps in the data.
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Chapter 4 
Assessment of factors relevant to the NHS 
and other parties
Central processing
Most GEP tests require samples to be sent to central processing laboratories and therefore 
time delays will be imposed on patient management pathways. This may also be an issue for 
Mammostrat, which is likely to require central processing. IHC tests and GEP tests that can be 
processed locally will provide faster results than assays that need to be processed centrally. There 
are also legal issues relating to possible litigation costs if errors occur when tests are performed 
in other legal jurisdictions. The impact of sending large numbers of blocks for central processing 
in terms of pathology services, tissue tracking, pathologist and technical staff time, data input on 
receipt, etc. would need to be explored.
Impact on NHS services
Tests that require the use of fresh tissue raise particular service configuration issues. Fresh 
tissue collection is not routine in the NHS and so there will be additional costs that would be 
considerable at hospitals where the dissection facilities are already filled to capacity (which is 
likely to be a significant proportion of hospitals) and where explicit staffing for collection of 
fresh tissue is not in place. Discussion with local clinicians indicated that capital costs could be 
at least £75,000 per hospital if new dissection tables are required, which is likely to be the case 
in many hospitals. If routine fresh tissue sampling is not in place (only a few research centres 
currently have this working arrangement) then additional staff costs for biomedical scientists and 
histopathologists will be incurred. If a full fresh tissue service was required and needed to cover 
all theatre time then additional staff costs could be £20,000–50,000 per year (Simon Cross, July 
2011, personal communication).
The impact on the chemotherapy service has not been considered. For instance, if additional 
women were prescribed chemotherapy as a result of these tests, NHS capacity (compared with 
current practice) may need to expand. Services are typically already running at full capacity and 
therefore this might mean delays in chemotherapy or the need for additional staff and beds.
Quality issues relating to immunohistochemistry tests
Lack of reproducibility of IHC assays will need to be taken into account when considering 
the use of IHC4 in local UK laboratories. Differences in IHC values can occur as a result of 
variability in several factors, including fixation, antigen retrieval, reagents and interpretation. 
A quality assurance programme will need to be considered, such as the UK National External 
Quality Assessment Service (NEQAS), given that these have in the past been shown to lead 
to marked improvements in between-laboratory agreement. Validation of the IHC4 score 
when carried out in a range of local laboratories is required. A guideline is currently in 
preparation (Professor Mitch Dowsett, July 2011, personal communication) to help standardise 
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the measurement of Ki-67. Guidelines will need to be developed through NEQAS to ensure 
consistency among all participating UK laboratories.
Patient anxiety
There is evidence to suggest that OncotypeDX improves patient anxiety levels and decisional 
conflict. This was based on a small study of 89 assessable patients with ER+, LN– breast cancer.76 
Before and after OncotypeDX testing, medical oncologists stated their adjuvant treatment 
recommendation and confidence in it, and patients indicated their treatment choice. Changes 
in oncologist treatment recommendations were evaluated and patients completed measures for 
decisional conflict, anxiety and quality of life. Such improvements in patient anxiety levels are not 
taken into account within the economic analysis.
Classification of patients in the intermediate group
Some GEP and expanded IHC tests classify a proportion of patients into an intermediate-
risk category. Evidence for the benefit of chemotherapy (in terms of reduction in the risk 
of recurrence) in these patients is less clear. It is also less clear whether or not physicians 
would recommend chemotherapy in addition to endocrine therapy for patients classified as 
intermediate risk with GEP or expanded IHC tests. This question is being addressed by the 
ongoing TAILORx187 study for OncotypeDX.
Categorical risk compared with continuous risk score
Some of the GEP and expanded IHC tests (MammaPrint, Mammostrat) classify patients into 
risk group only (categorical) and do not calculate a continuous risk score. This is likely to be less 
informative than a continuous risk score as it does not differentiate between patients who are at 
the lower end of the distribution and those who are at the upper end or those who are borderline.
Failure of the test/wrong results
Immunohistochemistry-based tests offer the advantage that biomarker expression is interpreted 
in situ, which allows the pathologist to ensure that the test is not confounded by expression 
of biomarkers in non-tumour tissue. Gene expression assays that homogenise the tissue and 
measure biomarkers that may be expressed in stroma run a greater risk of confounding the 
interpretation of biomarker expression levels.
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Chapter 5 
Discussion
Statement of principal findings
Clinical effectiveness
Thirty studies reporting data on analytical validity, clinical validity or clinical utility of the nine 
included GEP and expanded IHC tests for breast cancer were identified. Thirty-four studies (on 
OncotypeDX and MammaPrint) that had been included in previous systematic reviews were also 
retrieved and summarised.
OncotypeDX
The OncotypeDX evidence is the furthest along the validation pathway compared with other 
similar tests and the evidence base, in particular in relation to the clinical validity (prognostic 
ability) of the test, was consider to be reasonably sound. This review has identified recent studies 
supporting the clinical validity of the test. These are generally of moderate to high quality. Our 
findings indicate that there are no prospective studies reporting the impact of OncotypeDX on 
long-term outcomes such as OS. Four studies on the impact of OncotypeDX on decision-making 
indicate that the use of OncotypeDX leads to changes in decision-making for 31.5–38% of 
patients, but only one of these studies relates to the UK setting. Two studies on the predictive 
benefit of the test were identified: one was based on the same data used in the Paik et al. study48 
and one included LN+ patients. The first evidence relating to improvements in quality of life 
and reductions in patient anxiety as a result of using the test has been reported, but this is based 
on small patient numbers and further evidence is required. Key gaps in the evidence remain 
and few of the studies were considered to be of high quality (n = 3). A number of studies in the 
current review were judged to provide moderate-quality (although retrospective) evidence for 
OncotypeDX (n = 9). Further direct evidence of clinical utility of OncotypeDX is still required. 
This will be addressed by the ongoing TAILORx trial.
MammaPrint
The evidence base for MammaPrint, in particular in relation to the prognostic ability of the test, 
is developing but is based on small sample sizes (n ≤ 272). The evidence for MammaPrint is less 
robust than that for OncotypeDX. No MammaPrint studies used RCT data, the sample sizes were 
small and heterogeneous patient populations were studied, making generalisation of the findings 
difficult. None of the studies used UK-based patients and the data were all based on cohort 
studies. The test appears to be prognostic at 5 years although the validity of the test to predict 
longer-term outcomes does not seem to have been established. Robust evidence of clinical utility 
is needed as it is not yet clear to what extent the use of the MammaPrint test will change the 
management of patients. It is also unclear to what extent MammaPrint risk groups are predictive 
of chemotherapy benefit or how the use of MammaPrint will improve patient outcomes through 
increases in disease-free and overall survival. The evidence for MammaPrint to date is mainly 
derived from premenopausal women and this evidence may not be generalisable to an older 
population given that younger women are likely to be at higher risk of recurrence and are more 
likely to be classified as having poor prognosis using MammaPrint.
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PAM50
The PAM50 evidence base, in particular in relation to the prognostic ability of the test, is 
developing. The limitations of this evidence are based primarily on the fact that currently most of 
the evidence is unpublished (ARUP Laboratories, Salt Lake City, UT, USA).
Mammostrat
The evidence base for Mammostrat is developing and the evidence relating to the prognostic 
ability of the test is of reasonably high quality. These initial studies include a large sample size 
and one study provided external validation of the test in a UK population. A further study 
provides evidence relating to the benefit of chemotherapy by risk group, indicating that both 
low- and high-risk groups benefit whereas those in the moderate-risk group do not. Further 
evidence is needed to clarify these findings. Further evidence of analytical validity and clinical 
utility is also required. In particular, there was no published evidence on reclassification of risk 
groups compared with conventional risk classifiers and no evidence on the impact of the test on 
decision-making.
IHC4
The evidence base for IHC4 is currently limited to one study of clinical validity (prognostic 
ability). However, this evidence for clinical validity is relatively strong given that the test has 
been developed using a large cohort of patients and has been validated in an external cohort. 
This study allowed direct comparison with OncotypeDX. Further evidence is required on the 
analytical validity and clinical utility of IHC4.
BluePrint, Breast Cancer Index, Nottingham Prognostic Index plus 
and Randox Breast Cancer Array
The evidence base for the MammaPrint and BluePrint test combined (use of the BluePrint test for 
subtyping following the MammaPrint test), BCI, NPI+ and Randox BCA is limited to date and 
no firm conclusions can be drawn about these tests.
Cost-effectiveness
The four tests with the most well-developed clinical evidence base were considered within 
the economic evaluation. The EAG presented a primary analysis that compared OncotypeDX 
and IHC4 with current clinical practice in England and Wales. Based on the EAG model the 
incremental cost for adjuvant chemotherapy guided using OncotypeDX was estimated to be 
£29,503 per QALY gained compared with current clinical practice, assuming that the test 
was offered to all woman with ER+, LN–, HER2– early breast cancer under our base-case 
assumptions (assuming the test to be predictive of the benefit of chemotherapy). The IHC4 test 
was dominant compared with current clinical practice, providing more QALYs at a lower cost. 
The ICER for OncotypeDX increased substantially if the test was assumed to be prognostic only, 
that is, assuming the same relative reduction in the risk of recurrence from chemotherapy for 
all patients irrespective of the OncotypeDX RS classification. IHC4 remained dominant under 
this assumption. In incremental analysis, when the treatment decision using OncotypeDX was 
compared with that using IHC4, the ICER increased to £64,111 per QALY gained. In a second 
scenario, assuming that the test was offered only to women with a NPI score > 3.4, treatment 
guided using IHC4 remained dominant (i.e. provided more QALYs at a lower cost) compared 
with current clinical practice. The incremental cost for treatment guided using OncotypeDX was 
£9774 per QALY gained compared with current clinical practice and £31,125 per QALY gained 
compared with IHC4 (assuming that the test had predictive ability). A key area of uncertainty is 
whether tests are prognostic or also offer predictive ability.
It should be noted that the evidence base for IHC4 is less well developed and therefore the 
results of this analysis should be interpreted with consideration of the assumptions used in 
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the evaluation. One-way sensitivity analysis indicated that the ICER was most sensitive to the 
assumptions about the benefit reduction associated with chemotherapy, the time horizon of the 
model, the starting age of the cohort, the risk of recurrence and who would receive chemotherapy 
depending on the result of the test. IHC4 remained dominant compared with current clinical 
practice (i.e. provided more QALYs at a lower cost) except when the cost of IHC4 was raised to 
£400 (producing an ICER of £1557 per QALY gained compared with current clinical practice).
The IHC4 test provides a continuous risk score and so it was necessary to assume risk categories 
for the purposes of analysis. The benefits of chemotherapy by risk group were based on indirect 
evidence using the OncotypeDX classification; no additional benefit was assumed for IHC4. 
In the absence of evidence it was assumed that the likelihood of receiving chemotherapy based 
on the IHC4 risk classification would be the same as for OncotypeDX RS group, that is, that 
physicians would interpret the results from OncotypeDX and IHC4 in the same way.
There are other issues that need to be considered for these new tests, such as technical and 
logistical issues. The implementation of the OncotypeDX test will have an impact on pathology 
services, and issues of tissues tracking and additional pathologist and technical staff time should 
be considered. There are also issues in terms of turnaround time and legal issues relating to 
possible litigation costs in case of errors when tests are performed in another legal jurisdiction. 
There is no morphological correlation and tissues included in the analysis can be heterogeneous 
and the results will be affected by tumour cellularity. The accuracy of HER2 measurements with 
OncotypeDX also needs clarification. The IHC4 test, despite the lack of evidence, is promising 
and can be incorporated more easily into clinical practice and should provide results more 
quickly. However, there are also issues of variability for this test (time to fixation, different 
fixatives), and the need for standardisation of the method of Ki-67 assessment and the cut-off to 
be used. Quality assurance issues would need to be addressed before the implementation of IHC4 
in clinical practice.
For MammaPrint and Mammostrat there were significant gaps in the evidence available and 
data that have been used were not considered to be robust by the EAG. For this reason the 
analyses that were carried out evaluating the cost-effectiveness of MammaPrint and Mammostrat 
compared with current clinical practice in England and Wales were considered to be exploratory. 
Further clinical evidence will be needed to make the findings more robust.
Strengths and limitations of the assessment
Clinical effectiveness
The systematic review was conducted by an independent research team to a prespecified 
protocol using the latest evidence for nine GEP and expanded IHC tests. Extensive searches were 
undertaken to identify all literature relating to the clinical effectiveness of GEP and expanded 
IHC tests to guide the use of chemotherapy in breast cancer management.
The main limitation was the varied nature of the evidence base, relating to the study design for 
the evidence on clinical validity and clinical utility, making comparisons between tests difficult. 
None of the clinical studies had a prospective RCT design, although there are currently ongoing 
RCTs of both OncotypeDX and MammaPrint. Few studies, across all of the tests, used RCT data, 
with the majority of the evidence based on cohort designs. One of the most characteristic features 
of the studies across all tests was their heterogeneity. The studies varied considerably in their size, 
study design, patient populations and objectives. A large proportion of the studies were small 
and retrospective. Many studies used old archived tumour samples and some included the use 
of retrospective chart review to elicit treatment recommendations before and after testing. There 
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was a lack of standardised decision-making tools both within and between studies and non-
standardised methods of patient selection were used.
Studies relating to analytical validity, where available, appeared adequate, although for the 
majority of the tests the data are lacking and further studies are required. For MammaPrint 
and BluePrint, BCI, Randox BCA, Mammostrat, IHC4 and NPI+, no specific evidence for 
analytical validity has been reported, and for PAM50 the evidence for analytical validity is only in 
abstract form.
Economic evaluation
The economic assessment was conducted by an independent research team using the latest 
evidence for four GEP and expanded IHC tests. The EAG economic assessment has several 
strengths compared with previous evaluations. The evaluation used UK-specific data whenever 
possible, including for the baseline use of chemotherapy, risk of distant recurrence/recurrence 
and reclassification with the new test, so that its conclusions should be relevant to the UK setting. 
Notably, the EAG model used cancer registry data from ECRIC and WMCIU and data from the 
TransATAC trial, which are considered to provide the best reflection of current practice in the 
UK. The risk reclassification with OncotypeDX and IHC4 was taken from the TransATAC trial, 
and the risk of distant recurrence was taken from the same data source. The EAG economic 
assessment also considered an analysis of IHC4, which has not previously been undertaken, using 
direct evidence of the test compared with OncotypeDX. We also modelled women with a NPI 
score ≤ 3.4 and women with a NPI score > 3.4 separately to account for the prognostic value of the 
current treatment decision based on clinicopathological parameters and to allow a scenario to be 
conducted assuming that the test was offered to a subgroup of the population with a NPI score 
> 3.4. Extensive sensitivity analyses were undertaken to determine the impact of key parameter 
uncertainties on the cost-effectiveness ratio and a PSA was carried out to account for the joint 
uncertainty between parameters when appropriate.
Our analysis focuses on women with ER+, LN–, HER2– early breast cancer as this population 
is supported by the most robust clinical evidence. Other populations, such as women with 
a small number of positive nodes, might also benefit from the test, and results are likely to 
change if the population appraised is extended to women with ER– cancer or with positive 
nodes. We conducted two analyses, one assuming that the test was given to all women and one 
assuming that the test was given only to women with a NPI score > 3.4. This subgroup analysis 
was undertaken to explore the impact of targeting the tests at patients at intermediate risk. It is 
considered likely that the majority of women with a NPI score ≤ 3.4 would be considered low 
risk and would not receive chemotherapy under current practice or using the new tests and 
therefore the test would have a limited impact on the management of these women. Although 
this is relatively simplistic, and includes women at the top end of the NPI distribution who are 
likely to receive chemotherapy despite the result of the test, it does indicate that generally the 
cost-effectiveness may be improved by focusing the test in these women (although this was not 
the case in the exploratory analysis for Mammostrat).
Despite the strength of the analysis there were some significant limitations, mostly because of 
gaps in the evidence base, the quality of the studies within the evidence base in some instances 
and the necessity of using data from non-UK populations when UK data were not available. 
There were particular concerns over the data used to reflect the benefit associated with 
chemotherapy for the categorisation of patients with the new tests. In addition, the evidence base 
on the proportion of patients who would receive chemotherapy after classification with the new 
tests had limitations or was lacking (in the case of IHC4 and Mammostrat). There are particular 
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uncertainties relating to whether or not physicians would recommend chemotherapy to patients 
classified as intermediate risk with the new tests, as the evidence for the benefit of chemotherapy 
(reduction in the risk of recurrence) in these patients is less clear.
The exploratory analyses for Mammostrat and MammaPrint were subject to further uncertainties 
in the data. The exploratory analysis for Mammostrat used data from a subset of patients 
included in the Ring et al. study;125 however, the tests (CIC information has been removed). The 
exploratory analysis for MammaPrint used a wide range of assumptions and it was not possible 
for the EAG to present an ICER with confidence given the perceived lack of robustness of the 
data that have been used to populate the economic model.We did not perform an incremental 
analysis because of these differences in the quality of evidence between tests. These differences are 
not adequately reflected in the PSA. Although this may be considered a limitation, we considered 
that including MammaPrint and Mammastrat within an incremental analysis could potentially be 
misleading given the gaps in the evidence base and significant issues relating to the quality of the 
data used to populate the economic models for these two tests.
Uncertainty was increased by the model structure used and the significant number of 
assumptions that had to be made in the EAG model. These are discussed in Chapter 3, Discussion 
of the independent economic model results. Extensive sensitivity analyses were carried out to 
determine the factors that impacted most on the ICER and to determine why the results of our 
model differed from those of other UK evaluations. The EAG model used UK data whenever 
possible and modelled patients with low and intermediate or high NPI separately. The results of 
the EAG analysis for OncotypeDX suggest that the ICER may be higher than that reported by the 
manufacturer’s model. The difference in the ICER between the two models is attributable to the 
differences in model structure, the assumptions that have been made about the risk of recurrence 
and the different data sources used. The model developed by the manufacturer was built on data 
on changes in treatment decisions taken from the Holt et al. study.77 However, there are issues 
with this study, particularly that patients might not be representative of patients seen in clinical 
practice in the UK. This study indicated that 36.4% of patients with ER+, LN–, HER2– breast 
cancer (based on EAG analysis) were offered chemotherapy under current clinical practice, 
which appears high. Cancer registry data (used in the EAG economic model) suggested that 
about 14.4% of women with ER+, LN–, HER2– breast cancer currently receive chemotherapy 
(5% among women with a NPI score ≤ 3.4 and 34% among women with a NPI score > 3.4). The 
EAG model also used data from the TransATAC trial, which is considered to provide a more 
robust source of evidence for the risk of distant recurrence for patients treated with endocrine 
therapy in the UK. This also provided risk reclassification data in a large sample of patients and 
a direct comparison against IHC4. A key area of uncertainty is whether tests are prognostic only 
or offer predictive ability, that is, whether or not they identify high-risk patients who will benefit 
more in relative terms from reductions in the risk of recurrence following chemotherapy than 
low-risk patients.
A structural assumption was also examined in sensitivity analysis, modelling the population 
as a single group instead of separating patients by NPI. This was shown to influence the ICER. 
The explanation is that modelling patients as one group ignores the prognostic value of current 
treatment decision-making using clinicopathological parameters and therefore will be more 
favourable to the new test. The base-case analysis separated patients into two subgroups by NPI; 
it is unclear how the ICER would be affected if patients were separated using Adjuvant! Online.
No modelling work was undertaken on tests providing outputs in terms of intrinsic breast cancer 
subtype rather than risk of recurrence. This will be an important area for future modelling work.
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No economic assessment was provided for PAM50, NPI+, Randox BCA, BluePrint and BCI. This 
was because of significant gaps in the data and the uncertainty over how the tests would be used 
to inform clinical decision-making.
No direct comparison between tests was possible because of the differences in quality of the 
evidence. This therefore limits the conclusions that can be drawn from the analysis.
Uncertainties
The main uncertainties included:
 ■ The varied nature of the clinical evidence base, making comparisons between tests difficult.
 ■ The lack of prospective trials for the tests directly linking the use of the tests with final 
outcomes in terms of recurrence or survival. The economic model therefore needed to 
combine data from different sources to model how the results from the new tests translated 
into final outcomes in the form of QALYs, resulting in significant limitations – data used in 
the model were not always based on UK populations, were not always specifically taken from 
the ER+, LN–, HER2– population of interest and tended to be based on younger populations 
and populations treated with older, less effective, endocrine and chemotherapy regimens 
than are currently used.
 ■ The lack of data on the ability of the tests to classify patients in the relevant UK population.
 ■ The benefit of chemotherapy in terms of reduction in the risk of distant recurrence/
recurrence in patients classified as low, intermediate or high risk according to the new 
tests. Although evidence was available for three of the tests (OncotypeDX, MammaPrint 
and Mammostrat), there were limitations with these studies and it is also unclear how this 
evidence translates specifically to the ER+, LN–, HER2– population in the UK. A key area 
of uncertainty is therefore whether tests are prognostic only or are predictive of the benefit 
of chemotherapy.
 ■ The lack of UK data about how the tests will impact on decision-making, that is, the 
proportion of patients who would receive chemotherapy according to the risk classification 
with the new test. One small UK study was identified for OncotypeDX but this had some 
limitations. Also, there is a lack of evidence on how this impact is likely to differ between 
tests providing a continuous risk score and tests providing only a categorical risk label.
 ■ Some GEP and expanded IHC tests classify a proportion of patients into an intermediate-risk 
category. Evidence for the benefit of chemotherapy (reduction in the risk of recurrence) 
in these patients is not clear. It is more uncertain whether or not physicians would 
recommend chemotherapy in addition to endocrine therapy for patients classified as being at 
intermediate risk with GEP or expanded IHC tests.
 ■ How the test will be used in UK clinical practice, notably the group of women who are most 
likely to be offered the new tests.
 ■ The potential acceptance and adoption of the tests by UK physicians.
Other relevant factors
Our analyses do not capture the cost implications of any service reconfiguration issues. The use 
of fresh tissue by some tests would require a change in practice with regard to the handling of 
tissues by pathology laboratories. This would have major service reconfiguration and cost issues. 
The impact on the chemotherapy service has also not been considered. For instance, if additional 
women were prescribed chemotherapy as a result of these tests, NHS capacity (compared with 
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current practice) may need to expand. Services are typically already running at full capacity and 
therefore this might mean delays in chemotherapy or the need for additional staff and beds.
Most GEP tests require samples to be sent to central processing laboratories and therefore 
time delays will be imposed on patient management pathways. This may also be an issue for 
Mammostrat, which is likely to require central processing.
Currently, ER and HER2 testing is performed in most hospitals whereas PR testing is performed 
in a more limited number of hospitals. The potential introduction of the IHC4 test would require 
quality assurance issues to be addressed for the Ki-67 test. Because the IHC4 test is expected to be 
carried out locally, full validation would require evaluation of the IHC4 score when carried out 
in a range of local laboratories. A guideline is currently in preparation (Professor Mike Dowsett, 
July 2011, personal communication) to help standardise the measurement of Ki-67; however, 
reproducibility of the test would need to be confirmed and quality assurance programmes put 
in place.
Some of the tests (MammaPrint, Mammostrat) classify patients into risk group only (categorical) 
and do not calculate a continuous risk score. This is less informative than a continuous risk score 
as patients are classified into broad groups, for example low, intermediate or high. This does not 
allow differentiation between patients who are at the lower end or upper end of the distributions 
and those who are borderline; the impact that this additional knowledge would have on clinical 
decision-making is unclear.
Immunohistochemistry-based tests such as Mammostrat offer the advantage that biomarker 
expression is interpreted in situ, which allows the pathologist to ensure that the test is not 
confounded by expression of biomarkers in non-tumour tissue. Gene expression assays that 
require homogenisation of the tissue and measure biomarkers that may be expressed in stroma 
run a greater risk of confounding the interpretation of biomarker expression levels.
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Chapter 6 
Conclusions
Clinical effectiveness
Two of the tests (OncotypeDX and MammaPrint) have a reasonably large evidence base although 
there are some methodological weaknesses relating to this evidence in terms of the heterogeneity 
of patient cohorts and the retrospective study design. In addition, the MammaPrint evidence 
is typically based on observational data (small cohort studies) rather than randomised data, 
increasing the risk of selection bias. Further evidence is required on the clinical utility of all of the 
tests and specifically in UK-based populations.
The IHC4 and Mammostrat tests also demonstrate promise, presenting early evidence of the 
prognostic ability of the tests based on large UK-based validation cohorts. There is no predictive 
evidence for IHC4. PAM50 has an emerging evidence base; however, most of the evidence to date 
is in abstract form or unpublished. NPI+, Randox BCA, BluePrint and BCI have little evidence 
to date.
Cost-effectiveness
The economic analysis suggests that the use of the new tests may result in small increases in 
QALYs compared with currently used prognostic tools, but current limitations in the evidence 
base produce significant uncertainty in the results. A key area of uncertainty is whether tests are 
prognostic only or identify high-risk patients who will benefit from larger relative reductions in 
the risk of recurrence following chemotherapy than lower-risk patients. The economic analysis 
suggested that, of the four tests considered, treatment guided using IHC4 has the greatest 
potential to be cost-effective at a willingness-to-pay threshold of £20,000, given the low cost 
of the test. However, the evidence base to support IHC4 needs further research and the exact 
cost of using the test in the NHS needs to be investigated further. OncotypeDX has a more 
robust evidence base but further evidence on its impact on decision-making in the UK and the 
predictive ability of the test, specifically in an ER+, LN–, HER– population receiving current 
endocrine and chemotherapy regimens, is needed. For MammaPrint and Mammostrat there were 
significant gaps in the evidence available and the estimates of cost-effectiveness produced were 
not considered to be robust by the EAG.
Implications for service provision
The implications for service provision will vary by test. The impact of sending large numbers 
of blocks to central testing facilities in terms of pathology services, tissue tracking, pathologist 
and technical staff time, data input on receipt, etc. would need to be explored. The potential 
introduction of the IHC4 test would require quality assurance issues to be addressed for the 
Ki-67 element of the test. Currently, ER and HER2 testing is performed in most hospitals whereas 
PR testing is performed in a more limited number of hospitals. The use of tests requiring fresh 
tissue would be expected to have more major implications for service reconfiguration within 
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pathology departments in England and Wales as currently only a minority of centres in the UK 
have the structure and staff to handle fresh tissue.
Gene expression profiling tests requiring samples to be sent to central processing laboratories will 
impose time delays of up to 2–3 weeks on patient management pathways. This may also be an 
issue for Mammostrat, which is likely to require central processing.
Suggested research priorities
Future research priorities common to all tests include:
 ■ Studies investigating the predictive ability of GEP and expanded IHC tests. Do tests identify 
patients classified at high risk who benefit more in terms of larger relative reductions in risk 
of recurrence following chemotherapy than those classified at lower risk?
 ■ Prospective studies investigating how the tests will be used in clinical practice within the 
current decision-making process in England and Wales. Further evidence is needed for all of 
the tests demonstrating how they will be used in the current decision-making process and, 
especially, how this will impact on patient management decisions.
 ■ There is a need for pilot studies demonstrating how tests could be introduced in the UK and 
used within the current decision-making process and highlighting issues that this would 
raise for the NHS.
 ■ Studies investigating the use of continuous compared with categorical risk scores in terms of 
clinicians’ preferences and the potential differential impact on decision-making.
 ■ Studies providing evidence on how the subtyping information provided by some tests would 
impact on clinical decision-making in the UK.
 ■ The psychological impact of these tests needs more formal evaluation, in particular the 
impact of the test results on decision conflict, decision quality and regret for women 
considering chemotherapy. Quality of life data in women who have access to the tests or not 
would also be of value.
 ■ Further extension of the clinical evidence base to other populations who may benefit from 
the use of these tests, including patients with a small number of positive nodes.
Research specific to IHC4 includes:
 ■ Studies on the analytical validity of IHC4. There is a lack of data on the reproducibility of 
the IHC tests used to compose the IHC4 score, in particular the Ki-67 element. Studies need 
to investigate whether or not the incorporation of Ki-67 in clinical practice is feasible and 
whether or not results are reproducible.
 ■ Further studies to confirm the prognostic value of IHC4. There is also a need for studies 
directly comparing the use of IHC4 against current practice (NPI and Adjuvant! Online) in 
England and Wales.
Research specific to Mammostrat includes:
 ■ further evidence on analytical validity and risk reclassification.
Research specific to MammaPrint includes:
 ■ studies based on trial data – although the test is promising, most data are based on cohort 
studies or pooled analyses
 ■ research evidence to confirm the analytical validity and clinical validity of MammaPrint 
results based on FFPE rather than fresh samples.
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Appendix 1 
Search strategy
Update search for OncotypeDX and MammaPrint
Date limits: January 2009–May 2011
Filter: human studies only
1. exp Breast Neoplasms/
2. exp mammary neoplasms/
3. exp “Neoplasms, Ductal, Lobular, and Medullary”/
4. exp breast/
5. exp neoplasms/
6. 4 and 5
7.  (breast$ adj5 (neoplasm$ or cancer$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or 
sarcoma$ or dcis or ductal or infiltrat$ or intraductal$ or lobular or medullary)).mp.
8. (mammar$ adj5 (neoplasm$ or cancer$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or 
sarcoma$ or dcis or ductal or infiltrat$ or intraductal$ or lobular or medullary)).mp.
9. 1 or 2 or 3 or 6 or 7 or 8
10. MammaPrint.mp.
11. 70-gene.mp.
12. gene70.mp.
13. gene?seventy.mp.
14. seventy?gene.mp.
15. amsterdam profile.mp.
16. Oncotype.mp.
17. Oncotype DX.mp.
18. 21-gene.mp.
19. gene21.mp.
20. gene?twentyone.mp.
21. twentyone?gene.mp.
22. GHI Recurrence score.mp.
23. GHI-RS.mp.
24. 92-gene.mp.
25. gene92.mp.
26. gene?ninetytwo.mp.
27. ninetytwo?gene.mp.
28. RT-PCR (adj 5) 21.mp.
29. or/10–28
30. 9 and 29
Search for Randox Breast Cancer Array, BluePrint, PAM50, 
Breast Cancer Index, IHC4, Mammostrat, and NPI+
Date limits: 2002–May 2011
Filter: human studies only
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31. exp Breast Neoplasms/
32. exp mammary neoplasms/
33. exp “Neoplasms, Ductal, Lobular, and Medullary”/
34. exp breast/
35. exp neoplasms/
36. 4 and 5
37. (breast$ adj5 (neoplasm$ or cancer$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or 
sarcoma$ or dcis or ductal or infiltrat$ or intraductal$ or lobular or medullary)).mp.
38. (mammar$ adj5 (neoplasm$ or cancer$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or 
sarcoma$ or dcis or ductal or infiltrat$ or intraductal$ or lobular or medullary)).mp.
39. 1 or 2 or 3 or 6 or 7 or 8
40. Randox.mp.
41. Blueprint.mp.
42. 80-gene.mp.
43. gene80.mp.
44. gene?eighty.mp.
45. eighty?gene.mp.
46. PAM50.mp.
47. 50-gene.mp.
48. gene50.mp.
49. gene?fifty.mp.
50. fifty?gene.mp.
51. breast bioclassifier.mp.
52. Breast Cancer Index.mp.
53. Breast cancer gene expression ratio.mp.
54. 2-gene.mp.
55. Two-gene-index.mp.
56. 2-gene-index.mp.
57. Two?gene.mp.
58. gene?two.mp.
59. H?I.mp.
60. H:I.mp.
61. 5-gene.mp.
62. gene5.mp.
63. gene?five.mp.
64. five?gene.mp.
65. 7-gene.mp.
66. seven-gene.mp.
67. gene7.mp.
68. gene?seven.mp.
69. Theros.mp.
70. Biotheranostics.mp.
71. Theros breast cancer index.mp.
72. HOXB13$.mp.
73. homeobox?13$.mp.
74. interleukin?17B$.mp.
75. IL17BR.mp.
76. mammostrat.mp.
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77. five-biomarker-assay.mp.
78. IHC4.mp.
79. NPI+.mp.
80. Nottingham prognostic index plus.mp.
81. Nottingham prognostic index +.mp.
82. or/10–51
83. 9 and 52
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Appendix 2 
Example of the quality assessment checklist 
applied to included studies
A framework for assessing the internal validity of articles 
describing prognostic factor studies
Study feature Qualities sought
Sample of patients Inclusion criteria defined
Sample selection explained
Adequate description of diagnostic criteria
Clinical and demographic characteristics fully described
Representative
Assembled at a common (usually early) point in the course of their disease
Complete
Follow-up of patients Sufficiently long 
Outcome Objective
Unbiased (e.g. assessment blinded to prognostic information)
Fully defined
Appropriate
Known for all or a high proportion of patients
Prognostic variable Fully defined, including details of method of measurement if relevant
Precisely measured
Available for all or a high proportion of patients
If relevant, cut-off point(s) defined and justified 
Analysis Continuous predictor variable analysed appropriately
Statistical adjustment for all important prognostic factors
Intervention subsequent to inclusion in cohort Fully described
Intervention standardised or randomised
Source: Altman et al.37
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Appendix 3 
Assessment of multiple systematic reviews 
(AMSTAR): a measurement tool to assess the 
methodological quality of systematic reviews
Marchionni et al.33 Smartt34
1. Was an ‘a priori’ design provided?
The research question and inclusion criteria should be established before the conduct of the 
review
Yes Yes
2. Was there duplicate study selection and data extraction?
There should be at least two independent data extractors and a consensus procedure for 
disagreements should be in place
Yes Unclear
3. Was a comprehensive literature search performed?
At least two electronic sources should be searched. The report must include years and databases 
used (e.g. CENTRAL, EMBASE and MEDLINE). Keywords and/or MESH terms must be stated and 
where feasible the search strategy should be provided. All searches should be supplemented by 
consulting current contents, reviews, textbooks, specialised registers or experts in the particular 
field of study, and by reviewing the references in the studies found
Yes Yes
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
The authors should state that they searched for reports regardless of their publication type. The 
authors should state whether or not they excluded any reports (from the systematic review) based 
on their publication status, language, etc.
Yes Unclear
5. Was a list of studies (included and excluded) provided?
A list of included and excluded studies should be provided
Yes Yes (only for 
included studies)
6. Were the characteristics of the included studies provided?
In an aggregated form such as a table, data from the original studies should be provided on 
the participants, interventions and outcomes. The ranges of characteristics in all of the studies 
analysed, for example age, race, sex, relevant socioeconomic data, disease status, duration, 
severity or other diseases, should be reported 
Yes Yes
7. Was the scientific quality of the included studies assessed and documented?
‘A priori’ methods of assessment should be provided [e.g. for effectiveness studies if the author(s) 
chose to include only randomised, double-blind or placebo-controlled studies, or allocation 
concealment, as inclusion criteria; for other types of studies alternative items will be relevant]
Yes Yes
8. Was the scientific quality of the included studies used appropriately in formulating 
conclusions?
The results of the methodological rigor and scientific quality should be considered in the analysis 
and the conclusions of the review, and explicitly stated in formulating recommendations
Yes Yes
9. Were the methods used to combine the findings of studies appropriate?
For the pooled results, a test should be carried out to ensure that the studies were combinable, 
to assess their homogeneity (i.e. chi-squared test for homogeneity, I²). If heterogeneity exists a 
random-effects model should be used and/or the clinical appropriateness of combining should be 
taken into consideration (i.e. is it sensible to combine?)
Yes Yes
10. Was the likelihood of publication bias assessed?
An assessment of publication bias should include a combination of graphical aids (e.g. funnel 
plots, other available tests) and/or statistical tests (e.g. Egger regression test) 
No No
11. Was the conflict of interest stated?
Potential sources of support should be clearly acknowledged in both the systematic review and the 
included studies
Yes Yes
Source: Shea et al.38
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Appendix 4 
Summary of evidence relating 
to OncotypeDX
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Summary of evidence relating to OncotypeDX reported in the 
Marchionni et al. systematic review33
Analytical validity Clinical validity Clinical utility
Reported in four studies.39–42 
Technical and operational 
aspects were reported in 
two studies39,40 and test 
and assay variability and 
reproducibility were reported in 
three studies.40–42 Conclusion: 
Preanalytic issues relating to 
sample storage and preparation 
appeared to play a larger role 
than within-laboratory variation
Six studies reported overall 
success rate,41–44,48,49 which 
ranged from 78.9% to 98.9%
Not all of the studies provided 
detailed descriptions of the 
reasons for assay failure. 
When failures were reported 
they were mainly ascribed 
to an insufficient number of 
cancer cells in the specimens, 
poor RNA quality and, in a few 
cases, failure of the RT-PCR 
technique
Systematic review conclusion: 
Evidence existed for some of 
the operational characteristics 
of this test but there was 
limited evidence for the 
reproducibility of the test. 
Reasonable reproducibility 
of the test across different 
samples of the same block, 
and samples from different 
blocks. No direct evidence 
was available about the effect 
of sample preparation. There 
was indirect evidence that 
the overall success rate of 
extracting analysable mRNA 
was fairly high. Centralisation 
was considered to be a current 
strength of OncotypeDX with 
regard to reproducibility
Reported in four studies in relation to the determination of 
recurrence risk (prognosis)
Paik et al.42 studied the prognostic validity of OncotypeDX in an 
independent tamoxifen-treated population. The RS was shown 
to be significantly correlated with DFS (p < 0.001) and OS 
(p < 0.001). RS alone was a better predictor of distant recurrence 
at 10 years than traditional clinicopathological predictors
Esteva et al.44 failed to find a correlation between RS and distant 
breast cancer recurrence in untreated node-negative (LN0) 
patients. In the reverse of what was expected, well-differentiated 
tumours were correlated with poorer survival than higher-grade 
tumours
Cobleigh et al.43 reported that the RS score was significantly 
correlated with DRFS in a training set of LN0 patients. As this 
data set related to training and not validation, it was considered 
to present minimal evidential value
Habel et al.41 assessed the risk of breast cancer-specific mortality 
among women in a large case–control study of ER+, LN0 breast 
cancer patients treated with tamoxifen. The 10-year risk of death 
from breast cancer was 3% for patients with a low RS, 12% for 
patients with an intermediate RS and 27% for patients with a 
high RS. Multivariate analysis showed that RS and tumour size 
were independent risk predictors of breast cancer death in ER+, 
tamoxifen-treated patients (RR (relative risk) for RS (risk score) 
per 50 units = 7.6, p < 0.001) and untreated patients (RR (relative 
risk) for RS (risk score) per 50 units = 4.1, p < 0.001). The RS 
score also showed some prognostic value in ER– patients
Three posters describing studies that compared risk predictions 
provided by OncotypeDX assays and standard risk classification 
methods were reported.45,46,47 The data presented in these 
posters suggested that optimal predictions may come from 
a combination of gene expression tests and standard risk 
assessment methods
Systematic review conclusion: Fairly strong support for the 
clinical validity of the OncotypeDX test over and above standard 
clinical predictors in ER+, LN0 and tamoxifen-treated patients 
with a clear treatment indication for adjuvant chemotherapy. The 
authors noted, however, that it was not clear (1) how much the 
test added to the management of patients, (2) what proportion 
of patients would benefit from the use of the OncotypeDX test 
and (3) the stability of the observed risk categories in other 
populations, particularly those treated with current therapies
No published studies reported 
demonstrating clinical utility (direct 
evidence)
Two studies reported that provided 
preliminary evidence of the potential 
predictive power of OncotypeDX (indirect 
evidence)
Paik et al.,49 using specimens and data 
from an existing trial (NSABP B20), 
addressed the potential value of the RS 
in predicting chemotherapy benefit in a 
population of ER+, LN0 patients. This study 
compared a group of patients treated 
with tamoxifen and chemotherapy with a 
group of patients who were randomised 
to tamoxifen only. The RS was found to 
be correlated with chemotherapy benefit, 
defined in terms of 10-year DRFS, with 
a significant benefit from the use of 
chemotherapy in the high RS group 
(p = 0.001). However, in a multivariate 
analysis the benefit from chemotherapy was 
unclear because of large CIs in the low and 
intermediate RS risk groups
Oratz et al.48 reported that knowledge of 
the RS changed the clinicians’ treatment 
recommendations for 21% of patients 
and the actual administered treatment 
for 25% of patients. They did not report 
what the patients (or doctors) were told or 
understood about the risk of recurrence
Systematic review conclusion: the Paik 
et al. study49 represented the strongest 
evidence derived from already existing 
data regarding the clinical utility of the 
OncotypeDX test. This study also noted 
that, although prospective confirmation of 
these findings was required, the evidence 
provided reasonable justification in the 
interim for the use of the test by women in 
this specific population
Systematic review summary
The studies assessed in this review were heterogeneous in focus and quality. Few of the publications addressed technical aspects of the tests. A 
number of the reports focused on prognostic prediction. Only one study examined the prediction of treatment benefit. Most of the published evidence 
available for OncotypeDX was obtained using the marketed assay. Overall, the evidence presented for the clinical validity of OncotypeDX/21-gene 
signature in the systematic review was considered to have provided fairly strong support for the clinical performance of the test compared with 
standard predictors in a well-defined population (ER+, LN0, tamoxifen-treated women). It was considered that there was strong enough evidence of 
the clinical utility of the test in retrospectively collected data from one large clinical trial to provide reasonable justification for the interim use of the 
test in women in the same population group as the trial patients. There was little information about the impact of the test on clinical decision-making 
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Summary of evidence relating to OncotypeDX reported in the 
Smartt systematic review34
Clinical validity Clinical utility
Two studies reported on the clinical validity of 
the test50,51
The purpose of the Goldstein et al. study49 
was to evaluate the prognostic value of 
OncotypeDX in hormone receptor-positive, 
LN0 or LN+ patients and to determine 
whether or not it could better predict outcome 
at 5 years than a modified Adjuvant! Online 
algorithm. The 21-gene assay was a more 
accurate predictor of relapse than standard 
clinical features for individual patients with 
hormone receptor-positive operable breast 
cancer treated with chemotherapy/hormonal 
therapy and provides information that is 
complementary to features typically used 
in anatomic staging, such as tumour size 
and LN involvement. The 21-gene assay 
may be used to select low-risk patients for 
abbreviated chemotherapy regimens similar 
to those used in our study or high-risk 
patients for more aggressive regimens or for 
clinical trials
In the Wolf et al. study51 the authors sought 
to assess the correlation between standard 
clinical and pathological breast cancer 
characteristics and the RS in a cohort of 
Israeli breast cancer patients and to compare 
the stratification of patients using RS with 
that of commonly used clinical guidelines. 
High tumour grade, low PR expression, 
infiltrating ductal histology and HER2 
overexpression were found to be associated 
with a high RS. Patient age, tumour size, ER 
expression, and LN micrometastasis were 
found to correlate poorly with the RS. The 
ability of any of these variables, either alone 
or in combination, to predict the RS was 
limited. Similarly, none of the guidelines nor 
the Adjuvant! Online software could predict 
the RS. This study reported on a selected 
population of patients who were referred to 
undergo the OncotypeDX test. No association 
was noted between the RS and patient age 
or ER intensity and only a modest association 
was noted between the RS and tumour size. 
The clinical utility of these comparisons was 
not made clear
Summary of reported conference abstracts: 
Shak et al.59 demonstrated that the 
distribution of RS was similar for men and 
women with breast cancer
Four studies reported on the clinical utility (indirect evidence) of the test52–55
The purpose of the Asad et al. study52 was to determine whether or not the results of OncotypeDX 
influence the decision to administer chemotherapy. The OncotypeDX results influenced the 
decision for chemotherapy in 37 (44%) patients; four patients classified as low risk by the NCCN 
guidelines129 (tumours < 1 cm) were advised to have chemotherapy and 33 patients classified as 
high risk by the NCCN guidelines (tumours ≥ 1 cm) were advised to undergo hormone treatment 
only. The authors concluded that the OncotypeDX RS is significantly related to tumour grade and 
HER2/neu status. Comment: There was no evidence that OncotypeDX changed clinical outcomes
The Henry et al. study53 reported on the functional and clinically relevant impact of the RS on 
the adjuvant therapy administered to 29 patients with ER+, LN0 breast cancer, as well as its 
influence on a panel of five expert breast oncologists. They concluded that the RS contributed to 
chemotherapy changes in 31% of patients, with more changes made against than for adjuvant 
chemotherapy. The RS increased consensus recommendations by 10% but did not appear to 
increase the reported strength of panellists’ recommendations. Limitations: The small sample 
size increased the likelihood of a type 2 error (false-negative result) and the study lacked statistical 
power to draw definitive conclusions. Determination of therapy received was retrospective and 
may have been subject to the well-established biases (e.g. selection bias, information bias) 
associated with this methodology. Panellists were the same medical oncologists who administered 
chemotherapy and panellists may have remembered their recommendations from when they were 
actually managing these patients. The 2-month washout period may have been insufficient to erase 
all recollections of previous recommendations (recall bias). Although the RS predicts only distant 
relapse, Adjuvant! Online includes distant and local relapse, thus the estimate of recurrence for 
Adjuvant! Online was much higher (90%) than that for the RS and the chemotherapy decision for 
54% of patients was changed with RS information. One patient was male
Li et al.54 hypothesised that an integrated gene expression profile could a predict patient’s 
response to chemotherapy. The main purpose of this study was the validation of a new gene 
signature, which overlapped in part with OncotypeDX and the 70-gene signature. The authors 
reported that their integrated signature was a stronger prediction of chemotherapy outcome than 
the single signatures (OncotypeDX and the 70-gene signature). Comment: Neither OncotypeDX 
nor the 70-gene signature formed the main focus of this study. Both signatures were used in 
populations that were very different from those that the tests were validated for. The follow-up was 
short
The purpose of the Rayhanabad et al. study55 was to examine the utility of OncotypeDX in the 
prediction of recurrence and the degree of benefit from chemotherapy. Treatment received after 
OncotypeDX testing was compared with treatment based on NCCN guidelines.129 A total of 13 out 
of 18 high-risk NCCN, low-risk RS patients did not receive chemotherapy (p < 0.001); 11 patients 
with an intermediate RS received chemotherapy. OncotypeDX results changed management in 15 
(26%) patients (p = 0.05). The authors concluded that the use of gene assays altered recurrence 
risk stratification and the decision for chemotherapy in a significant number of patients. This 
allowed better individualised treatment for patients, reserving chemotherapy for those at high risk 
of recurrence, whereas low-risk patients were spared the morbidity associated with chemotherapy. 
However, Smartt reported that there were a number of serious limitations in this study, which 
threaten the validity of the reported results
Summary of reported conference abstracts: Most studies reported examined or modelled the 
impact of the RS on clinical decision-making in relation to adjuvant chemotherapy. Erb et al.56 
reported a significant decline in the use of adjuvant chemotherapy after the introduction of the test 
in the authors’ institution. Gold et al.,57 reporting on how clinicians integrated RS into their decision-
making, found that RS, tumour grade and size were all independent predictors of chemotherapy 
administration. Lo et al.58 examined the effect of knowledge of the RS on both patients and medical 
oncologists in relation to their adjuvant therapy choice. In total, 22% of oncologists and 10% of 
patients changed from chemotherapy to hormone therapy. The change in the other direction (i.e. 
from hormone therapy to chemotherapy) occurred in 3% and 8% respectively
NIHR Journals Library www.journalslibrary.nihr.ac.uk
190 Appendix 4
Systematic review summary
There were no additional studies reporting on the analytical validity of the test and this remains an area of weakness in the evidence story to date. 
In contrast to the studies reported in the original systematic review,33 the majority of these studies primarily addressed questions relating to the 
clinical utility of OncotypeDX, some reported further on the clinical validity or validity and utility of the test and one study reported, for the first time, 
on the use of the test in male breast cancer. The additional studies reporting on the clinical validity of OncotypeDX further endorsed the advantages 
of the test compared with standard clinicopathological assessment of risk and extended the examination of its prognostic value beyond clinical 
trial populations to a general population, as well as the cohort of male breast cancer patients. The studies reporting on the clinical utility of the 
test examined its ability to predict response to treatment or its impact on clinical decision-making. The latter studies all reported a positive impact 
of the test on clinical decision-making and generally claimed that there was a reduction in the number of patients who were or would have been 
considered for chemotherapy. However, the studies generally had methodological weaknesses that were likely to have overestimated the effect/
influence of the test and were not designed to assess the effect of the test on clinical outcomes. Studies examining the ability of OncotypeDX to 
predict response to adjuvant and neoadjuvant endocrine therapy and chemotherapy generally reported that OncotypeDX was predictive, to a greater 
or lesser extent, of response to therapy; however, as the design of the studies precluded any firm conclusions about the ability of the test to predict 
response to therapy, these studies did not materially add to the body of evidence in this area
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Summary of evidence relating to MammaPrint reported in the 
Marchionni et al. systematic review33
Analytical validity Clinical validity Clinical utility
Two technical studies60,61 provided 
evidence relating to the analytical 
validity of MammaPrint. Repeated 
gene expression measurements over 
time, within and across individual 
microarrays and across different 
laboratories, protocols, instruments 
and operators, provided data on the 
variability and reproducibility of the 
test. Buyse et al.61 reported an overall 
success rate of the assay of 80.9%
The systematic review concluded 
that the studies that used the 70-
gene signature provided useful 
information about the validity of the 
biological correlations underlying 
the profile. However, although these 
studies suggested that MammaPrint 
could be used in a clinical setting, 
they could not be considered to be 
direct validations of the assay. The 
review also noted that evidence 
underpinning the analytical validity 
of the test was obtained from a 
limited number of patients and a 
moderate number of replications. 
The only validation study using the 
MammaPrint assay (rather than 
the underlying 70-gene signature) 
showed that only about 80% of fresh-
frozen specimens were analysable
van’t Veer et al.63 reported on the development data for the 70-gene panel 
that formed the basis for the MammaPrint test. Using multivariate analysis, 
the 70-gene signature was found to be an independent predictor of 
metastases within 5 years, with an OR = 18 (95% CI 3 to 94)
van de Vijver et al.64 reported the first major validation of the 70-gene 
signature in a young (< 52 years) population with small (< 5 cm) tumours that 
were heterogeneous with respect to LN positivity, ER status, chemotherapy 
and tamoxifen treatment. Multivariate analysis showed that the MammaPrint 
prognosis group, tumour size and adjuvant chemotherapy were the strongest 
predictors of distant metastases. The ‘poor prognosis’ MammaPrint group 
had the largest HR (4.6, 95% CI 2.3 to 9.2). The authors demonstrated the 
prognostic value of the gene signature using survival curves stratified by 
conventional clinical indexes. The analyses showed substantial separation 
between 70-gene prognostic groups that were either low or high risk by 
clinical indices. Optimal prediction was achieved when the gene index 
and conventional clinical predictors were combined
Buyse et al.61 compared the MammaPrint assay with conventional clinical 
combination risk predictors in an independent, multicentre validation study. 
The specificity and sensitivity of the MammaPrint assay and the Adjuvant! 
Online algorithm were compared for prediction of distant metastases within 
5 years and for death within 10 years. Similar sensitivities were found in 
both methods, but a higher specificity was demonstrated for MammaPrint. 
The areas under the receiver operating characteristic (ROC) curves were 
comparable for MammaPrint and Adjuvant! Online (0.68 vs. 0.66 for distant 
metastases at 5 years). However, with ROC values much closer to 0.50 than 
1.00 neither prediction was particularly accurate
Glas et al.62 compared the commercial MammaPrint assay results with those 
obtained with a generic 70-gene signature test using the same patients as 
van’t Veer and van de Vijver. The results of the 70-gene signature used in the 
original cohorts applied equally to the commercial MammaPrint assay based 
on the signature
Summary: The authors concluded that, overall, the available published 
evidence supported MammaPrint as a better predictor of the 5-year risk of 
distant recurrence than traditional clinical predictors. However, the cohorts 
used for the development and validation of MammaPrint were considerably 
more clinically heterogeneous than those used for the OncotypeDX test. 
Despite this, MammaPrint had an 80% concordance with the OncotypeDX 
array-based RS classification when applied to the same patients. There 
was some evidence to suggest that the commercial MammaPrint test and a 
generic 70-gene signature assay produced comparable results
No studies on clinical utility 
were reported
The systematic review did 
not identify any published 
studies evaluating 
the ability of the 70-
gene signature or the 
commercial MammaPrint 
test to predict 
chemotherapy benefit
Systematic review summary
The review found studies that tested the MammaPrint assay, as well as studies about the 70-gene signature that the assay is based on. The 
studies that use the gene signature cannot be considered as validation of the assay itself. In terms of analytical validity, two recent papers looked 
at reproducibility between laboratories and found a good degree of agreement. RNA labelling emerged as a possible source of variation, and 
the question of reproducibility remains open. The only validation study using the MammaPrint assay itself showed that only 80% of fresh-frozen 
samples were useable, although it is hoped that the success rate would increase with the use of the assay. Studies of clinical validity overall show 
MammaPrint to be a better predictor of 5-year risk of distant recurrence than traditional algorithms and characteristics, although the validation and 
derivation cohorts were clinically more heterogeneous than those used for the OncotypeDX test. It remains to be seen how well it predicts in cohorts 
with greater homogeneity as used in the development of OncotypeDX. No studies that evaluated clinical utility were found
To conclude, the literature on the 70-gene signature includes numerous studies that focused more on its biological underpinning and less on the 
clinical implications of the gene expression profile. It is not yet clear which are the optimal patient populations for the use of this test, exactly what 
its performance is in those populations and how many of its predictions would result in different therapeutic decisions. Larger independent validation 
studies in therapeutically homogeneous groups are needed. Studies that test MammaPrint alongside standard predictors, develop the use of risk 
categories rather than a continuous scale and assess the assay’s stability in different populations are also needed
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Summary of evidence relating to MammaPrint reported in the 
Smartt systematic review34
Clinical validity Clinical utility
Two studies on clinical validity were reported
Mook et al.65
Rational and objective: Patients with axillary LN metastases are 
generally considered to have a poor prognosis and most will be treated 
with adjuvant chemotherapy; however, up to 30% of these patients 
would remain free of distant metastases without adjuvant chemotherapy 
(Early Breast Cancer Trialists’ Collaborative Group (EBCTCG),189 2005). 
In this study the authors sought to validate the prognostic value and 
accuracy of MammaPrint in an independent cohort of 241 patients with 
axillary LN metastases
Results: 41% of patients in the independent cohort (n = 241) had a 
good prognosis gene signature and 59% had a poor prognosis gene 
signature. There was a significant difference in DMFS (as the first event) 
and BCSS between the good and poor prognosis gene signature groups 
at both 5 and 10 years (p < 0.001). The poor prognosis signature group 
was associated with a shorter BCSS (HR 5.70; 95% CI 2.01 to 16.23; 
p < 0.001). The probability of distant metastases as the first event was 
significantly greater in the poor gene signature group (HR 4.13; 95% CI 
1.71 to 9.96; p = 0.002)
In univariate analysis significant predictors of BCSS were the number 
of positive nodes, tumour grade, ER status, HER2 status endocrine 
treatment and MammaPrint risk group. Only the number of positive 
nodes, endocrine therapy and MammaPrint risk group remained 
significant predictors in multivariate analysis. MammaPrint was the most 
powerful independent predictor in this analysis (HR 7.17; 95% CI 1.81 
to 28.43; p = 0.005)
Predictors of DMFS in univariate analysis were the number of positive 
nodes, tumour size, histological grade, ER and HER2 status, endocrine 
therapy and MammaPrint risk group. Only endocrine therapy was a 
significant independent predictor of DMFS in multivariate analysis (HR 
0.31, 95% CI 0.12 to 0.80, p = 0.02). MammaPrint risk group and 
number of positive nodes tended to be prognostic with HR = 2.99 (95% 
CI 0.996 to 8.99; p = 0.051) and HR = 2.29 (95% CI 0.99 to 5.29; 
p = 0.053) respectively
Adjuvant! Online classified 13% of patients as low risk and 87% as 
high risk; Adjuvant! Online and MammaPrint risk assessments were 
discordant for 77 patients (32%); 72 of these discordant patients were 
assessed as having a high risk of relapse by Adjuvant! Online and a 
good prognosis gene signature
When 209 Adjuvant! Online high-risk patients were stratified by 
MammaPrint the 10-year BCSS probability was 94% for the good 
prognosis gene signature group and 76% for the poor prognosis gene 
signature group (HR 4.12; 95% CI 1.45 to 11.76; p = 0.008). Subgroup 
analysis suggested that MammaPrint was predictive for BCSS in 
patients in different treatment groups and patients with ER+ tumours
One study on clinical utility (indirect) was reported
Bueno-de-Mesquita et al.67
Rationale and objective: In most hospitals tumour samples are routinely 
fixed in formalin and embedded in paraffin blocks. MammaPrint 
requires fresh tumour samples and one of the potential difficulties in 
the implementation of the test in daily clinical practice is the ease with 
which sample requirements can be met. In this prospective multicentre 
study the authors set out to evaluate (1) whether or not MammaPrint 
was suitable for use in routine clinical practice in the Netherlands, (2) 
the effect of the test on the use of adjuvant systemic treatment, (3) the 
proportion of patients with ‘poor’ compared with ‘good’ prognosis and 
(4) the concordance between risk predicted by MammaPrint and risk 
predicted by commonly used clinicopathological tools
The patient population and eligibility criteria: Patients were enrolled in 
this prospective multicentre study if they had unilateral primary operable 
invasive adenocarcinoma of the breast (TNM classification = T1–4, N0, 
M0) and were < 61 years of age. Sixteen participating Dutch hospitals 
contributed 812 women to the trial between 2004 and 2006. In total, 
81 patients had breast-conserving surgery, 70% had small (< 2 cm) 
tumours, 81% had ductal histology, 80% had grade II–III tumours, 80% 
were ER+, 84% ERBB2 negative and 85% LN–. Adjuvant systemic 
treatment varied: 39% of patients received no adjuvant treatment, 18% 
received chemotherapy, 13% received endocrine treatment and 29% 
received both chemotherapy and endocrine therapy. The median age of 
patients was 49 years and the median follow-up was 14 months (range 
0.3–36.4 months). Hospitals were eligible to participate only if they had 
structured multidisciplinary breast cancer care, used standard operating 
procedures, treated at least 100 patients a year and had a dedicated 
physician as the local co-ordinator
Endpoints and analyses: Differences between MammaPrint and 
commonly used histopathological guidelines were assessed using 
Pearson’s chi-squared test and the Cochrane–Armitage test for trends. 
The level of agreement between different risk assessment techniques 
was assessed using Cohen’s kappa. In addition to MammaPrint, the 
CBO guidelines,105 Adjuvant! Online, the NPI and the St Gallen guidelines 
were used to assess clinical risk. MammaPrint analyses were carried 
out blinded to clinical data and an initial recommendation for treatment 
using clinical criteria carried out before disclosure of the MammaPrint 
results
Results: Of the original 812 enrolled patients, 585 (72%) were eligible 
for the study. MammaPrint profiles were obtained in 427 (73%) of 
eligible patients. During follow-up five patients had distant metastases 
as the first event. According to MammaPrint, 51% of patients had a 
good prognosis signature compared with 57%, 31%, 58% and 17%, 
respectively, for the CBO,105 Adjuvant! Online, NPI and St Gallen risk 
assessments
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The second cohort of 106 previously studied patients64 (with one to 
three positive nodes) differed significantly from the independent cohort 
in terms of age (younger), axillary procedures, adjuvant systemic therapy 
and overall and median survival (10.3 years, range 1.6–21.2 years). 
The 10-year BCSS probability was 98% for the good prognosis gene 
profile and 64% for the poor prognosis gene profile. The poor prognosis 
signature was associated with shorter BCSS (HR 6.60; 95% CI 1.97 to 
22.10; p = 0.002) and a multivariate HR of 3.63 (95% CI 0.88 to 14.76; 
p = 0.07)
Conclusion: MammaPrint predicted disease outcome better than 
traditional clinical prognostic factors in patients with one to three 
positive nodes and was able to accurately identify LN+ patients with 
an excellent prognosis. The potential clinical utility of MammaPrint 
was demonstrated in 72 (34%) clinically high-risk patients with a good 
prognosis signature who had a 10-year BCSS of 94% and therefore 
might be spared chemotherapy
Wittner et al.66
Rationale and objectives: Most patients with breast cancer are older 
and present with smaller early-stage ER+ tumours than the cohorts of 
patients used to define and evaluate the MammaPrint gene signature. 
Decisions relating to the use of adjuvant chemotherapy in these older 
patients may be complicated by comorbidity. To explore these issues 
the authors carried out a retrospective evaluation of the prognostic 
value of MammaPrint in 100 older patients diagnosed and treated at 
the Massachusetts General Hospital (MGH) between 1985 and 1997. 
The study cohort of 100 patients was compared with the original Dutch 
cohort (NKI) of 151 LN0 patients used to validate the MammaPrint 
signature64
The patient population and eligibility criteria: Eligible MGH patients were 
consecutively diagnosed and treated patients with LN0 breast cancer 
and frozen primary tumour samples for whom histopathological and 
clinical information could be retrieved. The median age of the cohort 
was 62.5 years and the median duration of follow-up was 11.3 years 
(range 1.2–18.5 years). In total, 72% of patients had small tumours 
(≤ 2 cm), 94% were of histological grade II–III. A total of 21% of patients 
received chemotherapy and 24% hormonal therapy. Surgery included 
mastectomy (56%) and breast conservation (44%)
Results: The MGH cohort was significantly older (p < 0.001) than the 
original MammaPrint cohort.64 There were also significant differences 
(p < 0.005) in tumour size, histological grade and the proportion of 
patients undergoing systemic treatment
MammaPrint classified 27% of the MGH patients as low risk and 73% 
as high risk of distant metastases as the first event. The cohort had a 
significantly lower event rate than the original NKI cohort (p < 0.001); 
there was no difference in OS in the older MGH cohort because of death 
from other causes. Survival analysis discriminated between the high- 
and low-risk gene signature with non-overlapping CIs; however, because 
of the low event rate the difference was not significant. This contrasted 
with the significant difference between the low- and high-risk groups 
reported for the original Dutch NKI cohort
Clinical and molecular risk assessments were discordant in 27%–39% 
of patients depending on the clinical assessment tool used. The 
amount of discordance between the clinical guidelines themselves 
was between 7% and 40%. Adjuvant treatment was recommended for 
48% of patients based on the Dutch guideline alone; this increased to 
62% when the guideline was used with the prognostic gene signature. 
Overall, and once patient preferences had been taken into account, 
adjuvant systemic treatment was administered to 61% of patients. 
An increase in systematic therapy occurred in patients whose risk 
according to the Dutch guidelines and MammaPrint were discordant. In 
the final analysis, 50 (12%) more patients received endocrine treatment, 
54 (13%) patients had endocrine treatment added and 4 (1%) patients 
had endocrine treatment withheld. Sixteen (4%) more patients had 
chemotherapy, in 35 (8%) patients chemotherapy was added and it was 
withheld in 19 (4%) patients
Limitations: There was an early protocol change reducing the age of 
eligibility to < 55 years. It was not clear how representative the hospital 
sample was and the short follow-up time and low number of events 
precluded survival analyses
Quality: This was a well-conducted prospective clinical trial that 
demonstrated the feasibility of conducting the MammaPrint test routinely 
in Dutch hospitals. As reported, the study fulfilled 35 of 44 (80%) 
REMARK criteria for the reporting of tumour marker prognostic studies 
indicating a high level of adherence to the reporting guidelines
Conclusion: The study demonstrated a lack of congruence between 
well-known clinical guidelines for risk assessment in breast cancer. In 
approximately one-third of patients there was discordance between 
MammaPrint and clinical guidelines in the assessment of risk. The 
addition of MammaPrint to the standard Dutch clinical assessment of 
risk (modified by patient preference) increased by 20 the number of 
patients receiving adjuvant systemic therapy. However, although the 
study was able to demonstrate that MammaPrint had an impact on 
clinical decision-making the follow-up was not long enough to provide 
evidence of its effect on clinical end points such as DMFS or its utility in 
predicting treatment benefit
One study published as a conference abstract reported on clinical utility
Bender et al.68
In this study the authors present the results of a meta-analysis of 1637 
patients with MammaPrint outcomes (T1–2, LN–/+ invasive breast 
cancer and median follow-up 7.1 years) to determine the chemotherapy 
benefit of patients treated with adjuvant chemotherapy in addition to 
endocrine therapy. Patient samples were recruited from seven large 
data sets from multiple institutions across Europe
MammaPrint assigned 772 patients (47%) to a low-risk category and 
865 (53%) to a high-risk category. In total, 349 patients (21%) were 
treated with endocrine therapy and 226 (14%) were treated with 
chemotherapy and endocrine therapy. In patients with a poor prognosis 
MammaPrint profile the 5-year DMFS improved from 69% to 88% 
(HR 0.28, 95% CI 0.14 to 0.56, p < 0.001) when chemotherapy was 
added to hormone therapy. In multivariate analysis patients classified by 
MammaPrint as having good prognosis had no significant benefit from 
chemotherapy (p = 0.962)
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The NPV of MammaPrint in the MGH cohort was 100% (overall and 
at 5 and 10 years) compared with 88% in the original NKI cohort. The 
PPV was only 12% in the MGH cohort (because of the large number of 
patients classified as high risk who did not have distant metastases as 
the first event) compared with 52% in the NKI cohort. Sensitivity analysis 
varying the cut-off/classification threshold of MammaPrint did not 
improve the PPV. In a comparison between the Adjuvant! Online 10-year 
relapse risk for each MGH patient and MammaPrint, the latter identified 
an additional 21 patients who did not develop distant metastases as 
the first event, and an additional five patients when considering DMFS 
per se
Conclusion: MammaPrint had a high NPV and provided some 
information that was additional to that provided by Adjuvant! Online. 
However, with an extremely low PPV and insignificant differences in 
OS between MammaPrint high- and low-risk patients the prognostic 
utility of MammaPrint in this population remained unproven. Moreover, 
although MammaPrint classified a significant proportion of study 
patients as high risk, few of these developed metastatic disease
Four studies published as conference abstracts reported on clinical 
validity
Glas et al.70
Patients with ER+, LN0 from the original validation series63 were 
analysed for MammaPrint outcome according to grade. Kaplan–Meier 
analysis of 106 patients for DMFS at 10 years showed a significant 
difference between low risk (56 patients, 53%) and high risk (50 
patients, 47%) with a HR of 4.7 (95% CI 2.1 to 10.4). Good prognosis 
(low-risk) patients had a 10-year survival of 86%. In patients with 
grade II, ER+, LN0 breast cancer a significant separation of patients 
with good or poor prognosis according to MammaPrint was observed 
(p = 0.001). The probability of developing distant metastasis in the good 
prognosis group was < 10%; in the poor prognosis group it was 44%. 
MammaPrint provided a significant separation in recurrence risk in 
these patients, which improved guidance for the requirement of adjuvant 
therapy
de Snoo et al.69
A total of 566 tumour samples from women with ER+, LN0, HER2– 
breast cancer from five previously reported studies were classified 
using MammaPrint and the NCCN guidelines,129 and the 10-year BCSS 
determined according to each
MammaPrint classified 380 (57%) samples as having a good prognosis 
and 186 (33%) as having a poor prognosis. The NCCN guidelines129 
classified 7% as low risk and 93% as high risk. MammaPrint also 
identified approximately 66% of NCCN high-risk patients as having a 
good prognosis. There was an overall discordance between the two 
tools in 62% of cases. In total, 349 (62%) patients received no adjuvant 
treatment, 17% received hormone treatment only, 2% chemotherapy 
only and 20% both
It was concluded that MammaPrint poor-prognosis/high-risk patients 
demonstrated a benefit when adjuvant chemotherapy was added to 
hormone therapy. Patients classified by MammaPrint as good prognosis/
low risk for recurrence do not appear to benefit from the addition of 
chemotherapy to hormone treatment
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MammaPrint predicted a 10-year BCSS of 91% vs. 67% for the good 
and poor prognosis groups respectively (HR 4.0, 95% CI 2.0 to 7.9, 
p < 0.001). NCCN guidelines129 predicted a BCSS of 86% vs. 83% for 
the low- and high-risk groups respectively (HR 1.11, 95% CI 0.3 to 4.6, 
p = 0.888). Median follow-up was 3.5 years (range 0.1–21.1 years). 
In multivariate analysis (adjusted for known prognostic factors and 
adjuvant therapy), only MammaPrint and histological grade were 
independent predictors for 10-year BCSS with HRs of 2.8 (95% CI 1.3 
to 6.1, p = 0.008) and 1.9 (95% CI 1.1 to 3.1, p = 0.015) respectively. 
It was concluded that MammaPrint was a strong and independent 
prognostic indicator in ER+, LN0, HER2– breast cancer
Knauer et al.71
In this study the authors used MammaPrint to assess prognosis, BCSS 
and DMFS in 965 pT1 breast cancer tumour samples from seven 
previous studies. MammaPrint classified 526 patients (55%) as having a 
good prognosis and 439 (45%) as having a poor prognosis. In total, 562 
patients (59%) received no adjuvant treatment, 19% received hormone 
treatment only, 10% received chemotherapy only and 12% both 
hormone therapy and chemotherapy. MammaPrint accurately predicted 
differences in 10-year DDFS (HR 2.7, 95% CI 1.9 to 3.9, p < 0.01) and 
BCSS (HR 4.0, 95% CI 2.6 to 6.3, p < 0.01) for all T1 tumours. Similar 
results were obtained in multivariate analysis for all patients, adjusted 
for known prognostic factors and adjuvant therapy, as well as for 
adjuvant therapy-untreated patients. For the pT1a/b subgroup (n = 140), 
10-year DDFS was 93% vs. 78% for the good and poor prognosis 
groups (HR 3.9, 95% CI 1.0 to 15.2, p = 0.048), whereas in the T1c 
subgroup (n = 825) DDFS was 86% vs. 72% respectively (HR 2.6, 95% 
CI 1.8 to 4.0, p < 0.01). BCSS was 87% vs. 73% for the good and poor 
prognosis groups in the T1a/b subgroup (HR 2.4, 95% CI 0.8 to 7.7, 
p = 0.128) and 92% vs. 72% for the good and poor prognosis groups in 
the T1c subgroup (HR 4.4, 95% CI 2.7 to 7.1, p < 0.01)
It was concluded that MammaPrint was a strong and independent 
prognostic indicator in small breast tumours
Saghatchian et al.72
It has been shown that MammaPrint predicts disease outcome in 
patients with one to three positive nodes and four to nine positive nodes. 
In this study the authors report a further analysis of 519 LN+ patients 
from a consecutive series of patients from two hospitals based on 
adjuvant treatment received. Female patients diagnosed between 1984 
and 1995 with LN+, unilateral T1, T2 or operable T3 primary invasive 
breast carcinoma who received mastectomy or breast-conserving 
therapy and for whom fresh-frozen tumour material was available were 
eligible for the study
In total, 346 patients had one to three positive lymph nodes and 173 
had four to nine positive lymph nodes. Tumours were classified by 
MammaPrint as good prognosis/low risk in 212 patients (41%) and poor 
prognosis/high risk in 307 patients (59%) with strictly equal proportions 
among the two LN groups. With a median follow-up of 10.3 years, 
distant metastases occurred in 141 (27%) patients (116 as first event), 
and 103 (20%) died of their disease. It was concluded that combining 
nodal status and MammaPrint profiling allowed patients to be stratified 
for tailored treatment strategies. Patients with an elevated number of 
LNs and high genomic risk had a very poor prognosis and might need to 
be considered for stronger treatment combinations
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Systematic review summary
This review updates the review by Marchionni et al.33 and found an additional 11 studies, some journal publications and some conference abstracts. 
Analytical validity remains a weakness of the evidence base for MammaPrint, with no new studies identified. The majority of studies found across 
the two reviews provide evidence relating to the clinical validity of the test in heterogeneous populations. The additional studies reporting on the 
clinical validity of the test sought to validate the prognostic value and accuracy of MammaPrint in an independent cohort and to extend previous 
experience of the test in older patients with small tumours. Four studies reported subset analyses of data reported in previous studies examining 
the use of the test in very heterogeneous populations. The evidence relating to the clinical validity of MammaPrint was not always conclusive or 
supportive of the prognostic value of the test. Four studies suggested that the ratio could predict prognosis, one study failed to verify the prognostic 
utility of the test and in another the methods and results were at variance with those of other studies. Three studies focusing on clinically utility 
were identified: one journal article and two conference abstracts. The fully reported study provided important evidence of the potential impact of 
MammaPrint on decision-making in Dutch hospitals and the concordance between the gene profile and commonly used clinicopathological tools 
for risk prediction. A second study, published as an abstract only, presented initial results of a meta-analysis of 1637 patients from seven large 
multinational data sets to determine the benefit of adding adjuvant chemotherapy to endocrine therapy. The encouraging results of this study may 
eventually provide strong enough evidence to provide reasonable justification for the interim use of the test in women in the same population group 
as the trial patients. One study examined the budgetary impact of MammaPrint. As in the original review, the evidence for the clinical implications of 
using MammaPrint remains unclear 
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Appendix 6 
Studies identified by the electronic searches 
and other searches and excluded at the full 
paper stage for reasons not immediately 
apparent from the full text
Study Reason for exclusion
Schor et al. (2009)190 Not available within study timescale
Jancin (2010)144 Not available within study timescale
Bighin et al. (2010)191 Letter without sufficiently detailed data
Espinosa et al. (2009)192 Study of the research version rather than the commercial version of the 70-gene signature
Mook et al. (2010)108 Pooled analysis, therefore did not meet inclusion criteria
Knauer et al. (2010)110 Pooled analysis, therefore did not meet inclusion criteria
Knauer et al. (2010)111 Pooled analysis, therefore did not meet inclusion criteria
Bueno-de-Mesquita et al. (2011) 
(online version 2009 used)109
Pooled analysis, therefore did not meet inclusion criteria
Ma et al. (2008)193 Study of a previous version of the BCI
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Appendix 8 
Ongoing trials
The TAILORx188 and MINDACT187 trials aim to address the gaps in the literature (clinical utility data).
Anticipated data from TAILORx and MINDACT
TAILORx and MINDACT were recently initiated to prospectively evaluate the clinical utility 
(i.e. provide direct evidence that these tests in breast cancer patients lead to improvement in 
outcomes) of OncotypeDX and MammaPrint respectively. Definitive high-quality evidence of 
the effect of these tests on patient outcomes and their ability to predict treatment response is 
expected. TAILORx will provide information on the appropriate RS threshold for recommending 
adjuvant chemotherapy, and will not directly assess the effect of clinical decision-making with 
and without the test (as all patients will receive the test). The data generated may allow indirect 
inferences to be made. MINDACT will allow more direct inferences about the clinical utility as it 
will be compared directly with the use of a conventional risk index. For both trials, patient health 
outcomes will be end points.
TAILORx
This multicentre, partially randomised trial aims to assess whether hormone therapy alone or 
hormone therapy with combination chemotherapy is better for women who have a RS of 11–25 
(an intermediate risk score) when tested using OncotypeDX.91 The trial will also allow for the 
generation of new data on patients with very low RSs. Patients at the low end of the RS spectrum 
will be compared with a prespecified target of 95% recurrence-free survival.91 It should be noted 
that the cut-off values used in the TAILORx trial are different from those delineated in other 
studies of OncotypeDX.32
Population
Patients with ER+ and/or PR+, HER2/neu-negative tumours who are LN– (and who will be 
treated with tamoxifen) are eligible for inclusion.
Key aspects of the study design
 ■ Patients showing low RSs (≤ 10) by OncotypeDX testing will receive endocrine therapy alone.
 ■ Patients with high RSs (≥ 26) by OncotypeDX testing will receive endocrine therapy and 
adjuvant chemotherapy.
 ■ Patients with mid-range RSs (11–25) by OncotypeDX will receive endocrine therapy and be 
randomly assigned to chemotherapy or no chemotherapy.
After completion of the study treatment, patients will be followed up for up to 20 years.
Objectives
The primary objective is to assess whether or not women with an intermediate OncotypeDX 
score have better outcomes (DFS, DMFS, RFI and OS) when treated with either hormone therapy 
alone or hormone therapy with combination chemotherapy.
The secondary objectives include assessing whether or not low-risk patients (score ≤ 10) can 
safely be treated with hormone therapy alone (expect 95% to have DFS); to determine the DFS, 
DRFI, RFI and OS of patients with OncotypeDX RSs of ≤ 10; to compare the outcomes projected 
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at 10 years using classical pathological information with those made by the OncotypeDX 
test; to estimate failure rates as a function of OncotypeDX RS separately in patients treated 
with combination chemotherapy and in patients treated with no chemotherapy; to determine 
the prognostic significance of the OncotypeDX RS and of the individual RS gene groups 
(proliferation gene group, HER2 gene group, ER gene group, invasion gene group and other 
genes) in patients treated with these regimens.91
This study will not provide direct evidence for the value of OncotypeDX but will indicate whether 
or not adjuvant chemotherapy is of value within the trial’s intermediate RS range. This will 
provide better estimates of the degree of benefit gained by using the test, but cannot ascertain 
what therapeutic choices would have been made and what clinical outcomes would have 
occurred if only standard risk prediction methods were used. Information about what choices 
would have been made could be inferred by applying other prognostic methods retrospectively.33
Completion
TAILORx commenced in April 2006.The trial is currently still recruiting and has a primary 
completion date of April 2014. The target for recruitment is 11,248 participants and the study 
currently has 280 centres recruiting in the USA, Canada, Australia and Peru.
MINDACT
A partially randomised trial, MINDACT194 has recently been activated. The multicentre, 
prospective, phase III randomised trial will compare two different ways of assessing the risk of 
cancer recurrence and making therapeutic decisions: a ‘traditional method’ using Adjuvant! 
Online and the MammaPrint assay. The rationale for this study is that many women who 
actually have low-risk tumours are currently classified as average or high risk and therefore are 
recommended to receive adjuvant chemotherapy that ultimately may be of no benefit.
Population
Patients with histologically confirmed unilateral invasive breast cancer with T1–T3 
operable disease, up to three positive lymph nodes and no distant metastases are eligible for 
inclusion. It situ tumours were allowed. Patients must have undergone breast-conserving 
surgery or a mastectomy with a sentinel node procedure or full axillary clearance, and 
appropriate radiotherapy.
Key aspects of the study design
 ■ Patients at low risk by both MammaPrint and standard clinicopathological criteria will not 
receive chemotherapy.
 ■ Patients at high risk by both criteria receive chemotherapy.
 ■ Patients with discordant criteria, in which the clinicopathological prognosis using Adjuvant! 
Online is different to the gene expression prognosis using the 70-gene signature (which is 
estimated to be the case for 1920 patients), will be randomised to use either MammaPrint 
only or standard criteria to decide treatment. This is achieved by randomising patients to 
either receive or not receive chemotherapy. This will directly test whether or not the choice 
of chemotherapy guided by MammaPrint provides benefit over that guided by the Adjuvant! 
Online criteria.
 ■ All those who go on to have chemotherapy (i.e. those at high risk by both prognostic tests, as 
well as those with discordant criteria who went on to receive chemotherapy) are then eligible 
for further randomisation to treatment with anthracycline-based chemotherapy or docetaxel/
capecitabine-based chemotherapy.
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 ■ All hormone receptor-positive patients, regardless of previous randomisations and risk 
categorisations, are eligible for randomisation to two different endocrine treatment regimens, 
namely letrozole only or tamoxifen followed by letrozole.
 ■ Patients will be followed up for DMFS at 5 years and DFS. Follow-up will be for a minimum 
of 15 years after completion of the study treatment.
Objectives
The main objective of the trial is to confirm that patients with low-risk molecular prognosis 
and high-risk clinical prognosis can be safely spared chemotherapy without affecting DMFS 
and to demonstrate the superiority of the molecular profiling approach over the usual clinical 
assessment in assigning risk categories.
The trial has two further main objectives: (1) a comparison of docetaxel and capecitabine 
regimens (which are possibly associated with increased efficacy and reduced long-term toxicities) 
with existing commonly used anthracycline-based chemotherapy regimens and (2) to determine 
the best endocrine treatment strategy between a single-agent upfront aromatase inhibitor 
(letrozole) for 7 years and the sequential endocrine strategy of 2 years of tamoxifen followed by 
5 years of letrozole.
Completion
The trial is currently still recruiting and has a primary completion date of March 2019. The 
target for recruitment was recently increased from 6000 to 6600 participants and the projected 
proportion of patients who will fall into the discordant group is 32%.
Comparative summary of the design and characteristics of the TAILORx 
and MINDACT trials
Variable TAILORx MINDACT 
Trial Hormone therapy with or without combination 
chemotherapy in treating women who have 
undergone surgery for LN– breast cancer
A prospective, randomised study comparing the 70-gene 
expression signature with common clinicopathological 
criteria in selecting patients for adjuvant chemotherapy in 
LN– breast cancer (EORTC Protocol 10041 – BIG 3–04)
Trial type Prospective, controlled, partially randomised
Clinical utility
Non-inferiority design 
Prospective, controlled, partially randomised, open label
Clinical utility
Test OncotypeDX MammaPrint
Gene signature 21-gene 70-gene
Tissue sample type FFPE Fresh tissue
Non-molecular clinical profiling 
technique/prognostic tool 
(comparator) 
Adjuvant! Online Adjuvant! Online
Sponsor NCI (co-ordinated by ECOG) EORTC/TRANSBIG
Countries participating USA and Canada Europe
Target for recruitment 11,248 [7887 recruited to date, 4500 
randomised (45%?)]
6600 [2100 (32%) randomised] 
Date of trial start/activation April 2006 September 2006
Estimated accrual time of 3 years and a total duration of 
6 years 
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Appendix 9 
MammaPrint test: quality assessment and 
summary of results
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Appendix 10 
MammaPrint and BluePrint tests: quality 
assessment and summary of results
Methodological quality assessment of studies investigating the 
MammaPrint and BluePrint tests
Study feature Qualities sought Stork-Sloots et al. (2009) (abstract)114
Sample of patients Inclusion criteria defined Y
Sample selection explained U
Adequate description of diagnostic criteria N
Clinical and demographic characteristics fully described N
Representative (random or consecutive sample) U
Assembled at a common (usually early) point in the course of their disease U
Complete (all eligible patients were included) U
Follow-up of patients Sufficiently long Y (5 years)
Outcome Objective U
Unbiased (e.g. assessment blinded to prognostic information) U
Fully defined U
Appropriate U
Known for all or a high proportion of patients U
Prognostic variable Fully defined, including details of method of measurement if relevant U
Precisely measured U
Available for all or a high proportion of patients U
If relevant, cut-point(s) defined and justified U
Analysis Continuous predictor variable analysed appropriately U
Statistical adjustment for all important prognostic factors U
Intervention subsequent to 
inclusion in cohort
Fully described U 
Intervention standardised or randomised U
N, no; U, unclear/not reported; Y, yes.
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Summary of results: MammaPrint and BluePrint tests
Study
Outcomes/end 
points Results Authors’ conclusions Comments
Stork-
Sloots et al. 
(2009)114 
(abstract)
Five-year 
survival
Profile classified: 66% (712) luminal-like; 18% 
(194) ERBB2-like; 16% (173) basal-like
13% of the samples positive for ER/PR did not 
express a luminal-like gene profile
ERBB2-like or basal-like profiles showed equally 
poor 5-year survival rates of ~65%
ERBB2-like subset of MammaPrint low-risk 
patients (15%) showed an 89% (95% CI 71% to 
100%) survival rate without trastuzumab treatment
Luminal-like subtypes separated into high and 
low risk by MammaPrint showed survival rates of 
56% (95% CI 46% to 68%) for high risk and 94% 
(95% CI 90% to 99%) for low risk
The developed multigene profile can 
classify breast tumours into luminal-, 
ERBB2- and basal-like subgroups. By 
combining this molecular subtyping 
with the MammaPrint risk classification, 
specific groups of patients can be 
recognised who are at high risk of 
recurrence. The low-risk patients within 
the luminal- and ERBB2-like subclasses 
have a very low risk of recurrence. 
Implementation of this knowledge can 
improve the clinical management of 
breast cancer patients
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Appendix 11 
PAM50 test: quality assessment and 
summary of results
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Appendix 12 
Breast Cancer Index: quality assessment 
and summary of results
Methodological quality assessment of study investigating the 
Breast Cancer Index
Study feature Qualities sought Jerevall et al. (2011)122
Sample of patients Inclusion criteria defined Y
Sample selection explained Y
Adequate description of diagnostic criteria Y
Clinical and demographic characteristics fully described Y
Representative (random or consecutive) Y (random)
Assembled at a common (usually early) point in the course of their disease Y
Complete (all eligible patients included) N 
Follow-up of patients Sufficiently long Y
Outcome Objective Y
Unbiased (e.g. assessment blinded to prognostic information) U
Fully defined Y
Appropriate Y
Known for all or a high proportion of patients Y
Prognostic variable Fully defined, including details of method of measurement if relevant Y
Precisely measured Y (detail provided)
Available for all or a high proportion of patients Y
If relevant, cut-point(s) defined and justified Y (detail provided)
Analysis Continuous predictor variable analysed appropriately Y
Statistical adjustment for all important prognostic factors Y
Intervention subsequent 
to inclusion in cohort
Fully described Y
Intervention standardised or randomised Y
N, no; U, unclear/not reported; Y, yes.
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Appendix 13 
Mammostrat test: quality assessment and 
summary of results
Methodological quality assessment of studies investigating the 
Mammostrat test
Study feature Qualities sought
Bartlett et al. 
(2010)124
Ring et al. 
(2009)125
Ross et al. 
(2008)126
Sample of patients Inclusion criteria defined Y Y Y
Sample selection explained Y Y Y
Adequate description of diagnostic criteria Y Y Y
Clinical and demographic characteristics fully 
described
Y N (NA for one of the 
cohorts used)
Y
Representative (random or consecutive sample) Y (consecutive) U (unclear if either) Y (from a RCT)
Assembled at a common (usually early) point in 
the course of their disease
Y U U
Complete (all eligible patients were included) Y U U
Follow-up of patients Sufficiently long Y U Y
Outcome Objective Y Y Y 
Unbiased (e.g. assessment blinded to prognostic 
information)
Y U Y
Fully defined Y Y Y
Appropriate Y Y Y
Known for all or a high proportion of patients Y U U
Prognostic variable Fully defined, including details of method of 
measurement if relevant
Y Y Y 
Precisely measured Y (detail provided) Y (detail provided) Y (detail provided)
Available for all or a high proportion of patients Y Y U
If relevant, cut-point(s) defined and justified Y (reference 
provided)
Y (detail provided) Y (detail provided)
Analysis Continuous predictor variable analysed 
appropriately
Y Y Y
Statistical adjustment for all important prognostic 
factors
U Y Y
Intervention subsequent 
to inclusion in cohort
Fully described Y N Y (from prespecified 
treatment arms)
Intervention standardised or randomised N N Y
N, no; NA, not available; U, unclear/not reported; Y, yes.
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Appendix 14 
IHC4 test: quality assessment and summary 
of results
Methodological quality assessment of the study investigating the 
IHC4 test
Study feature Qualities sought Cuzick et al. (2011)84
Sample of patients Inclusion criteria defined Y
Sample selection explained Y
Adequate description of diagnostic criteria Y
Clinical and demographic characteristics fully described Y
Representative (random or consecutive sample) Y
Assembled at a common (usually early) point in the course of their disease Y
Complete (all eligible patients were included) Y
Follow-up of patients Sufficiently long Y
Outcome Objective Y
Unbiased (e.g. assessment blinded to prognostic information) U
Fully defined U
Appropriate Y
Known for all or a high proportion of patients Y
Prognostic variable Fully defined, including details of method of measurement if relevant Y (reference provided)
Precisely measured Y
Available for all or a high proportion of patients Y
If relevant, cut-point(s) defined and justified Y
Analysis Continuous predictor variable analysed appropriately Y
Statistical adjustment for all important prognostic factors Y
Intervention subsequent to 
inclusion in cohort
Fully described Y
Intervention standardised or randomised Y
U, unclear/not reported; Y, yes.
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Summary of results: IHC4
Study
Outcomes/
end points Results Authors’ conclusions Comments
Cuzick et 
al. (2011)84
Distant 
recurrence 
(within 
10 years)
TTDR
G1: 195 recurrences of which 145 were distant recurrences; in 
LN– women there were 101 recurrences of which 67 were distant 
recurrences
The median IHC4 score for all patients was –4.2 (IQR –29.9 to 29.9). 
The HR for a change from the 25th to the 75th percentile of the IHC4 
score for all patient was 5.7 (95% CI 3.4 to 9.7) in univariate analysis 
and 3.9 (95% CI 2.4 to 6.7) when added to clinical score
G2: IHC4 score was highly significantly predictive of outcome for 
a change from the 25th to 75th percentile in a univariate analysis 
(HR 4.8, 95% CI 2.2 to 10.2), and gave similar results when added 
to clinical score (HR 4.4, 95% CI 2.0 to 9.3, Δχ2 = 26.61, p < 0.0001)
Additional studies are 
needed to determine the 
general applicability of the 
IHC4 score
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Appendix 15 
NPI+ test: quality assessment and summary 
of results
Methodological quality assessment of the studies investigating 
the NPI+ test
Study feature Qualities sought
Green et al. and 
Nottingham 
Prognostics128
Nottingham 
Prognostics 
(abstract)128
Sample of patients Inclusion criteria defined Y U
Sample selection explained U U
Adequate description of diagnostic criteria N U
Clinical and demographic characteristics fully described N U
Representative (random or consecutive) U U
Assembled at a common (usually early) point in the course of their disease U U
Complete (all eligible patients were included) N U
Follow-up of patients Sufficiently long Y U
Outcome Objective Y U
Unbiased (e.g. assessment blinded to prognostic information) U U
Fully defined N U
Appropriate Y U
Known for all or a high proportion of patients Y U
Prognostic variable Fully defined, including details of method of measurement if relevant Y U
Precisely measured Y (detail provided) U
Available for all or a high proportion of patients Y U
If relevant, cut-point(s) defined and justified Y (detail provided) U
Analysis Continuous predictor variable analysed appropriately Y U
Statistical adjustment for all important prognostic factors Y U
Intervention subsequent to 
inclusion in cohort 
Fully described U U
Intervention standardised or randomised U U
N, no; U, unclear/not reported; Y, yes.
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Summary of results: NPI+ test
Study Outcomes/end points Results Authors’ conclusions Comments
Green et al. and 
Nottingham Prognostics128
(All AIC)
[CIC information has been 
removed]
[CIC information has been 
removed]
[CIC information has been 
removed]
[CIC information 
has been 
removed]
Nottingham Prognostics 
(abstract)128
(All AIC)
[CIC information has been 
removed]
[CIC information has been 
removed]
[CIC information has been 
removed]
NR, not reported.
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Appendix 16 
Tabulated summary of cost-effectiveness 
studies addressing the use of MammaPrint 
to guide the selection of adjuvant 
chemotherapy regimes in breast 
cancer management
Parameter Retel et al (2010)133 Chen et al (2010)132
Country Netherlands USA
Perspective (costs) Health care Payer perspective
Comparators (NPI, 
Adjuvant! Online)
Adjuvant! Online vs. MammaPrint
St Gallen vs. MammaPrint
Adjuvant! Online vs. MammaPrint
Starting age in the 
model
50 years Unclear 
Population Early operable breast cancer, LN–, ER+, HER2+/– ≤ 60 years, ER+/–, LN–
Model structure (type, 
health states)
Markov model with four mutually exclusive health states 
(disease free, relapse, distant metastasis and death)
Markov model with three mutually exclusive health states 
(no recurrence, death from cancer, death from other 
causes)
Definition of relapse Includes local, regional recurrence, secondary primary and 
contralateral breast cancer
Relapse included in terms of cost only (local, regional, 
contralateral, distant)
Time horizon 20 years Lifetime (99% of patients dead)
Endocrine therapy 
regime
All patients are assumed to receive 2.5 years of tamoxifen 
followed by 2.5 years of aromatase inhibitor
Endocrine therapy only given to ER+ patients; tamoxifen 
for patients receiving endocrine therapy
Chemotherapy regime 80% receive 6 cycles of FEC; 10% receive 6 cycles of 
docetaxel, doxorubicin and cyclophosphamide (TAC); 10% 
receive AC + paclitaxel (4 + 12 cycles) in combination with 
trastuzumab
Cost based on the following chemotherapy regimens: 
alkylating agents (58%), anthracyclines (51%), taxanes 
(25%) and antimetabolites (18%)
Benefit of 
chemotherapy
HR for trastuzumab: 0.64 (95% CI 0.54 to 0.76) Relative risk: 26% in ER+; 32% in ER–
Adverse events CHF was included Implicitly included in the cost of chemotherapy and 
QALYs
Quality of life EQ-5D; utilities extracted from Lidgren et al.148
No adjuvant systemic treatment (first year): 0.935
DFS (years 2–20): 0.935
Chemotherapy (year 1): 0.620
Endocrine therapy (years 1–5): 0.744
Trastuzumab (year 1): 0.620
CHF: 0.700
Relapse: 0.779
Distant recurrence: 0.685
Chemotherapy: 0.70 (6 months)
Recurrence free: 0.98
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Parameter Retel et al (2010)133 Chen et al (2010)132
Costs and resources 
used
Cost expressed in 2005 euros; costs of health states 
extracted from Lidgren et al.144
Chemotherapy: €8596
Endocrine therapy: €822
Trastuzumab: €36,298
CHF: €3453
Relapse (year 1): €12,181
Relapse (after): €2359
Distant metastasis (year 1): €14,303
Distant metastasis (after): €6813
MammaPrint: €2675
Cost expressed in 2007 US dollars
Chemotherapy: $35,964
Cost no recurrence (per year): $5928
Recurrence: $57,424
Terminal (cancer): $76,557
Terminal (other): $65,016
MammaPrint: $4200
Endocrine therapy (per year): $1383
Discounting Costs: 4%; benefits: 1.5% Costs: 3%; benefits: unclear
% of HER2+ 10% HER2+ excluded as assumed to receive trastuzumab 
anyway
Results for St Gallen or NCCN129 are not presented in this table.
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Appendix 17 
Critical appraisal checklist of the economic 
model comparing MammaPrint with 
Adjuvant! Online
Modelling assessments should include:
Retel et al. 
(2010)133
Chen et al. 
(2010)132
1 A statement of the problem Yes Yes
2 A discussion of the need for modelling vs. alternative methodologies Yes Yes
3 A description of the relevant factors and outcomes Yes Yes
4 A description of the model, including reasons for this type of model, and a specification of the scope, 
including time frame, perspective, comparators and setting. Note: n = number of health states within 
submodel
Yes Yes
5 A description of the data sources (including subjective estimates) with a description of the strengths 
and weaknesses of each source with reference to a specific classification or hierarchy of evidence
Yes Yes
6 A list of assumptions pertaining to the structure of the model (e.g. factors included, relationships and 
distributions) and the data
Yes Yes
7 A list of parameter values that will be used for a base-case analysis and a list of the ranges in those 
values that represent appropriate confidence limits and that will be used in a sensitivity analysis
Yes Yes
8 The results derived from applying the model for the base case Yes Yes
9 The results of the sensitivity analyses: unidimensional, best/worst case, multidimensional (Monte 
Carlo/parametric), threshold
Yes Yes
10 A discussion of how the modelling assumptions might affect the results, indicating both the direction 
of the bias and the approximate magnitude of the effect
Yes Yes
11 A description of the validation undertaken, including the concurrence of experts, internal consistency, 
external consistency and predictive validity
Unclear Unclear
12 A description of the settings to which the results of the analysis can be applied and a list of factors 
that could limit the applicability of the results
Unclear Unclear
13 A description of research in progress that could yield new data that could alter the results of the 
analysis
Yes Unclear
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Appendix 18 
Tabulated summary of cost-effectiveness 
studies addressing the use of OncotypeDX 
to guide the selection of adjuvant 
chemotherapy regimes in breast 
cancer management
Parameters Tsoi et al. (2010)135 OHTA (2011)134,136
Country Canada
Perspective (costs) Health care
Comparators (NPI, 
Adjuvant! Online)
Adjuvant! Online vs. Adjuvant! Online + RS
Starting age in the 
model
50 years
Population ER+, LN–, HER2– early breast cancer
Model structure (type, 
health states)
Markov model with five health states (risk reclassification, 
chemotherapy, recurrence free, distant recurrence and 
death)
Definition of relapse Distant metastases only Distant metastases only
Time horizon Lifetime
Endocrine therapy 
regime
5 years of tamoxifen
Chemotherapy regime Four cycles of AC – in the base case TC or FEC-D
Benefit of 
chemotherapy
30% relative risk reduction Low: no benefit; intermediate: 39% reduction; high: 74% 
reduction
Adverse events Minor (60%), major (5%)
Definition of high risk Intermediate was grouped with high risk for RS
For Adjuvant! Online, arbitrary decision so that same 
proportion of low cases between Adjuvant! Online and RS
Adjuvant! Online: low risk: mortality < 9%; intermediate risk: 
9% ≤ mortality < 17%; high risk: mortality ≥ 17%
Quality of life Different valuation methods (VAS – SG)
Adjuvant! Online/RS: 0.94
Major toxicity: 0.8
Minor toxicity: 0.9
No toxicity: 0.94
Recurrence free after chemotherapy: 0.98
Distant recurrence: 0.75
VAS–SG, visual analogue scale – standard gamble.
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Parameters Tsoi et al. (2010)135 OHTA (2011)134,136
Costs and resources 
used
2008 Canadian dollars; inflation rate assumed to be 5% 
per year
Oncotype: C$4,404
Chemotherapy per cycle: C$768.3
Major non-fatal toxicity: C$2459
Major fatal toxicity: C$28,385
Recurrence free (yearly): C$444
Tamoxifen (5 years): C$678
Distant metastases (21 months): C$35,023
Terminal care (last 3 months): C$21,367
The majority of costs have been adapted from Tsoi et al.135 
to reflect 2010 prices. The costs of OncotypeDX (C$4191) 
and chemotherapy have been updated
Discounting 5% for both costs and benefits
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Appendix 19 
Critical appraisal checklist of the economic 
model comparing OncotypeDX with 
Adjuvant! Online
Note that Tsoi et al.135 (2010) and the OHTA analysis134,136 were assessed together as they were based on the same economic model.
Modelling assessments should include
Tsoi et al. (2010)135/
OHTA134,136
1 A statement of the problem Yes
2 A discussion of the need for modelling vs. alternative methodologies Yes
3 A description of the relevant factors and outcomes Yes
4 A description of the model, including reasons for this type of model, and a specification of the scope, including time 
frame, perspective, comparators and setting. Note: n = number of health states within submodel
Yes
5 A description of the data sources (including subjective estimates) with a description of the strengths and 
weaknesses of each source with reference to a specific classification or hierarchy of evidence
Yes
6 A list of assumptions pertaining to the structure of the model (e.g. factors included, relationships and distributions) 
and the data
Yes
7 A list of parameter values that will be used for a base-case analysis and a list of the ranges in those values that 
represent appropriate confidence limits and that will be used in a sensitivity analysis
Yes
8 The results derived from applying the model for the base case Yes
9 The results of the sensitivity analyses: unidimensional, best/worst case, multidimensional (Monte Carlo/parametric), 
threshold
Yes
10 A discussion of how the modelling assumptions might affect the results, indicating both the direction of the bias and 
the approximate magnitude of the effect
Yes
11 A description of the validation undertaken, including the concurrence of experts, internal consistency, external 
consistency and predictive validity
Unclear
12 A description of the settings to which the results of the analysis can be applied and a list of factors that could limit 
the applicability of the results
Unclear
13 A description of research in progress that could yield new data that could alter the results of the analysis Yes
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Appendix 20 
Final scope
NATIONAL INSTITUTE FOR HEALTH AND CLINCIAL EXCELLENCE
Diagnostics Assessment Programme
Gene expression profiling and expanded immunohistochemistry tests to guide selection of 
chemotherapy regimes in breast cancer management
Final scope
April 2011
1 Introduction
The Medical Technologies Advisory Committee identified the Randox Breast Cancer Array 
(Randox BCA), a gene expression profiling test, as potentially suitable for evaluation by the 
Diagnostics Assessment Programme (DAP) on the basis of a briefing note. The Randox BCA 
is manufactured by Randox Laboratories Limited. This document has been updated following 
feedback from attendees at the scoping workshop held on 2 March 2011 and the assessment 
subgroup meeting held on 11 April 2011.The scope has been extended to include gene expression 
profiling and expanded immunohistochemistry tests for guiding selection of chemotherapy 
regimes in breast cancer management. The final scope outlines the approach for assessing the 
clinical and cost effectiveness components of this evaluation.
2 Target condition/indication
2.1 Breast cancer background
Breast cancer is the most common cancer in women in England. In 2008 there were 39,681 new 
cases diagnosed, an increase of 1,633 cases compared with 2007 (4%). Just over 10,000 women 
died from breast cancer in England in 2008, a rate of 26 deaths per 100,000 women. It is the 
second most common cause of cancer death in women, after lung cancer.
One in eight women will develop breast cancer at some point in their lives. Age is a known risk 
factor for developing breast cancer. Four out of every five new cases are diagnosed in women 
aged 50 and over, with cases peaking in the 60 to 64 age group (14% of all new cases).
Earlier detection and improved treatment for breast cancer have meant that survival rates have 
risen. Although incidence rates for breast cancer increased by more than 85 per cent between 
1971 and 2008, mortality rates have fallen by 33% since 1971. Survival from breast cancer is 
higher than that for cervical cancer and much higher than that of other major cancers in women 
– lung, colorectal and ovarian.
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2.2 Diagnosis
Sections 2.2 through 2.5 have been adapted from NICE clinical guideline – CG80 – Breast cancer 
(early & locally advanced).
In most cases, whether suspected at breast screening or through presentation to the GP, diagnosis 
in the breast clinic is made by triple assessment (clinical assessment, mammography and/or 
ultrasound imaging with core biopsy and/or fine needle aspiration cytology).
2.3 Primary systemic therapy (neoadjuvant therapy)
Neoadjuvant treatment in oncology is defined as additional treatment preceding the main 
therapy option; surgery is the main therapy option. Optimal management of breast cancer 
includes local control in the breast and the prevention of metastatic spread. Some patients will 
have developed occult metastatic spread before clinical or radiological detection of the primary 
tumour. There are also patients whose tumours at presentation are too large to be considered 
appropriate for breast conservation. Primary systemic therapy of invasive breast cancer may be 
offered in an attempt to enable breast conserving treatment and subsequent surgery (mastectomy 
or wide local excision). Histological examination is usually conducted to inform the treatment 
decision. Radiotherapy may then be offered according to similar criteria to those patients 
presenting de novo. Primary systemic treatment involves the use of systemic therapy, either 
chemotherapy or endocrine therapy, after diagnosis but before definitive surgery. Primary 
systemic therapy (also referred to as neoadjuvant therapy) can be successfully used to shrink 
the size of the primary tumour such that breast conservation may be achieved with a good 
cosmetic result but with a slightly higher risk of local recurrence comapred with mastectomy. 
Primary systemic therapy can also identify the efficacy of the systemic treatment regimen since 
the primary tumour is available to monitor response to the therapy. This option is of course 
not available if the primary tumour has been removed surgically. The use of primary systemic 
treatment allows targeting of occult metastatic tumour deposits at an earlier stage than the 
conventional approach of postoperative chemotherapy. Randomised trials of primary systemic 
therapy have failed to show a significant survival benefit, but more recent studies using current 
chemotherapy regimens have been able to identify subgroups of patients, such as those achieving 
complete pathological response at surgery, that have a survival advantage.
2.4 Surgery
Surgery is the mainstay of treatment for invasive breast cancer and is usually used as the first 
treatment option.
2.5 Postoperative assessment and adjuvant treatment planning
Following surgery, further information is obtained by histological examination, which provides 
prognostic information including histological grade, nodal status and tumour size. Factors 
predicting response to specific targeted therapies including hormone receptor and the human 
epidermal growth factor receptor 2 (HER2) statuses are also evaluated. These prognostic and 
predictive factors, together with patient characteristics, enable subsequent treatment planning to 
be undertaken by the breast cancer multidisciplinary team (MDT).
2.5.1 Predictive factors
Hormone receptors
Approximately 70% of invasive breast cancers are oestrogen receptor alpha (ER) positive and the 
level of ER assessed immunohistochemically provides useful predictive information regarding 
efficacy of endocrine therapy. ER status therefore forms part of the UK minimum dataset for 
histopathology reporting of invasive breast cancer. ER status is routinely determined on all 
invasive breast cancers and reported using a standardised technique (such as the Allred scoring 
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system). The prediction of likelihood of response of a breast cancer to endocrine therapies using 
ER assessment is not, however, precise; some patients with ER-positive disease will not respond 
to endocrine therapies. Additional discriminatory markers to predict response to endocrine 
agents with greater accuracy may prove useful. Progesterone receptor (PR) status has been 
considered as such an additional marker, but it does not appear to add useful information in 
ER-positive tumours. Divergent ER and PR status is uncommon (for example < 5% of cases 
are ER-negative but PR-positive) and the value of the addition of PR status in this situation 
in predicting likelihood of response to endocrine therapy is also unclear. Nevertheless, PR 
examination is routinely performed on all invasive tumours by some laboratories.
HER2 status
The clinical importance of amplification of the human epidermal growth factor receptor gene 
HER2 in breast cancer was recognised in 1987 and an association with poorer patient outcome 
was subsequently reported. HER2 positivity (protein over-expression or gene amplification) 
is seen in approximately 15% of early invasive breast cancer. Women whose breast cancers are 
HER2-positive may benefit from Trastuzumab therapy. Therefore, the HER2 status of an invasive 
breast cancer has become an essential part of selection of this therapy. Diagnostic tests for HER2 
over-expression and gene amplification include immunohistochemistry (IHC) and fluorescence 
in situ hybridisation (FISH). Breast cancers are reported as HER2-negative or HER2-positive 
according to standardized guidelines (i.e. those scoring 3+ by IHC, or 2+ and FISH amplified, 
as positive).
Determining hormone recptor and HER2 status – Immunohistochemistry
IHC is used to identify specific molecules in the breast cancer sample. Specifically, IHC is 
commonly used to show whether or not the cancer cells have hormone receptors (ER and/or 
PR) and/or HER2 receptors on their surface. The tissue is treated with antibodies that bind to 
the specific molecule. These are made visible under a microscope by using a colour reaction, a 
radioisotope, colloidal gold, or a fluorescent dye.
 ■ IHC for hormone receptor testing: guidelines for pathology reporting of breast disease 
recommend that results for the ER/PR be reported as negative or positive and accompanied 
by an Allred score. This score is based on the sum of two measures including 1) a percentage 
that tells you how many cells out of 100 stain positive for hormone receptors – a number 
between 0% (none have receptors) and 100% (all have receptors) is given and 2) a number 
between 0 and 3 is given to indicate the intensity of their staining. ‘0’ means that no receptors 
are present, ‘1’ a small number present, ‘2’ a medium number, and ‘3’ a large number.
 ■ IHC for HER2 receptor testing: guidelines for pathology reporting of breast disease 
recommend that results for HER2 be reported as a semi-quantitative system based on the 
intensity of reaction product and percentage of membrane positive cells, giving a score range 
of 0–3+. Samples scoring 3+ are regarded as unequivocally positive, and those scoring 0/1+ 
as negative. Borderline scores of 2+ require confirmation using another analysis system, 
ideally fluorescence in situ hybridisation.
 ■ Fluorescence in situ hybridisation (FISH): a laboratory technique used to look at genes or 
chromosomes in cells and tissues. Pieces of DNA that contain a fluorescent dye are made in 
the laboratory and added to cells or tissues on a glass slide. When these pieces of DNA bind 
to specific genes or areas of chromosomes on the slide, they light up when viewed under a 
microscope with a special light. HER2 FISH testing results are conventionally expressed as 
the ratio of HER2 signal to chromosome 17 signal. Tumours showing a ratio > 2 should be 
considered as positive.
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Expanded IHC tests are defined as those tests that measure biomarkers other than or in addition 
to ER, PR and HER2. These tests aim to provide similar information to gene expression profiling 
tests, in particular, the likelihood of cancer recurrence.
2.5.2 Adjuvant treatment planning
Adjuvant treatment in oncology is defined as additional treatment following the main therapy 
option; surgery is the main therapy option. While defined in this way, adjuvant treatment is 
viewed as an integral part of breast cancer management. Such adjuvant therapy typically consists 
of one or more of radiation, chemotherapy, and/or endocrine therapy/biological therapy. 
Planning adjuvant treatment is complex and incorporates a variety of prognostic and predictive 
factors. There are a number of tools to help the MDT with decisions on adjuvant treatment 
planning which assess prognosis and may estimate potential treatment benefit. These are 
described in the section on comparators (section 4.3).
2.6 Care pathway
The care pathway for this assessment can be ascertained from existing guidelines. NICE clinical 
guideline – CG80 – ‘Breast cancer (early & locally advanced): diagnosis and treatment’ should be 
used in the first instance. Other guidelines that may provide supplementary information include:
 ■ St Gallen consensus recommendations
 ■ National Comprehensive Cancer Network guidelines (NCCN).
3 Gene expression profiling
Greater understanding of the human genome, and subsequently, the genetic determinants 
of cancer and other diseases, has led to an array of genetic tests for use in health care. Gene 
expression profiling (GEP) is a relatively new technology for identifying genes whose activity may 
be helpful in assessing disease prognosis and guiding therapy.
GEP tests assess the identity and number of messenger RNA (mRNA) transcripts in a specific 
tissue sample. As only a fraction of the genes encoded in the genome of a cell are expressed by 
being transcribed into mRNA, GEP provides information about the activity of genes that give rise 
to these mRNA transcripts. Given that mRNA molecules are translated into proteins, changes 
in mRNA levels are ultimately related to changes in the protein composition of the cells, and 
consequently to changes in the properties and functions of tissues and cells (both normal and 
malignant) in the body.
Various assays are used in the management of breast cancer. These assays investigate the 
expression of specific panels of genes (also known as a gene profile or gene signature). They 
work by making use of different techniques to measure mRNA levels in breast cancer specimens 
including real-time reverse transcription-polymerase chain reaction (RT-PCR) and DNA 
microarrays. Many of these assays have been designed to measure the risk of cancer recurrence. 
Other uses of the assays include breast cancer sub-typing (using molecular classification systems), 
predicting the likely benefit from certain types of therapy (e.g. chemotherapy), or diagnosing 
breast cancer.
There are various ways of preparing the RNA, and different protocols used to prepare 
the specimens (e.g. formalin-fixed, paraffin-embedded, snap-frozen and fresh samples). 
Furthermore, there are varying algorithms that can be used to combine the raw data to obtain a 
summary measure. All of these factors can affect the reproducibility and reliability of GEP tests.
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The complexity of gene profiling has led to numerous efforts to develop IHC markers that are able 
to provide similar information to that given by GEP tests. One such test is IHC4, which looks for 
the presence of a proliferation marker, Ki67 in addition to testing for ER, PR and HER2.
The detailed use of gene expression profile tests, for improving chemotherapy choices for breast 
cancer is not currently covered in NICE guidance.
3.1 Improving chemotherapy choices
Systemic therapy options for breast cancer management include endocrine treatments, targeted 
biological agents and chemotherapy.
The decision about whether or not to use chemotherapy is a major challenge in breast cancer 
management. Chemotherapy is defined as the use of cytotoxic medications with the intention 
of preventing cancer recurrence in patients. Chemotherapy regimens containing Anthracycline 
have been used routinely in the adjuvant setting. It should be noted that, for the purposes of this 
assessment, chemotherapy does not include other forms of systemic therapy such as endocrine 
treatments or targeted biological therapy.
Although chemotherapy can reduce the likelihood of cancer recurrence and death for women 
with breast cancer, it has considerable adverse effects. Many women with early-stage breast 
cancer are advised to undergo chemotherapy, however, not all will benefit from it and some may 
remain free of disease recurrence at 10 years without it.
GEP and expanded IHC tests may be capable of better identifying those patients that are likely 
and unlikely to benefit from chemotherapy than conventional clinical and pathological risk 
assessment. Two types of information are most likely to be useful in this context. These are the 
molecular sub-type of the breast tumour and an indication of the likelihood of cancer recurrence. 
As well as providing information on the likely outcome/course of the cancer (prognostic 
information), molecular sub-typing and recurrence risk may also provide information on the 
likelihood of the patient benefitting from chemotherapy (predictive information). Predictive 
and prognostic information may be used to inform chemotherapy decisions in breast cancer 
management. Information on molecular sub-typing and recurrence risk can be found below.
3.1.1 Breast tumour sub-typing using molecular classification systems
Micro-array-based gene expression studies have revealed that, in addition to being clinically 
heterogeneous, breast cancer is also a molecularly heterogeneous disease. As a result, distinct 
molecular sub-types of breast cancer that exhibit different gene expression patterns and clinical 
outcomes have been developed. The prognosis and chemotherapy sensitivity of the various 
molecular sub-types are different. Luminal-like cancers tend to have the most favourable long-
term survival compared with the others, whereas basal-like and HER2-positive tumours have 
significantly worse long-term survival and are more sensitive to chemotherapy. However, it is 
important to note that these correlations are expected as there is a strong association between the 
molecular sub-type and conventional histopathologic variables (namely, ER and HER2 status).
Numerous classification systems have been published. The first of these was described by Perou 
and colleagues in 2000. Since then, this classification system has been refined to distinguish 
the luminal group into luminal A and luminal B, and the classification of normal-like is less 
commonly used as it is believed to be a potential artefact from the initial study. This classification 
system is commonly cited in the literature and includes the following sub-types, the IHC 
approximation is provided in brackets (ER = oestrogen receptor, PR= progesterone receptor, 
HER2 = human epidermal growth factor receptor 2):
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 ■ Luminal A (ER positive and generally HER2 negative)
 ■ Luminal B (ER positive (but a lower number of receptors than luminal A) and generally 
HER2 negative)
 ■ HER2 amplified (predominantly HER2 positive and ER negative)
 ■ Basal-like (generally ER, PR and HER2 negative (triple negative))
 ■ Unclassified/5NP (generally ER, PR, HER2, EGFR and CK5 negative).
Initial work to identify the molecular sub-types used hierarchical clustering to design a 
classification model (single sample predictor (SSP)) that allows a breast cancer to be classified 
using a nearest centroid classifier. Essentially, this means that new tumours are sub-typed based 
on how similar their gene profile is to tumours used and sub-typed in the initial data-set for the 
SSP. Several limitations of SSPs have been posited in the literature. These include the effect of the 
breast tumour samples and genes selected in defining the molecular sub-types. Consequently, 
it has been observed that different SSPs may not reliably assign the same tumour to the same 
molecular sub-type. More recently, a sub-type classification model based on a parametric 
clustering technique defined by three gene modules has been suggested to overcome the 
challenges of SSPs.
Although there is a body of literature on molecular classification systems, GEP tests used for 
molecular sub-typing, in most cases, are at the early stages of the validation pathway. Generally, 
studies of diagnostic test accuracy in defining the molecular sub-types when comapred with the 
classification based on ER, PR and HER2 status can be found in the literature.
Clinical experts contacted during scoping felt that molecular classification systems showed 
great potential, however, their views on the impact of these classification systems on treatment 
decisions (compared with current clinical practice) were mixed. Some experts felt that molecular 
classification systems were useful for predicting non-response to neoadjuvant chemotherapy. 
In addition, the basal-like classification captured other individuals with a poor prognosis who 
may be missed if only using the triple negative (ER/PR/HER2 negative) diagnosis by IHC. Other 
experts felt that little was known about the concordance between these molecular classifications 
with their prognostic and predictive value. Clinical experts also felt that if molecular classification 
systems were to be used in the clinical setting, they would do so as an adjunct to current clinical 
practice rather than replacing any part of it.
The impact of molecular classification systems on breast cancer management, when added to 
current clinical practice, is difficult to determine from the published literature. The literature 
on the use of molecular signatures in predicting non-response (or response) to neoadjuvant 
chemotherapy suggests that different molecular sub-types respond differently to neoadjuvant 
chemotherapy. However, it may also be possible to use IHC as a surrogate marker for the 
molecular classifications. An area of potential benefit may be that of individuals with basal-like 
breast cancer who are not identified using the triple negative (ER/PR/HER2 negative) diagnosis 
by IHC. Although figures in the literature vary, triple negatives may account for approximately 
7–20% of all breast cancers and it is thought that approximately 85% of all basal type tumours 
may be triple negatives. The literature suggests that many breast cancer researchers believe that 
molecular classification systems will change with further subdivision of these sub-types.
At present, molecular classification systems are not routinely used by physicians in the NHS in 
England. Guidelines on the use of molecular classification systems in breast cancer management 
were not identified during scoping.
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3.1.2 Recurrence risk
Therapeutic decisions for breast cancer management are based on risk estimates. Tests that 
improve such estimates have the potential to affect clinical outcomes in breast cancer patients 
either by avoiding unnecessary chemotherapy with its attendant morbidity or by employing it 
where it might not otherwise have been used, thereby reducing recurrence risk.
Much of the literature on gene expression profile test validation focuses on the analytical validity 
and clinical validity of those tests that measure recurrence risk. Some tests are further down the 
validation pathway and may have evidence on the clinical utility of the technology.
Tests measuring recurrence risk combine the measurements of gene expression levels within the 
tumour to produce a number associated with the risk of disease recurrence. These tests aim to 
improve on risk stratification schemes based on clinical and pathological factors currently used in 
clinical practice (see section 4.3).
Existing breast cancer guidelines have recommended the use of gene expression profile tests to 
help guide chemotherapy treatment decisions. For example, the 2009 (11th) St Gallen consensus 
meeting publication states ‘the Panel supported the use of a validated multigene-profiling assay, if 
readily available, as an adjunct to high-quality phenotyping of breast cancer in cases in which the 
indication for adjuvant chemotherapy remained uncertain.’
At present, GEP tests measuring recurrence risk are not routinely used by physicians in the NHS 
in England.
3.2 Scoping workshop feedback
Scoping workshop attendees felt that both molecular sub-typing and recurrence risk 
measurements may be used to stratify patients when considering chemotherapy. Attendees felt 
that these tests may be used with current clinical practice as opposed to replacing any part of 
current clinical practice.
The extensive use of chemotherapy in breast cancer management was discussed. Attendees felt 
that patients were over-treated with chemotherapy as it is difficult to identify those patients 
who are less likely to benefit from its use. This has been noted both anecdotally and in the 
scientific literature.
Therefore, the scope has been expanded from an evaluation of Randox BCA to include other gene 
expression profiling tests that are likely to influence the use of chemotherapy in breast cancer 
management. In addition, attendees felt it was important to include IHC tests that may fulfil 
this purpose.
Details of the interventions can be found in section 4.2 – Table 1.
4 Scope of the evaluation
The assessment has been expanded to include gene expression profiling tests and expanded 
immunohistochemistry tests that are likely to influence the use of chemotherapy in breast 
cancer management.
4.1 Population
People diagnosed with early invasive breast cancer.
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Note: Although the population for the assessment is broad, some GEP and expanded IHC tests 
may only be used in a sub-population. For example, women with early-stage invasive breast 
cancer (stage I, II or III), lymph node negative or positive (up to 3), oestrogen receptor positive 
or negative and HER2 positive or negative. Additionally, men with breast cancer should also be 
included in the assessment if data are available on the use of these technologies in men.
4.2 Interventions
Several GEP and expanded IHC tests that are likely to impact the use of chemotherapy in breast 
cancer management exist. Technologies identified during scoping are summarised in Table 1.
TABLE 1 Interventions identified during scoping
Test Manufacturer Purpose Description Target population*
Gene expression profiling tests
Randox BCA Randox Laboratories Molecular Sub-
typing + Recurrence risk
Low density biochip array
23 gene array
All women with breast 
cancer
Breast Cancer Index bioTheranostics Recurrence risk RT-PCR 
Assessment of H / I ratio 
(HOXB13 : IL17BR) and MGI 
(Molecular Grade Index) 
ER+, LN–
MammaPrint Agendia Recurrence Risk MICROARRAY
70 gene array
Early-stage (stage I or II), 
LN– or LN+ (up to 3), ER+ 
or ER–
MammaPrint +  
BluePrint
Agendia Recurrence risk + Molecular 
Sub-typing
MICROARRAY
70 gene array + 80 gene 
array
Early-stage (stage I or II), 
LN– or LN+ (up to 3), ER+ 
or ER–
OncotypeDX Genomic Health Recurrence risk and 
Predictive of chemotherapy 
benefit
RT-PCR
21 gene assay
Early-stage (stage I or II), 
LN–, ER+ patients who will 
be treated with hormone 
therapy
PAM50 ARUP Laboratories Inc. Recurrence risk and 
Predictive of chemotherapy 
benefit 
RT-qPCR
55-gene assay
Early-stage (stage I or II), 
LN–, ER+ patients who will 
be treated with hormone 
therapy
Expanded immunohistochemistry tests
IHC4 N/A Recurrence risk IHC test based on ER, PgR, 
HER2 and Ki67 
Plus clinical factors (age, 
nodal status, tumour 
size, grade, randomised 
treatment)
ER+
Mammostrat Clarient Recurrence risk IHC test based on P53, 
HTF9C, CEACAM5, NDRG1 
and SLC7A5 markers
Early-stage (stage I or II), 
LN–, ER+ patients who will 
be treated with hormone 
therapy
NPI+ Nottingham Prognostics A clinical decision making 
tool kit for all operable 
breast cancer patients 
providing prognostic and 
therapeutic predictive 
outputs
A multistep 
approach combining 
biological assessed 
by immunocytochemistry 
and traditional 
pathological and clinical 
variables
All patients with early 
(stage I or II) invasive breast 
cancer
*ER+/– = oestrogen receptor positive or negative, LN+/– = lymph node positive or negative.
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4.3 Comparators
Two existing algorithms are in use for predicting survival and the utility of adjuvant therapy in 
breast cancer and should serve as comparators. These include:
1. Nottingham Prognostic Index 
2. Adjuvant! Online
Nottingham Prognostic Index (NPI): the NPI is a well-established, validated and widely used 
method of predicting survival for operable primary breast cancer. This index was based on a 
retrospective analysis of 9 factors in 387 patients. Only 3 of the factors (tumour size, stage of 
disease, and tumour grade) remained significant on multivariate analysis. The NPI is calculated 
as: lymph node (LN) stage (1–3) + grade (1–3) + maximum tumour diameter, giving an observed 
range of NPI from 2.08 (LN negative, grade 1, 0.4 cm) to 6.8 (LN stage 3, grade 3, size 4.9 cm).
Adjuvant! Online: the Adjuvant! Online computer program is designed to provide estimates of 
the benefits of adjuvant endocrine therapy and chemotherapy. A version of Adjuvant! Online 
that will include HER2 status and the potential benefit of Trastuzumab is in development. It 
is believed that the current version (version 8) may underestimate the risk of mortality and 
does not take into account the negative impact of HER2 positivity or how this may be affected 
by Trastuzumab. Patient and tumour characteristics are entered into the program and provide 
an estimate of the baseline risk of mortality or relapse for patients without adjuvant therapy. 
Information about the efficacy of different therapy options is derived from Early Breast Cancer 
Trialists Collaborative Group meta-analyses in order to provide estimates of reduction in risk 
at 10 years of breast cancer related death or relapse for selected treatments. Results may be 
displayed and printed in graphical form to aid shared decision-making. Attendees at the scoping 
workshop suggested that there were some difficulties in applying the Adjuvant! Online data to the 
UK population.
4.4 Health outcomes
The outcomes of interest are the morbidity and mortality associated with invasive breast cancer 
and its treatment. These may include: 
 ■ Distant recurrence free survival – 10 years
 ■ Health-related quality of life, such as, adverse events associated with chemotherapy
Note: The health outcomes stated above are preferred for use in the assessment. However, the 
available data may be limited. In such cases, other data may be used. For example, total disease 
recurrence at 5 years or pathological complete response. 
4.5 Healthcare setting
These tests will be assessed for use in the adjuvant setting and are expected to be used in 
secondary and tertiary care.
Note: the neoadjuvant setting was considered for inclusion in the scope, however, it was 
anticipated that evidence on the use of these tests in the neoadjuvant setting would be lacking. 
Therefore, it was decided that the assessment should focus on the adjuvant setting only. 
5 Modelling approach
Tests to be included in the economic modelling will need to have sufficient data to allow 
modelling to proceed. The level of data required will be set by the external assessment group 
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(EAG). Both predictive and prognostic information may be used to inform chemotherapy 
decisions. Therefore, the EAG will seek to undertake economic evaluation of tests that provide 
either or both types of information.
5.1 Modelling possibilities
5.1.1 Molecular sub-typing
Guidelines recommending treatment decisions based on molecular sub-typing have not been 
uncovered during scoping. To allow the modelling of the role of sub-typing tests it would be 
necessary to link the accuracy of a diagnostic test to final health outcomes. Distinct molecular 
sub-types of breast cancer that exhibit different gene expression patterns and clinical outcomes 
have been developed. The prognosis and chemotherapy sensitivity of the various molecular 
sub-types are different. However, GEP tests used for molecular sub-typing, in most cases, are at 
the early stages of the validation pathway. Likely changes in treatment planning resulting from 
the results of sub-typing tests are as yet unclear. 
5.1.2 Recurrence risk
Validation studies exist for the diagnostic technologies dealing with recurrence risk. Data on 
analytical validity, clinical validity, clinical utility and economic evaluations (described in section 
5.2 below) are available in the published literature for certain diagnostic technologies. The 
availability of these data is expected to make it possible to conduct a thorough assessment.
5.2 Existing Models
Economic models for certain diagnostic technologies exist in the published literature (e.g. for 
MammaPrint and OncotypeDX). These economic evaluations seek to reclassify the risk category 
of patients who were initially defined by existing guidelines (e.g. NCCN) using the test in 
question. Resulting quality adjusted life years (QALYs) and costs have been reported.
5.3 Model structure 
Published studies that measure the clinical utility of gene expression profile tests using a 
prospective study design that follow patients from initial diagnosis through to final health 
outcomes have not been identified during the scoping phase. Two prospective studies, 
MINDACT (MammaPrint) and TAILORx (Oncotype), are ongoing. Consequently, it is likely 
that a linked evidence approach will need to be used in the modelling. That is, outcomes of the 
diagnostic tests to be assessed will need to be related to changes in final heath outcomes. 
5.4 Cost considerations
The Randox BCA is processed locally using the Randox Evidence Investigator Analyser. This 
analyser can be used to process other biochip arrays available from Randox Laboratories (e.g. 
ovarian cancer therapy response prediction assay, multiplex pathogen detection arrays for STIs 
and respiratory infections and drug metabolism SNP assays). At present, this analyser is not 
widely available in the NHS. Therefore, the Randox BCA will incur non-recurrent set-up costs to 
purchase the necessary equipment needed to process the test.
Generally, other gene expression profile tests for breast cancer are processed centrally by 
the manufacturer. 
Protocols used to prepare the tumour specimens can vary. These include formalin-fixed, paraffin-
embedded, snap-frozen and fresh samples. The costs between these protocols vary significantly 
and should be considered in the assessment.
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5.5 Health outcomes
QALYs will need to be calculated in the economic modelling. 
6 Equality issues
None identified during scoping. The population in the scope falls within the provisions of the 
Equality Act 2010 once a diagnosis of cancer has been made. 
7 Implementation
Support tools are developed by the implementation team at NICE. The implementation team 
does not get involved in developing the guidance recommendations but works alongside 
the guidance-producing programme, the communications team and field based teams to, 
among other things, ensure intelligent dissemination of NICE guidance to the appropriate 
target audiences.
Commissioners will need to know whether there are significant non-recurrent set-up costs 
associated with the introduction of the interventions listed in Table 1, particularly where these are 
likely to influence the location of services or the size of population they would need to serve.
Appendix A Glossary
Adjuvant therapy 
Adjuvant therapy is treatment that is given in addition to (proceeding) the primary (initial) 
treatment. It is designed to help reach the primary treatment goal (for example, disease 
eradication). Adjuvant therapy for cancer usually refers to surgery followed by chemotherapy or 
radiotherapy to help decrease the risk of the cancer recurring (coming back). Adjuvant therapy is 
considered as an integral part of treatment and is viewed as a non-surgical oncology treatment of 
(primary) breast cancer by clinicians. 
Allred score
The Allred score is a composite of the percentage of cells that stained and the intensity of 
their staining.
Amplification
In genetics, an increase in the frequency of replication of a DNA segment
Analytic validity 
Analytical validity in this context refers to a test’s ability to accurately and reliably measure the 
expression of messenger ribonucleic acid (mRNA) by breast cancer tumour cells. It is usually 
assessed by determining how much observed measurements provided by the test/technology 
differ from expected values derived from a standard reference. In the measurement of gene 
expression, however, there are no standard reference tests and an assessment of the analytical 
validity of the assays has to be obtained by more indirect methods. This involves an examination 
of test variability arising from tumour sampling, specimen handling, specimen preparation and 
biologic variation within and between different samples of the same tumour, and the effect of this 
on the reproducibility of test when repeated in the same patient, over time. 
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Biomarkers
A biological molecule used as a marker for a substance or process of interest.
Breast conserving surgery
Surgery in which the cancer is removed together with a margin of normal breast tissue. The 
whole breast is not removed.
Breast reconstruction
The formation of a breast shape after a total mastectomy, using a synthetic implant or tissue from 
the woman’s body.
Chemotherapy
The use of medication(s) (drugs) that are toxic to cancer cells, given with the aim of killing the 
cells or preventing or slowing their growth.
Clinical utility 
The clinical utility of a gene expression profile relates to its ability to discriminate between those 
who will have more or less benefit from a therapeutic intervention: the focus in the assessment of 
clinical utility is outcome. Other utilities which may be considered to be important include the 
effect of the test on clinical decision making (for example, choice of therapy). 
Direct evidence of clinical utility of a gene expression profile can only be provided in context of a 
randomized clinical trial where benefit can be measured in terms of an improvement of clinical 
outcomes such as overall survival, disease-free survival, chemotherapy toxicity, or quality of life. 
Prognostic estimates, though not direct estimates of benefit per se, may provide a crude estimate 
of benefit which may be relevant for patient decision making. They can also provide an upper 
limit on the degree of clinical benefit that may be expected. 
Clinical validity 
Clinical validity is usually defined as the degree to which a test accurately predicts the risk of an 
outcome (for example, time to distant metastases), as well as its ability to separate/discriminate 
patients with different outcomes into separate (high and low) risk classes. This is usually reported 
as the clinical sensitivity and specificity of the test.
Cytotoxic
Toxic to living cells.
DNA microarray
A DNA microarray (also commonly referred to as ‘gene chip,’ ‘DNA chip’) is a collection of 
microscopic DNA spots (defined ‘features’), commonly representing single genes or transcripts, 
arrayed on a solid surface by covalent attachment to chemically suitable matrices, or directly 
synthesized on them. DNA microarrays use DNA as part of their detection system. Qualitative 
or quantitative measurements with DNA microarrays use the selective nature of DNA–DNA or 
DNA–RNA hybridisation under high-stringency conditions and fluorophore-based detection. 
DNA arrays are commonly used for gene expression profiling, i.e., monitoring expression levels 
of thousands of genes simultaneously, or for comparative genomic hybridisation.
Endocrine therapy
Treatment of cancer by removing and/or blocking the effects of hormones which stimulate the 
growth of cancer cells.
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External assessment group
An independent group of researchers commissioned by NICE to review the evidence on a group 
of technologies. The external assessment group includes researchers who assess the quality of 
studies on the treatments, and health economists who look at whether the treatments are good 
value for money. The Diagnostics Assessment Committee bases its discussions on the diagnostics 
assessment report produced by the external assessment group.
Gene expression
Gene expression refers to the translation of the information encoded in a gene into an RNA 
transcript. Expressed transcripts include messenger RNAs (mRNA) translated into proteins, 
as well as other types of RNA, such as transfer RNA (tRNA), ribosomal RNA (rRNA), micro 
RNA (miRNA), and non-coding RNA (ncRNA), that are not translated into protein. Gene 
expression is a highly specific process by which cells switch genes on and off in a timely manner, 
according to their state. The study of mRNA expression in a cell is an indirect way to study the 
proteins counterpart.
Gene expression profiling
This term refers to any genomic techniques that measure the fraction of the genes that is 
expressed in a specific sample. This definition refers to techniques that allow the assessment of 
more than one gene at a time, especially microarray and real time RT-PCR.
Gene expression profile/pattern
This is any set of genes for which the expression in a specific sample is known. A gene expression 
profile may account for a variable number of genes, and the corresponding expression values 
may be obtained by different techniques. Gene expression profiles can be associated, by various 
techniques, to phenotypes.
Gene expression signature
This is an equivalent term currently in use to refer to a specific ‘gene expression profile,’ usually 
associated with a specific phenotype.
Grading
Assessing the degree of aggressiveness of a malignant tumour based usually on the appearance of 
its cells under the microscope.
Hierarchical clustering
A method which seeks to build a hierarchy of clusters that involves highly complex computation. 
In order to decide which clusters should be combined (for agglomerative clustering), or where 
a cluster should be split (for divisive clustering), a measure of dissimilarity between sets of 
observations is required. 
Histology
An examination of the cellular characteristics of a tissue using a microscope.
Hormone receptor
Proteins with a cell that bind to specific hormones.
Human epidermal growth factor receptor
A molecule on the surface of a cell which interacts with a specific growth factor and helps to 
control how rapidly the cells grow.
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Immunohistochemistry
A technique that uses antibodies to identify specific molecules in tissues which are examined and 
scored by a pathologist using a microscope.
Invasive breast cancer
Breast cancer where the malignant cells have broken through the lining layer of the normal 
tissues and extend into the fat and fibrous tissue of the breast.
Lymph nodes
Small structures which act as filters of the lymphatic system. Lymph nodes close to the primary 
tumour are generally the first site to which cancer spreads.
Malignant
Cancerous cells which can invade into nearby tissue and spread to other parts of the body.
Mammography
The process of taking a mammogram – a soft tissue x-ray of the breast which may be used to 
evaluate a lump or which may be used as a screening test in women with no signs or symptoms of 
breast cancer.
Mastectomy
Surgical removal of the breast.
Metastases
Deposits of cancer elsewhere in the body.
Metastasis
Spread of cancer away from the primary site to elsewhere in the body via the bloodstream or the 
lymphatic system.
Multidisciplinary team
A team with members from different healthcare professions (including for example, oncology, 
pathology, radiology, nursing).
Nearest centroid classifier 
This method computes a standardized centroid for each class. This is the average gene expression 
for each gene in each class divided by the within-class standard deviation for that gene. Nearest 
centroid classification takes the gene expression profile of a new sample, and compares it to each 
of these class centroids. The class whose centroid that it is closest to, in squared distance, is the 
predicted class for that new sample. 
Neoadjuvant therapy 
Neoadjuvant therapy is treatment that is given prior to the primary (initial) treatment. Surgery is 
regarded as the primary treatment in breast cancer.
Occult
Hidden, or difficult to observe directly.
Oestrogen receptor 
A protein within breast cancer cells that binds to oestrogens. It indicates that the tumour may 
respond to endocrine therapies. Tumours rich in oestrogen receptors have a better prognosis than 
those which are not.
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Predictive values/markers
A molecule that is assessed to predict the likely response to a specific treatment, for example 
oestrogen receptor to predict the likely response to endocrine therapy.
Primary systemic therapy
Systemic therapy given before surgery or radiotherapy.
Progesterone receptor
A protein within cells that binds to progesterone.
Prognosis
A prediction of the likely outcome or course of a disease; the chance of recovery, recurrence 
or death.
Prognostic factors
Disease characteristics that are correlated with the course of the disease and which are used to 
predict the likely outcomes.
Real time reverse transcriptase polymerase chain reaction (RT-PCR)
Real-time RT-PCR is a molecular biology technique that allows the amplification and the 
quantification in real time of defined RNA molecules from specific specimens. This technology 
has been used for several years in research and clinical settings to measure RNA molecules. In 
the first step DNA, copies of the investigated RNA molecules present in the template are obtained 
by a reaction named reverse transcription. Then DNA amplification is obtained using PCR, 
while the quantification of the accumulating DNA product is accomplished by the use of specific 
fluorescent reagents. The quantification of the target RNA molecule is based on the analysis of 
the accumulation curve of the complementary DNA, as measured by the fluorescence detected at 
each cycle of the reaction.
Reverse transcription
In biochemistry, reverse transcription is the enzymatic reaction induced on by the RNA 
dependent DNA polymerase. This enzyme, also known as reverse transcriptase, is a DNA 
polymerase enzyme that copies single-stranded RNA into DNA. This process is the reverse of 
normal transcription, which involves the synthesis of RNA from DNA.
Single sample predictor
A classification model that enables the sub-type of a single tumour to be identified using a nearest 
centroid classifier based on the initial hierarchical clustering of a small (typically) data set. 
Staging
Clinical description of the size and spread of a patient’s tumour, allocated by internationally 
agreed categories.
Systemic therapy/treatment
Medicine, usually given by mouth or injection, to treat the whole body rather than targeting one 
specific area.
Transcription
In genetics, the process by which genetic information on a strand of DNA is used to synthesize a 
strand of complementary RNA.
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Translation
In genetics, the process by which a messenger RNA molecule specifies the linear sequence of 
amino acids on a ribosome for protein synthesis.
Appendix B Abbreviations
BCA Breast cancer array
CG Clinical guideline
DAP Diagnostics Assessment Programme
DNA Deoxyribonucleic acid
ER Oestrogen receptor
FISH Fluorescence in situ hybridisation
GEP Gene expression profiling
GP General practitioner
HER2 Human epidermal growth factor receptor 2
IHC Immunohistochemistry
LN Lymph node
MDT Multidisciplinary team
MINDACT Microarray in node negative and 1-3 positive lymph node disease may 
avoid chemotherapy
mRNA Messenger ribonucleic acid 
NCCN National Comprehensive Cancer Network Guidelines
NHS National Health Service
NICE National Institute for Health and Clinical Excellence
NPI Nottingham Prognostic Index
PR Progesterone receptor
QALY Quality adjusted life year
RT-PCR Reverse transcription-polymerase chain reaction
SSP Single sample predictor
TAILORx Trial assigning individualised options for treatment (Rx)
Appendix C Related NICE Guidance
Refer to http://guidance.nice.org.uk/Topic/Cancer/Breast.
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Appendix E Equality Impact Assessment
The impact on equality has been assessed during this assessment according to the principles of 
the NICE Equality scheme.
1. Have any potential equality issues been identified during the scoping process (scoping workshop discussion, assessment subgroup 
discussion), and, if so, what are they?
None identified
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
N/A
3. Has any change to the draft scope been agreed to highlight potential equality issues? 
N/A
4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have 
changes to the stakeholder list been made?
Additional stakeholders have not been identified
Approved by Associate Director (name): Nick Crabb
Date: 26/04/2011
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Appendix F Attendees of the assessment subgroup meeting
The following people were in attendance at the assessment subgroup meeting held on 11th 
April 2011:
Name of representative Job Title Organisation
Standing Committee 
Members
Ian Cree Director, NETSCC-EME National Institute for Health Research
Christopher Hyde Professor of Public Health and Clinical 
Epidemiology
Peninsula Technology Assessment Group 
(PenTAG)
Specialist Committee 
Members
Carole Farrell Nurse Clinician The Christie NHS Foundation Trust 
Louise Jones Consultant Clinical Scientist Health Service Research Unit, University of 
Aberdeen 
Simon Pain Consultant Breast and Endocrine 
Surgeon
Department of General Surgery, Norfolk & 
Norwich University Hospital
Rob Stein Consultant and Senior Lecturer in 
Oncology
Department of Oncology 
UCL Hospitals
Ursula Van Mann Principal Clinical Scientist Health Service Research Unit, University of 
Aberdeen
External Assessment 
Group arriving at 13:00
Sue Ward Project Manager & supervisor for 
economic modelling
ScHARR, The University of Sheffield
Rachid Rafia Economic Modeller
Alison Scope Systematic Reviewer
NICE staff in attendance:
Name Title
Prof Adrian Newland Chair, Diagnostics Advisory Committee
Nick Crabb Associate Director, Diagnostics Assessment Programme
Hanan Bell Technical Advisor 
Jackson Lynn Project Manager, Diagnostics Assessment Programme
Gurleen Jhuti Technical Analyst, Diagnostics Assessment Programme
Farouk Saeed Technical Analyst, Diagnostics Assessment Programme
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Appendix 21 
Protocol
Technology Assessment Report commissioned by the NIHR HTA Programme on behalf of 
the National Institute for Health and Clinical Excellence – Protocol
10 May 2011
1. Title of the project:
Gene expression profiling tests and expanded immunohistochemistry tests to guide selection of 
chemotherapy regimes in breast cancer management
2. Name of TAR team and ‘lead’
ScHARR, University of Sheffield
Health Economic and Decision Science
The University of Sheffield
Regent Court
30 Regent Street
Sheffield
S1 4DA
Project Lead: Sue Ward
Tel: (+44) (0)114 222 0816
Fax: (+44) (0)114 272 4095
E-mail: s.e.ward@sheffield.ac.uk
Address for correspondence
Major documentation should be sent to the project lead (Sue Ward, s.e.ward@sheffield.ac.uk), 
the project administrator (Gill Rooney, g.rooney@sheffield.ac.uk) and the managing director of 
ScHARR-TAG (Eva Kaltenthaler, e.kaltenthaler@sheffield.ac.uk).
3. Plain English Summary
[This will be used on the HTA Programme website and for any appropriate research registers.]
Breast cancer is the most commonly diagnosed cancer in women in England. In 2008 there 
were 39,681 new cases diagnosed, an increase of 1,633 cases comapred with 2007 (4%). Just 
over 10,000 women died from breast cancer in England in 2008, a rate of 26 deaths per 100,000 
women. It is the second most common cause of cancer death in women, after lung cancer (ONS, 
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2010). Treatment usually involves surgery to remove the primary tumour and any involved 
lymph nodes: this may be followed by radiation therapy, endocrine therapy, Trastuzumab and/or 
chemotherapy depending on tumour and patient variables.
To help guide treatment decision making, several guidelines have been established. The 
guidelines used in England include the Nottingham Prognostic Index (NPI) and Adjuvant! 
Online. These guidelines assist clinicians in the selection of the most appropriate treatment 
for a particular patient. They provide information about prognosis which is largely based on 
pathological parameters (e.g., tumour size, grade and lymph node status) for NPI with the 
addition of ER receptor status, age and co-morbidity for Adjuvant! OnLine. However, it has been 
suggested that these clinical tools do not predict outcome and response to treatment particularly 
well (Paik, 2007). Different guidelines can give different results and it has been suggested that 
a large proportion of women with early stage breast cancer are over-treated. This may result 
in unnecessary use of toxic and expensive chemotherapy for women who derive no benefit or 
avoidable deaths in women for whom chemotherapy was withheld.
This presents a great challenge to clinicians in estimating prognosis and making therapeutic 
decisions particularly relating to the decision about whether or not to use adjuvant chemotherapy 
(chemotherapy after surgery) in women with early stage breast cancer. While chemotherapy 
may prevent relapse in some, not all women with early stage breast cancer will benefit and some 
women remain recurrence free at 10 years without chemotherapy. However, a subset of patients 
with a ‘good’ prognosis may still develop recurrence after curative surgery and adjuvant therapy.
Detailed multi-parameter cancer profiling, using either gene expression profiling or protein 
expression profiling (with immunohistochemistry) has been proposed as an approach to address 
these issues by identifying genes or proteins whose activity may be helpful in assessing disease 
prognosis and guiding therapy in this group of patients. Improved information on baseline risk 
(i.e. prognostic risk) and response to chemotherapy (i.e. predictive benefit) may help target 
chemotherapy on those patients who will benefit the most. Avoiding chemotherapy in patients at 
low risk of recurrence and who will therefore obtain limited benefit offers the potential for cost 
savings (in terms of avoided chemotherapy and avoided treatment of adverse events associated 
with chemotherapy) and the benefit of avoiding the disutility associated with adverse events. 
Accurately identifying those patients at highest risk of recurrence will maximise the survival 
gains from chemotherapy.
Since the systematic reviews by Marchionni et al. (2008) (search date from 1990 to January 2007) 
and Smartt (2009) (search date from 2007 to September 2009) several other studies of gene 
expression profiling have become available.
The aim of this review is to systematically evaluate and appraise the potential clinical and 
cost effectiveness of using gene or protein expression profiling tests to guide selection of 
chemotherapy regimes in breast cancer management.
4. Decision problem
[This will appear on the HTA Programme website and appropriate research registers]
4.1 Purpose of the decision to be made
The aim of the assessment is to answer the following research question:
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By guiding the selection of chemotherapy regimes in breast cancer management, will using gene 
or protein expression profiling tests in patients with early stage breast cancer improve health 
outcomes and quality of life comapred with currently used decision making protocols?
4.2 Clear definition of the intervention
Nine tests have been identified by NICE and will be included in this assessment: six are based on 
gene expression profiling and three on immunohistochemistry.
The gene expression profiling tests which are included are as follows;
 ■ The Randox Assay (BCA) (Randox Laboratories) is a cDNA-based expression biochip 
assay that aims to accurately define the clinical sub-types of breast cancer tumours prior to 
initiating treatment. The target population is all individuals with diagnosed breast cancer.
 ■ MammaPrint (Agendia) is based on microarray technology which uses a 70-gene expression 
profile. MammaPrint is intended as a prognostic test for women 61 years or younger with 
primary invasive ER+, or ER-negative (ER–) LN0 breast cancer.
 ■ Blueprint (Agendia) used is used in addition to MammaPrint for molecular sub-typing, is an 
80 gene microarray, the target population is patients with early-stage (stage I or II), LN– or 
LN+ (up to 3), ER+ or ER– breast cancer.
 ■ PAM50 gene expression assay (ARUP Laboratories Inc.) identifies the major intrinsic 
biological subtypes of breast cancer and generates risk of recurrence (ROR) score.
 ■ OncotypeDX (Genomic Health) quantifies gene expression for 21 genes in breast cancer 
tissue by RT-PCR. It is intended to predict the likelihood of recurrence in women of all ages 
with newly diagnosed Stage I or II, ER-positive (ER+) lymph node negative (LN0) breast 
cancer treated with tamoxifen. The test assigns the breast cancer a recurrence score. The test 
also looks at the expression of hormone receptor genes, both the estrogen receptor (ER) and 
progesterone receptor (PR) and can provide an indication of how responsive the cancer is 
likely to be to hormonal therapy.
 ■ Breast Cancer Index (Biotheranostics) is a RT-PCR assessment of the ratio of expression of 2 
genes, HOXB13 and IL17BR and the Molecular Grade Index (MGI) and gives an indication 
of recurrence risk. The target population are those with ER+ and LN– breast cancer.
The expanded immunohistochemistry tests for protein expression which are included are the 
IHC4, Mammostrat and Nottingham Prognostic Indicators plus (NPI+).
 ■ IHC4 assesses levels of four key proteins in a breast cancer sample, ER, PgR, HER2 and 
Ki-67. This permits broad categorisation into the 5 main tumour subtypes which determine 
treatment and prognosis.
 ■ The Mammostrat® test uses five immunohistochemical markers (SLC7A5, HTF9C, 
P53, NDRG1, and CEACAM5) to stratify patients into risk groups to inform treatment 
decisions. These markers are independent of one another and do not directly measure either 
proliferation or hormone receptor status.
 ■ NPI+ is a biomarker based prognostic assay which integrates 10 predictive biomarkers of 
long term survival and therapeutic response with existing clinical and molecular pathology 
knowledge to support individualised clinical decision making.
5. Report methods for synthesis of evidence of clinical effectiveness
A systematic review of the evidence on the clinical effectiveness of gene and protein expression 
profiling tests to guide selection of chemotherapy regimes in breast cancer management will be 
NIHR Journals Library www.journalslibrary.nihr.ac.uk
292 Appendix 21
conducted. For two of the tests MammaPrint and OncotypeDX a recent systematic review exists 
(Smartt, 2009) therefore a summary of this review will be provided plus an update of this review 
will be conducted by searching for evidence on each of the two named tests and alternative names 
for each test for the period January 2009 to present date, and from 2002 on the product names 
and alternative names for the seven remaining tests. The review will be conducted following 
the general principles recommended in CRD’s guidance (CRD, 2009), the PRISMA statement 
(Liberati et al., 2009), and The NICE Diagnostic Assessment Programme Interim Methods 
Statement (NICE, 2010).
Unpublished information received from manufacturers will be summarised separately. 
Unpublished information will only be considered if presented in a structured format, and the 
method reported in a sufficient detail. Due to the time constraints of the project priority will 
be given to peer-review articles in press, or submitted to peer-review journals, Other types of 
unpublished data, including research reports, databases and other non-peer reviewed materials 
will be considered only if deemed to provide important information by the Assessment Team and 
if time/resource constraints allow.
5.1 Inclusion and exclusion criteria
The titles and abstracts of records identified by the search strategy will be examined for relevance 
by one reviewer. Full papers of any potentially relevant records will be obtained where possible 
and screened by one reviewer. The relevance of each study to the review and the decision to 
include/exclude studies will be made according to the inclusion criteria detailed below. Any 
studies which give rise to uncertainty will be reviewed by a second reviewer with involvement of 
a third reviewer when necessary.
Population
Inclusion criteria: People diagnosed with early invasive breast cancer. Some tests may only be 
used in a sub-population. For example, women with early-stage invasive breast cancer (stage I, 
II or III), lymph node negative or positive (up to 3), oestrogen receptor positive or negative and 
HER2 positive or negative.
Interventions
Inclusion criteria: The assessment will include the gene expression profiling tests and expanded 
immunohistochemistry tests that have been identified by NICE. Tests to be included are: Randox 
Breast Cancer Array, MammaPrint + BluePrint, PAM50, MammaPrint, OncotypeDX, Breast 
Cancer Index, IHC4, Mammostrat and NPI+.
Comparators
The comparator will be current UK clinical practice. This includes the use of Adjuvant! Online 
or the Nottingham Prognostic Index (NPI), in combination with pathological parameters (eg, 
tumour size, grade and lymph node status), to predict survival and the utility of adjuvant therapy 
in breast cancer.
Outcomes
 ■ Analytic validity (ie the ability of the test to accurately and reliably measure the expression of 
mRNA or proteins by breast cancer tumour cells),
 ■ Clinical validity (ie the degree to which the test could accurately predict the risk of an 
outcome and discriminate patients with different outcomes),
 ■ Clinical utility in relation to harm, impact on clinical decision making, evidence of 
improvement in outcomes and health care costs.
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 – Primary clinical outcomes to include: distant recurrence free survival at 10 years, local 
recurrence free survival at 10 years, total disease recurrence at 5 years, pathological 
complete response.
 – Secondary outcomes to include: Health-related quality of life, including the impact of 
adverse events associated with chemotherapy. Reduction in overall chemotherapy use.
Setting
Tests which are used in secondary and tertiary care to make decisions about adjuvant 
chemotherapy treatment.
Study designs
Inclusion criteria: for the review of clinical effectiveness the best available level of evidence will be 
included, with priority given to controlled studies if available.
Exclusion criteria: studies will be excluded if they do not meet the inclusion criteria, appear to be 
methodologically unsound, or do not report methods and/or results in the necessary detail. The 
following will also be excluded:
 ■ animal models
 ■ preclinical and biological studies
 ■ editorials and opinion pieces
 ■ studies only published in languages other than English unless no other comparable data exist
 ■ reports published as meeting abstracts will be excluded unless comparable data do not 
exist in full published studies and in such a case will only be included where sufficient 
methodological details are reported to allow critical appraisal of study quality
 ■ studies applied only to breast cancer biology
 ■ studies relating to these tests only in the neo-adjuvant treatment setting
5.2 Literature searching
The search strategy for the systematic review will comprise the following main elements:
 ■ Searching of electronic databases;
 ■ Contacting manufacturers;
 ■ Contact with experts in the field;
 ■ Scrutiny of bibliographies of included papers;
 ■ Citation Searching of key papers.
The databases that will be searched include the following:
 ■ MEDLINE and MEDLINE in Process (for latest publications);
 ■ EMBASE;
 ■ The Cochrane Library (including the Cochrane Systematic Reviews Database, Cochrane 
Controlled Trials Register, CENTRAL, and NHSEED)
 ■ BIOSIS previews;
 ■ Web of Knowledge.
Recent relevant conference proceedings including the St Gallen International Breast Cancer will 
be screened. In addition, relevant reviews and guidelines will be identified through the following 
resources: Clinical Evidence, National Institute for Health and Clinical Evidence (NICE) website, 
NHS Evidence – National Library of Guidelines, SIGN Guidelines, the Guidelines International 
Network website and the Medicines and Healthcare products Regulatory Agency.
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Search terms will take into account product names and any alternative names for each of 
the tests. Product and alternative product names will be sought from information from 
manufacturers and their websites, searching full text of potentially included articles, review 
papers and their reference lists. A draft MEDLINE search strategy is included in Appendix 9.1)
The clinical and cost effectiveness searches will be limited by date from January 2009 to present 
for the OncotypeDX and MammaPrint (the search strategies from the existing systematic reviews 
appear to be of good quality and clearly reported and as a result all studies prior to September 
2009 should have been identified). A 9 month window of overlap will be used when updating 
the literature search of these reviews to account for any publications that may not have yet been 
indexed in major science literature databases when Smartt (2009) conducted her literature 
search. For the other tests searches will be conducted from 2002 to present date. This date has 
been identified as a suitable start date by checking previous systematic reviews and submissions 
of reference lists from manufacturers. The first evidence for the tests included in the previous 
systematic review (MammaPrint or OncotypeDX) was reported in 2002. As these tests are the 
most established tests and furthest along the validation pathway, evidence for the subsequent 
tests will not predate this.
Reference lists of included papers will be assessed for additional relevant studies and where 
necessary, authors of eligible studies will be contacted for further information. All searches will 
be limited to human studies. No limits relating to study design will be applied to the searches.
5.3 Study selection and data extraction strategy
Data will be extracted by one reviewer using a standardised data extraction form and checked by 
another. Discrepancies will be resolved by discussion, with involvement of a third reviewer when 
necessary. If time constraints allow, attempts will be made to contact authors for any missing 
data. Data from multiple publications of the same study will be extracted as a single study. 
Moreover, as part of this systematic review is an update of two existing reviews, all relevant data 
will be extracted from the reviews in the first instance, but will be cross checked for accuracy 
with the original papers. If necessary, additional data will be extracted from the original papers. 
Supplementary information received directly from manufacturers will be summarised and 
tabulated separately.
5.4 Quality assessment strategy
The nature of the quality assessment which will be undertaken will depend on the types of studies 
identified, but will be undertaken using appropriate and established tools.
Although there are no validated tools for the assessment of the quality of tumour marker/
gene expression profiling studies, Smartt (2009) used the general principles of the reporting 
recommendations for tumour marker prognostic studies (REMARK) to assess the quality of 
the studies. The REMARK guidelines were developed to encourage transparent and relevant 
reporting of study design, pre-planned hypotheses, patient and specimen characteristics, 
assay methods, and statistical analysis methods, in order to help others judge the usefulness 
of the data presented (McShane, Altman, Sauerbrei et al., 2005). However, these guidelines 
are not fully suited to genetic risk prediction studies. Recently Janseens et al (2011) developed 
a checklist for strengthening the reporting of the genetic risk prediction studies (GRIPS) by 
building on the principles established by prior reporting guidelines (STREGA, REMARK, 
STARD). For this review, we will assess the study quality using the relevant sections of the GRIPS 
reporting guidelines (Janseens et al., 2011). The assessment will be performed by one reviewer, 
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and independently checked by another. Discrepancies will be resolved by discussion, with 
involvement of a third reviewer when necessary.
5.5 Methods of analysis/synthesis
The results of data extraction will be tabulated and discussed as a narrative summary. If sufficient 
clinically and statistically homogenous data are available, data will be pooled using appropriate 
meta-analytic techniques to estimate a summary measure of effect on relevant outcomes. Clinical, 
methodological and statistical heterogeneity will be investigated.
6. Report methods for synthesising evidence of cost-effectiveness
A systematic review of the existing literature studying the cost effectiveness of the nine 
identified tests to guide selection of chemotherapy regimes in breast cancer management will 
be undertaken.
6.1 Identifying and systematically reviewing published cost 
effectiveness studies
Databases to be searched are shown in section 5.2. Cost-effectiveness studies will be identified 
using an economic search filter. A draft MEDLINE search strategy is presented in Appendix 1 
and will be adapted for use in other databases. In addition, relevant cost papers identified from 
the clinical effectiveness searches will be included in the economic review.
6.2 Evaluation of costs and cost effectiveness
The quality of identified cost-effectiveness studies will be assessed against a critical appraisal 
checklist adapted from the Drummond (Drummond 1996) and Eddy (Eddy 1985) checklists 
(Appendix 9.2).
6.3 Development of a health economic model
Preliminary discussion with clinical experts indicates that patients diagnosed with breast cancer 
follow the diagnosis/treatment pathway described in Figure 1. GEP and expanded IHC tests 
aim to improve the use of chemotherapy in breast cancer by stratifying patients and identifying 
those patients who will gain most benefit from chemotherapy. These tests may report two types 
of information – breast cancer sub-types and/or risk of recurrence. Tests developed to provide 
information on sub-types might be used either before surgery for informing decisions on 
neo-adjuvant therapy or after surgery for informing decisions on adjuvant chemotherapy. Tests 
predicting the risk of recurrence in a specific population are likely to be used further down in the 
treatment pathway after surgery, in conjunction with other information available about tumour 
size, grade etc, to guide the use of adjuvant therapy.
The objective of the economic evaluation will be to explore the cost effectiveness of tests in the 
adjuvant chemotherapy setting. The cost effectiveness of these tests in the neo-adjuvant setting 
will not be evaluated in this evaluation. The feasibility of modelling any individual test will be 
dependent on the level of evidence available, the robustness of data and time constraints within 
the project. Tests that do not have fully reported external validation studies (i.e validation on 
an independent dataset) will not be included in the economic evaluation. Evidence will be 
required on the impact on adjuvant chemotherapy treatment decisions of the new test, compared 
with current clinical practice (adjuvant online or NPI). Tests validated for use in predicting 
chemotherapy benefit will be distinguished from those using prognostic information as a proxy 
for chemotherapy benefit. Both predictive and prognostic information may be used to inform 
chemotherapy decisions. Therefore, the EAG will seek to undertake economic evaluation of tests 
that provide either or both types of information if suitable evidence allows.
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A preliminary review of the evidence suggests that less robust data are available for the effect 
of molecular sub-typing tests comapred with the risk of recurrence tests. The potential role 
of sub-typing tests would be to add additional information into the existing decision making 
process. For instance information on luminal status may provide an indication of the likelihood 
of patients responding to chemotherapy. However, it is expected that evidence on the impact of 
sub-typing on decision-making will be limited or even lacking completely.
We anticipate the appropriate comparators for the risk of recurrence after surgery to guide the 
use of chemotherapy is expected to be the NPI score, Adjuvant! Online or any adaptation of these 
tools in clinical practice. It is expected that there might be some variation in clinical practice in 
the UK.
The primary outcome from the model will be an estimate of the incremental cost per additional 
quality-adjusted life year (QALY) gained associated with the use of tests to improve the use of 
chemotherapy in breast cancer. Secondary outcomes (health benefits) will also be presented. 
Costs and benefits will be captured using a lifetime horizon and modelled in line with the NICE 
Diagnostic Assessment Programme Interim Methods Statement (NICE, 2010). The model will 
adopt the perspective of the UK NHS and personal social services (PSS) with costs and benefits 
discounted at an annual rate of 3.5%. Modelling assumptions will be taken from the literature, 
supplemented by clinical expert opinion where required. Tests needing fresh samples (such as 
MammaPrint) may require significant re-organisation of pathology services, with resulting costs. 
Quality of life data will be reviewed and used to generate the quality adjustment weights required 
to estimate QALYs. Costs will be derived from national sources (e.g. NHS reference costs, 
national unit costs, British National Formulary) and data provided by the manufacturers.
The development of the model is likely to be an iterative process. A conceptual model will be 
developed in conjunction with clinical experts to capture the current pathway of care for the 
diagnosis and management of breast cancer and how the new tests would change the pathway 
if routinely available in the NHS. The conceptual model will indicate the data requirements 
which will be sought both from the published literature and within commercial in confidence 
data held by the manufacturers. The model is likely to evolve following discussions with project 
stakeholders and the specialist committee members (SCMs), and according to the availability 
of data. It is anticipated that there may be limited evidence for some of the parameters that will 
be included in the economic model. Therefore, the uncertainty around the parameter estimates 
will be modelled to take this into account. A range of scenarios will be presented varying main 
model assumptions to identify parameters that impact the most the ICER and to represent 
the uncertainty in parameters estimate. Furthermore, Probabilistic sensitivity analysis (PSA) 
will also be carried out using Monte Carlo simulation. The uncertainty in each parameter will 
be represented using a probability distribution. The decision uncertainty will be presented as 
the probability that each intervention is the most cost-effective for a given cost-effectiveness 
threshold. Cost-effectiveness acceptability curves will also be presented to illustrate graphically 
the decision uncertainty.
7. Handling the company submission(s)
All relevant data submitted by the manufacturers/sponsors will be considered if received by the 
TAR team no later than 27 May 2011. Data arriving after this date is unlikely to be considered, 
except data specifically requested by the Assessment team. If the data meet the inclusion criteria 
for the review they will be extracted and quality assessed in accordance with the procedures 
outlined in this protocol.
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Any economic evaluations included in the company submission, provided it complies with 
NICE’s advice on presentation, will be assessed for clinical relevance, reasonableness of 
assumptions and appropriateness of the data used in the economic model. If the TAR team judge 
that the existing economic evidence is not robust, then further work will be undertaken, either by 
adapting what already exists or developing a de-novo model
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FIGURE 1 Diagnosis and management pathway in breast cancer.
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Any ‘commercial in confidence’ data taken from a company submission, and specified as 
confidential in the check list, will be highlighted in blue and underlined in the assessment report 
(followed by an indication of the relevant company name e.g. in brackets). Any ‘academic in 
confidence’ data provided by manufacturers, and specified as such, will be highlighted in yellow 
and underlined in the assessment report. Any confidential data used in the cost-effectiveness 
models will also be highlighted.
8. Competing interests of authors
None
9. Appendices
9.1 Draft search strategy
Update search for OncotypeDX, and MammaPrint
Date limits = January 2009 – date
Filter = human studies only
1. exp Breast Neoplasms/
2. exp mammary neoplasms/
3. exp “Neoplasms, Ductal, Lobular, and Medullary”/
4. exp breast/
5. exp neoplasms/
6. 4 and 5
7. (breast$ adj5 (neoplasm$ or cancer$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or 
sarcoma$ or dcis or ductal or infiltrat$ or intraductal$ or lobular or medullary)).mp.
8. (mammar$ adj5 (neoplasm$ or cancer$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or 
sarcoma$ or dcis or ductal or infiltrat$ or intraductal$ or lobular or medullary)).mp.
9. 1 or 2 or 3 or 6 or 7 or 8
10. MammaPrint.mp.
11. 70-gene.mp.
12. gene70.mp.
13. gene?seventy.mp.
14. seventy?gene.mp.
15. amsterdam profile.mp.
16. Oncotype.mp.
17. Oncotype DX.mp.
18. 21-gene.mp.
19. gene21.mp.
20. gene?twentyone.mp.
21. twentyone?gene.mp.
22. GHI Recurrence score.mp.
23. GHI-RS.mp.
24. 92-gene.mp.
25. gene92.mp.
26. gene?ninetytwo.mp.
27. ninetytwo?gene.mp.
28. RT-PCR (adj 5) 21.mp.
29. or/10–28
30. 9 and 29
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Search for Randox, Blueprint, PAM50, Breast Cancer Index, IHC4, 
Mammostrat, and NPI+
Date limits = 2002 – date
Filter = human studies only
1. exp Breast Neoplasms/
2. exp mammary neoplasms/
3. exp “Neoplasms, Ductal, Lobular, and Medullary”/
4. exp breast/
5. exp neoplasms/
6. 4 and 5
7. (breast$ adj5 (neoplasm$ or cancer$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or 
sarcoma$ or dcis or ductal or infiltrat$ or intraductal$ or lobular or medullary)).mp.
8. (mammar$ adj5 (neoplasm$ or cancer$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or 
sarcoma$ or dcis or ductal or infiltrat$ or intraductal$ or lobular or medullary)).mp.
9. 1 or 2 or 3 or 6 or 7 or 8
10. Randox.mp.
11. Blueprint.mp.
12. 80-gene.mp.
13. gene80.mp.
14. gene?eighty.mp.
15. eighty?gene.mp.
16. PAM50.mp.
17. 50-gene.mp.
18. gene50.mp.
19. gene?fifty.mp.
20. fifty?gene.mp.
21. breast bioclassifier.mp.
22. Breast Cancer Index.mp.
23. Breast cancer gene expression ratio.mp.
24. 2-gene.mp.
25. Two-gene-index.mp.
26. 2-gene-index.mp.
27. Two?gene.mp.
28. gene?two.mp.
29. H?I.mp.
30. H:I.mp.
31. 5-gene.mp.
32. gene5.mp.
33. gene?five.mp.
34. five?gene.mp.
35. 7-gene.mp.
36. seven-gene.mp.
37. gene7.mp.
38. gene?seven.mp.
39. Theros.mp.
40. Biotheranostics.mp.
41. Theros breast cancer index.mp.
42. HOXB13$.mp.
43. homeobox?13$.mp.
44. interleukin?17B$.mp.
45. IL17BR.mp.
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46. mammostrat.mp.
47. five-biomarker-assay.mp.
48. IHC4.mp.
49. NPI+.mp.
50. Nottingham prognostic index plus.mp.
51. Nottingham prognostic index +.mp.
52. or/10–51
53. 9 and 52
9.2 Critical appraisal checklist for economic evaluations using key 
components of the British Medical Journal checklist for economic 
evaluations (Drummond & Jefferson 1996) together with the 
Eddy checklist on mathematical models employed in technology 
assessments (Eddy 1985)
Reference ID
Title
Authors
Year
Modelling assessments should include: Yes/No
1 A statement of the problem;
2 A discussion of the need for modelling vs.. alternative methodologies
3 A description of the relevant factors and outcomes;
4 A description of the model including reasons for this type of model and a specification of the scope including; time 
frame, perspective, comparators and setting. Note: n = number of health states within sub-model
5 A description of data sources (including subjective estimates), with a description of the strengths and weaknesses of 
each source, with reference to a specific classification or hierarchy of evidence; 
6 A list of assumptions pertaining to: the structure of the model (e.g. factors included, relationships, and distributions) 
and the data;
7 A list of parameter values that will be used for a base case analysis, and a list of the ranges in those values that 
represent appropriate confidence limits and that will be used in a sensitivity analysis;
8 The results derived from applying the model for the base case;
9 The results of the sensitivity analyses; unidimensional; best/worst case; multidimensional (Monte Carlo/parametric); 
threshold.
10 A discussion of how the modelling assumptions might affect the results, indicating both the direction of the bias and 
the approximate magnitude of the effect;
11 A description of the validation undertaken including; concurrence of experts; internal consistency; external consistency; 
predictive validity. 
12 A description of the settings to which the results of the analysis can be applied and a list of factors that could limit the 
applicability of the results; 
13 A description of research in progress that could yield new data that could alter the results of the analysis
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Ward et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced 
for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated 
with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha 
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
301 Health Technology Assessment 2013; Vol. 17: No. 44DOI: 10.3310/hta17440
Details of TAR team
1. Ward Sue Ms (Project Manager & supervisor for economic modelling)
Senior Research Fellow
Health Economic & Decision Science (HEDS)
School of health & related research (ScHARR)
The University of Sheffield
Regent Court
30 Regent Street
Sheffield
S1 4DA
Tel: (+44) (0)114 222 0816
Fax: (+44) (0)114 272 4095
E-mail: s.e.ward@sheffield.ac.uk
2. Rafia, Rachid Mr (Economic modeller) 
Research Associate, HEDS
Address – as above
Tel: (+44) (0)114 222 0739
Fax: (+44) (0)114 272 4095
E-mail: r.rafia@sheffield.ac.uk
3. Scope, Alison Dr (Systematic Reviewer)
Systematic reviewer, HEDS.
Tel: (+44) (0)114 222 0670
Fax: (+44) (0)114 272 4095
E-mail: a.scope@sheffield.ac.uk
4. Evans, Pippa (Information Specialist)
Information Specialist, HEDS,
Tel: (+44) (0)114 222 0801
Fax: (+44) (0)114 272 4095
E-mail: p.evans@sheffield.ac.uk
Major documentation should be sent to the project lead (Sue Ward, s.e.ward@sheffield.ac.uk), 
the project administrator (Gill Rooney, g.rooney@sheffield.ac.uk) and the managing director of 
ScHARR-TAG (Eva Kaltenthaler, e.kaltenthaler@sheffield.ac.uk).
Timetable/milestones
Progress report (to NETSCC, HTA who forward it to NICE within 24hr): 15 July 2011.
Draft assessment report (simultaneously to NICE and NETSCC, HTA): 22 August 2011.
Assessment Report (simultaneously to NICE and NETSCC, HTA): 19 September 2011.
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